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Abstract
A prescribed medicine is the most frequent treatment provided for patients in
the NHS. The safe and effective management of medicines is therefore central
to the quality of health care. In 2003, 21% of the population of England were
aged 60 or more, and this will continue to increase. Increased morbidity in the
elderly, coupled with the growing elderly population, has profound implications
for the use of medicines. Almost 60% of prescriptions are for older people.
Government objectives are to ensure that older people gain the maximum
benefit from their medication to maintain or increase their quality and duration of
life, and that they do not suffer unnecessarily from illness caused by excessive,
inappropriate, or inadequate consumption of medicines. However, despite
national guidance and standards, patients often do not get the best from their
medicines, and may suffer avoidable adverse effects.
Using an action research approach, I therefore explored the use of medicines in
older people in a hospital setting, elicited the views of patients and staff on the
use of medicines and identified how the management of medicines, and hence
patient care, can be improved. The research comprised four phases. Phase one
aimed to establish an understanding of the health care environment within
which the study would be conducted, in particular, the nature of patient care in
different specialties and settings; the culture relating to therapeutics within the
trust; current practice and standards of care relating to medicines; problems
relating to medicines use; and attitudes to change in these areas. Phase two
reflected on emerging themes and identified key issues in the use of medicines.
In phase three I developed and implemented a new model of care in the study
Trust, and in phase four I evaluated the model in the study setting and explored
issues which would influence its adoption throughout the Trust. The
methodologies used included ethnography, participant observation, case
studies, an evaluative study and focus groups and interviews with patients and
staff.
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The study identified several serious issues concerning patient safety, the culture
relating to medicines, inefficiency and competency of professionals. Medication
errors occurred frequently and were rarely reported. Patients were frequently
admitted to hospital because of medication problems and readmissions
occurred because of problems with discharge medication. Drug therapy was
poorly documented in patient notes and communication with GPs about
medicines and treatment plans was rarely comprehensive. Inefficiencies in
medicines management impaired patient care and caused waste. Delays in
supplying medicines lead to patients missing doses, often for several days.
Medicines were not viewed as an important part of patient care and, while
hospital staff acknowledged the shortcomings, these were often viewed as
inevitable and not a priority for improvement. Staff, particularly junior doctors
and nurses, sometimes lacked essential competencies in medicinal
therapeutics.
I therefore implemented a model of pharmacy practice, fully integrated within
the health care team, which included comprehensive drug histories on
admission, systematic medication reviews throughout hospital stay, patient
education and advice, advice to medical and nursing staff, enhanced
communication with primary care teams and discharge planning. As a result,
errors and omissions in patients' medication were significantly reduced. The
quality of information provided to patients and general practitioners at discharge
was enhanced. Adverse drug reactions were identified and avoided. Evidence-
based, appropriate prescribing was ensured in study patients. Interviews with
patients demonstrated increased satisfaction with their care.
This study was undertaken in a particular hospital setting and results cannot be
generalised. The nature and level of medicines management in hospitals varies
widely and many hospitals have successfully implemented elements of the
model described here. Nevertheless, there is no reason to believe that the study
Trust is unique. Many Trusts display similar shortcomings in their current
approach to therapeutics, and in the apparent obstacles to achieving change.
My findings, supported by the literature, indicate that these hospitals will find
change difficult to achieve. The evidence suggests that pharmacy staff
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themselves may represent the biggest obstacle (rather than lack of resources,
frequently cited as a barrier to progress). Pharmacists need to have confidence
in their clinical skills, to secure the support of other clinical staff, and to be
committed to improving services to patients. Pharmacy managers must exercise
clinical leadership and advocacy in articulating the need for change and the
benefits for patients and the organisation. The evidence shows that resources
will then invariably follow.
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1. CHAPTER 1 - INTRODUCTION
12
The safe and effective management of medicines is central to the quality of
health care. A prescribed medicine is the most frequent treatment provided for
patients in the NHS. Nearly all patients are given medication as a result of a
visit to hospital, with 7,000 individual doses administered daily in a 'typical'
hospital and up to 40% of nurses' time spent administering medicines (Audit
Commission, 2001). An estimated 200 million prescriptions are issued in
hospitals each year and General Practitioners (GPs) in England issued 650
million prescriptions in 2003 at a cost of £7.5 billion. The total cost of medicines
in all sectors of the NHS is estimated to be £10 billion per annum.
In 2003, 21% of the population of England were aged 60 or more, and this will
continue to increase (Department of Health, 2001 a, Department of Health,
2004a). The increasing burden of illness among the elderly means older people
have a much greater need for health and social services than the young,
therefore the bulk of health and social care resources are directed at their
needs. Almost two thirds of general and acute hospital beds are used by people
over 65 years. There were 404 finished consultant episodes (FCE5) per 1000
population aged 60-74 in 2003-04, compared with 261 for all ages. This
increased to 735 FCEs per 1000 in people aged 75-84 or more (Department of
Health, 2004a).
Increased morbidity in the elderly, coupled with the growing elderly population,
has profound implications for the use of medicines. In 2003 almost 60% of
prescriptions were for older people (as defined by prescription charge
exemption status: women aged 60 and men aged 65) who received on average
35 prescriptions per head compared with 13.1 for all ages and 7.7 for people
aged 16-59 (Department of Health, 2004b). Four in five people over 75 years
old take more than one medication, with 36% taking four or more (Health
Survey for England 1998. Volume 1: Findings).
The Government is committed to raising the quality of service and reducing
variations in delivery within the NHS and a policy framework is set out in the
NHS Plan, National Service Frameworks and the Programme for Pharmacy in
the NHS ( Department of Health, 2001b, Department of Health, 2001a,
Department of Health, 2001c, Department of Health, 2001d, Department of
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Health, 2000b, Department of Health, 2000a, Department of Health, 1999a,
Department of Health, 2000c). A statement of good practice is set out in the
National Service Framework for older people. Its objectives are to ensure that
older people gain the maximum benefit from their medication to maintain or
increase their quality and duration of life, and that they do not suffer
unnecessarily from illness caused by excessive, inappropriate, or inadequate
consumption of medicines.
Despite guidance and standards set by the Government, often patients do not
get the best from their medicines, and suffer unnecessarily. Within this study I
attempt to identify how the management of medicines in hospitals, and hence
patient care, can be improved.
In chapter 2, I give an overview of the literature relating to this research
beginning, in section 2.1 with some background regarding myself and why I
embarked on this research. In 2.2, I discuss literature regarding adverse drug
events and I examine issues concerning the competencies of health care
professionals in therapeutics in section 2.3. I then explore literature relating to
communication between primary and secondary care in section 2.4 and in
section 2.5 examine the literature relating to patient education about their
medicines and compliance. In section 2.6, I discuss the way forward in
enhancing patient care with respect to medicines, in particular the
Government's position and the role pharmacists have in this. Finally in section
2.7, I present literature to provide a background and rationale to the
methodologies employed in this study.
In chapter 3, I present the 'preliminary phase' of this project, methods I and
results 1. This chapter describes the first two phases of the research, phase 1,
an initial phase to gain an understanding of the problems relating to medicines
in the study Trust. This involved gathering and analysis of preliminary data.
Phase 2 of the project involved reflection on emerging themes and identification
of key issues relating to the use of medicines. In section 3.2, I describe the
overall approach used for this study then in 3.3 describe the setting. In 3.4, I
describe the methods used for data collection in this preliminary investigation
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and in section 3.6, I present the results, which include a selection of case
summaries.
In chapter 4, I present the 'implementation and evaluative phase' of the project,
methods 2 and results 2. This chapter describes the final two phases of the
research phase 3, development and implementation of a new model of care
providing a more patient focussed approach to pharmacy services and phase 4,
evaluation of the model in the study setting and exploration of issues, which
would influence adoption throughout the study Trust. In section 4.2, I describe
the new model of care, how this was implemented in the study Trust, and the
methods used for evaluation. Finally, in section 4.3, I present the results from
the evaluative study.
Finally, in chapter 5, I summarise and discuss the main findings from this study.
In section 5.2 the main findings are summarised then in section 5.3, I relate my
findings to existing literature. In section 5.4, I explore the challenges, and
limitations and strengths within the study and in section 5.5, I discuss the
implications for future research. Finally in section 5.6, I talk about the
implications my study has for future practice within the study Trust and beyond.
15
2. CHAPTER 2 LITERATURE REVIEW
16
2.1.	 INTRODUCTION
Although considerable efforts have been made to improve quality of care within
the NHS, failures to deliver safe and effective drug therapy often result in poor
clinical outcomes and economic consequences.
In this literature review, I will outline some the issues relating to medicines use
in the health care setting. Following on from this I will consider the role
pharmacy staff have in the management of medicines and patient care, and will
evaluate evidence relating to this. Finally I will give a theoretical discussion of
the methods employed in this study and the rationale for them. I begin with my
personal background and interest in the subject.
2.1.1.	 My background
I have been practising as a pharmacist since 1997, primarily working in
hospitals in the North of England. I undertook my pre-registration training and
worked as a basic grade pharmacist at a large teaching hospital, working here
for a total of 21 months. As a basic grade pharmacist, my job involved
participation in dispensary services, sterile and non-sterile manufacturing,
cytotoxic and central intravenous antibiotics services, and drug information. I
was also involved in co-ordination of clinical trials and provision of education
and training for student technicians and pre-registration pharmacists. Whilst
working at this hospital I gained some experience of working on wards through
provision of clinical pharmacy service to neurology, general paediatric and
paediatric oncology wards.
I then worked in another large teaching hospital as a C grade pharmacist for 3
years and my job was primarily clinical, providing ward based pharmacy
services to neonatal and paediatric departments, and a neuro-rehabilitation
department. This clinical pharmacy service included attendance at Consultant
ward rounds, providing therapeutic advice for doctors, nurses and patients,
monitoring prescribing and development of evidence-based treatment
guidelines. Whilst working at this hospital I also provided anticoagulant
management services, provided education and training for pharmacy, nursing,
17
and medical staff both in-house and externally, and provided support for drug
information and manufacturing services.
As a practising pharmacist I thought that, sometimes people seemed to receive
poor standards of care with respect to their medication, and medication related
problems frequently occurred. For example I observed that patients sometimes
didn't receive their usual medication in hospital for various reasons. I found that
mistakes occur and the attitudes of doctors and nurse seemed to be blasé. I
encountered people admitted to hospital because they appeared to be suffering
adverse reactions from medication. In my experience patients often seemed not
to be given sufficient information about their medication. Communication
relating to drug therapy across the primary secondary care interface appeared
to me to be poor and this led to problems in continuity of care. Problems relating
to medication, in my experience, resulted in readmission of patients to hospital.
These observations drew me to the research idea and my experience is
mirrored in the literature, which I now discuss.
My strategy for the literature review encompassed searches of the Medline and
Cochrane databases, together with specific searching in relevant journals, for
example the British Medical Journal, Quality and Safety in Healthcare and
Journal of Advanced Nursing through their websites. I searched under a
number of relevant key words grouped within the broad headings of adverse
events, learning from adverse events, health professionals' competency in
therapeutics, communications, patient education and compliance and action
research methodologies. I also undertook hand searching of relevant texts and
government documents. I did not impose any date restrictions on the searches.
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2.2.	 ADVERSE EVENTS RELATING TO MEDICINES
In this section I will talk about adverse drug events starting with a description of
the concept of medication errors in 2.2.1 and adverse drug reactions in 2.2.2,
then going on to discuss their incidence in 2.2.3. I will also in this section outline
the human and financial implications, which include harm to patients and
sometimes death, distress for relatives, expense and waste for the NHS and
anguish for the health professionals involved. In section 2.2.4 I examine the
causes of medication errors, discussing firstly in section 2.2.4.1 approaches to
looking at errors and their causes for example, the person centred approach
and the system approach to human error then moving on to talk about the
'Swiss cheese' model of accidents. Prescribing errors are the most frequent and
probably the most serious form of medication error, which I discuss in section
2.2.4.2; dispensing errors occur less frequently which I talk about in section
2.2.4.3, but administration errors, described in section 2.2.4.4, occur more often
and can be due to a number of causes which include poorly written
prescriptions, inadequate labelling , transcriptions errors, drug name confusion,
incorrect dose calculation and inadequately trained personnel. I then go on to
consider medication errors in specific patient groups, particularly people with
allergies, seriously ill people and children, in section 2.2.4.5. In section 2.2.5 I
consider some of the factors which influence the ability of organisations to learn
from failure discussing the cyclical process of learning in section 2.2.5.1,
barriers to learning in section 2.2.5.2 and how these can be overcome in section
2.2.5.3. Finally, in section 2.2.6 I outline the Governments commitment to
improve patient safety with particular reference to documents such as, 'An
organisation with a memory' 'Building a Safer NHS for patients: implementing
an organisation with a memoiy', 'Building a safer NHS for patients: improving
medication safety' and guidance issued for safe administration of intrathecal
chemotherapy. I also outline the work of the recently established National
Patient Safety Agency (NPSA).
Every day patients are being injured because of unwanted effects of medicines
such as side effects or adverse drug reactions, or through medication errors.
Such injuries occur relatively frequently and many are avoidable. Many adverse
drug reactions are predictable and can be avoided or minimised; however,
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some are unpredictable and therefore unavoidable. Medication errors, in
contrast, can always be avoided.
2.2.1.	 Medication errors
Patient safety and medication errors have become a major concern for the
public, government and for the professions concerned. Medication errors are
probably the most prevalent form of medical error and there is evidence that
they occur in all healthcare settings (Department of Health, 2000d, Leape et a!.,
1991). In many countries of the world, medication errors account for about a
quarter of all patient safety issues (Department of Health, 2001e).
A medication error has been defined as:
"Any preventable event that may cause or lead to inappropriate
medication use or patient harm while the medication is in the control of
health professional, patient or consumer" (National Coordinating Council
for Medication Error Reporting and Prevention.)
Medication errors may be related to professional practice, products, procedures,
environments or systems including prescribing; ordering; dispensing and
distribution; preparation and administration; labelling, packaging and
nomenclature; education and communication; or use and monitoring of
treatment.
2.2.2.	 Adverse drug reactions
An adverse drug reaction (ADR) has been defined by the World Health
Organisation (WHO) as:
aAny response to a drug which is noxious, unintended and occurs at
doses used for prophylaxis, diagnosis or therapy" (World Health
Organisation, 1970).
ADRs can be separated into two categories (Rawlins and Thompson, 1991).
Type A reactions are usually predictable from the pharmacology of a drug and
are augmented responses to drugs which tend to be dose dependent. Type B
reactions are bizarre effects that are unpredictable on the basis of a drug's
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pharmacology. Type B reactions are generally unrelated to dose and although
comparatively rare, they often cause serious illness and death. They are
generally due to hypersensitivity or an 'idiosyncratic' mechanism.
2.2.3.	 Medication error and adverse drug reactions:
incidence, human and financial implications
Much of the academic literature comes from overseas and although it is
accepted that these findings can be transferred to the UK, there is relatively little
reliable information to quantify the problem of adverse events in the NHS.
Data from the Medicines Control Agency indicate nearly 10,000 hospital
patients each year have serious adverse reactions to drugs (Department of
Health, 2000d). ADRs cause significant morbidity and mortality and account for
approximately 5% of all admissions to hospital (Einarson, 1993). ADRs are
implicated in up to 17% of hospital admissions of older people (Cunningham et
a!., 1997, Mannesse eta!., 2000), and whilst in hospital up to 17% of older in-
patients experience ADRs (Mannesse eta!., 1997). Almost 7% of hospital
patients suffer serious ADRs and 0.3% suffer fatal ADRs (Lazarou et a!., 1998).
ADRs increase the length of hospital stay and costs, may result in increased
frequency of GP consultations and delay the improvement of symptoms (Audit
Commission, 2001).
Because of low reporting rates the incidence of medication errors in the NHS,
however, is unknown. There are various reasons behind under reporting, for
example, errors may be intercepted before reaching the patient and some
errors may be unnoticed. Errors, which result in harm or injury to patients, are
more likely to be reported than those where the patient has not come to any
harm. Because of the fear of discipline, there may be a tendency not to report
'near misses' or potential errors and a failure to report errors which are
considered to be 'minor'.
Retrospective studies of case records in the United States and Australia have
revealed a substantial rate of adverse events in hospital practice.
21
Brennan eta! reviewed the medical charts of 30,121 patients admitted to 51
acute care hospitals in New York state in 1984 and identified adverse events in
3.7% and, of these, 14% died (Brennan eta!., 1991, Leape eta!., 1991).
Adverse events that were due to drugs were the commonest type (19% of all
adverse events identified), occurring in 0.7% of a!! patients admitted.
In the Quality in Australian Healthcare Study, (Wilson eta!., 1995), a population
based study modelled on the Harvard study, investigators reviewed the medical
records of 14, 179 admissions to 28 hospitals in New South Wales and South
Australia in 1995. An adverse event occurred in 16.6% of admissions, half of
which were considered preventable. Of these adverse events 77% resulted in
disability that resolved within 12 months, but in 14% the disability was
permanent and in 5% the patient died; 51% of adverse events were considered
to have been preventable. Adverse events were estimated to account for 8% of
hospital bed-days and to cost the Australian healthcare system $4.7 billion a
year. The proportion of adverse events due to drugs was not reported (Wilson
eta!., 1999). In Australia the higher rate of adverse events was attributed in part
to methodological differences between the two studies but a real difference in
rates of injuries between the two populations could not be excluded (Weingart
et a!., 2000).
Similar rates to the Harvard study were found in a more recent replication of the
Harvard study in Colorado and Utah (Thomas et a!., 2000), with adverse events
occurring in 3% of hospital admissions. Adverse drug events were the leading
cause of non-operative adverse events accounting for 19% of all adverse
events. Over one third of adverse drug events were preventable and 10%
resulted in permanent disability. Preventable adverse events were more
common among elderly patients and the authors suggest this is probably
because of the complexity of their care (Thomas and Brennan, 2000).
The Harvard investigators defined adverse events stringently, using disability
and injury as prerequisites. This underestimates the error rate as many errors
don't produce injury because they are caught in time, the patient is resilient, or
because of good fortune.
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Moving beyond simply reviewing patients records, in comparison, Bates et a!
used both record review and prompted self-reports from clinicians, and found
that adverse drug events occurred among 6.5% and potential adverse drug
events occurred among 5.5% of 4031 adult patients admitted to two teaching
hospitals in Boston over a 6 month period (Bates eta!., 1995b). Of the adverse
drug events, 28% were due to errors, making the rate of serious medication
errors (that is, preventable adverse drug events plus potential adverse drug
events) 7.3%. This is a much higher rate than the 0.7% rate of the Harvard
study's review of medical records.
In a prospective study in the United States, 256 elderly patients, aged 65 years
or over, were interviewed one month after discharge, following a medical
hospitalisation (Gray eta!., 1999), 20% were found to have suffered an adverse
drug event within one month following discharge and individuals at particular
risk were those with lower cognition who were discharged with several new
medications.
A small-scale pilot study of hospital in-patients in London indicates a similar
incidence of adverse events in the UK (Vincent eta!., 2001). In their study of
over 1000 records in two acute hospitals, Vincent et a! found that almost 11 % of
patients experienced an adverse event, over half of which were deemed
preventable, adding a mean 8.5 days in hospital with additional costs of
£290,000. More worryingly, at least a third of these events led to disability or
death. 12% of adverse effects were related to medicines use. This was a pilot
study but there is no reason to believe that the results are unrepresentative and
if extrapolated to the NHS in England adverse event generate up £2 billion
direct costs per year in additional bed days. This is in addition to the costs of
litigation, staff time, impact on patients and staff, and the wider economic
consequences.
Intravenous medication errors occur frequently and are associated with
considerable harm. In a study on 10 wards in two UK hospitals, Taxis and
Barber found that errors occurred in almost half the IV drug preparations and
administrations, I % of which were severe, 29% had potentially moderate
consequences and 19% had potentially minor consequences (Taxis and Barber,
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2003). Similar rates have been reported in other studies (O'Hare eta!., 1995,
Hartley and Dhillon, 1998, Wirtz eta!., 2003).
In the US it is estimated that medication errors kill 7000 patients each year (an
equivalent figure in the UK would be 1500 deaths), and the number of deaths
because of medication errors and adverse effects of medicines used in
hospitals increased from 2,876 in 1983 to 7,391 in 1993 (Phillips DP eta!.,
1998). The Adverse Drug Event Prevention Study Group in the US reported that
1.8% of admissions result in harmful medication errors (Leape eta!., 1995).
It is claimed that there is also evidence of an upward trend in the UK and in
2000 there were nearly 1100 deaths in England and Wales due to medication
errors or adverse reactions to medicines, 5 times more than in 1990, see figure
2.1 (Audit Commission, 2001). This data is based on an analysis of International
Classification of Disease (lCD) codes. Previous reports of increases in
medication related deaths using lCD codes have been criticised due to
uncertainty of coding classification. In 1995 -1996 the ICD-9 coding system was
changed to lCD-I 0, raising the possibility that coding changes have contributed
to the observed increase in deaths (Cox and Marriott, 2002). The incidence of
ADR5 in the literature has remained fairly constant over the years which casts
further doubt on the reported surge in medication related deaths. However, lCD
codes poorly detect adverse drug events, as diagnoses may be inaccurate, and
since physicians may consider they are used only for administrative purposes,
they may be less concerned with accurate recording of lCD codes (Cox A R et
a!., 2001). It is therefore uncertain whether there has been an upward trend in
medication related deaths.
Despite the fact that ADRs account for up to 5% of hospital admissions,
estimates indicate that only 6.3% of reportable ADR5 are submitted to the
Committee of Safety of Medicines (CSM) yellow card scheme (Smith et a!.,
1996). The perceived seriousness of an ADR is one factor influencing the
decision to report, but serious well known reactions are often not reported.
Therefore the incidence of medication related deaths in the Audit Commission
report may be a severe underestimate. The true extent of medication errors
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and adverse drug events is unknown because of inadequate definitions and
different reporting arrangements. The Audit Commission reported that only one
hospital from the 26 visited had a comprehensive error and near miss reporting
system in place (Audit Commission, 2001).
The National Patient Safety Agency (NPSA), a special health authority, has
been established to collect and analyse information from NHS organisations,
assimilate data relating to patient safety from reporting systems and feedback
lessons learned into service delivery (National Patient Safety Agency 2003.
Business Plan 2003-2004.). By the end of March 2001, the Agency had
completed a study, working with 28 pilot NHS Trusts and based on the
Department of Health's guidance set out in Doing Less Harm, to test the
feasibility of collecting, recording and analysing 'near miss' and adverse incident
data that involved actual or potential harm to NHS patients. During this pilot
study 9% of incidents reported involved medicines (National Patient Safety
Agency 2003. Report of pilot data audit.).
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Figure 2.1 The number of deaths in England and Wales from medication
errors and the adverse effects of medicines, 1990 to 2000 (Source: ICD-9
and lCD-b data) (Audit Commission, 2001).
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Medication errors lead to great personal misery and injury, diminish public
confidence, and are expensive and wasteful for the National Health Service.
They are an important cause of morbidity and account for one-fifth of deaths
due to all types of adverse event in hospital (Ferner and Whittington, 1994). If a
doctor is grossly negligent and the patient dies as a result, the doctor can be
charged with manslaughter. Ferner (2000) described 17 cases involving 21
doctors accused of manslaughter after deaths due to errors in drug treatment or
anaesthesia in the UK between 1970 and 1999.
Whilst the primary concern must of course be the human cost, the financial
costs of adverse events are alarming. Litigation claims cost the NHS £400
million in 1998/1999 in addition to an estimated £2.4 billion for existing and
expected claims (Department of Health, 2000d). One-fifth of all clinical
negligence litigation stems from hospital medication errors.
Medical Defence Union data show that one-quarter of all indemnity paid out
following litigation claims after adverse events in general practice results from
medication errors. Between 1995 and 2001 the Medical Defence Union handled
216 claims against GPs that were directly related to errors in prescribing,
monitoring or administering medicines, (Medical Defence Union, 2001), and of
1000 claims to the Medical Protection Society, almost 20% arose from
medication errors (Medical Protection Society, 2001). It is estimated that
medication errors alone cost the NHS about £500 million a year in additional
days spent in hospital (Department of Health, 2001e). To this must be added
the unknown cost of errors in primary care and community care, along with
indirect costs such as those arising from litigation. The potential savings from
reducing serious medication errors are substantial (Department of Health,
2004c).
Data suggest that adverse drug events are a major international problem, with
huge human and financial implications. It is therefore vital that health care
organ isations address these avoidable failures to maxim ise patient safety and
minimise waste, and research such as this study is a prerequisite to this.
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2.2.4.	 Causes of medication errors
Humans make mistakes in healthcare as in any other field, and individuals must
sometimes be held accountable for their actions, in particular if there is
evidence of gross negligence or recklessness. In the great majority of cases
however, the causes of failures stretch far beyond the actions of individuals
immediately involved. In the complex environment of healthcare, numerous
factors contribute to failures in the service. Activity aimed at learning from and
preventing failures to improve patient safety needs to address their wider
causes.
2.2.4.1.	 Approaches to examining errors
In this section I look at some approaches to looking at the causes of errors and
classification of errors in general, in particular human error which can be viewed
using the person centred approach or the system approach, and then I discuss
the 'Swiss cheese' model of examining accidents.
2.2.4.1.1.	 Human error
Human error may sometimes be the factor that immediately precipitates a
serious failure, but there are usually deeper, systemic factors at work which if
addressed would have prevented the error or acted as a safety-net to mitigate
its consequences. There are two ways of viewing human error: the person
centred approach and the system approach (Reason, 2000).
The person centred approach remains the dominant tradition within medicine,
as elsewhere, and focuses on errors made by individuals. It centres on the
psychological precursors to errors, such as forgetfulness, inattention,
carelessness, poor motivation, negligence and recklessness. Counter-
measures are aimed at individuals rather than situations and these invariably
fall within the "control" paradigm of management. Reactions tend to be
disciplinary measures, writing more procedures to guide individual behaviour or
naming, blaming and shaming. Followers of this approach tend to treat errors as
moral issues, assuming that bad things happen to bad people, what
psychologists have called the just world hypothesis (Lerner, 1970). A serious
weakness of the person approach is that by focusing on the individual origins of
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error it isolates unsafe acts from their system context. As a result, two important
features of human error tend to be overlooked. Firstly, the best people can
make the worst mistakes - error is not the monopoly of an unfortunate few.
Secondly, far from being random, errors tend to fall into recurrent patterns. The
same set of circumstances can provoke similar errors, regardless of the people
involved (Reason, 2000). The systems approach takes a holistic approach to
failures, recognising that many of the problems facing organisations are
complex, ill-defined and result from the interaction of a number of factors. It
accepts that humans are fallible and therefore errors are inevitable, even in the
best run organisations (Kohn et a!., 2000). Errors are seen as being shaped and
'provoked' by 'upstream' factors which include the organisation's strategy, its
culture and the approach of management to risk and uncertainty.
Countermeasures are based on the assumption that though we cannot change
the human condition, we can change the conditions under which humans work
to make them less error provoking. Rather than focusing on the individual it
concentrates on how and why did the defences fail and what factors helped to
create the conditions in which the errors occurred. Understanding the factors
that contribute to errors enables system defences to be developed in order to
prevent repeated failures. This is the approach to analysing adverse events that
I will adopt in my research.
2.2.4.1.2.	 The Swiss cheese model of system accidents
NHS organisations have developed barriers, defences and safeguards to
prevent medication errors such as procedures and protocols, but these have
been shown to be inadequate at times. These defences form layers, some of
which are engineered (physical barriers, automation and alarms) others rely on
people, procedures and protocols.
In an ideal world, each defensive layer would be intact; but in reality, they are
more like slices of Swiss cheese, having many holes - though unlike in the
cheese, these holes are continually opening, shutting, and shifting their position
(Reason, 1997). The presence of holes in any one "slice" does not normally
cause a bad outcome. Usually, this can happen only when the holes in many
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layers momentarily line up to permit a trajectory of accident opportunity—
bringing hazards into damaging contact with victims, see figure 2.2.
The holes in the defences arise for two reasons: active failures and latent
conditions (Reason, 1990). Nearly all adverse events involve a combination of
these two sets of factors.
Active failures are the unsafe acts committed by people who are in direct
contact with the patient or system. They take a variety of forms: errors (slips,
lapses, fumbles and mistakes) and procedural violations, for example deviations
from safe operating practices, procedures or standards. In contrast with errors,
which arise primarily from informal problems (forgetting, inattention, etc),
violations are more often associated with motivational problems such as low
morale, poor examples from senior staff, and inadequate management
generally (Vincent eta!., 1998). An error occurs when a planned action fails to
achieve a desired outcome. Reason described two basic types of error
(Reason, 1990).
• Slips and lapses, where the actions do not go according to plan, for
example: omitting to administer a prescribed drug to a hospital patient,
intending to write a prescription for 100mg of a drug but writing 300mg
instead, picking up the wrong syringe. Slips and lapses are more likely in
the presence of tiredness, interruptions, and distraction by competing
tasks, all of which are inevitable in clinical practice.
• Mistakes, where the plan itself is inadequate to achieve its objectives,
for example: failing to prescribe a drug that is indicated in a patient,
writing a prescription for 300mg of a drug not knowing that the usual
dose is 100mg (Department of Health, 2004c). Mistakes particularly arise
when a task is unfamiliar or where there is insufficient information to
formulate an analytical solution.
Active failures have an immediate and usually short-lived effect on the
defensive layers.
Latent conditions are comparable to "resident pathogens" within the system.
They arise from decisions made by designers, builders, procedure writers, and
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top-level management. All such strategic decisions have the potential for
introducing pathogens into the system. Latent conditions have two kinds of
adverse effect: they can translate into error provoking conditions within the local
workplace, (for example, time pressure, understaffing, inadequate equipment,
fatigue, and inexperience) and they can create long lasting holes or
weaknesses in the defences (for example, untrustworthy alarms and indicators,
unworkable procedures, design and construction deficiencies, etc). Latent
conditions may lie dormant within the system for many years before they
combine with active failures and local triggers to create an accident opportunity.
Unlike active failures whose precise forms are hard to predict, latent conditions
are always present and they can be identified and remedied before an adverse
event occurs.To use another analogy, active failures are like mosquitoes. They
can be swatted one by one, but they still keep coming. The best remedies are to
create more effective defences and to drain the swamps in which they breed.
The swamps, in this case, are the ever present latent conditions (Reason,
2000). Figure 2.3 illustrates the anatomy of an organisational accident
according to this scheme of active and latent failures. The accident sequence
begins with the negative consequences of management decisions and
organisational processes (Reason, 1995). The latent failures thus created are
transmitted along various organisational and departmental pathways to the work
place (operating theatre, ward) where they create the local conditions that
precipitate errors and violations. The model represents the people who are
directly involved as the inheritors rather than the instigators of an accident
sequence, though this does not necessarily imply that blame is "upstream".
In health care there can be relatively few protective layers separating danger
from harm, and human elements are often the last and most important
defences.
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Figure 2.2 The "Swiss cheese" model of accident causation (Reason,
1997)
(eg mistakes, procedural violations)	 Hazards
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Successive layers of defences, barriers and safeguards
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Figure 2.3 Organisational accident model based on work by reason
(Reason, 1990).
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Adverse medication events can occur at all stages of the medication process
from prescribing, to dispensing and administration, and I review each of these
three stages now, along with risks in specific patient groups.
2.2.4.2.	 Prescribing errors
The most frequent and probably the most serious medication errors occur in
prescribing, (Bates eta!., 1995a), such as selecting the wrong drug, dose,
route, form or frequency (Leape eta!., 1995, Leser eta!., 1990, Lesar eta!.,
1997). Errors occur in up to 1.5% of hospital prescriptions, (Dean eta!., 2002),
and in primary care errors occur in up to 11% of prescriptions (Sanders and
33
Esmail, 2003). If undetected, prescribing errors will be systematically applied
and can result in significant harm or death.
The following definition of a prescribing error has been adopted by a recent UK
report (Dean eta!., 2000):
"A clinically meaningful prescribing error occurs when, as a result of a
prescribing decision or a prescription writing process, there is an
unintentional significant reduction in the probability of treatment being
timely and effective or increase in the risk of hairn when compared with
generally accepted practice."
Prescribing errors occur for many reasons including inadequate knowledge of
the patient and their clinical condition, inadequate knowledge of the drug,
calculation errors, illegible handwriting, drug name confusion, use of
abbreviations, dosage formulation, zeros and decimal points, unusual routes of
administration, uncommon and/or complicated dosage regimens, repeat
prescribing and poor history taking (Department of Health, 2004c).
In a study at a 550 bed teaching hospital within the UK, pharmacists
prospectively identified 88 potentially serious prescribing errors in a 2 month
period (Dean et a!., 2002a). The hospital operates a ward pharmacy service
whereby pharmacists routinely examine drug charts to check that medication
orders are clear, legal and clinically appropriate. Prescribers who made 44 of
the mistakes were interviewed to assess reasons for the errors and a
questionnaire was used to investigate the factors which may have contributed to
the error. Human error theory was used to analyse the findings (Reason, 1990).
Most mistakes were made because of slips in attention, or because prescribers
did not apply relevant rules (the active failures). Risk factors or error-producing
conditions include work environment, workload, whether or not doctors were
prescribing for their own patient, communication with the team, physical and
mental well-being and lack of knowledge. Organisational factors or the latent
conditions which were also identified included inadequate training, low
perceived importance of prescribing, a hierarchical medical team and an
absence of self-awareness of errors.
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The absolute frequency of prescribing errors leading to patient harm is not
known. Almost all studies have involved detection of errors by pharmacists, and
avoidance of harm to patients. In one UK hospital, potentially serious errors
which were identified and averted by pharmacists, occurred in 0.4% of
prescriptions. The majority of errors (54%) were associated with the choice of
dose and most serious errors originated in the prescribing decision. This is an
example of a 'mistake' type of active failure (Dean et al 2002b).
2.2.4.3.	 Dispensing errors
Data from hospitals suggest that dispensing errors occur less frequently than
prescribing errors, but can cause serious harm to patients (Spencer and Smith,
1993). Predisposing factors for dispensing errors include: drug name confusion
and transcription errors, 'mistake' types of active failure; and inexperienced
staff, low staffing, and high workload which are latent conditions. Other causes
include: failure to clarify an ambiguous or badly written prescription or applying
an incorrect dispensing label, 'lapse' types of active failure; and similar
packaging and lack of check by a second person which are latent conditions.
The ten drugs most commonly involved in dispensing errors from the UK
Dispensing Error Analysis Scheme are prednisolone, MST, isosorbide
mononitrate, warfarin, aspirin, lisinopril, carbamazepine, diclofenac, co-codamol
and flucloxacillin (Department of Health, 2004c). Dispensing errors involving
prednisolone, warfarin, lisinopril, morphine and carbamazepine are known to
have caused serious harm to patients. Drugs less commonly involved in
dispensing errors, but nevertheless occasionally causing serious patient harm
include; ciclosporin, digoxin, methotrexate and tramadol.
Pharmacists sometimes need to compound medicines from a formula, and
some serious errors have occurred in extemporaneous dispensing.
2.2.4.4.	 Administration errors
About 80% of medicines are prescribed and dispensed in primary care and are
taken by patients in their own homes or care homes. In hospitals medicines are
administered sometimes by doctors but more commonly by nurses. There is
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also a growing trend for patients to self-administer medicines in hospital, if
appropriate.
An administration error has been broadly defined as:
"any discrepancy between the intentions of the prescriber and the
treatment actually received by the patient."
(Department of Health, 2004c).
A failure at any point in the medication process from prescribing to
administration may cause a drug administration error. In UK hospitals
administration errors occur in approximately 5% of medicine doses due, (Barber
and Dean, 1998), however the majority of these are not harmful, typically
involving missed or delayed doses. Most studies have been limited to oral drug
administration and have used small sample sizes. Most research on drug
administration errors has been carried out in secondary care. The rates of
administration errors in primary care and community healthcare settings are not
known.
Many types of administration error may occur (American Society of Health-
System Pharmacists, 1982), for example: doses incorrectly omitted; incorrect
drug, dose, dosage form given; drug given at the wrong time or by the wrong
route; administration of drugs with compromised physical or chemical integrity;
incorrect infusion rate; inappropriate technique of administration; incorrect
reconstitution of drug prior to administration; and accidental duplication of dose
administration.
Poorly handwritten prescriptions, verbal orders, transcription errors and
inadequate labelling are frequent causes of drug administration errors
(Department of Health, 2004c). Other common causes are drug name
confusion, equipment failure or malfunction, inaccurate dose calculation,
inadequately trained personnel and abbreviations (ASHP report, 1993).
Personal factors such as lack of knowledge, fatigue, stress and distractions also
contribute to administration errors.
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Drugs given by the intravenous route have the greatest potential for harm if
given incorrectly (Department of Health, 2004c). The Department of Health has
made this type of error one of its prime targets in increasing patient safety.
Preparation of injectable drugs is frequently associated with medication errors
such as (Clinical Resource and Audit Group, 2002): incorrect dose calculation,
selection of the wrong drug or diluent, mislabelling of syringes, incorrect method
of preparation, incompatibility of constituents, instability of final product and
microbial or particulate contamination. The risk of error may be increased when
drugs are prepared in busy, cluttered clinical rooms.
For oral drug administration, the most common type of error is omission (Barber
and Dean, 1998). High rates of dose omission may be due to hospital drug
distribution systems being unresponsive to clinical demands. The time delay
between a prescription being written and the medication arriving on the ward
can lead to missed doses especially when drugs are prescribed outside
pharmacy opening hours. Up to half of all inpatient prescriptions are written
outside traditional weekday pharmacy opening hours (Audit Commission, 2001).
2.2.4.5.	 Specific patient groups
In this section I discuss the risks of adverse drug events in specific patient
groups, specifically for patients with allergies, seriously ill patients and children
and then relate this to my proposed study.
2.2.4.5.1.	 Medicines use in people with allergies
Serious harm has occurred when patients have been prescribed drugs to which
they have a pie-existing allergy. Blood products, vaccines, antibiotics, aspirin,
and other non-steroidal anti-inflammatory drugs (NSAID5), heparin, muscle
relaxants used in anaesthetics and many other drugs have the potential to
cause anaphylaxis in susceptible individuals.
25 of 234 claims to the Medical Defence Union by hospital doctors, (Medical
Defence Union, 2001), and 11 of 193 claims to the Medical Protection Society
by General Practitioners (Medical Protection Society, 2001), involved allergic
drug interactions.
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Inadvertent prescribing and administration of medicines where the patient has a
documented allergy may be a result of the allergy history of the patient not
being available at the time of prescribing, or a lack of prominent information
within the prescribing system. Even when the allergy status of a patient has
been available, patients may be given a combination product containing a
contraindicated medicine, where both the prescriber and the person
administering the drug were unaware of the constituents of the product
(Department of Health, 2004c). This occurred when a 63 year old woman
recovering from a hysterectomy died after receiving a dose of intravenous
penicillin. She was documented to have an allergy to penicillin on the front of
her medical notes, although the prescribing doctor had not seen this warning
when the prescription was signed. She was also wearing a red wrist-band
labelled "penicillin sensitive". She was given Augmentin®, a proprietary product
which contains amoxicillin (BBC news online, 2000).
2.2.4.5.2.	 Medicines use in seriously ill patients
Complex drug treatment regimens in the seriously ill patient greatly increases
the risk of medication errors, especially drug administration by the wrong route.
Giving a drug by the wrong route has been shown to be a frequent
administration error in studies from America and Europe (Department of Health,
2004c).
The United States FDA reported that wrong route accidents caused 12% of
fatal medication errors. A review of 469 medication error related deaths
reported to the US FDA between 1993 and 1998 identified giving the drug by
the incorrect route as the third most prevalent type of error, involving 57
patients. 14 patients died as a result of an intravenous drug being administered
intrathecally, eight deaths were associated with an oral product being given
intravenously, four patients die as a result of an intramuscular injection being
given intravenously and one died as a result of an IV injection being given
intramuscularly. 30 other wrong route incidents were not categorised further
(Phillips eta!., 2001).
Intrathecal maladministration of drugs that should instead have been
administered by the intravenous route is a rare, but always very serious,
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medical accident. Since 1985, 13 such accidents have been reported in medical
literature or to the Committee on Safety of Medicines, but it is not known
whether there are any more than this because no comprehensive central record
is kept of such adverse events (Department of Health, 2000d). Of the 13
documented accidents, 12 involved intrathecal injection of a ymca alkaloid
(vinblastine, vincristine, and vindesine). These drugs are strongly neurotoxic
and can kill if incorrectly administered. They can be administered by the
intravenous route, but are fatal if injected into the spine.
2.2.4.5.3.	 Medicines use in children
A medication error in a child may be more serious than the same error in an
adult. Drug dosing for children can be complex because of the need for
additional calculations based on weight or surface area, and because of
variations in metabolism. Errors in prescribing for children often occur because
of poor handwriting, misplaced decimal points and calculation errors. Despite
widespread awareness of the risk, decimal point errors involving potent drugs
such as digoxin and opiates continue to occur and can be fatal.
2.2.4.5.4.	 Summary
As I have described, adverse drug events represent a particular challenge in
specific patient groups. Patients are susceptible to serious harm if they are
prescribed a drug to which they are allergic. Many commonly prescribed drugs
can cause anaphylaxis in vulnerable people. In my research, I will examine
recording of allergy status and the attitudes of medical staff towards this.
Seriously ill patients are also at greater risk of medication errors and as these
patients are often cared for on general medical wards, this is of particular
relevance. Children are also particularly vulnerable to medication errors
although I will not examine this. Older people tend to use more medicines
(Department of Health, 2001a), and for this reason, they are clearly at an
increased risk of adverse drug events. This, coupled with multiple pathologies
and an age related altered capacity to handle medicines makes this patient
group particularly susceptible. This is one of the reasons that older people were
selected as the target population within this study.
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2.2.5.	 Learning from failure
Human error may be the factor that immediately precipitates a serious failure
but there are usually deeper, systemic factors at work which if addressed would
have prevented the error or acted as a safety net to mitigate its consequences
(Department of Health, 2000d). Activity to learn from and prevent failures must
therefore address their wider causes. Changing behaviour towards safer care
comes about through learning at the level of the individual health professional,
at the organisational systems level, and at points in between (Firth-Cozens,
2001).
To ensure lessons are embedded in practice, activity must stretch beyond
simply diagnosing and publicising lessons from incidents. Within the NHS
learning from incidents is often passive, i.e. valid lessons have been drawn from
experience, but they have not been fully implemented. It is only through active
learning, where lessons are embedded into an organisation's culture and
practices, that the benefits of experience are actually realised. For example
when prescribing errors occur, the emphasis should not be on simply identifying
and exposing, but the actual underlying factors, which precipitate such errors,
should also be investigated. Once lessons have been drawn from errors, efforts
to change culture must be made, rather than merely advertising the issues in
the hope that individuals will alter their behaviour.
In this section I will discuss the actual process of organisational learning with
reference to the learning cycle. I then go on to discuss barriers to learning from
failure and ways in which these can be overcome.
2.2.5.1.	 The learning loop
Organisational learning is a cyclical process, the key components of which can
be described with reference to an approach which has been adapted from a
model used by British Petroleum (Department of Health, 2000d), (figure 2.4).
The first half of the learning cycle is concerned with identification of learning
opportunities and development of sound solutions. This involves monitoring of
service delivery activity, including adverse events and the experience of others.
Once potential and actual risks have been identified, they must be properly
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analysed to identify lessons for policy and practice. Lessons need to be distilled
to make sure the essence of the learning points is properly captured, and their
validity tested in theory or practice.
The second part of the learning process is to make sure that the sound
solutions are put into practice. Learning points need to be translated into
practical policies and actions that can be implemented at the appropriate level.
Action to implement and apply improvements on the ground is an essential part
of the learning process. Lessons can be 'learned' on one level, in that there is a
strong awareness of what needs to change and why, but if there are barriers in
place to the application of that learning in practice the active learning process
will fail. To sustain long-term change solutions also need to be firmly embedded
into the culture and routine practice of the organisation. Finally, continuous
monitoring of changes and improvements in practice is an essential part of
ongoing learning and improvement.
It is at the stages of implementation and embedding that the learning loop often
seems to fracture. There is much literature with examples from a range of
different sectors where lessons had been clearly and correctly drawn from
experience, but for one reason or another these lessons had not been
translated into effective organisational learning.
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Figure 2.4 The Learning Cycle
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2.2.5.2.	 Barriers to learning
In general, individuals learn from their mistakes because they cause them
emotional pain, but often those around them fail to do so. Even when
individuals learn from mistakes, what they learn may not always be useful.
Focussing on individuals makes it harder for systems to learn, to spread the
impact of events or accidents beyond their immediate environment. A number of
'barriers to learning' have been identified (Smith and Elliot, 1999, Toft and
Reynolds, 1997, Firth-Cozens, 2001).
An undue focus on the immediate event rather than on the root causes of
problems, allocating responsibility at the sharp end of care where the health
professional and patient interact often occurs. Organisations tend to latch onto
one superficial cause or learning point to the exclusion of more fundamental but
sometimes less obvious lessons. Core beliefs, values and assumptions often
develop over time and any learning that contradicts these is restricted.
Organisational learning often fails to occur because of bureaucracy, a lack of
clear purpose or feedback mechanisms, ineffective communication and other
information difficulties, cultural issues around a lack of openness, centralised
authority and blame where errors are seen as indicating competence.
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Pride in individual and organisational expertise can lead to denial and to a
disregard of external sources of warning, particularly if a bearer of bad news
lacks legitimacy in the eyes of the individuals, teams or organisations in
question. Human alliances lead people to "forgive" other team members their
mistakes and act defensively against ideas from outside the team. High stress
and low job-satisfaction can have adverse effects on quality and can also
engender a resistance to change. A failure to acknowledge the real emotional
context of healthcare and high stress levels is likely to make any attempts at
real cultural change impossible. The sheer size and complexity of healthcare
organisations means they do not lend themselves well to attempts to intervene
directly at the organisational level and often through the inability to recognise
the financial costs of failure, a powerful incentive for organisations to change is
lost. Overcoming barriers to learning and creating an informed culture
In her review of the literature on teams, culture and managing risk, Jenny Firth-
Cozen suggests a number of ways in which the barriers to active learning can
be overcome or minimised (Firth-Cozens, 2001). Raising awareness of the
costs of not taking risk seriously with more routinely available data on the
human and financial costs of adverse events encourages active learning. By
focusing on "near misses" as well as actual incidents the emotion from an
incident can be removed which allows learning to take place more effectively. It
is also easier to keep near miss data anonymous, itself a factor in encouraging
reporting. Bearers of bad news may fear that they will be ostracised or silenced,
therefore ensuring that concerns can be reported without fear, with clear rules
about what must be reported, and regarding reporting as good behaviour rather
than as disloyalty will all help. A systems approach to risk is essential in terms
of cultural change in that it has the effect of spreading responsibility throughout
all levels of the organ isation. So long as the acceptance of responsibility at
managerial level is communicated and seen to be taken seriously, this will help
negate an authoritarian top down culture. Just as importantly, this sharing of
responsibility will reduce the level of emotional response that takes place at the
sharp end, which should allow learning to take place more readily and more
appropriately.
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Effectively-led teams are effective mechanisms for culture change. Teams need
to be firmly linked into the wider management structure to ensure that alliances
within them do not hamper learning. Team-based training can also be a useful
tool here and using external input to stimulate learning. External input can help
teams to think outside established parameters and challenge assumptions
about the way things are done and user involvement can be of particular value
in encouraging learning. Team should ensure that they are able to hear the
voices of those staff with the most experience of what can go or has gone
wrong in patient care, whether or not they are of lower rank than their
colleagues.
It is essential to give a high-profile lead on the issue and it should be made
clear both nationally and locally that safety and quality are key goals. Staff
concerns should also be recognised with emphasise placed on the personal
and service benefits of change rather than just the threats.
2.2.5.3.	 Summary
In this section I have discussed the importance of actively learning from failures.
The learning cycle begins with identification of risks and identifying lessons for
practice, then making sure that the solutions are put into place, then continuous
monitoring of changes. This can be applied directly to my research, as I intend
to examine current services and then develop solutions to improve care. I have
described barriers to learning, which include focussing on individual events
rather than the problems within systems, lack of feedback systems, ineffective
communication and defensive athtudes within teams. Knowledge of these
barriers and how to overcome them will be of particular importance in
attempting to change practice within and beyond this study setting. In particular,
focussing on teams as effective change agents will be important.
2.2.6. Improving patient safety
The chief medical officer's report An Organisation with a Memory reviewed the
scale and nature of serious failures in NHS health care and specifically how the
NHS can learn from such failures to make patient care safer in the future
(Department of Health, 2000d). The report stated that there has been no
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reliable system for learning from adverse events and service failures and
introducing change to prevent similar events recurring. As a result, patients
suffer unnecessary and avoidable harm because lessons from past experience
have not been learned and specific serious errors can be repeated a number of
times over a period of years. The repeated erroneous spinal administration of
ymca alkaloids (Department of Health, April 2001), is the most striking example
although similar pafterns are seen with other medicines such as overdoses of
methotrexate (Cambridgeshire Health Authority, July 2000), and opiate
analgesics. Other examples include children being given incorrect dosages due
to calculation errors, administration errors and incidents following failures in
communication (Department of Health, 2004c).
An organisation with a Memoiy identified various barriers to active learning
within the NHS and made a number of recommendations (Department of
Health, 2000d), in particular:
• introduction of unified mechanisms for reporting and analysis of adverse
events and near misses
• encouraging a more open and questioning culture in which errors or service
failures can be reported and discussed
developing mechanisms for ensuring that lessons learned actually changes
practice
developing a wider appreciation of the value of the system approach to
preventing errors.
In May 2001, Building a Safer NHS for patients took forward the Government's
plans for improving patient safety, which included the specific commitment to
reduce by 40% the number of serious errors in the use of prescribed drugs by
2005 (Department of Health, 2001e), and to reduce to zero the number of
patients dying or being paralysed by maladministration of spinal injections. In
November 2001, the Department of Health issued mandatory national guidance
for safe administration of intrathecal chemotherapy and updated this in October
2003 (Department of Health, November 2001, Department of Health, October
2003).
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Medication errors are an early priority of the NPSA and in early 2004 the Health
Minister launched a national reporting and learning system (NRLS) to enable
the NHS to report all types of adverse events and near misses, including
medication errors. The core purpose is to improve patient safety and the NPSA
has four major roles:
• collect and analyse information,
• assimilate other safety-related information from a variety of existing
reporting systems,
• learn lessons and ensure they are fed back,
• where risks are identified, produce solutions, specify national goals and
establish mechanisms to track progress.
By December 2004 the NPSA hit its deadline that 607 NHS organisations can
report to the NRLS and 90% of organisations are reporting through this route.
From its pilot data audit, 33 adverse events involving intravenous potassium
solution were reported and a Patient Safety Alert to raise awareness of risks
and safety precautions associated with concentrated potassium solutions has
subsequently been issued (National Patient Safety Agency 2003. Report of pilot
data audit.).
The Government's overarching aim is to embed a culture of safety within the
NHS and ensuring that drug treatment is safe is central to this. The recent
report, 'Building a safer NHS for patients: improving medication safety'
(Department of Health, 2004c), addresses this aim, providing guidance for
health professionals and NHS organisations. The report provides specific
guidance to improve safety at all stages of the medication process, for example
active management and review of long-term repeat prescribing; clear treatment
plan; shared with all health professionals involved in the patient's care;
appropriate training for all staff involved in the handling of medication;
discussing medication with patients at the time of administration; and clear
procedures for the documentation of allergies. The report also stresses the
need for accurate information about current drug therapy on admission to
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hospital and timely and reliable communication following discharge. Staff should
ensure patients understand their discharge medicines and can take them
properly. The report highlights that training of undergraduates in pharmacology
and therapeutics should be strengthened where appropriate. Primary Care
Trusts and NHS Trust boards are told they should ensure strategies are in place
for reporting and learning from medication errors and building error traps into
medication processes.
2.2.7.	 Summary
In this section I have discussed some of the problems that are encountered in
the use of medicines, specifically medication errors and adverse drug reactions.
In section 2.2.3 I talked about the scale of the problem of adverse events in the
UK and overseas, and the consequences for individuals and organisations. This
is very relevant, as I will be recording and analysing any adverse events I
encounter throughout the course of my study and obtaining the views of health
care workers and patients.
In section 2.2.4 I discussed the causes of adverse drug events, and different
methods of examining errors, initially looking at human error using the person
centred approach, which focuses on blaming individuals, and then the systems
approach, which focuses on organisational factors shaping and provoking
errors. This is particularly pertinent to my work facilitating my understanding of
the factors that contribute to adverse events in order to suggest safer systems. I
described the Swiss cheese model of accidents, whereby defence layers in
organisations, such as procedures and protocols have many 'holes' which are
continually shifting and only when the holes in many layers momentarily line up,
can an accident occur. This will relate to my work as I will be investigating many
aspects of medicines use within the study Trust, examining potential problem
areas and 'holes', in order to minimise risk to patients. I talked about active
failures and latent conditions causing 'holes' in defences and will find this
helpful in identifying error-provoking conditions. I will concentrate more on
examining latent conditions, rather than active failures which focus more on
individual mistakes rather than the underlying problems.
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I showed that prescribing errors are the most frequent and probably most
serious type of error, with dispensing errors occurring less frequently, but
administration errors can occur more often. My work will therefore concentrate
on prescribing and administration of medication, and my attention has been
drawn to how errors occur in these activities.
I then went on to discuss the challenge adverse drug events represent in
specific patient groups, particularly patients with allergies, seriously ill patients,
children and older people. My work is predominantly in a general medical
setting, so I will encounter many of these high-risk patients.
In section 2.2.5 I considered some of the factors that influence the ability of
organisations to learn from failure and talked about the learning loop, barriers to
learning and how these may be overcome. This will be very relevant to my
work, as it will allow me to suggest more successful strategies to learn from any
issues identified in the project.
Finally, in section 2.2.6 I described what the Government are doing to improve
patient safety, referring to several recent documents, and outlining the work of
the NPSA. This is of course very relevant to my work as improving patient
safety is a key objective of this study.
2.3.	 HEALTH CARE PROFESSIONALS' COMPETENCY IN
THERAPEUTICS
In this section I discuss the challenges facing health care professionals in the
management of therapeutics. I examine health care professionals' knowledge of
and competency in therapeutics, focusing in section 2.3.1. on the training of
doctors, specifically, undergraduate medical students in section 2.3.1.2, and
postgraduate medical training in section 2.3.1.2. In section 2.3.3. I discuss the
roles and responsibilities nurses have in therapeutics for example
administration of medicines and more recently prescribing. I examine the pie
and post-registration training of nurses and their competency to undertake
these roles. I then consider and contrast the training pharmacists receive in
therapeutics in section 2.3.4, and finally in section 2.3.5. I explore the concept
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of a shared approach to learning between professionals as a more appropriate
preparation for the teamwork that is required in the real world.
Prescribing, dispensing and administration of medicines are complex and skilled
tasks. Health care professionals need to understand the actions, indications and
contraindications, doses and adverse effects of drugs. In the UK, most of the
initial assessment and treatment of acutely ill patients is provided by trainee
doctors. However deficiencies in trainees' knowledge, skills and athtudes have
been identified (Rolfe and Harper, 1995, Montgomery eta!., 1994, David and
Prior-Willeard, 1993, Gould eta!., 1994, Teahon and Bateman, 1993, Smith and
Poplett, 2002), and these have the potential to influence patient outcome and
contribute to the high level of clinical error in the NHS. Undergraduate
programmes do not always adequately develop the knowledge or skills needed
for safe medicines practice (Department of Health, 2004c). Concerns have
recently been expressed that the core curricula at medical schools do not
provide a thorough knowledge of safe medicines prescribing and administration
(Department of Health, April 2001). More recently, the Audit Commission report
"A Spoonfu! of Sugar" highlighted concerns that most junior doctors working in
NHS hospitals feel they do not receive adequate training and support to enable
them to deal with medicines (Audit Commission, 2001). The report raised
concern that current undergraduate medical courses "do not provide a thorough
knowledge of safe medicines prescribing and administration" for junior doctors.
A recent review (Barber eta!., 2003), highlighted the "poverty of teaching
medical students about therapeutics in general and prescribing in particular."
Nurses perform many roles which require knowledge about medications.
Deficiencies in pharmacology teaching in nurse education have also been
highlighted and theory-practice gaps identified (King, 2004).
2.3.1.	 Training of doctors in therapeutics
In this section I discuss the training of undergraduate medical students, in
particular the manner in which the undergraduate curriculum has developed
with respect to therapeutics, and deficiencies that have been highlighted by
doctors themselves. I then move on to discuss post-graduate training, in
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particular outlining the three training grades in the UK: pre-registration house
officer (PRHO), senior house officer (SHO) and specialist registrar grade (SpR).
2.3.1.1.	 Undergraduate medical training
It is essential for patient safety and to ensure high quality patient care that the
undergraduate curriculum provides a good understanding of the clinical
pharmacology of common drugs in therapeutic use, including contraindications,
drug interactions and toxicities (Maxwell et a!., 2002). The current shortcomings
in education for medical students about therapeutics and prescribing have been
highlighted by health professionals themselves (Maxwell and Walley, 2003,
Rawlins, 2003). Tomorrow's Doctors published in 1993 (General Medical
Council, 1993), by the General Medical Council (GMC) outlined core
recommendations for the undergraduate curriculum, emphasising closer
integration between subjects, reduced factual burden, greater student choice
and problem based learning. Whilst this changed undergraduate education for
the better in many ways, individual disciplines were marginalised, such as
clinical pharmacology and therapeutics that teach skills that all doctors require.
These recommendations have recently been updated (General Medical Council,
2003), and although the council highlight the management of disease and use
of drugs as key learning objectives, little specific guidance is offered. The GMC
state that graduates must know about and understand the principles of
treatment. This should include, for example, the effective and safe use of
medicines as a basis for prescribing, including side effects, harmful interactions,
antibiotic resistance and genetic indicators of the appropriateness of drugs, how
to evaluate effectiveness against evidence, and how to take account of patients'
own views and beliefs when suggesting treatment options. However, few
courses ensure that undergraduates are taught and tested on how to prescribe
and give drugs safely (Maxwell et a!., 2002).
Whilst drugs are prescribed predominantly by doctors in the UK, prescribing
rights are now being extended to other health professionals. Current
programmes for training nurse and pharmacist prescribers (35 days of theory,
and two months' supervised prescribing) are a stark contrast to the training
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doctors receive for prescribing, and might be looked upon enviously by medical
students.
The study cited in section 2.2.4.3. in which doctors who had made serious
prescribing errors (most of which were inappropriate choice of dose) were
interviewed, lack of knowledge about prescribing was identified as a key factor
(Dean eta!., 2002). Some doctors said that they don't learn about doses at
medical school. Learning about how to choose the dose seems to fall into a
chasm between medical school and employment.
Medical students also have expressed concerns about their training in
therapeutics and competency to prescribe and administer drugs (Ellis, 2002). In
a letter to the British Medical Journal a medical student expresses her worry at
the prospect of prescribing. 'Where's my teaching on this (prescribing)? ! had a
series of !ectures at the end of the second year that probably amounted to
about eight hours." She also expresses concern about the supervision she will
receive as a pre-registration house officer (PRHO), "From what I have seen,
house officers are generally left to get on with it on their own."
In a study utilizing ratings of graduates on how well prepared for the role they
are carrying out, Clack identified deficiencies in aspects of training in medicine
and concluded that undergraduate skills may not adequately prepare students
for their PRHO year (Clack, 1994). Particular deficiencies highlighted included
clinical pharmacology and medical ethics.
A study in Manchester used questionnaires to examine and compare the
perceptions of graduates and educational supervisors concerning how well
prepared graduates were for their first post (Jones eta!., 2001). Respondents
were asked to rate how well prepared they were for a list of broad areas of
competence, on a five point scale, with 'very well prepared/competent' and 'not
very well prepared/competent' as the range; the mid-point label was 'quite well
prepared/competent'. Of the 18 broad areas of competence listed, only four
were rated more than 'quite well prepared' by at least 50% of the graduates.
Rating was similar for the educational supervisors. Nearly one third of
graduates rated themselves at less than the mid-point for diagnosis, decision
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making and provision of treatment including prescribing and only one quarter
felt their course had prepared them well in understanding the principles of
evidence based medicine. In rating their competence for specific tasks, 58%
rated themselves at less than the midpoint for writing a prescription, and 60% at
less than the midpoint for calculating drug dosages. Amongst qualitative
responses, several comments from graduates related specifically to preparation
for administering drugs to patients:
"I was the last of the year that studies the old course and don't feel it
provided adequate training of the essential, but perhaps mundane, duties
that form the majority of a house officer's workload, e.g. fluid prescriptions
and treating electrolyte levels/disturbances and pain control/managing
nausea."
A general comment from a supervisor was:
"The undergraduate course does not prepare one for the practical day-to-
day aspects of the PRHO job, e.g. prescribing medications, commencing
IV antibiotics, setting up a drip. The 'bread and butter' of the job!"
Doctors should be competent to prescribe before they start doing so and their
competence should be demonstrable (Barber et al., 2003). Students should
demonstrate their competence by being given the drug charts and medical
records for several patients and checking the prescribing for appropriateness.
Doctors should then be asked to prescribe new drugs for these patients.
2.3.1.2.	 Postgraduate medical training
In the UK, each stage of medical training is managed by a variety of
professional, managerial and educational bodies, making it more difficult to
improve clinical education. Postgraduate training involves a series of stand
alone, or loosely linked appointments across three training grades (Parsell,
2001, Calman et al., 1999), PRHO, SHO and a new specialist registrar grade
(SpR) which has recently been introduced to higher specialist training, see
figure 2.5.
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Figure 2.5 Outline of postgraduate training in the UK
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In 1997, the GMC outlined central requirements to improve PRHO training in its
report The New Doctor (General Medical Council, 1997), and this was reviewed
in 2002 (General Medical Council, 2002). The revised draft of The New Doctor
is couched in terms of 'outcomes' rather than 'experience'. A two-year
Foundation Programme has recently been introduced which encompasses the
PRHO year and the first year of SHO training (Departments of Health in
England et a!., 2003). At the end of the first year of the Foundation Programme
PRHOs must demonstrate that they can achieve the outcomes set out in The
New Doctor required for full registration. The second year will aim to instil
doctors with basic practical skills and competencies in medicine.
The Academy of Medical Royal Colleges recommended improvements to the
SHO grade (Academy of Medical Royal Colleges, 1996), and the GMC
emphasised the need for structured training and supervision in its report The
Early Years (General Medical Council, 1998). In both reports, the GMC stresses
that good prescribing practice, acute and chronic pain relief, the principles of
evidence based practice and assessing the quality of care should be covered
through in-house service training and where appropriate educational sessions.
To comply with European law regarding specialist training and registration, the
Joint Committees responsible for Higher Specialist Training in the UK have
drawn up detailed curricula for specialist registrars training in each discipline
(Mucklow, 1998). However, although prescribing will appear in the Training
Record for trainees in medical specialties as a generic skill requiring
endorsement from the educational supervisor, specific mention of the principles
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and practice of drug therapy is not at all universal among the specialist
curricula. Trained specialists will have fulfilled requirements for certification in
their chosen field and training will include knowledge of how to use drugs in the
management of conditions presenting to the specialist, but may not cover the
many other drugs that patients are taking which are not related to the
presenting complaint.
Research has suggested that junior doctors' 'on the job' education and training
can vary in quality and quantity (Wilton, 1995, Wilson, 1993, Bogg eta!., 2001).
The proportion of time spent in formal training is equally variable, and in some
studies it was reported as less than 1 hour a week, (Wilton, 1995, Wilson,
1993), with teaching duties being delegated to junior or appropriate non-medical
staff (Wilton, 1995).
A study in which PRHOs perceptions of work role, job requirements and mental
health were explored by use of questionnaires (n = 56) including a diary of
activities and interviews with randomly selected participants (n = 18), found that
the average weekly proportion of time spent on organised continuing education
was 5% (Bogg eta!., 2001). One-fifth of PRHO time was spent on routine
administrative tasks, perceived as lacking in training or educational elements.
Problems relating to senior house officer (SHO) education and training, for
example poor supervision, unstructured education, inadequate careers advice,
minimal assessment, poor working conditions and difficulty obtaining study
leave have also been documented over several years (Grant eta!., 1989,
Standard Committee on Post-graduate Medical Education, 1991, COPMED and
UK Conference of Deans, 1995).
In 1996 a survey of senior house officers and registrars about the educational
and training components of their posts found that, over-all, one-third of doctors
thought that their training was inadequate and three-quarters wanted a greater
amount of formal education (Panayiotou and Fotherby, 1996). The majority of
doctors time was spent on routine work and most considered that training
constituted less than 10% of their working time.
54
2.3.1.3.	 Summary
In this section I have discussed the knowledge and skills that doctors require to
manage therapeutics safe and effectively, and the training they receive from
undergraduate, through to postgraduate level. Undergraduate training in
therapeutics is clearly lacking and medical students and graduates have
concerns about their competency to prescribe and administer drugs. Similarly,
postgraduate training, despite recent reforms, remains variable. I will be
exploring the competency in therapeutics of doctors in my study.
2.3.2.	 Nurse training in therapeutics
Nurses in the UK are accountable to the nursing and Midwifery Council, and are
guided by government policies. The 'Code of Professional Conduct' (Nursing
and Midwifery Council, 2002a), states that nurses should acknowledge any
limitations, and if necessary improve levels of knowledge and competence, as
they are accountable for their practice. In 'Guidelines for the Administration of
Medicines' (Nursing and Midwifery Council, 2002b), it is emphasised that
nurses administering medication must exercise professional judgement and
apply knowledge and skill. They must know the therapeutic uses, normal
dosage, side effects, precautions, and contraindications of the drug to be
administered.
In 'Making a Difference' (Department of Health, 199gb), the government has
highlighted changes in the context of nursing, including the extension of nurses'
prescribing rights, and it has stated that by 2004 the majority of nurses should
be able to prescribe. (Department of Health, 2001b).
The Government has moved rapidly to extend prescribing by nurses,
pharmacists and other health professionals. The aim is to improve access to
care, and make better use of the skills of health professionals.
Currently, nurses who are qualified to do so and registered by the Nursing
and Midwifery Council (NMC) can prescribe from the nurse prescribers'
formulary (NPF). Nurses who are qualified and registered to do so have been
able, since April 2002 to prescribe from the nurse prescribers extended
formulary (NPEF). This contains a much wider range of medicines including
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about 180 prescription only medicines for the treatment of about 80
conditions. They can also prescribe any of the GSL or P medicines that GPs
are able to prescribe. (Department of Health, 2002). The NPEF contains 6
controlled drugs including codeine and dihydrocodeine. The government took
primary legislation in the Health and Social Care Act 2001 to enable prescribing
by pharmacists and other health professionals (HMSO, 2004). Under
regulations made under this Act, nurses and pharmacists may, if suitably
qualified and registered, be supplementary prescribers, working within a clinical
management plan agreed with a doctor. There is no formulary and any
medicine may be prescribed provided the requirements of the clinical
management plan are met (Department of Health, 2003a, HMSO., 2003).
Controlled drugs are currently excluded from supplementary prescribing
although the Home Office is proposing to amend the misuse of drugs
regulations to permit their inclusion (Home Office Drug Legislation &
Enforcement Unit, 2OO). The Department o% eath a'iso unäeitoo'K public
consultation in 2004 on a further extension of nurse prescribing to include a
range of drugs for emergency care, including thrombolytics (Medicines and
Healthcare Products Regulatory Agency, 2004a). Under the new proposals,
nurses could prescribe medicines used to treat Jife-threaten)ng conditions such
as blood clots, D'T and meningitis.
Knowledge of pharmacology and therapeutics is essential if nurses are to work
within the limits of the Nursing and Midwifery Council Code of Conduct and
undertake these new extended prescribing roles. However, concerns have been
expressed relating to the scientific inadequacies of pre-registration nurse
education and training. The introduction of a new curriculum in the late 1 980s
removed much of nurses' education about pharmacology and therapeutics and
this sent an implicit message about the relative importance of medicines, which
was reinforced on the wards. Current emphasis on behavioural sciences rather
than bioscience has meant that nurses may be lacking in this important area of
scientifically based patient care, and nursing may be facing a widening theory-
practice gap (Thornton, 1997, Jordan, 1994).
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Latter et a! (2000), using a case study design, examined the pharmacology and
therapeutics education of pre-registration nursing students. Multiple data
collection methods were used and multiple perspectives were utilised. The 'unit
of analysis' to serve as cases consisted of three educational institutions offering
pre and post registration nurse education programmes. Multiple methods of
data collection at each site involved focus group discussions with lecturers and
practitioners, individual interviews with key personnel, non-participant
observation at teaching sessions, post observation interviews with students and
curriculum analysis. The researchers found that there was insufficient taught
pharmacology, which was common to each institution. The perceived deficiency
was related to both the potential amount of pharmacology knowledge that
nurses need to know, and the knowledge required for their fitness to practice.
For example, at one site students felt that pharmacology sessions were
insufficient and they did not feel confident talking to patients about their
medicines. Teaching strategies were found to be ineffective and material was
not tailored to nurses' needs. Results were consistent across data sources and
also across sites which, together with their similarity to results from a
comprehensive literature review, further strengthened their findings. The
multiple methods employed in this study allowed an in-depth examination of the
therapeutics education of nurses. This study is very relevant to my research as I
intend to use multiple methods, in particular observation, interviews and focus
g rou PS.
Since nurses are the principle health care professionals involved in the
administration of medicines, it is worrying that much of the literature suggests
that nurses do not always possess a knowledge base adequate to fulfil this role
(Boggs eta!., 1988). A comparison of nurses', doctors, and pharmacists'
knowledge of the hazards of medication found that nurses were significantly
less knowledgeable than both pharmacists and physicians (Markowitz et a!.,
1981). A more recent study also found that nurses were not adequately
prepared for their responsibilities in administering drugs and that their self-rated
knowledge was higher than their actual knowledge (Ives eta!., 1996).
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King (2004) interviewed 10 qualified nurses from an emergency admissions unit
in a city in the north of England to explore nurses' pharmacology needs. She
found that the nurses had a limited understanding of the subject and were
dissatisfied with the teaching of the subject, which resulted in anxiety on
qualifying. This is consistent with Clancy et a! (2000), who found that 98% of
nurses and students surveyed expressed a wish for more education of the
biological sciences in order to prepare them for practice. Similarly, Bullock and
Manias (2002) suggest that nurses who have a stronger knowledge base in
pharmacology would be better prepared to fulfil their roles in the management
of patients' drug therapies and medication education. Using questionnaires they
explore the perceptions and expectations of lecturers involved in teaching
pharmacology about teaching and learning pharmacology in pre-registration
nursing courses using questionnaires. The questionnaire was distributed to all
university campuses in Victoria, Australia, that are involved in undergraduate
nursing education. The questionnaire examined: the integration of
pharmacology teaching into nursing, range and depth of classroom-based
pharmacology teaching, approaches to teaching and learning, nursing practice
in a clinical context, related importance of patient education and communication
skills, and the appropriate professional background of academics teaching
pharmacology to pre-registration nursing students. They found a great variation
between institutions as to the number of hours devoted to pharmacology and
when it was offered. A number of respondents indicated that they were
dissatisfied with the preparation of graduates and their knowledge base in
pharmacology. They conclude that a review of nursing curricula is required to
improve the knowledge base of nurses in pharmacology and to facilitate their
skills in life-long learning.
Courtney (1991) used questionnaires to establish the views of both students
and teachers on the biological sciences in three schools of nursing. Nurse
teachers ranked the behavioural sciences as more important than did the
students. Most students ranked the level of pharmacology teaching as too low,
and only one in 10 of students and staff felt they had adequate knowledge of
pharmacology.
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Morrison-Griffiths et a! (2002) undertook a questionnaire survey of all nurse
education institutions in England to identify current pharmacology education
provided for pre-registration nurses. Teaching of pharmacology in pre-
registration nurse education was found to vary greatly between the different
universities. Pharmacology is usually integrated into the curriculum with very
little time devoted solely to the subject. Almost a fifth of institutions did not
formally assess pharmacology knowledge at all, which is worrying since a large
part of hospital nursing involves the administration of drugs. Less emphasis is
placed on the theoretical knowledge of pharmacology, with some aspects of
pharmacotherapeutics considered unimportant or not taught. The study
suggests that may nurses may be inadequately prepared for the role that they
are expected to perform once qualified.
The lack of pharmacology and therapeutics in nurse training and education is
reflected in the demands of nurses themselves for more scientific education. In
particular, nurses have asked for more training in psychopharmacy, (Jordan et
a!., 2002, Davis and Hemingway, 2003, Hemingway and Freeman, 2002,
Hemingway, 2003), applied pharmacology, diagnostic skills and critical
evaluation skills, (Otway, 2002), drug therapies for organ based conditions, the
recognition of adverse drug reactions, and issues pertinent to drug
management, (Sodha et a!., 2002), general pharmacology and nurse
prescribing (Giles, 2001).
While and Rees' (1993) reported, in their study of health visitors and district
nurses, that most participants did not feel competent in prescribing medications
and had a poor understanding of the medicinal products in the nurse prescribing
formulary.
The large amount of time nurses in clinical practice spend on the aspects of
care related to medication is not reflected by the small amount of time devoted
to pharmacology teaching (Ashurst, 1993). The possible consequence is many
nurses experience difficulties managing patients medication (Jordan and Potter,
1999, While and Rees, 1993), or communicating knowledge of medication to
patients and their carers (Latter eta!., 2000). However the reason nurses
experience difficulty may be due to lack of time as they are too busy.
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Although nurses undertake postgraduate education before they can prescribe,
basic pharmacology should nevertheless be covered in pre-registration training
as a firm base on which to build further teaching. Educational courses should
provide students with the propositional and process knowledge forms that will
promote capability as they become experienced nurses (Fraser and
Greenhalgh, 2001). This theoretical foundation will provide the educational
building block to support future clinical update and postgraduate study.
Additional education is required to maintain competence and ensure clinical
practices are evidence based and up to date. The education of nurse
prescribers should be continuous and not limited to an individual course.
Nurse employees and their employers have a responsibility to update
themselves both in terms of product and clinical update. The breadth and depth
of pharmacology, and continual developments necessitate self-directed,
continuous life long learning in practice.
2.3.3.	 Pharmacist training
Pharmacists have now extended their training to 5 years. Until recently however
they have been unable to prescribe, although they often intervene to prevent
prescribing disasters, and increasingly, write discharge prescriptions for pre-
registration officers to sign.
Pharmacists qualifying now have a strong knowledge base on which to build
prescribing skills. Under European Union requirements, all undergraduate
programmes must contain at least 1000 hours of directed learning on the
actions and uses of drugs and medicines. The four year degree programme is
followed by one year's approved postgraduate training and a further
practice examination. Approved training programmes for supplementary
prescribing by pharmacists (who must have at least 3 years' clinical
experience) are now in place in 25 UK universities, focussing mainly on
clinical prescribing skills. These lead to registration by the Royal
Pharmaceutical Society of Great Britain as a supplementary prescriber.
There is early anecdotal experience of successful supplementary prescribing by
pharmacists (Lavendar, 2005). As at March 2005, 400 pharmacists had
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successfully completed the training. In March 2005 the Department of Health
published a formal consultation document on independent prescribing by
pharmacists. One of the proposed options would enable suitably qualified
pharmacists to prescribe from the entire British National Formulary (Medicines
and Healthcare Products Regulatory Agency, 2005).
The Department is also developing proposals for supplementary prescribing by
chiropodists, optometrists, physiotherapists and radiographers (Medicines and
Healthcare Products Regulatory Agency, 2004b).
2.3.4.	 Multiprofessional learning
The Government is committed to a new approach to service delivery in which
the old hierarchical ways of working are giving way to more flexible team
working between different clinical professionals (Department of Health, 2001b).
There is an increasing overlap of knowledge and skills between health care
professionals and changes in health service delivery have blurred the
boundaries which define the roles and responsibilities of the various health
professions.
A key aim of the NHS Plan (Department of Health, 2001 b), is to make better
use of the skills and expertise of all NHS staff and nurses and other staff, such
as pharmacists, physiotherapists, radiographers, and optometrists will have
greater opportunity to extend their roles. By 2004 over half of them will be able
to supply medicines.
At undergraduate or professional training levels, doctors, nurses, pharmacists,
health care professionals and managers are educated separately, but in the real
world have to work in teams. Workers from each healthcare discipline currently
train in isolation from one another and as part of this process become
'professionally socialised' into ways of working which delineates them from
other healthcare professionals. In addition to having its own training, each
professional group is located within its own hierarchy, leading to the situation
where each healthcare professional is part of a 'professional pyramid', and this
has tended to compound professional isolation and tribalism. The existence of
separate ideologies, hierarchies, professional bodies, training, experiences,
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therapeutic focus, departments and uniforms will necessarily tend to create
separate workforces within a total workforce.
Shared learning at relevant stages within schools of medicine, nursing and
pharmacy would help to foster an understanding of the contributions different
professions make to medication processes (Greene eta!., 1996). The
emphasis should be on 'shared learning' as opposed to 'shared teaching'.
Shared teaching refers to learners from different professions sifting side by side
in lectures where the development is not supported be deliberate educational
strategy or intended learning outcomes, for example, collaborative team
workers (Horsburgh et aJ., 2001). n shared teachrng arrangements suOeffis
are typicaiJy 'passive' recipients and interactve )earn,ng may be m/n'ma). Thefe
is some evidence that this may actually reinforce stereotypes and foster
resentment (Areskog, 1988).
In contrast, interprofessional learning is an educational process through which
students are provided with structured learning opportunities for shared learning,
to enable the acquisition of knowledge, skills and professional attitudes which
could not be achieved effectively in any other way (Horsburgh eta!., 2001).
Through this, health professional students can understand the complexities of
working in a multiprofessional environment. Shared learning aims to develop
adaptable, flexible, collaborative team workers with high level interpersonal
skills, who understand the contribution each health profession makes to patient
and health outcomes. It intends to reduce or limit prejudices which might exist
between professionals and increase the mutual understanding of the
professions. Introducing shared learning at the beginning of health
professionals' careers may offer significant advantages as at this stage
professional identities have not been formed.
Examples of interprofessional training within the United Kingdom can be found
at Southampton University and St George's Hospital Medical School, London.
(Department of Health, 20010. The Faculty of Medicines, Health and Biological
Sciences at Southampton has developed a common learning programme for
interprofessional learning and teaching in healthcare education and practice.
This will result in every student experiencing both inter-professional and
62
profession-specific learning and teaching in each year of their programme. The
aim is to ensure that education and training is driven by the needs of the
modern health service and patient-centred care. This type of programme is vital
to illustrate relevance to practice and enable recognition of the role of
colleagues in the service to underpin development of a multidisciplinary
environment.
The Faculty of Health and Social Care Sciences at St George's have developed
a Common Foundation Programme (CFP). The CFP is designed to meet the
preparatory needs of this range of healthcare students within a multi-disciplinary
environment. It offers the opportunity for each professional group to acquire
certain generic abilities, knowledge and understanding from which to develop
their discipline-specific skills and competencies. The multi-disciplinary context of
the programme is designed to facilitate a collaborative inter-professional
atmosphere where student groups can work together and begin to understand
the different dimensions of other healthcare professional roles.
I feel this is particularly relevant to my study as I will be exploring the concept of
pharmacists working as members of the medical team on the ward providing a
multidisciplinary approach to patient care. My idea is that pharmacists would
work alongside doctors and nurses and for this to be successful I believe it is
essential that health care professionals have good interprofessional skills and
understand each others roles and contributions to patient care. I suspect that a
lack of understanding of responsibilities and competencies, along with
interprofessional barriers may adversely effect truly successful team working
and I will explore the views of health professionals themselves.
2.3.5.	 Summary
In this section I have discussed the knowledge of and competency in
therapeutics of the different healthcare professionals who are involved in patient
care with respect to medicines. In section 2.3.1 I examined the training of
doctors at both the undergraduate and postgraduate levels and in section 2.3.2
I look at nurse training in therapeutics. I moved on to discuss and compare
pharmacists' training and finally talked about multiprofessional approaches to
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learning and how this could impact on team working and the management of
therapeutics. This area of the literature is clearly very relevant to my research
as my main objective is to improve patient care with respect to medicines and I
will be examining, very closely, the competency the healthcare professionals
demonstrate with respect to therapeutics and their own perceptions of their
preparation and training for their roles. This will help me identify problem areas
and suggest potential solutions.
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2.4.	 COMMUNICATIONS BETWEEN HOSPITALS AND
PRIMARY CARE
Effective communications are essential when patients are transferred between
primary, secondary and tertiary care, however medication problems occur at
such 'handover points'. Poor communication of key clinical information on both
admission and discharge frequently compromises patient care and can lead to
poor outcomes which I discuss in this section. In section 2.4.1 I examine the
problems arising when an accurate record of the medication patients are taking
prior to their admission is not obtained. I also discuss the scale of the problem,
consider the reasons why accurate drug histoñes are often not obta,neO anO the
effect on patients care. I examine approaches that have been employed to
study this area and consider these in my own study design.
In section 2.4.2 I discuss information transfer from secondary to primary care,
when patients are discharge from hospital, and problems that arise. I discuss
the methods of transferring information and problems in continuity of patient
care.
2.4.1.	 Medication histories
Accurate information about current drug therapy is vital when patients are
admitted to hospital to enable a correct clinical assessment and to plan future
treatment. This is particularly important when patients are concurrently or
sequentially treated by several physicians. Inaccurate drug histories taken on
admission can lead to inappropriate drug therapy in hospital (Feely eta!., 1984),
and referral letters from GPs do not always contain full information about drug
therapy (Claoue and Elkington, 1986). Inaccuracies in the medication history
may lead to duplication of drugs, unwanted drug interactions, discontinuation of
medication use, missed diagnoses and failure to detect drug related problems.
Studies on the completeness of hospital medical records with respect to the
drugs a patient uses directly prior to hospital admission are scarce and have
several limitations. The completeness of hospital medical records have been
evaluated by comparison with patient questionnaire information only, by
comparison with records from the patient's GP, or by comparison with
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computerized files of dispensed prescriptions in community pharmacies.
Studies, however, tend to focus on one source of information for comparison.
A study in the Netherlands investigated the comprehensiveness of medication
histories when patients are admitted to hospital (Lau et a!., 2000). This was a
prospective study in which patients admitted to a general ward of two acute
care hospitals, over a two year period, were included in the study. The
researchers interviewed patients to solicit information about all medicines used
before admission and extracted the medication history from hospital medical
records. Pharmacy records over a 1 year period before the admission were
collected from the community pharmacy where the patient was registered and
this was compared with the registration of drugs in hospital medical records.
Homeopathic drugs and 'over the counter' (OTC) drugs were excluded, and
errors in dose and frequency were not considered in the analysis. The
investigators found that the medication history in the hospital medical record is
often incomplete. 61 % of all patients had one or more omission errors, (drugs
that were in use but not recorded in the hospital medical record), whilst 17%
had three or more omission errors. 26% of the prescription drugs in use were
not recorded. 11% and 1.6% of all patients had one and two commission errors
respectively (drugs registered in the medical records but not being used by the
patient at the time of admission). In total 67% of patients had one or more
registration errors (the combination of omission and commission errors) and
18% had three or more. Registration errors covered a broad spectrum of drugs
and included many drugs considered important such as cardiovascular and
antidiabetic drugs, and NSAIDs. The researchers comment that their estimate
of the completeness of the inpatient medical record was probably conservative
as they took into account only errors of omission and commission and did not
consider errors in dose or regimen.
These results are comparable with those of Beers et a! (1990). The study
design was similar, however, instead of using pharmacy records, an extensive
questionnaire with specific questions asked to patients to identify drugs not
recorded in the medical record was used, thus introducing the possibility of
recall errors by the patient. The investigators reviewed the written drug history
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recorded upon admission of 122 patients age 65 and over, and compared it to a
structured history they obtained from the patient two days later. Failure to
record the use of a medication or the recording of a medication the patient
denied using appeared at least once in the hospital records of 83% of patients
studied. Three or more errors were found in 46% of patients records. After
reviewing the data and excluding OTC, topical, and cold medications, the
researchers still reported that, with regard to important drugs, 60% of patients
had one error and 18% had three or more. In agreement with Lau et a/they
found omission errors were far more common than commission errors (Lau et
a!., 2000). Estimation of commission errors could be too low though, as patients
tend to deny their nonadherence to medical advice (Cramer and Spilker, 1991).
Van Hessen eta!. (1990) studied the continuation of outpatient medication in
205 patients after admission to hospital by comparing community pharmacy
records with hospital-pharmacy records. This study differs however, in that the
actual completeness of medication histories is not assessed, rather the potential
effects on the patient. Drugs that were in use according to the community
pharmacy records, but were not retrievable in the hospital pharmacy records,
were categorized by an expert panel as discontinuations that will not cause
problems, as discontinuations that will probably not cause problems, or as
discontinuations that should not have occurred, unless purposefully done on the
advice of the attending physician. In the last, most serious category of
discontinuations, 15 discontinuations in 12 patients (6%) were considered
inadvertent as no information was found that could explain the discontinuation.
The evidence for the conclusion of the authors, that information of drug histories
obtained at the time of hospital admission is not always accurate is indirect, as
the completeness of the medical records was not studied, and as other reasons
such as an omission to record the reason for stopping a drug in the medical
history might account for the lack of information.
Patients are often unable to report accurately the drugs they are taking
(Schwarz eta!., 1984), and they often deem certain things not to be
medications, such as things they put on their skin or in their eyes. Doctors also
bear this responsibility, and do not always take the time to ask all the necessary
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questions to obtain a complete history, and then don't double-check their
information after the acute situation (Walker, 1991).
In an American study, Gleason et a! (2004), conducted a study to identify the
type, frequency and severity of medication discrepancies in admission orders
and assess whether pharmacist-obtained and reconciled admission histories
reduced the number of medication errors and the potential for harm.
Reconciliation consisted of comparing the medicines listed in the admission
orders to the documented medication information in the history obtained by the
physician, the patient's admission profile (a form completed collaboratively by
the nurse and patient) and information obtained during the pharmacist
conducted interview. From August 2002 to July 2003 medication reconciliation
was conducted with a convenience sample of patients directly admitted to a
725-bed tertiary care, academic medical centre. The researchers interviewed
patients who were directly admitted within 24 to 48 hours of admission to obtain
their allergy histories and medicines currently being taken, including all
prescription and non-prescription medications, vitamins, herbal remedies, and
any other products used to supplement the patient's health. This was then
compared with allergy and medication histories documented in the patient's
medical record. 204 out of 2046 patients (10%) admitted during the study
period, were interviewed. The mean amount of time required to obtain a
medication history was 11.4 minutes per patient (range I to 75 minutes) and the
mean patient age was 58.6 (range 19 to 96). A mean of 1.2 discrepancies per
patient was identified and the pharmacists made 97 interventions involving 55
patients. Using a validated rating scale, the research nurse and research
pharmacist estimated that in the absence of pharmacist intervention, 22% of the
discrepancies could have resulted in harm to the patient during hospitalisation,
and 59% may have resulted in harm if continued beyond discharge. This is
particularly noteworthy as their sample excluded patients who had difficulty
communicating their medication histories and higher risk patients e.g. in
intensive care, or patients transferred from other hospitals. A limitation of this
study however, is the possibility of recall bias. Because of the stress of
hospitalisation patients or their carers may not recall the complete medication
regimen (Beers eta!., 1990). To overcome this in my research I intend to use
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other sources such as the GP records, to validate the patient's account of their
medication.
Several other solutions have been suggested (Walker, 1991). One is for
patients to carry a list of the medications they are taking, but this presents
problems if they are not kept up to date. Another answer is to have patients
bring their medication into hospital with them but this isn't without problems as
many elderly patients hoard medication or may take medication given to them
by well-meaning friends.
A series of case studies from a large university hospital in America,
demonstrated several near misses, identified by pharmacists, related to
patient's self-reported medication histories (Jacobson, 2002). In each case the
admitting doctor insisted that the patient's self report was reliable, when in fact,
it was inaccurate. The report states that many physicians who were initially
irritated with pharmacist's enquiries later acknowledged the diligence of
pharmacists to be valuable. The author suggests using open-ended questions
when interviewing patients to elicit more accurate information, which I will adopt
in my study.
2.4.2.	 Discharge information
On discharge, patients' medication regimen and treatment plan need to be
communicated in a timely and reliable manner to ensure safe and seamless
transfer of care back to the primary care team. However, when patients are
discharged communication is often slow and incomplete (Department of Health,
2004c). Delays in communicating information about the patient's hospital
inpatient episode and discharge medication mean that this information is not
available to the GP to enable continuation of care.
Drug therapy is often altered when patients are in hospital and if patients are
unaware of the changes and the GP hasn't received the relevant information,
they can be inadvertently prescribed drugs that are no longer indicated,
duplicate drugs and drugs that interact or are contraindicated. Doctors may
overestimate patients' understanding of the discharge treatment plan (Calkins et
a!., 1997). Patients' misunderstanding of the discharge treatment plan can lead
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to poor outcomes in the community. It has been reported that patients being
discharged from hospital have a poor understanding of their medication (Cantrill
and Clark, 1992, Dyson eta!., 1995). One study, for example, showed that 80%
of elderly patients who had been prescribed a new drug whilst in hospital did not
know what it was for (Cantrill and Clark, 1992). Patients had a poor
understanding of side effects that might be expected and precautions they
should take, and did not know for how long they should be taking the
medication.
Discharged patients may continue to take drugs that are no longer indicated or
necessary, or drugs prescribed at discharge may be inadvertently stopped after
their return home. Cochrane eta! (1992) followed up 50 elderly patients 6 to 14
days after discharge, when the drugs supplied by the hospital should have run
out and a further supply obtained from the GP. A pharmacist visited each
patient's home and used a structured verbal questionnaire to elicit information
about the drugs, and where possible all drugs held by the patient at the time of
the visit were inspected. The prescription issued on discharge and the drugs
actually being taken by the patient at home after discharge were compared.
Patients were also asked about information supplied to them by health care
professionals during their hospital stay. After returning home the drug regimen
of 45 patients differed from that prescribed on discharge, with 11 patients taking
a different dose,10 having stopped drugs and 20 taking new drugs. Changes in
drug name and strength also occurred. Most of the patients had not been
reviewed by their GP and so these changes could not be attributed to clinical
judgement. Possible influencing factors included an incomplete drug history,
continuation of drugs taken before admission and changes in the prescription
not attributable to a conscious clinical decision. After returning home, patients
recalled little information being given about drugs in hospital. 46 patients could
not remember being told when to take their medication, 41 patients could recall
being told the purpose of their drugs, and 30 patients said that they weren't
informed they must obtain further supplies of medication when they ran out. The
authors conclude that closer communication is needed between hospital and
community health care professionals to ensure that patients are informed about
their discharge prescription and continuation of treatment.
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Burns et a! (1992) visited 56 elderly patients on or after the 5th day post
discharge and assessed their medication. By the day of the visit 15 of the 56
patients had not had a new prescription issued (27%) and had exhausted the
hospital supply and 27 patients (48%) had old prescribed medications available
at home.
The problems arising from poor communication of prescription details at
discharge were highlighted by the Department of Health in 1991 (Department of
Health, 1991), in an executive letter which stressed the need for "notification in
adequate time of the patient's diagnosis and drug therapy so that any ongoing
treatment may be maintained". One study showed that 10% of discharge
summaries did not include a diagnosis, and up to 22% did not record treatment
at discharge (Mottram et a!., 1994).
There are currently two methods of transferring discharge medication to general
practice from hospital, the preliminary discharge letter (PDL) and the
subsequent consultant discharge summary (CDS). As the two documents are
written and sent to the GP separately, and more likely by two different people,
this provides the potential for errors if they do not agree. A study conducted in
Ashton-under-Lyne to determine the nature and extent of medication related
problems post-discharge from hospital followed up 63 patients after their
discharge (Gardiner, 1998). The investigators contacted the GP practices and
discovered that for most patients there was a lack of continuity in one or more
aspects between drugs given on discharge and those recorded in the GP
computer. There were also very few PDLs which gave exactly the same
information as the corresponding CDS. This led to many patients receiving
prescriptions from their GP post-discharge, which differed in some aspect from
their discharge prescription. The medication of patients readmitted to hospital
within six months of discharge was also audited. Most patients had their drug
therapy altered between discharge and readmission to hospital. Some changes
could be attributed to clinical decisions made by the GP or at the hospital
outpatient clinic but others could not.
Jones et a! (1998) similarly found that errors occur in the prescribing of
medicines following discharge and demonstrated that continuity of care is not
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up to the standard which is required to deliver maximum benefit to patients.
They state that issuing a discharge prescription is extremely valuable as it
informs the GP of medication changes immediately, as oppose to waiting weeks
for a full discharge letter, however their results indicate that often this does not
happen effectively, resulting in patients receiving wrongly prescribed medicines.
They found that prescriptions are sometimes issued to patients within a few
weeks after hospital discharge, without reference to the discharge prescription,
and anecdotal evidence suggests that mistakes also occur when medically
unqualified staff update record systems without the intervention of a health care
professional.
A study in Glasgow to ascertain whether GPs and community pharmacists
wanted or received information on the reasons for drug therapy changes
implemented in hospital found that 96% of GPs and 94% of pharmacists said
they would like this information to ensure continuity of care (Munday et a!.,
1997), 58% of GPs were not satisfied with the information they receive about
their patients' discharge drug therapy. The preferred method of receiving the
information was via a modified hospital discharge letter.
2.4.3.	 Summary
Communications across the interface must be improved to ensure the risks
associated with drug therapy are minimised and that patients gain maximum
benefit from their medicines. From this section it is clear that therapeutic
problems often occur when patients are transferred between primary and
secondary settings. Drug related problems can occur at the time of admission
as a result of inaccurate drug histories and discharge back into the community
because of unreliable, untimely communication of treatment plans and lack of
patient understanding.
This section is particularly pertinent to my research and I have encountered the
problems outlined frequently whilst working as a pharmacist in two acute NHS
hospitals. Transfer of information about medicines is an area I intend to address
in my study and this literature has helped me develop my research approach
and attempts to develop and implement interventions aimed at improvement.
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2.5.	 PATIENT EDUCATION AND COMPLIANCE
In this section I discuss patient involvement in their care with respect to drug
therapy, in particular communications between health care professionals and
patients and behaviour of patients with respect to their medication. In section
2.5.1 I begin by considering various terminologies encountered in this literature.
I move on in section 2.5.2 to discuss why patients sometimes deviate,
intentionally or unintentionally, from prescribers' instructions and consider this
from both the health care professional view point and that of patients
themselves. In section 2.5.3 I discuss the incidence of non-compliance
medication regimens looking at specific patient groups, such as people with
rheumatoid arthritis, cancer patients and people with CHD etc. Then in section
2.5.4 I discuss ways to promote patients' compliance with their medication in
particular focussing on patient education.
2.5.1.	 Terminology and patient compliance
The terms used to describe medicines use which does not fully conform to
professionals' recommendations include non-compliance, non-adherence and
lack of concordance (Carter and Taylor, 2003). Compliance can be defined as
'the extent to which the patient's actual history of drug administration
corresponds to the prescribed regimen' (Urquhart, 1994). This definition
includes both quantity and timing of doses. For the purpose of this thesis the
terms adherence and compliance have been accepted as synonymous.
Concepts of compliance or adherence have now been subsumed within the
framework of concordance, which seeks to promote the taking of medicines
through informed agreement between patient and professional. In 1997 the
Royal Pharmaceutical Society of Great Britain published its report "From
compliance to concordance: achieving shared goals in medicine taking". This
was the culmination of two years' work carried out by a multidisciplinary working
group whose original brief was to examine the problem of patients' non-
compliance with prescribed medication. The working group came to the
conclusion that the model of compliance was unhelpful as it carried the
assumption that patients should merely carry out doctors' orders, and gave no
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value to patients' own ideas or experiences. The report introduced the concept
of concordance, which was described as follows:
"The clinical encounter is concerned with two sets of contrasted but
equally cogent health beliefs - that of the patient and that of the doctor.
The task of the patient is to convey her or his health beliefs to the doctor;
and of the doctor, to enable this to happen. The task of the doctor or
other prescriber is to convey his or her (professionally informed) health
beliefs to the patient; and of the patient, to entertain these. The intention
is to assist the patient to make as informed a choice as possible about
the diagnosis and treatment, about benefit and risk and to take full part in
a therapeutic alliance. Although reciprocal, this is an alliance in which the
most important determinations are agreed to be those that are made by
the patient."
(Royal Pharmaceutical Society of Great Britain, 1997).
The emphasis of concordance is on communication about medicines, while the
concept of compliance focuses on the behaviour of individual patients. Albeit
controversial, compliance remains the most widely cited term in the national and
international literature on this topic, and the term will continue to be used in this
thesis.
Non-compliance with medicines is a widespread, intractable problem, and it
significantly compromises the well being of patients (Raynor, 1992). Up to 80%
of patients may be 'non-compliant' in their medication taking, (Dunbar-Jacob
and Sclenk, 2001), although this varies between patient groups and types of
illness.
2.5.2.	 Why are patients non-compliant?
Previously, it was felt that the patient alone was the cause of non-compliance
and patients who refused to do as they were told, or took an irrational attitude to
prescribed medicines that could be doing them good, had only themselves to
blame. Patients who deviate from the prescribers' instructions can be intentional
or unintentional non-compliers (Barber, 2002). Those who intentionally do not
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comply have made the decision consciously; the others wish to comply but
cannot for some reason and there is overlap between these groups. Some
patients who forget to take their medicine (unintentional non-compliance) will do
so because their view of the medicine, its importance and risks, may have made
taking the medicine a low priority, and hence more easily driven out of mind by
other matters.
Deliberate non-compliance can be in the patient's interest, for example, correct
titration of the dose and frequency of analgesics, and taking hypnotics and
laxatives only when required, even if the medicines are prescribed to be taken
regularly.
Unintentional compliance can result from a number of factors, all of which are
more likely to occur with more complex regimens (Cramer, 1991, Cramer et a!.,
1989, Jacobs eta!., 1988, Eison eta!., 1990). Forgeffulness is the single most
common problem with medication compliance, the result of which is partial
compliance. Although patients have essentially accepted their diagnosis and
need for treatment and are making an effort to participate, they neither achieve
their intention nor receive maximum benefit.
Patients may not be given sufficient information to comply even with a simple
regimen. Verbal information is largely forgotten (Ley 1973), and if written
information is not given, patients' lack of understanding is likely to contribute to
non-compliance (Ley 1982), and this must be regarded as non-intentional.
Factors that are predictive of non-compliance are (Carter and Taylor, 2003):
• demographic indicators, for example age, gender and socio-economic status
• medication characteristics, for example side effects, complexity of regimen
• psychosocial issues, for example social support, family functioning, self
esteem
Patients' beliefs and perceptions about medication affects compliance, (Home
and Weinman, 1999), for example the extent to which they are perceived as
harmful, whether a medicine is perceived as necessary to maintain health, and
whether there might be adverse consequences such as side effects or
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dependency.
2.5.3.	 Estimates of non-compliance
In a US study, one-third of patients with arthritis attending hospital
rheumatology clinics had 'adjusted' their medication during the previous week
(Chewning eta!., 2001). Of these, 61% intentionally added or missed doses; the
rest forgot. About half were on eight or more different medicines at one time. As
the number of drugs increased, patients became more likely to change their
regimen without seeking professional advice.
In their review of compliance with oral antineoplastic agents, Partridge et a!
(2002) found that compliance rates are variable, and sometimes very poor.
'Non-compliance' appears to be higher in patients taking cancer medication
regimens perceived to be for preventive rather than curative purposes.
Evidence shows that appropriate coronary heart disease (CHD) medication
regimens can deliver major health gains cost effectively, but poor compliance
reduces their benefits. Sung et a! (1998) reported that only one-third of patients
took at least 90% of their lipid-lowering treatment. Others have estimated
discontinuation rates in this context to be 50% after one year and 85% after two
years (Insull, 1997). A review by McDermott et a! (1997) found that non-
compliance with CHD treatment was associated with a lower survival rate.
Patients with or at risk for coronary artery disease or congestive cardiac failure
and who were classified as noncompliant with treatment, were twice as likely to
die as those who were compliant. Non-compliance may also increase morbidity.
One study in the McDermott et a! review found that up to 43% of hospitalised
cardiovascular disease patients were non-compliant, while another found that
non-compliance was one of the two most common reasons for hospital
admission.
A review of studies in the US showed that patients on antidepressants took an
average of 65% of the prescribed amount, compared to an observed 76%
compliance in physical disorders (Cramer and Rosenheck, 1998). Other
research has claimed that depressed patients are three times more likely to be
non-compliant with medical treatment recommendations in general, as
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compared to non-depressed patients (Di Matteo et a!., 2000). A national clinical
survey of suicide in psychiatric patients revealed non-compliance with treatment
is common before suicide (Appleby and et a!, 1999).
Recent research from Scotland revealed that, among 2920 people with type 2
diabetes, adequate compliance (defined as taking more than 90% of prescribed
medication) was found in less than one-third of those prescribed sulphonylureas
and/or mefformin (Donnan et a!., 2002). Patients taking both drugs achieved
only 13% compliance.
In a study of epileptic patients, 72% said they never miss taking their anti-
epileptic drugs (AEDs), 15% reported missing a dose less than once a week,
9% missed more than once a month, and 4% said that, at least once a week
they did not take their treatment as prescribed (Buck eta!., 1997).
Greenstein and Siegal (1998) found that one-fifth of patients who underwent a
renal transplant were non-compliant (as measured by self-reporting, and
defined as one or more medication doses missed within the previous four
weeks). Despite the importance of taking immunosuppressive medication to
ensure good organ function and avoid rejection, many post-transplant patients
are reported to be non-compliant. A review of research on non-compliance rates
with immunosuppressive therapy reported figures ranging from 2% to 68%
(Chisholm, 2002). Post transplant patients tend to become less compliant over
time. In one study of renal transplant patients, 95% were compliant five months
after the operation, but only half continued to be so after 12 months (Chisholm
et a!., 2000).
Non-compliance to antiviral therapy has been identified as a critical factor in HIV
treatment failure (Markowitz, 2000).
Estimates of drug non-compliance in the elderly vary, ranging from 40% up to
75% (Salzman, 1995). If patients are not given enough information they may
deviate from even simple regimens; written information is rarely given and
verbal information is often forgotten. However, a recent study (Cline et a!.,
1999), found that, despite receiving written and verbal information, 27% of older
people discharged from hospital after heart failure were classed as
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noncompliant 30 days later. The majority remembered receiving oral
information, but less than one in four recalled any written information they were
given. Nine percent did not remember receiving any information at all. Half the
patients surveyed could not recall the dose of their medication and nearly two-
thirds did not know what time of day to take them. In a Danish study, 40% of
elderly patients did not know the purpose of their medication, only 20% knew of
the consequences of non-compliance, and less than 6% knew about possible
side effects of the drugs prescribed for them (Barat et a!., 2001).
Elderly patients are more likely than average members of the overall population
to:
• be living alone
• be taking multiple medicines with high dose frequencies
• have decreased dexterity and/or cognitive functioning
Combined with lack of knowledge, these factors can lead to unintentional non-
compliance. There is also evidence that older people are as likely as people in
any other age group to make a rational and intentional decision to change or
stop their medication without seeking professional advice. One study found that
one-third of the older patients surveyed had altered their medication regimens,
primarily because of experienced side effects, adjustments made in response to
symptom changes and the perceived inefficacy of treatments prescribed (Lowe
and Raynor, 2000).
2.5.4.	 Interventions to improve compliance
A review by Rotter et a! (1998) found that interventions to improve compliance
generally had a weak to moderate effect. However, even modest improvements
could have beneficial effects, save lives and costs. Combined-focus
interventions were more successful than single-focus ones, the most effective
being a combination of educational, behavioural and effective communications.
This educated patients about their illness and treatment, taught behavioural
strategies to enable people to cope better with symptoms and medication taking
and addressed emotions and moods.
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More recently a Cochrane review of interventions (Haynes et a!., 2002) to
improve compliance found that there had been few well conducted studies, and
that many interventions failed. Nearly all the successful studies used complex
mixtures of interventions.
Compliance-related interventions should be designed to help the patient make
an informed choice about their medicine taking, rather than to 'improve
compliance' perse (Home, 2001).
To promote compliance with medication regimens, patients must be given
sufficient, accurate information about their prescribed medicines, by
professionals with the necessary skills and knowledge to deliver this. In this way
patients will be empowered to take a more active role in managing their drug
therapy
Tomorrow's doctors encouraged and emphasized improving communication
between doctors and patients as a further important factor in decreasing the
number of medical errors (General Medical Council, 2003).
2.5.5.	 Summary
In this section I have discussed the various terminologies used around this
subject and moved on to discuss why patients may deviate from medication
regimens. I talked about the scale of the problem then examined possible
interventions to improve compliance. This literature is extremely relevant to my
work as a large part of my study will be examining ways in which we can help
patients manage their medicines and I see this as a particularly valuable role for
pharmacists working on the wards. In particular I will explore interventions such
as patient education to improve compliance and education for doctors and
nurses, so they are better equipped to give patients the full support they need
with their medication.
Clearly, there is a wide range of potential interventions to improve the use of
medicines in older people. These include nursing and medical strategies, and
also the use of information technology. However, for the purposes of this study I
have focused on the contribution that pharmacists can make, for a number of
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reasons: pharmacists receive extensive training in the actions, uses and
adverse effects of drugs; these skills are generally acknowledged to be under
utilised in the NHS; and developing the contribution of pharmacy is now an
important element in Government policy.
2.6.	 WHAT CAN BE DONE?
In this section I explore the way forward in enhancing patient care with respect
to medicines. In section 2.6.1 I discuss the Government's strategy for the NHS
to improve quality of care and patient safety and their vision for hospital
pharmacy. The Government is committed to raising the quality of service and
reducing variations in delivery within the NHS and a policy framework is set out
in the NHS Plan, National Service Frameworks and the Programme for
Pharmacy in the NHS. I move on, in section 2.6.2 to examine the development
of hospital pharmacy services and in section 2.6.3 discuss the progression of
clinical pharmacy services. I then introduce the concept of pharmaceutical care
in section 2.6.4, and the evolution of pharmacists into more patient focused
health care providers. In section 2.6.5 I go on to examine the current realities in
pharmacy services and research into pharmacy practice, and the practical
reality is that pharmaceutical care is poorly developed in many hospitals. Within
this section I discuss work that has been done to evaluate various elements of
pharmaceutical care and explore the methods of assessing service provision. I
begin with ward-based pharmacy services in section 2.6.5.1 which tend to be
evaluated by measuring pharmacist interventions into patient care and
recording advice given to medical staff. I examine pharmacists' involvement in
patient counselling and the impact this can have on compliance in section
2.6.5.2 moving on in section 2.6.5.3 to discuss the impact of pharmaceutical
services at the primary/secondary care interface, in particular admission
medication history taking, and discharge planning. Finally I discuss the issues
associated with changing practice within organisations and the implications for
this research in section 2.6.6.
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2.6.1.	 The Government's strategy
The NHS plan sets out radical proposals for reform in the NHS. The key aims
are: to improve quality of care; to re-shape care around the patient, thus
improving access to care; and to make better use of the skills and expertise of
all NHS staff (Department of Health, 2001 b). The Government's Programme for
Pharmacy within the new NHS outlines the important role pharmacy has in
delivering this plan (Department of Health, 2000c). The need to make the most
of the medicines in hospitals, as the service delivery model for hospital care
changes, is emphasised. Hospitals are called upon to review their systems
regarding medicines, to make them more efficient, convenient and safe, and
more patient focussed. The Government have stressed the need to make the
most of pharmacists' clinical skills and have emphasised the important role that
pharmacists have in establishing and underpinning clinical governance
wherever medicines are used in hospitals.
National Service Frameworks (NSFs) set out national standards of care and
define service models for specific service areas or care groups. NSFs have
already been published for mental health (Department of Health, 1 999a),
coronary heart disease (Department of Health, 2000b), diabetes (Department of
Health, 2001 c), children's services (Department of Health, 2001d), renal
services (Department of Health, 2004d), and for older people (Department of
Health, 2001a). A national service framework for long-term conditions was
launched in 2005. A National Cancer Plan has also been issued (Department of
Health, 2000a).
Current NHS strategies therefore provide an excellent platform for developing
the role of pharmacists. For example, the objectives of the National Service
Framework for Older People include (Department of Health, 2001a):
by 2002 all people over the age of 75 years should have their medicines
reviewed at least annually and those taking four or more medicines should
have a review every 6 months.
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all hospitals should have 'one stop dispensing/dispensing for discharge'
schemes and, where appropriate, self-administration schemes for medicines
for older people.
. by 2004 every primary care organisation will have schemes in place so that
older people get more help from pharmacists in using their medicines.
As a qualified pharmacist, I see this as a unique opportunity to ensure the skills
and expertise of pharmacists that have previously been under utilised, are used
most appropriately. This prompted my desire to undertake research into a new
model of practice, initially within a particular client group, for example the
elderly.
Traditionally, the hospital pharmacist has worked behind the scenes, with little
direct patient contact. However, I believe that patient care and outcomes would
be improved if pharmacy services were restructured to allow pharmacy staff to
assume shared responsibility for drug management, as part of the
multidisciplinary team.
2.6.2.	 Development of hospital pharmacy services
The NHS act (1946) brought existing hospital pharmacy services into the newly
formed NHS (Holloway, 1991). With the advent of a national hospital service,
hospital pharmacists had high hopes of at last achieving the status and
remuneration appropriate to their important work. Their hopes, however, were
not realised and their battle for better pay and recognition continued.
In 1955 the first Linstead Report (Ministry of Health, 1955), reviewed hospital
pharmacy services and found that there was a shortage of staff in hospital
pharmacies due to low salaries, lack of definition of the function of the
pharmacy in the hospital and ignorance among pharmacists of their potential
role in hospitals. One of its recommendations was that all hospital pharmacies
should be under the control of a pharmacist. The ministry of Health then
surveyed functions and staffing and their report, which was unpublished,
emphasised the need for organisation of hospital pharmacy services to ensure
efficiency and economy (Ministry of Health, 1955). An MSc conducted at
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Manchester found that few of its recommendations were implemented (Moss-
Barclay, 1976).
After the Noel Hall report in 1970 (Department of Health and Social Security et
a!., 1970), new grading and structures were created for pharmacists and
technicians. In the context of clinical pharmacy, the report emphasised the
hospital pharmacists' consultative role, recognising their knowledge of clinical
pharmacology and their advisory role in prescribing. The report stated that
pharmacists had a role in advising on formulation, stability, incompatibilities and
conditions of storage, dosage and administration methods, quantitative and
qualitative identification of drugs, drug interactions, contraindications and side
effects, and costs and sources of drugs. Development of drug information
services was suggested and the new ward pharmacy system highly praised.
2.6.3.	 Clinical Pharmacy
Since the Noel Hall report, in the UK, clinical pharmacy has developed and this
was endorsed by the Department of Health in 1988 as a means of increasing
cost-effective use of medicines and enhancing patient care (Department of
Health, 1988b, Department of Health, 1988a, Department of Health and Social
Services, 1989). It recommended the provision of clinical pharmacy services in
hospitals, such as monitoring and modifying of drug therapy, discharge
counselling and clinical trials support. Similar recommendations were made by
pharmacy organisations (United Kingdom Clinical Pharmacy Association,
Harrison eta!., 1988), and in the 1986 Nuffleld report on pharmacy (Pharmacy,
1986).
In the earliest official UK document on clinical pharmacy, The United Kingdom
Clinical Pharmacy Association (UKCPA) defined clinical pharmacy and states
that it includes educating patients on drug use, educating health care staff,
advice and information on drugs, provision of pharmaceutical expertise for
clinical problems and surveillance of drug use (United Kingdom Clinical
Pharmacy Association). The Nuffield Report (Pharmacy, 1986), described a
clinical pharmacist as someone who would "help particularise the medication to
be used.....the pharmacist can contribute to the choice of drug regimen,
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particularly when more than one condition is being treated. The pharmacist
should be in a position to supply the physician with evaluated information on
pharmaceutical and therapeutic aspects of drug use as well as on the toxic
profile of drugs. He can help decide which dosage form or formulation of an
active principle should be used and the best route of administration of a
medicine; he may be expected to undertake responsibility for deciding the
formulation of a medicine or other treatment which the clinician has prescribed;
and he may take responsibility for dosage calculations" but would not diagnose.
"The contribution of the pharmacist is additive to, and not a substitute for, that of
the doctor". In 1988 the Regional Pharmaceutical Officers (RPhOs) Committee
(Harrison et a!., 1988), said that clinical pharmacists "should help individualise
patients' medication, promote patient compliance and promote the safe, rational
and economic use of medicines".
The Department of Health has long recognised the importance of clinical
pharmacy in minimising both clinical and financial risk (Department of Health,
1988b). Enabling pharmacists to contribute more fully to patient care reduces
patient morbidity and saves money (Bond and et a!, 1999).
The Department of Health described clinical pharmacy as a developing role "in
which pharmaceutical skills are systematically applied to medicine usage both
at the policy-making level and in the treatment of individual patients" but the role
was limited to help at the request of the doctors (Department of Health, 1988b).
The Department views the role of the hospital clinical pharmacist as assisting
the doctor in prescribing decisions and monitoring and modifying drug therapy,
independently counselling patients on the ward prior to discharge and having a
function in clinical trials of medicines.
2.6.4.	 Pharmaceutical care
The role of the pharmacist is evolving from product orientated custodian to more
patient focused health care providers and the term pharmaceutical care is more
appropriate to this. The term clinical pharmacy has come to be used generally
to describe the knowledge, skills and attitudes required by a pharmacist to
contribute to patient care.
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Hepler and Strand originally defined the concept of pharmaceutical care more
than 10 years ago as:
"The responsible provision of drug therapy for the purpose of achieving
definite outcomes that improve a patient's quality of life."
(Hepler and Strand, 1990)
They further refined the definition as:
"the process through which a pharmacist co-operates with a patient and
other professionals in designing, implementing and monitoring a
therapeutic plan that will produce specific therapeutic outcomes"
This in turn involves three major functions:
• identifying potential and actual drug related problems
• resolving actual drug related problems
• preventing potential drug related problems.
These aims are central to a great deal of pharmacy is trying to achieve in the
NHS. The Department of Health in England has adopted the term 'medicines
management' rather than pharmaceutical care. Medicines management has
been defined by Tweedie and Jones as:
"the systematic provision of medicines therapy through a partnership of
effort between patients and professionals to deliver best patient
outcomes at minimised cost."
(Tweedie and Jones, 2001)
Although the concepts are related, there has been extensive debate about the
terminology and the two terms are not necessarily synonymous. However, for
the purposes of this research, the two concepts have been accepted as being
convergent.
The philosophy of pharmaceutical care has been given new emphasis by a
range of measures recently introduced by Government and the profession. The
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Government is committed to raising the quality of service and reducing
variations in delivery within the NHS. There is a very strong underlying political
drive to achieve this with a policy framework set out in the NHS Plan, National
Service Frameworks and the Programme for Pharmacy in the NHS.
Furthermore, the Royal Pharmaceutical Society of Great Britain's "Pharmacy in
a New Age" strategy, which outlines the profession's future aspirations, strongly
promotes the developments in areas such as management of prescribed
medicines, management of long-term conditions and advice and support for
other healthcare professionals (The Royal Pharmaceutical Society of Great
Britain, September 1997), that are central to the concept of pharmaceutical
care.
2.6.5.	 Current realities in pharmacy service provision and
research
There is broad agreement between Government and the profession about the
development of pharmacy services and pharmaceutical care. In addition to this
the Royal College of Physicians (RCP) has suggested that pharmacists could
take on some of the work currently undertaken by doctors. A working report
noted that pharmacists taking on some of the work of doctors "would be in
keeping with their desire to take on an extended clinical role for which they are
now being trained," and the aim was to remove the existing "tribal" boundaries
(Royal College of Physicians, 2001).
A well-developed clinical pharmacy service has been identified by the Audit
Commission as a crucial component of efforts to reduce the risk of medication
errors and adverse effects of drugs in hospitals and the commission would like
to see pharmacists working as full members of the clinical team (Audit
Commission, 2001). In its report, the Commission questions whether NHS trusts
throughout England and Wales possess adequate resources to provide all
aspects of clinical pharmacy services and highlights the need to link medicines
management to clinical governance.
However, although there is a growing literature on pharmaceutical care in UK
hospitals, the practical reality is that pharmaceutical care is poorly developed in
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many hospitals. Cotter, Mckee and Barber, in a comprehensive review in 1995
said that:
"clinical pharmacy processes are diverse, ill-defined and sometimes
difficult to measure ... the shortage of evaluative studies in clinical
pharmacy reflects its ad hoc development in the UK and the failure of
managers to fully and objectively assess new seivices."
(Cotter et a!., 1995)
Since then, there have been no substantive studies that suggest progression
towards achieving widespread delivery of pharmaceutical care on any
significant scale. There is wide variation in the amount of time pharmacists
spend on clinical pharmacy activities (Audit Commission, 2001).
Moreover, because we have no holistic model of total pharmaceutical care in
the UK, the term has come to mean almost anything that pharmacists do, over
and above direct operational activities. As a result of this lack of an evidence
base, the standard of pharmaceutical care varies enormously from patient to
patient. Robust, rigorous research is therefore required to identify best practice
in pharmaceutical care and to provide a reliable evidence base on which to
develop future provision.
Research into pharmacy practice has been hampered by the profession's need
to concentrate on issues such as overcoming inadequate facilities, staffing
shortages, medication errors, formulary management and the increasing use of
more potent and complex medicines (Child D et al., December 2001). Although
there is clearly a long way to go yet, the signs for pharmacy practice research
are becoming more promising. 'Pharmacy in the Future - Implementing the
NHS Plan' acknowledges that hospital pharmaceutical services have come a
long way over the past 20 years (Department of Health, 2000c). Medication
reviews, one-stop dispensing, use of patients' own drugs, concordance issues,
links with primary care, increased roles for technicians and pharmacist
prescribing are important roles for hospital pharmacy that have been
highlighted, and these appear in the literature with increasing frequency to
demonstrate the efficacy of hospital pharmacy. In 'A Vision for Pharmacy in the
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New NHS', published in 2003, the Government reinforced its intention of
developing wider clinical roles for pharmacists in all sectors (Department of
Health, 2003b).
Although no cohesive model of pharmaceutical care has been evaluated in UK
hospitals, there is a substantial body of work that has evaluated various
elements of pharmaceutical care.
2.6.5.1.	 Ward-based pharmacy services
Clinical pharmacy services to wards have been evaluated by measuring
processes, such as interventions into patient care through monitoring of
prescriptions and provision of information and advice on therapeutics to medical
staff. Published studies have often contained weaknesses in design and
execution and are therefore subject to significant bias.
Nevertheless, the impact of pharmacist interventions on prescribing quality have
been shown (Hawkey eta!., 1990, Eado, 1992). In addition, doctors almost
always accept pharmacists' recommendations to alter drug therapy with over
95% of recommendations being accepted (Barber eta!., 1997, Batty and
Barber, 1992, Wood and Bell, 1997).
An intervention into drug therapy is defined as 'interference or action taken by
the pharmacist to improve drug therapy'. In pharmacy practice research, many
studies have used monitoring interventions or contributions that pharmacists
make, to provide quantitative and qualitative data on pharmacists' input into
patient care (Hawkey eta!., 1990, Lannigan, 1994, Clark eta!., 1995, Hubbard
and Alder, 1992, Glinn, 1993, Hatoum eta!., 1988, Bertch eta!., 1988, Eadon,
1992).
Wood and Bell conducted a study to implement a model of analysing the level
of involvement of pharmacists in drug therapy decisions (Wood and Bell, 1997).
Over a three month period events were recorded for one week of each month,
by six ward-based and six dispensary-based pharmacists. Overall the
pharmacist's advice was accepted by prescribers on 97% of occasions,
resulting in a change to drug therapy in 82% of cases. They showed that ward-
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based pharmacists were far more likely to influence the outcome of drug
therapy decisions than those based in dispensaries. Their results showed that
for ward-based pharmacists, their work location provides them with an
increased opportunity to behave proactively and to be involved in the drug
therapy decision-making process. In addition the perceived impact on patient
care (significance of the intervention) was greater when pharmacists were ward-
based, rather than simply providing traditional ward visits.
Barber et a! conducted a study monitoring pharmacist interventions in which all
pharmacists who visited patient wards in 27 acute care hospitals recorded their
daily ward visits and their clinical interventions, during 5 consecutive days
(Barber et a!., 1997), 248 pharmacists visited 10,478 beds and proposed 3,501
interventions. Of these 3371(96%) were accepted, 56 were rejected and 74
were unresolved. The most frequent reasons for the intervention involved the
dose (29%), the need for therapy (21%), the choice of drug (14%), and the
route (12%).
Batty and Barber carried out a survey in one English region (31 acute hospitals
with 10,337 beds) over 7 days (Batty and Barber, 1992). Pharmacists advised
doctors on 2095 occasions, most commonly relating to the dose and frequency
of administration, and this was accepted in 96% of instances.
Some studies look at perceived contribution to patient care by assessing clinical
significance of interventions. However, many fail to include an independent
assessor, and are therefore subject to bias.
Hawkey et a! (1990) analysed the interventions made by 35 pharmacists at 6
hospitals, over 28 days. These interventions were analysed for their potential for
preventing harm by one doctor. 769 interventions were made (2.9% of all
prescriptions); 7.8% of these were on prescriptions with major potential for harm
and 22.8% had appreciable potential for harm. 86% of pharmacist-interventions
were accepted, with wrong dose (280), dose not stated (50) and excessive
duration of antibiotics being the commonest problems. Assessment by a juror of
one doctor is open to potential invalidity and bias. Bias due to the collection of
data by pharmacists is also a possibility.
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Leach eta! (1981) conducted a retrospective survey of a random sample of
prescriptions form 6 wards in one general hospital for prescribing errors for
three months before and after the introduction of a ward pharmacy service. A
prospective study was performed of the contribution made by three ward
pharmacists. Personal records were made of the activities carried out by three
ward pharmacists on 13 medical and 5 surgical wards over three months.
Pharmacists noted any drug related problem that they detected, their action, the
result, and any questions asked by ward staff. Also a questionnaire survey of
medical and nursing staffs' opinions on the value of the service was carried out.
The results showed that a ward pharmacy service reduced errors and
ambiguities of prescribing by 40-50%, assisted in the safe and more effective
use of medicines in hospitals and was valued by medical and nursing staff. The
main weaknesses of this study were potential bias due to pharmacists self-
recording and assessing their activities with no independent assessment and
confounding (possible non-comparability of time periods).
Dhillon et a! (2000) showed that 467 interventions of major significance were
identified in 33 Trusts over a one week period. The pharmacist's advice was
accepted in 98% of cases. The data was further validated by a panel of clinical
pharmacists and it showed that 325 patients had a major adverse drug event
prevented. If these figures were extrapolated to provide annual rates in these 33
Trusts, approximately 17,000 patients had a major adverse drug prevented.
Stubbs et a! (2004) studied the nature and effectiveness of pharmacists'
interventions in correcting prescribing errors they detected during a one-month
period in a psychiatric hospital. Pharmacists in the course of their work in
pharmacy and on the wards, recorded on data entry forms, details of
prescriptions they considered contained prescribing errors. They also recorded
whether or not the drugs had been administered. Data were scrutinised by the
two study pharmacists and a consultant psychiatrist involved in the study. 211
errors were detected in 188 prescribed items, with prescription writing errors
(76%) more common than decision making ones (24%). Pharmacists corrected
errors in 92% of instances, however the drug had already been administered in
65%. The potential severity of prescribing errors was rated by the investigators
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and 11.4% were considered to have potential to cause harm for example
prescribing ibuprofen with lithium, omitting antidepressant on discharge
medication and incorrect high starting dose for quetiapine. Again, bias may
have been introduced in this study due to a lack of independent assessment, as
the 3 investigators rated all the pharmacist interventions.
Griffith et a! demonstrated the beneficial effects of pharmacy services on
hypnotic prescribing in a hospital setting (Griffith and Robinson, 1996). As part
of an on-going pharmacy audit, a policy was implemented to try and improve
prescribing habits resulting in the average monthly number of sleeping tablets
prescribed falling from 2392 to 734.
Pharmacists have traditionally had an important quality control role in checking
patients' medication. The Audit Commission reported that typically, pharmacists
within six hospitals in the Oxford region, amend between one-fifth and one-
quarter of inpatient prescription charts, for a variety of reasons that reflect
shortcomings in the basic rules of prescribing (Audit Commission, 2001).
In a study detailed in section 2.2.4.2, pharmacists were the main source of
defence, identifying and rectifying all the 88 serious prescribing errors reported
in the study (Dean et a!., 2002). Prescribers who made 44 of the mistakes were
interviewed and pharmacists were specifically mentioned in 16 interviews.
Doctors welcomed help from pharmacists, since they not only identified
mistakes, but also provided an educational role to the individuals in doing so.
However, some junior doctors suggested that they trusted the pharmacists carry
out this role so much so that they would sometimes not bother to look up doses.
The presence of pharmacists on ward rounds as a full member of the patient
care team reduces prescribing errors significantly, (Leape et a!, 1999),
enhances patient care and reduces drug costs.
Cloete and Heath (1997) recorded and costed changes in drug therapy resulting
from pharmacist interventions on psychiatric consultant ward rounds, over a 12
month period. There was a 29% reduction in the number of drugs prescribed
per patient, the number of patients taking more than one antipsychotic dropped
from 54% to 29% and those taking more than two antipsychotics from 2.5% to
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zero. The number of patients on antipsychotics who were also taking an
anticholinergic dropped from 62.5% to 43%. The calculated saving in the drugs
bill over the 12 month period was £3212.
Although some studies have examined the economic benefits of particular
aspects of pharmaceutical care, such as the impact on drug costs, there are no
UK studies that address a full economic evaluation, taking into account factors
such as potential cost minimisation through avoidance of medication errors and
adverse reactions, reduced hospital re-admissions, reduced length of hospital
stay and/or social costs.
In this section I have shown that ward-based pharmacists have an important
role in improving patient care and advice is almost always accepted by
prescribers. Inclusion of pharmacists in medical teams gives greater scope for
them to contribute proactively rather than reactively. This literature is especially
important for my study as it provides support for my hypothesis about the value
of pharmacists working on wards and being more intimately involved with
patient care. It also gives me guidance about how to design my study,
particularly in attempting to strengthen my approach. Intervention monitoring is
clearly a valuable method of assessing the impact ward-based pharmacists can
have on patient care, although it has limitations, for example it is difficult to link
their effect to patient outcomes, which I discuss in more detail in section 2.7,
and different people assessing interventions may disagree on their clinical
significance. In my study I intend to use two independent pharmacist assessors
to measure the significance of any interventions into patient care in an attempt
to avoid bias. The literature has helped me understand the limitations of
intervention monitoring and I discuss this later in my thesis.
2.6.5.2.	 Compliance and patient education
Several, mainly small, studies have shown that verbal education improves
patient knowledge and compliance in the short term and that, subjectively,
patient responses are favourable (Cotter et a!., 1995).
MacDonald et a! (1977) assessed the value of patient education by a
pharmacist and memory aids in improving compliance in geriatric patients.
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Patients were allocated to one of three groups. 60 patients were educated by a
pharmacist for 15 minutes prior to discharge and their understanding was
formally assessed. 45 patients were counselled in the above manner but were
also issued a memory aid such as a daily calendar specifying the medication
schedule. 60 patients acted as controls receiving no counselling from the
pharmacist, receiving only the brief description of tablets from nursing staff. All
patients completed a mental status questionnaire (MSQ) and all were able to
take their tablets before leaving hospital. A week after discharge patients were
asked to detail their dosing schedule and describe the purpose of their tablets.
Compliance was checked using a tablet count. Patients in the three groups
were similar in age, sex, MSQ score and number of tablets being taken.
Improved compliance was seen in the educated groups at follow-up and this
was statistically significant. The use of memory aids did not improve
compliance. Multiple errors were more common in patients who had not
received any education. The validity of this study however, is questionable as
tablet count may not give a reliable indication of the number of tablets being
taken and does not measure when tablets were taken. The examination of
patients' knowledge of their dosage schedule reduced this potential problem but
the assessment of patients' knowledge by the educating pharmacist may have
biased the results.
Johnston et a! conducted a randomised controlled trial in a single hospital
(Johnston eta!., 1986). The control group received the usual nurse education
on discharge whereas patients in the test group were given additional education
by a clinical pharmacist. Later on the day of education, a psychologist blindly
assessed the patients' knowledge using a standardised format. 13 controls and
14 test patients were recruited and those educated by the pharmacist were
significantly better informed about their medicines than controls (P<0.02). The
independent assessment helped reduce bias, but the lack of post discharge
follow-up made it difficult to assess the true effects of pharmacist education.
Goodyer et a! randomly allocated elderly patients with chronic stable heart
failure to receive a 3 month pharmacist education programme, or no education
(Goodyer eta!., 1995). Compliance improved for the pharmacist educated
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group by 32% but remained unchanged for controls. Medication knowledge, 6
minute exercise test and peripheral and pulmonary oedema scores improved for
the educated group only, remaining stable or worsening in the control group.
Improved compliance due to intensive medication education by a pharmacist
had a small but measurable beneficial effect on objective measures of heart
failure.
Wandless and Whitmore, however, found that education by a pharmacist in
elderly patients at a day hospital had no effect on compliance (Wandless and
Whitmore, 1981). They randomly allocated patients with a mental test score
(MTS) of 20 or more to a control or test group. A pharmacist educated the test
patients and the control group had no education. Compliance was assessed by
tablet count. Test patients' initial understanding of their medication regimen was
assessed by the pharmacist by asking them to recall their dosage regimen. 23
patients were allocated to the control group and 30 patients to the test group.
Patients were similar in age, MIS and number of prescribed medicines but their
error rate in recalling their dosage regimens were significantly different. Before
pharmacist education 13 test patients were non-compliant; after education 14
were non-compliant. Differences in patients at baseline, the use of tablet counts
to assess compliance and the use of the pharmacist educator to assess
knowledge and errors make the results subject to bias and confounding.
As already discussed, the concept of concordance is now promoted and
research in this area is currently growing. For example, Blenkinsopp et a!
showed that a structured intervention significantly improved clinical outcomes in
people with hypertension, albeit in a primary care setting (Blenkinsopp et a!.,
2000). From previous research and interviews with 40 hypertensive patients
they developed a questioning protocol for pharmacists to use with patients
which contained questions about:
. whether the patient was having any difficulties with medication,
. how often the patient had forgotten to take the medicine, increased or
reduced the dose, missed doses or stopped taking the medicine altogether,
. what side effects patients experienced,
94
. whether patients wanted more information about his/her condition or
medication,
• if patients had any questions.
25 community pharmacists were randomised into intervention or control sites
and were asked to recruit 20 patients receiving treatment for hypertension. The
pharmacists in the intervention group delivered the intervention to a total of 117
patients on two or three occasions, two months apart, and on each occasion the
pharmacists recorded the patients responses to the questions, the actions the
pharmacists took and the length of the conversation. The pharmacists in the
control group provided normal care to 115 patients. Data from the patients'
medical records showed that those who had uncontrolled blood pressure before
the study were significantly more likely to have controlled blood pressure after
the study if they received the intervention than if they were in the control group.
The patients in the intervention group also reported significantly increased
adherence and greater satisfaction with several aspects of pharmacy services
after the intervention.
In this section I have presented several studies which demonstrate the benefits
on compliance that pharmacist counselling of patients can have. One study
failed to demonstrate any effect. This literature has been especially helpful
when considering how I will assess patient compliance and the best way to
intervene to improve patients' understanding of their medication regimen, and
therefore the opportunity for compliance at home. Clearly there are problems in
assessing compliance and the effect that counselling has on this. I intend to use
careful patient questioning to gain a measure of compliance rather than tablet
count, as I feel that particularly in a hospital setting, where patients often do not
bring all their tablets from home, this is more appropriate. The intervention in
this study will involve two-way communication between patient and pharmacist,
based on a patient centred approach in which the pharmacist assesses
patients' experience of their condition and treatment, and a structured
questioning protocol to identify patients' medication problems (Cox et aI.,2004).
Interventions such as this appear to have an impact on many outcomes
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including patient medication knowledge, satisfaction, changes in health and
adherence.
2.6.5.3.	 Evaluation of pharmaceutical care services at the
primary/secondary care interface
In this section I present research into pharmacy input at the point of admission,
undertaking drug histories, and at discharge, to facilitate continuity of care. I
discuss various pharmacist interventions at the primary/secondary care
interface and methods used to evaluate these.
Admission medication histories taken by pharmacists have consistently been
shown to be more accurate and complete than those taken by junior medical
staff, (Truitt eta!., 1982, Titcomb, 1989, Badowski eta!., 1984), although there
is little information on the contribution this makes to patient outcomes.
Dodds (1982) compared the drug history taken by a pharmacist using a
specifically designed questionnaire, to that of the doctor's normal history for 302
patients admitted to a gynaecological ward over 4 months. In the first month of
comparison, the doctor omitted 41% of entries recorded by the pharmacist, and
in the second month omitted 21%. Of ADRs detected by the pharmacist, the
doctor missed 56% in the first month and 15% in the second month. The study
was biased because the doctor was aware of more information at the time of
drug history taking than the pharmacist. This study, although lacking data on
outcome, showed that the process of care was enhanced.
As part of a five month study on three care of the elderly wards, to evaluate
provision of a pharmaceutical care service, Binyon (1994) undertook a drug
history procedure and pharmaceutical assessment for 38 patients. The results
state 24 cases of treatment being adjusted and improved based on information
obtained from the pharmacist drug history procedure, although the types of
drugs or clinical significance of these are not assessed.
Badowski et a! (1984), validated a questionnaire to be used by a pharmacist to
obtain a drug history and determine the clinical importance of the extra
information obtained by the pharmacist compared with that obtained by the
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physician. Once the validity of the questionnaire was confirmed using six
simulated patients, a pharmacist used the questionnaire to interview 80 newly
diagnosed patients and was blinded to the physician's drug history, which
served as a control. The additional drug history information was shared with the
physician as soon as it was obtained as it was deemed unethical not to do so.
The results were reviewed by a panel consisting a doctor and two clinical
pharmacists, to determine if additional information had indeed been obtained,
and the clinical importance of this. The pharmacist obtained at least one piece
of additional information for 76 of the 80 patients. The expert panel concluded
that 11% of drug histories obtained by the pharmacist contained clinically
important information missed by the physician, for example, well-defined
allergies to antibiotics, contraindications to drugs, and drug interactions. It is not
stated whether the panel were independent to the study therefore potential bias
could not be identified.
In a recent study, outlined in section 2.4.1, Gleason et a! concluded that
reconciliation by pharmacists of discrepancies in admission medication histories
and orders decreased opportunities for medication errors and the potential for
patient harm (Gleason et a!., 2004).
Pharmacist involvement in discharge also facilitates continuation of care and
enhances patient outcomes. There is evidence that pharmacists are five times
more accurate than doctors in writing discharge prescriptions (Stevenson,
1998). The studies examining the effectiveness of pharmacy input into
discharge of patients are subject to the same biases as previously mentioned
intervention studies i.e. the same pharmacists delivering and evaluating the
intervention.
Shaw et a! evaluated the effect of pharmacy discharge planning on the
pharmaceutical care issues experienced by 97 discharged mental health
patients (Shaw et a!., 2000). Patients recruited from three acute-admission
psychiatric wards were randomly allocated to either an intervention group
(receiving a baseline pharmaceutical needs assessment, information about
medicines and then a pharmacy discharge plan sent to their community
pharmacy) or a control group (no such additional pharmaceutical care).
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Domiciliary visits were carried out at one, four and 12 weeks post-discharge and
medicine knowledge and the number and types of medication problems
experienced were assessed at each visit. Fewer medication problems were
recorded for the intervention group and there was a trend for reduced
readmissions, but this was not statistically significant.
Following a pilot phase on an acute admissions ward, Cattell et a!, assigned 68
patients from one surgical and one medical ward, to have their discharge
medication organised by either a pharmacist (intervention group) or using the
existing system (control group) (Cattell eta!., 2001). Median discharge
prescription processing time (time from discharge decision to patient discharge)
was significantly less in the intervention group than in the control group (322
versus 460 minutes, P=0.0056). The median discharge prescription dispensing
time was significantly greater with the existing system than when prescriptions
were transcribed by the discharge pharmacist (240 versus 177 minutes,
P=0.005). Integration of a pharmacist into the discharge system was found to
improve the timeliness of discharge, benefiting hospital bed management.
Significant reductions in wastage and release of medical time were also
demonstrated.
Cromarty et a! recruited 90 elderly patients to a test or control group on
discharge (Cromarty eta!., 1998). A pharmacy information letter providing
information on the discharge medication was given to the test group of patients
only, at discharge and a copy was sent to the patient's GP, community
pharmacist and community nurse. The provision of this letter was valued by
patients and significantly decreased the incidence, once home, of medication
related problems.
Patients whose medicines are assessed by pharmacists both before and four
weeks after discharge from hospital require less long-term social support, are
less likely to be readmitted or to suffer adverse effects from their medicines
(Green, 2000). In a project at a UK general hospital lead by Green, patients
considered suitable for early discharge were visited by a 'collaborative care'
pharmacist 48 hours before being sent home. Patients' take home medicines
were reviewed by the pharmacist and a care plan was drawn up identifying any
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potential risks, for example continuation of drugs that had been intended for
short courses, falls possibly due to medication and complicated drug regimens.
Patients were pleased to be visited and the earlier discharge increased the
number of beds available. The collaborative care pharmacist used a scoring
system to assess the patient's level of risk from their medicines and their ability
to cope with their dosing regimens and those with higher scores were most
likely to need continued support. This project won the Shared Care Section of
the Pharmaceutical Care Awards 1999.
Subsequently, a study has been undertaken to validate this scoring system
(Ranson et al., 2003). Over a four month period, 99 patients were referred by
the Collaborative Care Service (a team made up of physiotherapists,
occupational therapists, carers and a pharmacy team which aims to facilitate
the transition of patients from hospital into the community). A pharmacist saw
patients prior to discharge and scored them using the risk assessment tool
(RAT). All patients were followed up 2 to 4 weeks after discharge by a second
pharmacist, blind to the risk score, who carried out a semi-structured interview
to identify medicine related problems (MRPs). 51 patients were given a high-risk
score and 48 a low-risk score. 294 MRP5 were identified on follow-up, of which
79% were from the high-risk group. There was a significant difference in the
mean number of MRPs in the high-risk group compared to the low risk group. A
strong correlation was found between the total risk score and MRPs and the
authors concluded that the RAT was effective at highlighting patients who would
most benefit from extra pharmaceutical input following discharge.
Despite evidence supporting pharmacist involvement to improve seamless
pharmaceutical care at discharge, (Dobrzanski and Reidy, 1993, Coombes and
Home, 1994, Cantrill and Clark, 1992, Lord, 1999, Milliken and Rea, 1997),
many of these schemes have been restricted to certain wards or selected
patients or have formed part of a research project that has proved difficult to
expand or continue because of staffing difficulties. In addition, bed pressures
may lead to hasty discharges which preclude proper discharge planning even
when resources are available. In 1987, 40% of nearly 200 patients discharged
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from Welsh hospitals had less than 24 hour notice of their impending discharge
(Victor and Vetter, 1987).
In 1999, Sexton et a! sent a questionnaire to each NHS Trust providing acute
hospital services in the UK, with a covering letter to the chief pharmacist
requesting it be forwarded to the most appropriate pharmacist for completion
(Sexton eta!., 2000). The response rate was 73.4%, and virtually all discharge
prescriptions were hand written by junior doctors. The major contribution of
pharmacists was screening the prescription against the ward prescription chart,
but a quarter of Trusts replied that even this did not happen. Hospitals used a
wide variety of methods to communicate information about medicine regimens
to GPs and discharge counselling, telephone 'help-lines' and clear medication
records to patients also varied widely. The authors conclude that there is still a
wide variation within hospital pharmacy practice in meeting the medicines-
related needs of patients at discharge.
In this section I have discussed the value of pharmacists working closely with
patients at the time of admission and discharge from hospital to ensure
optimum patient care with respect to medicines. It is clear that pharmacists
have a particularly useful role in obtaining drug histories. This literature is
particularly useful as I will be examining how doctors obtain drug histories and
how accurate they are, and if there are similar problems, as I suspect, at the
study trust, I will develop an intervention aimed at improvement. The studies
have guided me in how I will conduct my work, especially how drug histories
should be obtained and how to assess the benefit of this method. It is important
not only to quantify the discrepancies between different methods of taking drug
histories, but to look at the clinical significance.
It is also evident that pharmacists have an important role in coordinating
discharge medication. The studies suggest that patients experience fewer
MRPs when pharmacists are involved in assessing pharmaceutical needs,
planning discharge medication and providing information to patients. There is
also evidence that patients with more complicated medication regimens can be
targeted as they have more MRPs following discharge. Patients were found to
appreciate pharmacist involvement, time to discharge may be shortened and
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possibly readmission rates reduced. This literature has again helped me plan
how l will conduct my study in particular developing and assessing discharge
interventions. Planning for discharge must start early in the patient's stay to
enable patients needs with respect to their medicines to be met.
2.6.6.	 Changing practice
Achieving wholesale change in practice may be difficult. Recommendations
made based my research will probably be insufficient to change practice.
Professional behaviour is influenced by organisational and community
environments of practice as well as beliefs, attitudes and knowledge (University
of York. NHS Centre for Reviews and Dissemination, 1999).
Before attempting to implement a new approach to pharmacy practice it is
essential that factors which are likely to influence the proposed change are
identified. Organisations are thought to move through a series of stages in the
process of change. For example an early model still in use today suggests three
stages: Unfreezing of old behaviours or practices, i.e. a recognition that the old
ways of doing things are no longer sustainable, changing to a new position,
maybe through exposure to new information and refreezing of new attitudes,
practices or policies through reinforcement and support (Lewin, 1951).
Barriers are factors which impede the implementation of change in professional
practice. They have been classified as those related to the individual health
care professional (knowledge, skills, attitudes, habits), to the social context of
care provision (reactions of patients, colleagues, authorities) or to the
organisational context (available resources, organisational climate, structures
etc). To implement a new approach to pharmacy practice effectively the factors
which may either enhance or inhibit the change of practice must be identified,
and taken into account.
It is well established Government policy to break down professional barriers
where they adversely affect patient care. The service developments and
extension of the roles of pharmacy staff proposed from this research therefore
fit in very well with Government's vision for the NHS. The old stereotypes of
doctors, nurses and pharmacists must be broken down, with shifting of role
boundaries to reflect the needs of patients. Work organisations, however, try to
define the various roles in their hierarchies as closely as possible so that there
will be no conflict about different people's rights and responsibilities (Banton,
1965). In one sense it is in the interest of the patient to have subdivisions within
the workforce as each professional group has its own body of knowledge and
skills to offer the patient, for example a pharmacist has specialist knowledge
relating to therapeutics. Whilst the separatist way of working, and professional
isolation has this advantage for patients, it is vital for healthcare workers to work
as a team, communicate well and share therapeutic aims to ensure optimum
patient care.
This is very important within my study as it is essential that I identify how the
barriers to implementation will be overcome and how it is possible for the
pharmacist to be accepted into the multidisciplinary team. From my previous
experience I feel that the most important obstacles are people, specifically
different professional groups. The culture in the Trust and issues of professional
autonomy and practice are also obstacles to implementing change. It is vital
that I consider these issues throughout the course of this study.
2.6.7.	 Summary
In section 2.6 I have discussed strategies for improving medicines aspects of
patient care. I have examined the Governments strategy and commitment to
improving the quality of patient care, and their vision for pharmacy services to
deliver this. I have discussed the development of hospital pharmacy services,
the progression to clinical pharmacy and then the concept of pharmaceutical
care. I then described the current realities in pharmacy services and research in
this area. Finally I explored the difficulties which may be faced in attempting
change within organisations, and issues which will need to be addressed. This
literature is particularly relevant as it demonstrates that my research is in line
with current Government policy and aspirations of the pharmacy profession. In
addition it gives some background about the development of pharmacy services
and the current position. This will assist in developing my interventions and give
me studies in similar areas to which I can compare and contrast my data to help
theorising and discussion of results.
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2.7.	 ACTION RESEARCH
In this section I will discuss action research, starting with a brief overview of
action research, then in section 2.7.1 I explain some of the problems
researchers face when trying to develop methodologies to assess the impact of
interventions. In section 2.7.2 I discuss the various typologies and distinguishing
criteria that have been used to differentiate between different types of action
research. Then in section 2.7.3 I explore the application of action research in
health care, in particular in nursing in section 2.7.3.1, in medicine in section
2.7.3.2 and pharmacy and medicines management in section 2.7.2.3. In section
2.7.4 I discuss the value of qualitative methods in health care research. In
section 2.7.4.1 I introduce ethnographic technique moving on to discuss its use
specifically in health care research. In section 2.7.4.2 I describe participant
observation, in section 2.7.4.3 I discuss interview techniques and in section
2.7.4.4 I describe the use of focus groups. I finally move on to talk about data
analysis and theorizing using grounded theory in section 2.7.4.5 I describe
method triangulation in section 2.7.4.6.
In this study, I have used action research methodology, as it is particularly
suited to identifying problems and their solutions in clinical practice (Hart and
Bond, 1995). Action research is a style of research rather than a specific
method, and may employ a range of research methodo1oies. Adopttn this
approach does not constrain a study to particular qualitative or quantitative
methods; a range of methods can be used, enabling triangulation of data which
will help overcome the problems of any single approach. Because of the
complexity of the study setting this was considered to be a particular advantage.
Kurt Lewin is recognised as the founder of action research, introducing the term
as a way of generating knowledge about a system at the same time as trying to
change it. Lewin was a social scientist, concerned with intergroup relations and
minority problems in the United States. He placed much emphasis on the need
for practical joint studies between social scientists and practitioners, aimed
towards social change through a problem solving approach (Lewin, 1946).
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Action research is particularly suited to identifying problems in clinical practice
and helping develop potential solutions - serving to bridge the gap between
theory and practice. Action research is powered by the processes of enquiry,
intervention and evaluation, and it aims at both taking action and creating
knowledge or theory about that action. It is cyclical in nature and underpinned
by a collaborative and democratic philosophy - that is, it involves a supportive
partnership of researchers and researched, being concerned with doing
research with and for people, not on them. In this way action research
empowers both researchers and participants (Hart and Bond, 1995, Webb,
1989, Meyer, 1993, Holter and Schwartz-Barcott, 1993). Similarly, Meyer's
definition of action research, incorporates three important elements: its
participatory character; its democratic impulse; and its simultaneous
contribution to social science and social change (Meyer, 2000). These elements
are reflected in the current study. Both patients and health care practitioners
were active participants feeding their views and experiences into the research
process and significantly influencing development of the model of care. The
study has identified improvements in care and has added to the knowledge
base underpinning the development of pharmaceutical care.
It has been suggested that professional practitioners often engage in practice a
less than effective levels because they follow routines, and furthermore, their
actual practice does not necessarily coincide with their 'better knowledge', or
espoused theories about good practice (Kim, 1999). Practitioners may not even
be aware of this divergence. Action research that includes reflective practice is
a way of determining why professional practice diverges from the ideal.
In essence, action research involves a cyclical process which identifies a
problem in practice, reflection and analysis to assess the problem and develop
a plan for improvement, action to implement change and evaluating and
learning from the change process. The cycle continues, with findings fed back
into practice with the aim of continuous improvement (figure 2.6).
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Specifying learning 	 Action planning
Exploring general findings	 Selecting and planning
RESEARCH	 inte,ventions
INTO ACTION
	
2
Evaluating	 Action taking
Reviewing the consequences 	 Implementing change
Figure 2.6 The cyclical process of action research
Lewin described the process as a spiral of steps, initiated by a general idea and
general objective (Hart and Bond, 1995). The first step is fact-finding about the
original idea; planning and further fact-finding; taking action, which may involve
modification of the original idea; evaluating the action; and on the basis of this
further planning and modification takes place and a decision is made about the
next step. The next step then proceeds in the same way as the first, so that,
rational social management, therefore proceeds in a spiral of steps each of
which is composed of a circle of planning, action and fact-finding about the
result of the action."(Lewin, 1946)
105
2.7.1.	 Methodological difficulties
In this section, I give a brief explanation of the problems researchers face when
trying to develop methodologies to assess the impact of interventions into
patient care.
The major difficulty in evaluating the efficacy of patient centred pharmacy
services is the problem of linking their effect to patient outcomes. The impact of
a pharmacist's contribution to patient outcome is difficult to measure as it is only
one part of the total patient care package provided by health care professionals.
Even a specific indicator like the use and choice of drugs is influenced by
several factors such as: patients themselves, doctors and other members of the
healthcare team, hospital policies and the wider prescribing policy environment,
e.g. NICE. Furthermore, even obtaining consensus of what constitutes a reliable
or acceptable outcome measure of clinical pharmacy performance can be
problematic (Fowler and Campbell, 2001).
Although outcome measurement is considered to be the ultimate test of
effectiveness of a service, difficulties in measurement mean that research into
pharmaceutical care has tended to focus on structure and process. There is a
tacit assumption that if these are improved, then patient outcomes will similarly
benefit. These studies are only reliable if we can be certain of the relationship
between process and structure variables and true clinical outcomes. A further
difficulty is that, although hospital pharmacists frequently influence therapeutic
decisions, their input is rarely recorded in the medical record.
The Medical Research Council has defined the concept of a 'complex
intervention' as comprising a number of separate elements, which seem
essential to the proper functioning of the intervention, although the "active
ingredients" of the intervention (that are effective) are difficult to specify
(Medical Research Council, April 2000).
Clearly, pharmaceutical care is a complex intervention. It is multi-factorial with
patients receiving a range of services. The "active ingredients" of
pharmaceutical care are not easily defined, and there are many intangible
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elements such as the pharmacist's personality, expertise, skill mix, patient
characteristics, inter-professional relationships and organisational culture.
Even if all other influences on patient outcomes were absent or could be
controlled, pharmaceutical care itself would remain intrinsically difficult to
evaluate because of this complexity. This explains the attraction of
methodologies that seek to reduce the complexity by focussing on discrete
segments of care such as medication histories - they can yield valuable results
but fail to capture the real impact on patient experience.
Direct measurement of patient outcomes is often not possible for ethical
reasons, for example studies estimating the potential impact of pharmacist
identification and correction of prescribing errors, on patient and economic
outcomes. These studies can only "estimate" the expected impact rather than
"measure" the observed impact that prescribing errors would have in the
absence of pharmacists' interventions. This represents the only practical
method of evaluating the impact of some pharmaceutical care interventions.
The alternative is to knowingly allow prescribing errors and medication errors to
occur so it is possible to observe and measure their impact on patient
outcomes. This is obviously unethical. There may indeed be some important
aspects of pharmaceutical care for which true patient outcomes may never be
available.
Similarly, problems arise in attempting to use comparisons in evaluating
pharmaceutical care. Now it is unethical to compare pharmaceutical care
services with a "no service scenario".
Most published studies have used quantitative methodologies. However,
qualitative studies can yield valuable insights into patient experience and are
widely used in other areas of health services research. Combining both
methodologies can provide a powerful tool to research complex interventions
such as pharmaceutical care.
In summary, designing studies such as my own is very difficult and careful
consideration must be given to methods used. I should therefore pay particular
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attention to my methods when presenting and discussing the results. I will now
give a brief rationale and background for the methodologies employed in this
study.
2.7.2.	 Action research in process: typologies
Various typologies and distinguishing criteria have been put forward to
differentiate between different types and models of action research. Hart and
Bond (1995) suggested seven criteria which identify different types of action
research, and which together differentiate action research from other
methododologies. In their typology, action research:
. is educative for those involved,
. deals with individuals as co-workers of social groups,
is problem-focussed, context specific and future orientated,
. involves a change intervention,
. aims at improvement and involvement,
. involves a cyclical process in which research, action and evaluation are
interlinked and
. is founded on a research relationship in which those involved are
participants in the change process.
Using these criteria, Hart and Bond identify four basic types of action ;search:
the 'experimental type' which is most closely associated with the early
days of action research and the scientific approach to social problems,
the 'organisational type' which represents the application of action
research to organisational problem solving, including problems such as
restriction of absenteeism, and has its core concern to overcome resistance
to change and create more productive working relationships,
the 'professionalising type' which is informed by an agenda grounded in
practice which also reflects the aspirations of the new professions, such as
nursing, teaching and social work to enhance their status on a par with the
108
established professions such as law and medicine, and to develop a
research-based practice and
• the 'empowering type' which is most closely associated with community
development approaches and is characterised by an explicit anti-oppressive
stance to working with vulnerable groups in society.
Moving across the typology from the 'experimental' to the 'empowering' type,
can be interpreted as a developmental process as action research has shifted
from a scientific approach to social change to a more qualitative approach
involving negotiated solutions.
Against a nursing background, Holter and Schwartz-Barcott (1993) have
identified an alternative framework which has three approaches:
• the 'technical collaborative approach' which aims to test a particular
intervention based on a pre-specified theoretical framework, with the
researchers having greater control. This approach is deductive and
predictive and would be encompassed within Hart and Bond's 'expenmental
action research',
• the 'mutual collaboration approach' which brings researcher and
practitioner together to identify problems and seek possible causes and
ways of intervening to change them. This approach is deductive and
descriptive and is comparable to Hart and Bond's 'organisational type' of
action research and
• the 'enhancement approach' which attempts to align theory and practice,
to resolve problems, and develop practitioners' skills in identifying and
solving problems by raising their collective consciousness. This broadly
corresponds with Hart and Bond's 'professionalising type' of action research
but also overlaps with their 'organisational type'. The main aim is the
improvement of professional practice at the level of organisational and
cultural change.
Whilst these typologies are useful in understanding the wide range of action
research, its inherent flexibility means that it is not always possible to delineate
action research into specific categories or types. In practice the typology are not
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distinct: they overlap and in the course of a project the style and strategies
adopted may shift from one type to another as it moves through the spiral of
cycles (Hart and Bond, 1995).
2.7.3.	 Action research: application in health care
The original application of action research was to problems in American industry
in the 1940s (Lewin, 1948). More recently, this approach has been adopted
successfully in education (Carr and Kemmis, 1986, McNiff, 1988, Whyte, 1991),
and in health care, which I now discuss
2.7.3.1.	 Nursing
Action research is increasingly used to improve nursing practice, education and
management, and professional development. Towell and Harries (1979)
adopted action reseacth to tacthtate ctane 	 p	 tnc.	 .t'n
involved them acting as facilitators of change, giving advice and emotional
support to participants. They saw it as a means whereby staff could "take back
the authority for clarifying their own roles and establishing conditions under
which they could organise their work most effectively." Meyer (1993) reviewed
studies in nursing and some of the methodological issues that arose,
particularly the nature of the collaborative nature of the relationship between
researcher and participants. Tichen and Binnie (1993) used action research to
address problems of developing new nursing roles and shifts in power
relationships within the ward team.
East and Robinson (1994) applied an action research approach to facilitate the
transition from the traditional ward sister nurse role, to the new 'ward managers'
in a district general hospital. Hospital managers and senior ward nurses had
divergent views concerning the source of challenges and problems within the
hospital. The researchers explored both sides of the story, and identified
possibilities for opening up common ground to facilitate change. Stark (1994)
describes how the action research process, which is underpinned by self
reflection, has the potential to develop practitioners both professionally and
personally.
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Action research has been used to explore ways of improving stroke care and
rehabilitation (Gibbon and Little, 1995), and more recently Kilgour undertook an
action research enquiry into a health visitor programme for parents of school
children with behavioural problems (Kilgour and Flemming, 2000).
Taken together, these and many other studies show that action research is a
valuable approach to problems in nursing care, through analysis and reflection,
development of action plans for improving care, and implementation and
evaluation of those plans.
2.7.3.2.	 Medicine
In contrast, action research has been used much less in studies in medicine,
where experimental or structured survey methodoJogies have been
predominant. However, some studies using this approach are now beginning to
appear. Murray et a! used action research to define the health and social needs
of a community in Edinburgh, identified priorities for change and formulate joint
action plans between the residents and the extended primary care team
(Murray et a!., 1994). Robinson and Stacey developed guidelines on palliative
care in the community for primary care teams (Robinson and Stacey, 1994).
The Royal College of Physicians in England has mounted an action research
study to explore the roles of clinicians and managers in overcoming barriers to
implementing clinical audit (Berger, 1998). Hampshire et a!, noting that there
were few examples of the use of action research in general practice, used this
approach in 14 practices to improve child health surveillance. They concluded
that this was a successful method for promoting change in primary care but that
measuring the impact of change was difficult (Hampshire eta!., 1999).
2.7.3.3.	 Pharmacy and medicines management
Despite the increasing use of action research in health care sethngs, most
notably in nursing, and its evident relevance to the complexities of current
issues in pharmacy practice and the use of medicines, researchers in these
fields have been slow to adopt this methodology and there are very few
published studies. One reason might be that, like medical researchers,
pharmacists have been more comfortable with traditional approaches such as
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randomised controlled trials or structured surveys. Gilbert et a! (2002) used a
participatory action research approach to design and evaluate a model for
implementing home medication reviews. A collaborative approach involving
general practitioners, pharmacists and patients, was adopted to solve problems
as the research process progressed. A participatory action research approach
has also been used in Denmark to improve the quality of patient counselling in
community pharmacies, by comparing the staffs views on, knowledge of and
behaviour towards patients, with the views, perceptions and medicines use of
those same patients (Haugbølle eta!., 2002).
In summary, action research has been demonstrated to be a valuable tool for
improving quality in health care, albeit primarily in a nursing setting. It has wider
applications in health services research. It lends itself particularly well to the
current research, which aims to address complex issues of the use and safety
of medicines, professona practice and cu'iture, new roes for pharmacists and
facilitation of change.
2.7.4.	 Qualitative methods in action research
Because the issue of quality in health care is complex and often ill-defined, it is
intrinsically difficult to evaluate. The assessment of quality of services cannot
only be confined to measurement by the objective, value free, systematic
processes of quantitative methods, such as measuring waiting times. Rather, it
requires an understanding of processes, and individuals' experiences and
perspectives of what constitutes high or poor quality care. Experimental and
quantitative methods are less well suited to answer these questions.
Qualitative approaches are an essential part of health services research, as
they enable access to areas not amenable to quantitative research. The
emphasis in qualitative research on meanings and experiences make this
approach particularly useful for quality assessment and improvement.
Most qualitative research is inductive in nature, moving from observation to
hypothesis rather than hypothesis testing or deductive. For example, within the
qualitative tradition it is emphasised that in order to get behind respondents'
formal public statements and behaviour to uncover their personal perceptions
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and actual day to day actions, it is important not to impose prior categories and
concepts from the researcher's own professional knowledge on to the process
of data collection (Bryman and Burgess, 1993).
2.7.4.1.	 Ethnographic technique
Ethnography has its origins in cultural anthropology and sociology, although
now it is being increasingly used in other fields of enquiry such as health care
research. Ethnography is a descriptive account where people's behaviour is
studied in everyday contexts, rather than under experimental conditions created
by the researcher (Hammersley, 1990). Data are gathered from a range of
sources, for example, detailed observations, informal or overheard
conversations, unstructured interviews and analysis of documents. The
approach to data collection is 'unstructured' in the sense that it does not involve
following through a rigid plan set up at the beginning and the categories used
for interpreting what people say and do are not pre-given or fixed. The does not
mean that the research is unsystematic but simply that initially the data are
gathered in as raw a form, and as wide a front, as possible. Ethnography can be
considered similar to the sort of approach we all use in everyday life to make
sense of our surroundings. The primary concern is discovering the nature of the
social world through intense study of particular settings or people. In essence,
ethnography involves the researcher spending some time in the company of
those being studied. Hammersley and Atkinson (1983) gave the following
explanation:
"The ethnographer participates, overtly or covertly, in people's lives for
an extended period of time, watching what happens, listening to what is
said, asking questions; in fact collecting whatever data are available to
throw light on the issues with which he or she is concerned."
(Hammersley and Atkinson, 1983)
The purpose of participating is to obtain a holistic view of how people live and
work within their own context. Ethnography is usually focused on a single
setting or group, of relatively small scale, carried out in everyday settings.
Analysis of data focuses on the meanings and functions of individuals' actions
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and mainly takes the form of verbal descriptions and explanations, with
quantification and statistical analysis playing a subordinate role at most
(Hammersley, 1990).
2.7.4.1.1.	 Ethnography: application in healthcare
In health care, ethnography has been seen as a useful way of accessing beliefs
and practices, allowing these to be viewed in the context in which they occur
and thereby aiding understanding of behaviour surrounding health and illness
(Morse and Field, 1996). Coombs (2003) used ethnography to explore decision
making between doctors and nurses in the intensive care environment in order
to examine contemporary clinical roles in this setting. She found that whilst the
nursing role in intensive care has developed, this has had little impact on how
clinical decisions are made and both medical and nursing staff identify conflict
during patient management discussions.
Through an ethnographic case study approach of a critical care unit, Manias
and Street (2001) explored how nurses and doctors constructed their practices
through knowledge to inform their decision-making. Ethnography has also been
used to understand the illness experience of patients with congestive heart
failure (Mahoney, 2001).
Within pharmacy practice, an ethnographic approach has shown that there are
differences in the nature and quality of advice and services provided by
community pharmacies depending on their location (Rogers eta!., 1998).
Ethnography is particularly useful in understanding the organisation of health
care (Morse and Field, 1996). Understanding why organisations operate the
way they do and how they can be improved is seen to demand methods that go
beyond questionnaires and surveys. Since my research depends on an
understanding of phenomena in the natural setting, i.e. the study trust, an
ethnographic approach was considered appropriate. Within my study
ethnographic technique will enable an understanding of practice and behaviour
relating to medicines within the trust studied and inform service developments.
Ethnography can provide a nuanced understanding of the organisation and
allow comparison between what people say and what they do.
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2.7.4.2.	 Participant observation
The systematic observation of organisational sethngs, team behaviour and
interactions is especially useful in studying quality issues as it allows the
researcher to uncover everyday behaviour and discover what really happens in
particular health care settings (Pope et a!., 2002). An important advantage of
observation is that it can help to overcome the discrepancy between what
people say and what they actually do. Observations can be participative or non-
participative according to the degree to which the researcher is involved with
the group of study. Participant observation has been described as an attempt to
understand the phenomenon by observing from inside a group, to understand
how people, including the researcher, interpret various situations (Bowling,
1997). In contrast, a non-participant observer maintains distance from the
phenomenon under study and does not interact in everyday activity of the group
under study, but instead tries to blend into the background in an attempt to
reduce any effect their presence may have on the groups' behaviour (Pretzlik,
1994). Attempts to define the role of an observer may not always fit neatly into
the two categories of participant and non-participant observation, and elements
of the two may be combined. The extent of participation varies according to the
nature and setting of the research and Gold (1958) identified four categories:
Complete participant, participates in a group's activities whilst concealing
their role from the group.
The participant as observer spends most of the time participating in the
groups' activities whilst undertaking observation, with the group's
knowledge.
. The observer as participant spends most of the time observing and only a
small proportion of time participating in normal group activity.
Complete observer, does not participate in group activities, but is only
concerned with observing behaviour.
One of the main problems with observation is the effect of the observer on the
'observed', which may lead people to be self-conscious and cause modifications
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in actions or behaviours. This is known as the 'Hawthorne effect' (Mays and
Pope, 1995).
There are however important issues to consider when using this type of
observation. There are ethical considerations, and covert participant
observation is rarely justified (Mays and Pope, 1995).
2.7.4.3.	 Interviews
There are three main types of interview: structured, semi-structured and in-
depth interviews (Arksey and Knight, 1999, Britten, 1995). Structured interviews
consist of administering structured questionnaires, and interviewers must ask
questions in a standardised manner, sticking rigidly to the script. This type of
interview is used only for collecting standard information from informants, and
as each person is asked the same questions, answers are more comparable,
allowing for robust testing of the hypothesis.
In-depth interviews are less structured than this. The researcher suggests the
subject for discussion but has few specific questions in mind and uses probes
as a stimulus to obtain more detailed information about what the interviewee
said. The direction is largely set by the informant and the interviewer adopts a
more passive, less directive role.
Where more specific information is required a semi-structured format is used.
Semi structured interviews are conducted based on a loose structure consisting
of open-ended questions that define the area to be explored, at least initially,
and from which the interviewer may diverge in order to pursue an idea in more
detail. This the most common and most diverse of the three formats.
Interviewers are free to follow up ideas, probe responses and ask for
clarification or further elaboration. Informants can answer questions in terms of
what they see as important and there is scope for them to choose what and how
much to say about a particular topic.
2.7.4.4.	 Focus groups
Focus groups are a form of group interview that capitalises on communication
between participants in order to generate data (Kitzinger, 1995). The idea
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behind focus group method is that the group processes can help people explore
and clarify their views in ways that would be less easily accessible in a one to
one interview. The method is particularly useful for allowing participants to
generate their own questions, frames and concepts and to pursue their own
priorities on their own terms, in their own vocabulary. Focus groups have been
defined by Kitzinger and Barbour as:
"Group discussions exploring a specific set of issues that are focussed
because the process involves some kind of collective activity" (Kitzinger
and Barbour, 1999).
Interaction is key to the method, giving a high level of face validity, because
what participants say can be confirmed, reinforced or contraindicated within the
group discussion.
Tapping into interpersonal communication is also important because this can
highlight (sub) cultural values or group norms (Kitzinger, 1995). By analysing
the operation of humour, consensus and dissent, and the narrative used within
the group, common and shared knowledge can be identified. For this reason
focus groups are particularly useful for examining work place cultures, for
example that in an acute NHS Trust. Focus groups have the added advantage
within this study, following an action research approach, of making participants
feel that they are an active part of the research process.
Combining focus groups with other qualitative methods such as ethnography
(Baker and Hinton, 1999), and individual interviews (Michell, 1999), as in my
study, can be very valuable.
2.7.4.5.	 Data analysis and theorizing using grounded theory
A grounded theory approach to data analysis was adopted in this study.
Grounded theory follows an inductive approach whereby theories emerge out
of, or are grounded in, data (Glauser and Strauss, 1967). A grounded theory
approach involves the following stages (Silverman, 2001):
i) an initial attempt to develop categories which illuminate the data
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ii) an attempt to 'saturate' these categories with many appropriate cases in
order to demonstrate their relevance
iii) developing these categories into more general analytical frameworks with
relevance outside the selling
Grounded theorising has two components: theoretical sampling and the
constant comparative method (Hammersley, 1981). Theoretical sampling
involves selection of cases based on emergent concepts to further develop
those concepts, as a way of developing a theory. The analysis relies on
systematic and rigorous searching of text for categories and themes. Initially
data are read and reread to identify and index themes and categories: these
may centre on particular phrases, incidents or types of behaviour. Once a few
analytical categories have been generated, the constant comparative method
can be used to further develop the model. Each segment of data is taken in turn
and its relevance to one or more categories having been noted, it is compared
with other segments of data similarly categorised.
2.7.4.6.	 Method triangulation
In its broadest sense, method triangulation involves using a combination of
methods to explore the same topic (Kimchi and Polivka, 1991). Each method
can look at the topic from a different perspective and these perspectives can be
used as a means of comparison and contrast. Using multiple methods produces
different kinds of data on the same topic.
Triangulation derives from navigation and involves locating a position by
referring to two or more coordinates. Sailors could identify their true position at
sea with reference to known fixed points, such as stars. The direct application of
this to the social world would suggest that if you measure the same
phenomenon from different angles or positions, you will get an accurate reading
or measurement of it (Mason, 1996). However, different methods and data
sources are likely to throw light onto different social phenomena or research
questions and therefore may not be directly comparable. The results, therefore,
from each method cannot be used straighiforwardly to corroborate (or
otherwise) each other.
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Furthermore, triangulation implies that there is one, objective and social reality
or location which can be discovered using appropriate triangulation points.
Using several approaches in the study of one phenomenon does not
necessarily mean that each provide data to complete the whole picture or that a
single consistent picture will be obtained. Some findings may indeed be
contradictory, but rather than considering these incorrect, such findings can
enhance understanding of the phenomenon and the research methodology.
Myers and Haase (1989), emphasising the importance of different data sources,
suggest that in studies of bonding between mother and infant, 'the subjective
descriptions of mothers' progressive ability to anticipate their infants' needs' can
be contrasted with the objective observations of mother-infant interaction'.
2.7.5.	 Summary
In this section I have given an overview of and rationale to the action research
approach used in this study and I considered the methodological difficulties
associated assessing the impact of interventions into patient care. I discussed
the various typologies used to differentiate between different types of action
research. I then explored the application of action research in health care, in
particular in nursing, medicine, and pharmacy and medicines management. I
discussed qualitative methods in health care research in particular ethnographic
technique, participant observation, interview techniques and focus groups.
Finally, I talked about data analysis and theorizing using grounded theory and
method triangulation. This literature is very important for my research as I will
be adopting an action research approach in this study and will use the
qualitative methods described in this section. It gives some background to these
methods, helps to rationalise their appropriateness for my research and guides
me in their use.
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3. CHAPTER 3- PRELIMINARY PHASE:
PHASE ONE AND PHASE TWO
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3.1.	 INTRODUCTION
As I have shown in chapter 2, despite the efforts made to improve the quality of
care in the NHS, failure to deliver safe and effective drug therapy often results
in poor clinical outcomes and waste. This can be a particular problem in the
care of older people. I therefore designed this study to investigate the extent of
such failures, the views and attitudes of health professionals and patients, and
the impact of pharmacy-led interventions. These issues are highly relevant to
current drives to improve care of older people, and County Durham Health
Authority therefore agreed to provide financial support for this project.
In this chapter I will describe the preliminary phase of the project. In section 3.2
I will describe the overall approach used for this study, which, as detailed in
section 2.8, is action research. I move on to introduce the study setting and
methods and finally I present the results from this preliminary phase.
There is a recurrent broad theme throughout the literature that pharmacists'
skills and expertise could be better used to improve the use of medicines in
hospitals (Hawkey eta!., 1990, Griffith and Robinson, 1996, Barber eta!., 1997,
Batty and Barber, 1992). This has been reflected in Government health policy
for many years (Department of Health, 1988, Department of Health, 2000).
Moreover my personal experience in several acute hospitals in the North of
England confirms this picture of underutilisation of pharmacists and the
consequent suboptimal use of medicines. However, the literature also shows
that clinical pharmacy processes are diverse, ill-defined and sometimes difficult
to measure, and that there is a shortage of evaluative studies (Cotter et a!.,
1995). The service model that will best deploy pharmacists' skills to produce
maximum benefits for patients therefore remains unclear.
Having not worked in the trust prior to the start of the project, I was not familiar
with the health care environment within which the study would be conducted, in
particular, the nature of patient care in different specialities and settings; the
culture relating to therapeutics within the trust; current practice and standards of
care relating to medicines; problems relating to medicines use; and attitudes to
change in these areas. The research therefore comprises four phases:
121
Phase one - a preliminary phase to gain an understanding of these factors -
methods one, to gather and analyse preliminary data
Phase two - reflection on emerging themes and identification of key issues
relating to the use of medicines - results one, of preliminary analysis
Phase three - development and implementation of a new model of care -
methods two, and
Phase four - evaluation of the model in the study setting and exploration of
issues which would influence adoption throughout the trust - results two.
This chapter therefore encompasses phase one and phase two of the research
3.2.	 DESIGN OF STUDY: AN ACTION RESEARCH
APPROACH
As outlined in 3.1 above, for a number of reasons the precise nature of the
research problem was unclear at the start of the project. Moreover the research
was conducted in a dynamic and politically sensitive health care setting which
required considerable flexibility. Action research was therefore adopted, as it is
focuses on problem solving and improvement, and allows the approach to be
adapted and refined as the research process unfolds (East and Robinson,
1994).
Before adopting an action research approach, a number of alternative
methodologies were considered but felt to be inappropriate. Quantitative
surveys of patients and health care staff may identify some issues but could not
be relied to capture all the problems in medicines use; and they would not allow
for testing of new models of care. Consensus methods such as the Delphi
technique are founded on opinion rather than observation (Bowling, 1997); they
are unlikely to identify the specifics of care at patient level in this clinical setting;
and, again, they would not test new models of care. On the other hand, an
experimental intervention study, while enabling a new model to be tested, would
need to be narrow and specific to identify differences between the groups; and it
would be difficult, if not impossible to control the many confounding variables
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that influence patient care. An experimental approach would raise ethical
issues. It would involve assumptions about the model to be tested and it would
not readily identify issues arising from the broad culture and practice of
medicines use in the hospital.
In applying for ethical approval, the purpose of the research was clearly
explained, and the individuals which might be interested in or affected by the
work were identified. It was implicitly stated within the application that where
possible fully informed consent would be obtained from participants at each
stage of the project, for example patients and health care staff to be observed in
particular settings, patients to included in the evaluative study, health care staff
to be interviewed. Ethical approval from County Durham Health Authority Ethics
Committee was granted (see appendix 6.1).
3.2.1.	 Action research in the current study
Applying Hart and Bond's criteria described in section 2.9.2 to the current
research, the primary focus is professionalising as it involves change and
reform in pharmacy practice and the wider use of medicines. It has a strong
educative base in that it involves reflective practice in which professionals
develop by embedding new knowledge and actions in the everyday experience
of delivering care. The project has a strong practitioner focus, primarily involving
doctors, pharmacists and nurses. The problem focus is defined by issues
identified by these professional groups, with important input from users i.e. the
patients. The problems emerge from the professional/practical experience of
working within an acute hospital. The change intervention is professionally led
and its resolution is in the interest of research based practice and
professionalisation. It proceeds in a spiral of cycles and, importantly, there is a
collaborative relationship between the practitioners and the researcher. The
roles were on many occasions merged, as I was also actively delivering care.
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3.3.	 SETTING
The research was conducted in an acute university hospital trust in the North of
England. At the time of the study, the trust comprised:
• a main general hospital with 665 beds,
• three community hospitals with inpatient beds for rehabilitation and care of
elderly people who require intermediate care, together with a range of out
patient services and
• two day hospitals.
The preliminary phase of the study encompassed several areas of the trust,
including the admissions unit, community and day hospitals and out patient
clinics. The main study (phases three and four), discussed in chapter 4, was
conducted on two acute medical wards within the main hospital, ward A and
ward B. Patients admitted to these wards were usually under the care of one of
four consultants in general medicine who were fully supportive of the project.
Ward A had 30 beds, with patients generally under the care of two of the
consultants. Ward B had 28 beds, with patients generally under the care of the
other two consultants. Occasionally, because of bed shortages elsewhere in the
hospital, patients under the care of other consultants were accommodated in
these wards, but were not included in the study.
The patients studied were elderly people (over 60 years) with a range of
diagnoses. Recruitment to the study was opportunistic (convenience sampling),
with patients being included in the study as they were admitted to the wards.
3.4.	 DATA COLLECTION
As outlined in 3.1 above the study comprised four phases: a preliminary phase
to gain an understanding of the issues; a reflective phase to identify key
problems relating to the use of medicines; development and implementation of
a new model of care and evaluation of the model and exploration of issues
which would influence adoption throughout the trust.
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A range of data collection techniques were used in the various phases of the
study. In the preliminary phase, I collected data using ethnographic techniques
with participant and non-participant observation; document analysis and
informal discussions with patients and staff. In the reflective phase, further
literature searches were conducted to identify relevant findings and compare
them with data emerging from the study setting and also to develop research
instruments for use in the third phase. In the implementation and evaluation
phases, data were collected from interviews and informal discussions with
patients, hospital and primary care staff; document analysis; and participant
observation. In addition, in the evaluation phase, focus groups were conducted
with pharmacy staff and interviews were conducted with doctors and nurses.
In this chapter I will describe the methods used in the preliminary phase of my
study, which I refer to as 'phase one'. I will then move on to describe and reflect
on the findings from the preliminary phase, which I refer to as 'phase two'.
3.5.	 PHASE ONE: NEThODS ONE - ASSESSWENT OF
THE PROBLEM
As stated in the introduction, this study began in a context of concern relating to
quality of care relating to medicines use, aithough the exact natvre ohe
problems were unclear. The first phase, in this project, following an action
research approach, was to confirm the existence of problems relating to the use
of medicines in the study setting, and to assess the nature of the problems
identified. I describe this approach in detail in section 2.7.
3.5.1.	 An ethnographic approach
Since the research depends on an understanding of phenomena in the natural
setting, i.e. the study trust, an ethnographic approach was considered
appropriate, as discussed in section 2.7.4.1. Within the current study
ethnographic technique enables an understanding of practice and behaviour
relating to medicines within the trust studied and inform service development.
Through the nature of methods which can be adopted, ethnography can provide
a nuanced understanding of an organisation and allow comparison between
what people say and what they do.
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	3.5.1.1.	 Data analysis and theorizing using grounded theory
In keeping with a grounded theory approach, as I discussed in section 2.7.4.5,
my study initial conceptual categories were derived from the data and more
fieldwork was undertaken to further elaborate on these using theoretical
sampling. A diverse range of individuals and settings were included and using
the constant comparative method the emerging themes were developed. All the
data relevant to each category were identified and examined and each item was
checked and compared with the rest of the data to establish and validate
analytical categories. Overlapping and interconnecting themes were merged
under broader headings where appropriate.
	
3.5.1.2.	 Participant observation
I describe the rationale to this method in section 2.7.4.2. In this project most of
the observations were participative, and my role was known to patients and
health care staff, and I was involved in the everyday activities within the study
settings. Observations of clerking patients following admission, consultant
clinics and observation on the pharmacy department were non-participant.
Participant observation was considered to be an appropriate method for
understanding the experiences of doctors, nurses and patients with respect to
the management of medicines. I worked along side doctors and nurses to
observe events, together with their interpretation and explanation of them, whilst
also using my pharmacy expertise to contribute to patient care, where
appropriate. This allowed me to appreciate what happens on the wards with
respect to medicines, and what the strengths and weaknesses of the present
ways of working are. Non-participant observation in ward activities was deemed
inappropriate, as it would be unethical for me to ignore a situation where patient
safety is compromised. Gold's 'participant as observer' typology most suitably
describes the researchers approach in this study (see section 2.7.4.2)
Through participant observation, I attempted to minimise the impact I had on the
areas studies, and after a while I became accepted by the various groups
observed, as natural. 'Participant as observer' as adopted in this study, poses
fewer ethical dilemmas than covert participant observation.
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Approval within the study hospital was obtained through negotiation with four
general medicine consultants, and appropriate health care staff such as junior
doctors and nurses. Informed consent was obtained from individual participants
wherever possible, and they were informed that I would be observing particular
activities relating to medicines. I explained to patients that I was undertaking
research to try and improve the way medicines are managed and used in
hospitals and asked if they minded me having a conversation with them about
their feelings and experiences.
It was important that I struck up sufficient rapport and understanding with the
groups to conduct the research. I had to integrate quickly into the hospital
environments, and mix with the various health care staff. I explained my
purpose to all staff and engaged them in discussions about what they are doing
and why. The main study environment was two acute medical wards within the
study hospital, although other areas within the Trust were also investigated. An
observation schedule for each setting was used to prompt me to record the
information required for the research and this ensured important data was not
missed. The schedule used on the wards and in clinics included prompts to
record: time spent talking about medicines; dialogue with patients about
medication; errors relating to medicines; doctors knowledge and attitudes of
therapeutics; patients' experience and attitudes; documentation relating to
medicines and discharge planning and arrangements. The observation
schedule used in the pharmacy included prompts to record: how prescriptions
and drug orders from wards are processed and returned to the wards;
interruptions by phone calls from wards enquiring about the progress of orders;
and the attitudes of pharmacy staff.
Various activities in a variety of settings were studied:
. Patients' admission to hospital, and the process of clerking patients in by
junior doctors was observed on six occasions. This was undertaken in the
accident and emergency department and the admissions ward. I sat with the
junior doctor and patient and recorded my observations.
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• I participated in and observed 16 wards rounds, on the two main wards
studied, and one ward round on the admissions ward.
• Two hour observations were undertaken at three day hospitals where I
helped out where I could, helping the nurses and chatting to patients. I also
undertook two hour non-participant observations at three consultant
outpatient clinics. I sat in with the consultants at the clinics and took notes as
they saw patients.
• Activities on the two main wards studied during a three month period from
May to July 2000 were observed. During this time, I worked fulitime on the
wards and contributed to patient care when appropriate. I recorded my
observations relating to: prescribing behaviours; ordering, supply and
administration of medicines; interaction between medical staff and patients
and between the vacous staff on the wards; and pateit noemer ii Theil
own care.
• Activities within the pharmacy department were recorded, using non-
participant observation, on three occasions for two hour periods, and
included: dispensing of prescriptions; supply of medicines to wards;
communication with wards; and overall involvement of pharmacy staff in
patient care.
Recording data in the field is difficult in participant observation and where
detailed field notes could not be made immediately, I often had to take discreet
notes, or make mental notes and transcribe these at a later time, usually within
24 to 48 hours.
3.5.1.3.	 Method triangulation
In order to gain a detailed and broad insight into the practices and behaviours
relating to medicines, method triangulation was used to explore the research
issues from different angles, in a rounded, multi-faceted way. This is described
in detail in section 2.7.4.6. Ethnographic technique, using observations,
analysis of patients' records and informal discussions allowed an in-depth,
detailed picture of the subject under study across various dimensions.
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3.5.1.4.	 Analysis of patients' records
The notes for 40 patients admitted to the two acute medical wards being studied
within the three month period, May to July 2000, were thoroughly examined.
The intention of this was to gain insight into: the actual documentation of
medicines use; communication between primary and secondary care; and the
accuracy of drug histories taken following admission and subsequent
medication prescribed.
Detailed field notes were taken. In particular, data were recorded relating to:
• notes recorded at the time of admission, including drug histories.
• diagnoses.
• GP referral letters.
• records relating to drug therapy throughout the current and previous
admissions.
discharge information supplied to GPs, including the immediate discharge
notification letters and the discharge summary written by the consultant.
3.5.1.5.	 Informal discussions and interviews
Within the study hospital I had informal interviews and discussions with:
• the four general medicine consultants who were supportive of the project
• six house officers, four senior house officers and two registrars
• six nurses and two ward clerks
• six patients
• various pharmacy staff.
Informal interviews and discussions were generally undertaken opportunistically
within the course of my work on the wards. They varied in length from 5 minutes
to 30 minutes. I arranged times to chat with the nurses as they were extremely
busy and I talked to the doctors when they had a spare moment, usually in the
afternoon.
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Topics discussed with the doctors included: work patterns; processes within the
hospital relating to medicines; problems they encounter with medicines;
knowledge of therapeutics; and communication between primary and secondary
care.
Discussions with the nurses covered: drug rounds; staff, shifts and handing
over; ordering and supply, storage and administration of medicines; prescribing
practice; information given to patients about medicines; the involvement of
patients in their care; discharge of patients and problems with medicines.
The ward clerks were asked about: systems and procedures on the wards;
admission and discharge of patients; processing information to GPs, and
practice or community nurses; transferring patients to other wards or hospitals;
and discharge to residential or nursing homes.
Informal discussions with patients focussed on: what they know, or would like to
know about their medicines; their satisfaction with current standards of care;
experiences with their drug therapy; and compliance with medication regimens
and whether prescribing was concordant.
None of the dialogues were tape recorded as specific arrangements for these
were not planned in advance, although field notes were made immediately
afterwards.
3.6.	 PHASE TWO: RESULTS ONE - REFLECTION AND
IDENTIFICATION OF ISSUES
During the ethnographic study I gained insight into the health care environment
within which the study would be conducted, in particular the nature of patient
care in different specialities and settings; the culture relating to therapeutics
within the trust; current practice and standards of care relating to medicines;
problems relating to medicines use; and attitudes to change in these areas.
I became familiar with ward processes regarding medicines, such as ordering,
storage, prescribing and administration. I became known amongst staff and
became accepted as more a part of the team rather than an outsider who had
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come to do research on them. This also facilitated phase three of the project,
which would involve actually implementing a change of practice.
Several problems were identified that could be detrimental to patients and their
well-being, and involve or have the potential to involve significant risk. A
selection of cases highlighting problems relating to medication are summarised
in section 3.6.11.
3.6.1.	 Drug histories
From my observations, analysis of patients' records and informal discussions
with doctors and nurses, it was apparent that accurate and complete drug
histories were frequently not obtained when patients were admitted to the study
hospital. Very little time was spent inquiring about medicines, and doctors did
not thoroughly probe patients about their medicines. The process of history
taking was compromised by frequent interruptions, which lead to information
being missed. Sometimes patients were very ill and taking a drug history was
therefore not the first priority. It appeared that lack of therapeutic knowledge
sometimes resulted in inaccurate drug histories.
The admitting doctor rarely checked the list of medicines taken in the drug
history with the General Practitioner (GP), and when it was not possible to
obtain a complete drug history, this was rarely followed up. When it was not
possible to obtain a complete drug history at the time of admission, and this was
ascertained later, the complete list of medicines was rarely then recorded in the
patient's notes. The doctors simply prescribed them on the prescription chart.
Often doctors prescribed medicines without being aware of a clear indication.
Doctors never asked about 'over the counter' medicines, herbal or homeopathic
medicines and didn't always ask about allergies. When allergies were recorded,
the nature of the reaction was frequently not ascertained. None of the patients
were asked about current or previous side effects of their medicines. Patients'
understanding of and compliance with medication was not ascertained and the
prescribing process was far from concordant.
131
Patients sometimes brought their repeat prescription lists with them, and when
this was available, doctors frequently just used that for the drug history. These
lists were often incomplete, inaccurate or out of date.
Not all patients referred by a GP had a referral letter, and the information
relating to medicines varied when letters were provided. Even when a
comprehensive list of medication was available from the GP letter, recorded
drug histories still sometimes differed.
Inaccurate drug histories are not necessarily detrimental to patient care. Often,
despite the inaccurate or incomplete drug history, patient's usual medicines
were prescribed, but the drug history recorded in the notes did not reflect this.
3.6.2.	 Inappropriate prescribing
My observations revealed that inappropriate prescribing sometimes occurred
and this included: over-treatment, increasing the risk of adverse drug reactions;
under-treatment; and prescribing contraindicated drugs, leading to drug-disease
interactions; continuing drugs with no clear indication and without appropriate
review; prescribing drugs where there is no evidence base or drugs of limited
clinical value; and prescribing drugs which are not included in the hospital
formula ry.
Doctors appeared unwilling to stop medication if they did not initiate the
treatment and the patient did not appear to be suffering any adverse effects
from it, whilst sometimes patients were not receiving drugs from which they
would benefit. On occasions, drugs were prescribed to treat the side effects of
other drugs. Sub therapeutic doses were sometimes prescribed although
excessive dosing also occurred, which increases the risk of adverse effects.
Intravenous (IV) antibiotics were often continued longer than necessary in some
patients. Non-formulary drugs were frequently prescribed. The potential for
adverse drug reactions and drug interactions was often not considered. When
patients were discharged, doctors were rarely selective in the medications they
prescribe on the discharge prescription, as it is quicker and easier to transcribe
everything from the kardex, rather than consider what the patient actually needs
to go home with.
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3.6.3.	 Involvement of patients in their care
Some patients felt that doctors were not very understanding and most wanted to
be told more about their medicines. Some patients felt that doctors don't have
time or are reluctant to explain their medicines. These following extracts from
informal interviews with patients illustrate these aspects:
"I told my Dr that the dipyridamole was making me feel a bit funny, but
she just said 'there's nothing that can be done about that, you have to
take either that or the aspirin to stop you having a stroke' but I can't take
aspirin she knows that, they're not very understanthng there."
Patient DW
"It would be nice to be told more about your medicines, as then you'd
know why you are taking them and what they do, then you wou'dn't mind
taking them so much."
Patient MT
"You are scared to take medicines if you don't know anything about
them, when you're told information you're more likely to take them."
Patient HD
"Some authorities assume you know everything, well we don't. We know
nothing about our tablets. We need it to be explained."
Patient FG
Patients want written and verbal information about their medicines.
"People don't realise that when you're at home often you can't remember
what you were told in hospital.....older people have a tendency to forget"
Patient CD
Some patients told me that they receive repeat prescriptions from their GPs but
often see them infrequently, therefore don't have the opportunity to ask about
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their tablets. Observation of doctors and discussions with patients revealed
patients were rarely given comprehensive information about their medicines.
For example, a patient had never been given vital information about how to take
his medication, which resulted it him not benefiting from the treatment, see case
1. Another patient was not informed of the consequences of consuming certain
food and drinks whist taking a monoamine oxidase inhibitor, see case 2. Drugs
were started and this was often not explained to the patient. During my
observation of an outpatient clinic, a patient was commenced on fludrocortisone
for neuropathic postural hypotension. The consultant said to the patient, "here,
take these", but gave no explanation as to why they had been started or
instructions about taking them.
My observations and discussions with doctors and nurses revealed that warfarin
counselling was rarely undertaken by doctors, and the responsibility for this fell
with the nurses. However, nurses said they were not trained to do this and there
was no protocol for exactly what patients need to be told. The level of
information given to patients therefore varied greatly. Some nurses omitted vital
information, which has the potential for significant risk to the patient.
Some patients, despite receiving information, ignored it. For example a patient
was taking isosorbide mononitrate three times daily (9am, 2pm and 11pm),
without a nitrate free period. The consultant explained to him that he must take
his last dose no later than 5pm so he has a nitrate free period, to prevent nitrate
tolerance developing. The patient said that he had a 'crushing' angina attack
that morning but he would not accept that he must have a nitrate free period. He
said his GP told him it was fine for him to have his last dose at 11pm and that
some patients needed a late night dose to prevent early morning angina. The
consultant said this was absolute rubbish, but the patient would not be
convinced.
There were occasions where doctors did inform patients about their therapy, for
example, a patient was unhappy about being commenced on digoxin as he had
been admitted previously with digoxin toxicity. He told the doctors that those
tablets make him really ill. The junior doctor explained to him about the
134
therapeutic range of digoxin and that they would be monitoring his blood levels
very carefully.
3.6.4.	 Admissions related to drug therapy
It is clear from the literature that medication is frequently implicated in
admissions and I observed frequent instances of medication problems resulting
in admission. During the ethnographic study I encountered 145 patients and 31
of these admissions were directly related to drug therapy (21.4% of the
admissions recorded). Eight patients were admitted because of problems which
were highly likely due to non steroidal anti-inflammatory drugs (NSAID), see
case 3. One patient had been admitted to the hospital in 1999 with gastritis. She
was taking Naprotec (a NSAID - naproxen and misoprostol) for arthritis, and
aspirin for transient ischemic attacks and this was thought to be responsible for
her gastritis. The consultant had recommended to the GP that her analgesia be
revised altogether and the Naprotec be stopped, and gastro-protection added to
her regimen. This had not been done, and she was re-admitted on this
occasion, six months later, with a gastro-intestinal (CI) bleed. This case also
highlighted that even when hospital doctors supply clear information to GPs this
is not always acted upon. This iatrogenic admission could have been avoided.
Other examples of drugs associated morbidity I observed, included: A patient
taking warfarin, with an INR of 10 (target 2.5) suffered a gastro-intestinal bleed;
several patients admitted with drug induced postural hypotension, for example a
patient already on frusemide and dothiepin, which can cause a postural drop in
blood pressure, who was recently commenced on an ACEI, see case I ; a
patient admitted having had a fall, which was thought to be due to a
hypoglycaemic episode as she was taking a high dose of a suiphonylurea see
case 4; an admission due to a carbamazepine overdose; increasing heart
failure with atenolol; several patients with diuretic induced low sodium and
potassium; a patient with lithium toxicity; a patient in hyperosmolar non-ketotic
acidosis coma, with steroid-induced diabetes; patients with confusion due to
excessive use of hypnotics and anxiolytics; a patient with renal failure taking
Volsaid®
 (diclofenac) and a patient with chronic renal failure thought to have
been worsened by Ponstan® (mefanamic acid).
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36.5.	 Communications across the interface
I observed that communications both from the hospital to GPs, following
discharge and from GPs to hospitals when patients are admitted were often
poor. When patients are referred by GPs to hospital as an acute admission,
sometimes there was no referral letter at all. Even when a referral letter is
provided, there may be no information relating to medicines, or if it was present,
was sometimes incomplete or inaccurate. This could lead to patients' therapy
being incorrect following admission, as admitting doctors rarely questioned the
accuracy of this information on the GP referral letter, and many used this as the
main source of their drug history.
Of the 40 patients' notes analysed, 33 were referred by the GP, and seven were
emergency admissions and therefore would not have a GP referral letter. Of the
33 referred by a GP, the GP provided a referral letter for 24 patients, nine had
no letter. Three of the 24 GP referral letters did not contain any information
about medicines. Of 21 letters that did refer to the patient's medicines, the
information in 15 of these was incomplete or inaccurate. Complete and accurate
information relating to drug therapy was provided by GPs for only six out of the
33 patients referred by their GP.
Some GPs stated in the referral letter that the patient will bring along a list of
their medicines, or that the medicines are 'as enclosed', however frequently
patients do not have a list of their medicines and there is no 'enclosed' list.
When GPs did provide a list of drugs sometimes doses or frequencies were
omitted. For example, the referral for a patient stated that they took Adalat®,
atenolol, aspirin, and frusemide, but gave no doses. Another referral letter
stated the patient's sodium valproate dose as a single daily dose, but did not
indicate how this was split throughout the day. The information given by the GP
can conflict with that given by the patient, for example a patient claimed they
were taking prednisolone 17.5mg daily, whereas the GP stated they were taking
35mg daily.
When patients were discharged, GPs were rarely given explicit information
about changes to patients' medication, during the admission, on the preliminary
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discharge letter (PDL). Of the 40 patients notes analysed only two of the PDLs
referred to changes to drug therapy, and only one gave a complete and
accurate account of all alterations. Examples of omitted dose changes were an
increase in digoxin dose, and decrease in clobazam dose.
Decisions to discontinue medicines were often not communicated to GPs, for
example, lisinopril stopped because a patient had postural hypotension, long-
term prednisolone stopped in a patient with rheumatoid arthritis, and naproxen
stopped as the patient no longer needed it.
Information about new medication commenced was often not communicated to
GPs such as: amlodipine for high blood pressure; warfarin for atrial fibrillation;
Didronel PMO for osteoporosis prophylaxis; metoprolol and lisinopril following a
myocardial infarction; and lansoprazole for gastritis. It was just assumed GPs
would continue prescribing these, following discharge.
Information given to GPs from the hospital, relating to follow-up of patients with
respect to their drug therapy was poor. For example GPs were rarely instructed
to take follow-up blood tests that were required, such as urea and electrolytes
when an ACEI has been commenced or the dose changed, haemoglobin levels
in anaemic patients discharged on iron therapy, potassium levels in a patient
discharged on high dose bronchodilators, corticosteroids and frusemide (CSM
advice), or sodium levels in a patient who presented with drug induced
syndrome of inappropriate antiduiretic hormone (SIADH). It could be argued,
however, that GPs should undertake this follow-up as a matter of course, and
therefore instruction from the hospital is not necessary. I felt however, that it
could only be of benefit to include such information on discharge letters.
Details about anticoagulant management initiated in hospital and subsequent
follow-up were frequently omitted. Treatment plans following discharge were
often not communicated to GPs, for example dose reductions. I encountered
four patients who were discharged on a treatment dose of lansoprazole of 30mg
and the intention was that this should be reduced to maintenance dose of 15mg
after four weeks (National Institute of Clinical Excellence, 2000). None of the
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discharge letters contained this information. The cost implications are
significant.
One patient had been previously admitted with digoxin toxicity and the digoxin
had been stopped. The GP was not instructed to restart the digoxin however,
and the patient was later readmitted with recurrence of atrial fibrillation.
I often observed incomplete PDLs in terms of key information, such as the
patient's name, date of birth, address, date of admission and discharge,
whether the patient has allergies, identity of the consultant, and the name of the
patient's GP. This wasted time as pharmacy had to contact the ward to obtain
this information to ensure that the prescriptions were complete.
Key clinical information was also sometimes omitted from PDLs such as:
anticoagulant control during admission; most recent blood pressures prior to
discharge for a patient admitted with uncontrolled hypertension; details of a CT
scan for a patient admitted having had a fall; and a diagnosis of pernicious
anaemia along with instructions to continue hydroxocobalamin injections. Even
when clear information was given to GPs about patients' medicines this is not
always acted upon, see case 3.
Consultants also write a discharge letter following the preliminary discharge
letter (PDL). From analysis of patients notes, I found that these consultant
discharge summaries (CDS) did usually contain information about medication,
and listed the patient's medicines on discharge. The CDLs, however, were also
often incomplete with respect to medicines and on occasions did not match the
information relating to medicines in the PDL. This is also reported in the
literature (Gardiner, 1998). In addition, the CDS was usually written more than a
month after the PDL.
3.6.6.	 Errors
I observed that prescribing and administration errors sometimes occurred but
were rarely recorded. Errors were rarely recorded in patients' notes, and
although there were systems within the study Trust for reporting incidents these
were often not followed for errors involving medication, especially near misses
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and errors that were considered to be of little harm to patients. For example, a
patient was prescribed captopril (ACEI), and the doctors decided to change this
to lisinopril, the hospital formulary preference for an ACEI, and as it is given
once daily it may improve compliance. The captopril however was not crossed
off the drug chart when the lisinopril was commenced and for one day the
patient received both captopril and lisinopril. The same patient was commenced
on warfarin, and her aspirin was stopped. The same day however aspirin was
restarted, with no explanation given in the notes, and she received three days of
both, increasing her risk of haemorrhage.
The dose of frusemide was to be reduced from 40mg to 20mg for a patient as
he was found to have a postural drop in his blood pressure. The 20mg dose
was prescribed, but the 40mg dose was not discontinued for a further two days.
This resulted in the accidental administration of 60mg (both the 40mg and 20mg
dose) of frusemide for two days. This may have delayed his discharge. A similar
mistake occurred when a patient's thiazide diuretic was changed from Dyazide®
to bend rofuazide. Although the bendrofluazide was started, the Dyazide® was
not stopped until four days later. The patient was given both for four days.
On occasions, errors occurred when doctors wrote discharge notification letters,
some of which had the potential for considerable risk, see case 5. Drugs were
sometimes unintentionally omitted, for example ferrous sulphate was missing
from the discharge prescription for a man with anaemia. Doctors made mistakes
such as prescribing frusemide 8mg daily, instead of 80mg daily. Although this
did not harm the patient I observed that nursing and pharmacy time was wasted
finding out the correct dose. A patient was prescribed prochlorperazine 50mg
three times daily on his discharge prescription, a ten fold overdose. Again I
observed this wasted time as pharmacy had to contact the ward, and it had the
potential for significant clinical risk, had the mistake not been noticed. Junior
doctors were under time pressures and discharge prescriptions were written in
haste which can only contribute to errors occurring, a problem also observed by
this staff nurse in an interview:
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"It's not just the time aspect of writing discharge prescriptions at the last
minute, it's also the safety aspect of it as well, especially with the newer
house officers.. ..lots of errors do occur"
Staff nurse RM
Sometimes nurses transcribed the drugs from the drug chart to the discharge
prescription, and filled in the patient's details to speed the process up. I
observed that often junior doctors would sign these without checking them,
especially if they were under time pressures.
Dosing errors were sometimes made, for example the admitting doctor recorded
a patient as taking clonazepam 125mg at night, and this was then prescribed.
The recommended maintenance dose in the BNF is 4 to 8 mg daily (BNF,
2002). The nurses had spotted the mistake, as that dose would have to have
given with 62 tablets of 2mg. The error, however, was not highlighted to the
doctors until day three of his admission. Tinzaparin was prescribed for a patient
as the volume, without the strength. As two strengths are available, 10,000
unit/mI and 20,000 units/mI, there was considerable potential for error.
Nurses filled out reminder charts for patients which are given to patients without
being checked and these were sometimes incorrect. This might be potentially
confusing for patients and may result in medicines being taken incorrectly.
There are checking procedures throughout processing discharge prescriptions
which are undermined by this practice.
3.6.7.	 Poor documentation of therapy
From analysis of 40 patients' notes it appeared that drug therapy is often poorly
documented, for example information about initiation and discontinuation of
drugs, or dose changes. Examples include not documenting information about
initiation of anticoagulation, or why antibiotics have been started. A patient was
taking nifedipine prior to admission but it was not prescribed following
admission. It was likely that this was because she had increasing heart failure,
but this was not documented. A patient was given a test dose of an ACEI but it
was not continued and there was no record in the notes about this. Drugs were
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frequently stopped with no recorded reason. A patient usually took atenolol but
this was changed to metoprolol with no explanation in the notes.
Hydroxocobalamin was started with no reason recorded, see case 6.
There were, however, examples of good practice, for example doctors would
sometimes write a treatment plan in the notes of the consultant ward round
recording which drugs were to be started or stopped. This varied between junior
doctors and consultants. Other examples of good practice were observed when
specialists were asked to review patients, for example a consultant cardiologist
wrote the following detailed treatment plan about a man suffering from
confusion thought to be caused by amiodarone:
"that the amiodarone may well have caused his confusion I therefore
recommend it be stopped and replaced with a beta-blocker for rate
control. However this patient has COPD, and as beta-blockers are
contra-indicated in COPD, nothing should be prescribed as he is not
symptomatic."
3.6.8.	 Supply and administration of medicines
I observed problems around the supply and administration of drugs. This often
delayed patients receiving their prescribed medicines. Ordering of medicines
not stocked on wards was sometimes erratic and untimely, see case 1. A further
example concerned a patient not receiving a dose of her antidepressant until
day four of her admission because the nurses did not order it immediately.
Another patient who was fitted with a PEG did not receive her usual
prednisolone or Didronel PMO® even though these could have been
administered via the PEG.
I observed that patients with inhalers and eye drops tended to keep them in
their bedside lockers. Nurses frequently signed the drug chart as the patient
having 'self administered', but they did not supervise this and this was not in line
with the hospital policy on the prescription, supply and administration of drugs.
From my observations, it was apparent that many patients weren't taking/using
the medication, however some patients did do this themselves.
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When nurses administered drugs they initial the appropriate box on the drug
chart, which corresponds to the time of dose given, and the date. This indicates
only whether the dose has been given or not, but the chart does not enable an
explanation to be recorded if doses are omitted. The nurses on the wards
studied circled their initials if a dose was not given as prescribed. On the chart,
at the bottom of each date column, there is a small space, entitled 'comments'.
In theory the nurses fill this in to explain a 'circled initial'. This however did not
always happen, and was often left blank. Only the nurse who did not give the
dose knew the reason for this and if they were not available, other nurses and
doctors could not easily ascertain why a drug had not been administered. In
addition, if more than one drug was omitted on the same day (i.e. you would
have to use the same small space at the end of the column for comments) it
was very difficult to distinguish which drug any comments related to. I observed
that important information regarding drug administration was often not
communicated to doctors on the ward rounds.
From observations and discussions with nurses I discovered that patients' own
medicines were sometimes mislaid when they were transferred between wards.
One patient did not receive her usual hormone replacement therapy (HRT)
throughout her entire admission, as all her medicines were 'lost' on her transfer
from the admissions ward and the nurses did not order a new supply of HRT for
the patient.
When discharge medication arrived back on the ward from pharmacy the
porters often leave it in the nurses office on the ward. This office was never
locked and often bags of medication are left unattended, which has risk
implications.
I observed the pharmacy department was extremely busy processing
prescriptions and wards frequently phoned to enquire about the progress of
prescriptions and drug orders. This held work up in the pharmacy and resulted
in further delays in prescriptions being processed and returned to the wards. All
pharmacy staff expressed frustration about this and felt that the nurses do not
realise exactly what is entailed in processing prescriptions and drug orders.
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They criticised the wards for lack of organisation and forward planning with
respect to discharge prescriptions.
3.6.9.	 Competency of doctors and nurses relating to
therapeutics
Some doctors and nurses appeared to have insufficient knowledge of
therapeutics. Doctors were sometimes unaware of treatment guidelines for
certain conditions, such as initiation of anticoagulation in patients with atrial
fibrillation. Often therapy with a low molecular weight heparin was commenced
with warfarin, when there is no evidence base for prescribing low molecular
weight heparin in newly diagnosed AF and warfarin alone is sufficient.
Some doctors and nurses did not know the purpose of some drugs, for example
a patient was admitted with renal failure, and the doctor wrote the following in
her discharge letter:
"Admitted with high potassium of 6.9. Acute renal failure, probably due to
urinary tract obstruction/infection. Ultrasound of kidneys was normal.
Ultrasound of bladder showed it had thickened walls and had a post-
micturation residue of l2Oml. Renal function improved with calcium
resonium."
The discharging doctor is incorrect in writing that the patient's renal function
improved with calcium resonium. Calcium resonium is an ion exchange resin,
which binds to potassium in the gut, releasing calcium in exchange. It lowers
potassium over a period of hours or days; it does not improve kidney function.
This may have been a slip by the doctor or it may reflect a lack of therapeutics
knowledge. In a further example, whilst I was observing a junior doctor taking a
drug history, she asked me what lamotrigine was and what the dose should be.
Of course, doctors and nurses do have training in therapeutics and therefore
possess a certain amount of information relating to drugs. However, from my
discussions with them and observations, it appeared that sometimes this is
lacking and a particular concern was that doctors and nurses do not always
take action to address this.
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It seemed that knowledge of adverse drug reactions was lacking. A patient was
seen in an outpatient clinic who was suffering numbness around his waist. He
was taking simvastatin which can cause peripheral neuropathy and
paraesthesia. This was not considered by the consultant who referred the
patient for X-rays and a magnetic resonance imaging (MRI).
I observed that doctors sometimes spelt drugs incorrectly, for example mitazolin
instead of mirtazipine see case 2. On occasions incorrect doses were
prescribed, for example a patient who had a very low calcium blood level and
which was believed to be due to hypoparathyroidism was being treated with
alfacalcidol 250 nanograms daily. The hypocalcaemia was persisting and the
consultant decided she needed more alfacalcidol, and to increase it to 500
nanograms daily. The BNF states that the starting dose of alfacalcidiol in the
elderly is 500 nanog rams, which should be adjusted to avoid hypercalcaemia,
with a maintenance dose of 0.25mcg - lmcg daJy. The dose she was started on
was too low; this may have prolonged her symptoms and possibly the length of
her admission.
In another example, a patient with continuous fitting was prescribed a sub-
therapeutic dose of diazepam. The doctors were unaware that the dose was
sub-therapeutic and only when I pointed this out was the dose increased. The
intention was to commence intravenous (IV) phenytoin as the fitting did not
stop. Electrocardiogram monitoring is required when phenytoin is administered
intravenously and only one nurse on the ward was able to do this. She was due
to finish her shift so there was no nurse available to monitor the patient and the
coronary care unit would not take the patient. The decision was made that the
phenytoin therefore could not be prescribed, and the dose of diazepam was
increased again. Eventually the fitting stopped. This patient's care was
compromised as fully competent staff were unavailable.
A patient with atrial fibrillation was commenced on an inadequate dose of
digoxin, which resulted in a delay in controlling his heart rate, and alleviating his
symptoms.
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Doctors were not always aware patients were actually taking certain drugs, for
example a patient was administering his own sleeping tablets which he had in
his bedside locker. Another patient was taking simvastatin which he kept in his
locker. The medical staff did not know about this, and it was not prescribed on
his drug chart. I observed that nurses allowed some patients to administer their
own medicines, but at the time of the study hospital policy did not allow this as
there was nowhere secure to store the drugs next to the patient's bed and
anyone had access to them. No formal assessment was undertaken to assess
whether patients were capable of administering their own medication, this was
purely subjective depending on the opinion of individual nurses. When patients
brought in their own medicines nurses did not assess whether the medicines
were suitable for use. If patients were not deemed capable of managing their
own medicines, any that are brought into hospital were taken from the patient
and stored in a locked cupboard in the treatment room. There were no records
of these medicines and the cupboard was always full and messy. Nurses often
forgot to give medicines back to patients. When medicines were returned to
patients whose drugs regimen had not changed, however there was significant
potential for error because of the system.
Doctors sometimes lacked knowledge of therapeutic drug monitoring, for
example a digoxin level was requested by a doctor four days after it had been
started. Approximately five half lives should elapse before sampling after
initiation of digoxin. With a half life of about 36 hours sampling should not be
carried out until seven days after starting digoxin. Measurement of heart rate is
the primary method of monitoring clinical effect, and maintenance doses are
generally determined according to renal function and heart rate response.
Monitoring of digoxin blood levels was often unnecessarily undertaken, wasting
time and money. On the other hand, sometimes therapeutic drug monitoring
wasn't undertaken although appropriate, see case 1. Another patient taking
theophylline was started on ciprofloxacin which causes an increase in
theophylline blood levels. Theophylline blood levels must be monitored but the
junior doctors were not aware of this.
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I observed that doctors and nurses were often unfamiliar with different
formulations of drugs such as modified release preparations, see case 4.
Nurses were administering nifedipine LA 30mg daily as three nifedipine MR
10mg tablets, as they were unaware of the difference between the two
formulations. The brand of mesalazine was not indicated on the drug kardex for
a patient. This is very important as there are three different slow release
formulations, with different release profiles and the brand should always be
stated.
From my observations, doctors did not always follow hospital policy with respect
to controlled drugs (CDs), see case 5. This may have been because they were
not always fully aware of hospital policy or because of time pressures or
because they simply couldn't be bothered. However, CD prescriptions are
complicated to write and there is a lot for doctors to remember when writing
them. If they are unsure doctors should enquire about the correct procedures
when handling CDs.
Patients were sometimes given medicines to take home from ward stock
without the appropriate labels and instructions such as inhalers and glyceryl
trinitrate sprays. Alternatively, patients were sometimes given medicines to take
home, that had been ordered by the ward to be administered during a patient's
admission, for example Didronel PMO®, but again the appropriate label and
instructions were missing.
3.6.10.	 Delays in discharge
From observations, and discussions with nurses it appeared that delays in
discharge sometimes occur because the discharge notification letters are not
written in adequate time therefore discharge medicines are not available in a
timely fashion. Patients are often told on the morning ward round that they can
go home, but the discharge prescriptions are not written until after the ward
round has finished at midday, or even afternoon after the junior doctors have
had lunch. Ambulances cannot be booked until the discharge medication is on
the ward, and if prescriptions don't get to pharmacy until the afternoon, they
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often don't arrive back on the ward until after 5pm. Then it is too late to book an
ambulance, and the patient's discharge can be delayed until the next day.
It is reasonable that discharge prescriptions should not be written in haste
during the ward round, as this may result in errors. However, some
prescriptions could be written in advance, as medication would not change
before discharge, but this is rarely done. The decision of a discharge date was
made in advance for several patients, but the doctors frequently left it until the
actual day of discharge to write the prescription. Even when the prescription
was written in advance often it was not sent to pharmacy until the actual day of
discharge. There are however limitations in pre-empting discharge prescriptions
in this manner, which I will consider in the discussion.
I observed that on occasions nursing and pharmacy time was wasted chasing
up discharge prescriptions. There was no method of recording if a discharge
prescription had been written, if it had been sent down to pharmacy, or whether
it had arrived back on the ward. This resulted in nurses phoning up pharmacy to
check whether a prescription was ready, when they didn't even know whether it
had been written and sent down to pharmacy. My observations and discussions
with pharmacy staff revealed that time was often wasted looking for the
prescription, when it may not even exist.
3.6.11.	 Case summaries highlighting issues identified
The following are a selection of case summaries which highlight some of the
problems I have discussed.
Case I - Patient RS
This patient was admitted with dizziness and falls, which were thought to be due
to postural hypotension caused by frusemide, dothiepin and lisinopril. The
lisinopril was stopped. He was also taking carbamazepine, which can cause
dizziness, drowsiness and ataxia, particularly in the elderly. The doctors did not
mention this, and did not check his carbamazepine blood levels, which would
have been appropriate, as the side effects are dose related and correlate to
serum concentration.
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He was also taking Didronel PMO ® prior to admission for osteoporosis and this
was prescribed on his drug chart. No doses however were given and the chart
was annotated 'no stock' by the nurses. On day five of his admission it was
discontinued. The family of this patient could have been asked to bring in this
man's own Did ronel PMO® pack from home. This avoids additional costs for the
hospital and interrupting his cycle (Didronel, one tablet daily for 14 days and
Cacit®, one tablet daily for 76 days).
If this was not possible it would have been better if ward staff ordered it from
pharmacy immediately. As it is on the formulary, it would have arrived on the
ward the same day. It should not have been discontinued, as he had a
diagnosis of osteoporosis and needed treatment. However, it is probable that
missing a few days during this admission would have little effect on his
condition.
He was prescribed codeine phosphate for pain. Two days later he became
constipated because of the codeine, so three different laxatives were
prescribed. He then developed diarrhoea.
On day six of his admission Didronel PMO ® was again prescribed, and ordered
from pharmacy. The patient had a week without his Did ronel PMO ®. A
discussion with the patient revealed that he had been taking his Didronel with
his breakfast for the last 14 years. Food should be avoided for at least two
hours before, and after a dose, if not it is passed out without being absorbed.
He may therefore have not fully benefited from the treatment. According to the
patient he had never received the appropriate counselling either from his GP or
his pharmacist. The patient said, 'Well nobody told me any different."
On day 11 he was discharged. The doctor prescribed Didronel PMO ® on the
discharge prescription but did not mark that the patient had a pack on the ward.
Fortunately, someone in pharmacy remembered that a pack had been sent up
to the ward, for that particular patient, so phoned the ward to check. If that
person in pharmacy had not done this another pack would have been supplied,
which would have potentially been a waste of money if the pack he was using
on the ward was thrown away. It also would duplicate work in pharmacy. This
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also wasted time as pharmacy had to contact the ward, and the nurses then
had to find out if there was a pack on the ward. The pack however, should have
been returned to pharmacy so a new label with instructions could be placed on,
but it was not. The patient was also discharged with senna, despite suffering
from diarrhoea.
Case 2— Patient FG
A patient had been taking Nardil ® (phenelzine), a monoamine oxidase inhibitor
(MAOI), for a considerable time, and had been admitted several times suffering
postural hypotension. The patient had been seen in outpatient clinics several
times also. Following a recent outpatient appointment the consultant highlighted
that she was taking a MAOI for depression, which interacts with her
antihypertensive medication, enhancing the antihypertensive effect and can
cause postural hypotension. The consultant wrote to the GP, stating,
"This lady clearly needs antihypertensive medication.....In light of the
side effects profile and potential for interactions, do you think a MAO! is
appropriate for this patient?"
Phenelzine was however continued, and the patient was readmitted on this
occasion with postural hypotension. Various doses of phenelzine had been
recorded throughout the notes, ranging from 15 to 50mg three times daily.
50mg three times daily is three times the recommended daily dose and it was
unclear what dose she had actually been taking prior to this admission. During
this admission, it was decided that this should be changed to a more
appropriate antidepressant, which would not have a hypotensive effect. The
psychiatrist advised mirtazipine 15mg daily. The withdrawal schedule for
phenelzine, before mirtazipine can be commenced should be over four weeks,
(BNF, 2002), but in this patient was over one week. This was more rapid than
recommended and with the potential risk of withdrawal symptoms. She did not
appear to suffer any however.
Confusing and incorrect information was given to the GP about changing this
patient's medication. The house officer had written a separate summary letter
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regarding the change from Nardil to Mirtazipine, and no information was
included about this in the main PDL. The HO wrote:
"Notes for GP", Phenelzine 15mg bd until 2/7, then l5md od from the 2/7 - 5/7.
Stop pheneizine, allow 2 wk period between, stopping pheneizine and starting
'mitazolin' 15mg on. Thanks.
Mitozolin is not the correct name for the drug that is to be started. Mirtazipine is
a drug which is infrequently used, and this may have been confusing for the GP.
In addition, her GP name and her allergy to penicillin was not recorded on the
discharge prescription.
The patient should have been advised that the rules about which foods and
drinks to avoid whilst taking phenelzine, must also be followed for the two
weeks after stopping the drug. The patient told me that no one had given this
information.
Case 3 - Patient WW
This patient was admitted with rectal bleeding. He had been using indomethacin
suppositories, prescribed by his GP prior to this admission. During the
admission the decision was made to stop the suppositories as they can irritate
the rectal mucosa and inhibit prostaglandin synthesis which can cause rectal
bleeding. The patient also had been taking long term antibiotic therapy with
trimethoprim, for a chest infection. The consultant suggested that the rectal
bleeding may possibly have been caused by a super infection due to the
antibiotic therapy, and it was stopped. However, this information was not
communicated to the GP in the PDL, there were no instructions not to restart
these drugs. No information regarding this was included in the CDS written 3
weeks following his discharge. When I contacted the GP one month following
the patients' discharge the patient was still receiving indomethacin, although the
trimethoprim had not been restarted. During the patients admission the dose of
his clobazam dose had been reduced. The GP was not informed of this either.
Ferrous sulphate had been started as the patient was anaemic, but no
information was given in the discharge notification letter as to how long this
should be continued for.
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Case 4— Patient BH
This patient was referred to accident and emergency by her GP following a fall.
She was taking the maximum dose of glipizide, 20mg daily, in four divided
doses. The dose should have been prescribed as two divided doses. Glipizide
was not on the hospital formulary, therefore not stocked by pharmacy and
should have been changed to gliclazide, a cheaper drug which can be given
once daily. The ward, however, used a supply brought in by the patient, which
could be argued as reasonable, so long as sufficient for the admission and
when the patient goes home. The patient was also prescribed isosorbide
mononitrate 60mg SR, which is non-formulary.
She was also taking diltiazem MR 120mg daily for angina, and the GP had
specified the brand as Adizem®, as recommended by the BNF. On the ward
however, the nurses were giving the diltiazem dose as two 60mg Tildiem®
(diltiazem standard formulation with a duration of action that requires
administration three times daily). This was hazardous for the patient as
diltiazem blood levels may be too high in the morning following a dose, which
may result in toxic levels and side effects, and blood levels later in the day will
be too low and she may have an angina attack. This standard formulation is
required to be given three times daily. The nursing staff were not aware of the
differences between the preparations, and the doctors weren't aware this was
happening. The drug chart should have been endorsed with the brand of
diltiazem which is the preferred hospital formulary brand, Angitil SR ®
 (this is
equivalent to Adizem SR®).
It was clear from my observations and discussions with staff that the discharge
of this patient was delayed 24 hours and nursing and pharmacy time was
wasted sorting out problems with the discharge medication. The discharge
medication could not be supplied on the day the prescription arrived in
pharmacy, as the prescribing doctor could not be contacted until the following
day and there were various problems on the prescription. When pharmacy staff
contacted this doctor the following day the prescription had to be re-written
because of all the problems:
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• 'Isosorbide mononitrate 60mg daily' was prescribed. The patient was
actually taking the modified release (MR) preparation, lmdur ®. When
contacted, the house officer did not know the difference between the MR
and instant release preparations. I advised the house officer to prescribe
isosorbide mononitrate 20mg bd, in accordance with hospital policy. This
should have been done when the patient was admitted.
• 'Diltiazem 120mg om' was prescribed, without specifying the formulation.
When pharmacy staff phoned the ward to find out what she had been getting
on the ward, the nurses explained what they had been giving (two 60mg
standard Tildiem®). The house officer was then contacted to check this, but
did not know the difference between the different diltiazem brands and
preparations. I was on the ward at the time and explained she had been
taking Adizem® MR 120mg daily prior to admission. Although usually given
twice daily the patient had been stable on this dose for several years so the
house officer was advised to prescribe the equivalent preparation of Angitil®
SR (the hospital formulary preference) 120mg od.
• The HO had prescribed glipizide 5mg qds on the discharge Rx. The ward
had been using the patient's own, and pharmacy does not stock glipizide.
Had pharmacy been informed they could have ordered it in advance ready
for the discharge prescription. The patient was changed to gliclazide.
Case 5— Patient MS
This patient was referred by her GP with collapse and agitation. The GP
suspected she had taken an overdose of carbamazepine, and that she was
addicted to Diconal®, which she takes for osteoporosis. The admitting doctor
recorded her drug history as only carbamazepine 200mg, but gave no
frequency and the GP gave no information about her medication. The only
medication she was prescribed following admission was a course of
trimethoprim for a urinary tract infection, and co-codamol.
Despite the suspected overdose, a blood carbamazepine level was not
checked. This could be considered reasonable as a CT scan revealed she had
suffered an intracranial bleed so she was transferred to another hospital for
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neurosurgical assessment. There was no communication about her medication
from the study Trust to the second hospital, and when she returned two days
later there was no information from the second hospital to the study Trust.
Six days following admission the doctors still did not know what her usual
medication was, and this is stated in her notes, but the GP still was not
contacted. On day seven she was prescribed carbamazepine 200mg daily,
although it was not clear why this dose was started as there was no dose
documented in her notes. On day eight she was prescribed codeine for pain
and in her notes recorded 'the patient is very, very distressed as she is not
receiving her usual Diconal®, when the nurses attempted to give her codeine
phosphate, she spat it back out at them.'
On day eight, codeine was stopped and she was prescribed diamorphine and
paracetamol, to be given when she requires them for pain. The GP was
contacted on day eight and gave a list of her usual medicines: Carbamazepine,
Diconal ® , trifluoperazine, ranitidine, Calcichew D3® and dothiepin. The GP
explained that the Diconal® was supplied on a daily basis as she was known to
take more than the prescribed daily dose. She was then prescribed all her
medicines, although Calcichew D3® was mistakenly not re-commenced until
day 15 of admission.
19 days following admission, she was discharged. There were numerous
problems with the discharge notification letter. It did not state the GP name,
consultant name, date of birth, date of admission, or whether the patient had
any allergies. She had been commenced on antihypertensive therapy and this
was not communicated to the GP. Diconal® is a controlled drug (CD), and
therefore must be written on a separate CD prescription form according to
hospital policy. Initially the doctor had written it on the main prescription, and
was instructed by pharmacy to write a separate CD prescription.
The house officer rewrote it on a CD prescription but prescribed seven days,
and the consultant had instructed that patient was only to receive one day of
everything as she may take more than the prescribed dose. I highlighted this
and house officer rewrote the prescription for the third time for one day only.
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This patient could have been sent home with seven days of Diconal®, which she
is known to be addicted to. This wasted nursing and pharmacy time and
delayed the patient's discharge.
Case 6 - Patient CB
The continuing care of this elderly patient following discharge was compromised
by the incomplete and inadequate information supplied by the hospital to the
primary care team. He was admitted with general deterioration and social
problems. During the admission he received antibiotics for a chest infection and
was given an injection of hydroxocobalamin I mg. Hydroxocobalamin is given
for vitamin B12 deficiency such as pernicious anaemia and the recommended
dose in the absence of neurological complications is 1mg on alternate days for
one to two weeks, then 25Omcg thereafter until the blood count returns to the
normal range, then 1mg every two to three months (BNF, 2002). This patient's
therapy was inappropriate as he received only one dose during his admission.
There was no documentation of why this had been started in his notes. He was
also commenced on ferrous sulphate as he had a low haemoglobin and folic
acid. Although no diagnosis was recorded in the notes from his blood count it
was clear he had pernicious and iron deficiency anaemia. When he was
discharged, the information provided was very confusing. The GP was not
informed of the patient's anaemia in the discharge notification letter, nor were
any instructions relating to future therapy communicated i.e. two to three
monthly hydroxocobalamin injections. Without these his condition may
deteriorate significantly. Neither folic acid nor ferrous sulphate were included in
his discharge medication and no reference was made to these in the discharge
letter. He had received only eight days treatment in hospital. It appeared,
however, that this omission was a mistake as there was no record in his notes
that either had been stopped and both drugs were continued on his hospital
drug chart. In addition to this the nurses discharge summary stated that the
patient's medication included ferrous sulphate and folic acid. This would have
been very confusing for the primary care team.
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Case 7 - Patient MW
This patient had been attending the outpatient clinic for some time prior to this
admission. She had initially been referred because of vertigo and falls. Her
medication was thyroxine, bendrofluazide and co-proxamol. Following one
appointment the consultant stopped the bendrofluazide, which she took for
hypertension, and changed this to amlodipine, as she had low sodium and
potassium. She was also suffering from palpitations and ectopics which he
believed to be due to hypokalaemia, secondary to bendrofluazide. This was
communicated to the GP. Despite this, however, the GP later restarted her
bendrofluazide and she was readmitted on this occasion, with low sodium and
potassium. I was however, unaware of the GPs reasons for restarting the
bend rofluazide, which may have been reasonable.
3.7.	 SUMMARY
This chapter describes the preliminary, investigative phase of the study which
aimed to examine the nature of patient care in different specialities and settings
within the study Trust; the culture relating to therapeutics within the Trust;
current practice and standards of care relating to medicines; problems relating
to medicines use; and attitudes to change in these areas.
The main issues identified were:
. accurate and complete drug histories are frequently not obtained when
patients were admitted
. sometimes prescribing is inappropriate
. patients are often not given sufficient information about their medicines and
do not feel involved in their own care
• medication is frequently implicated in admission
• communications both from the hospital to GPs, following discharge and from
GPs to hospitals when patients are admitted are poor
• prescribing and administration errors occurred and are rarely recorded
• drug therapy is poorly documented in patients' notes
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. there are problems around the supply and administration of drugs
. some doctors and nurses have insufficient knowledge of therapeutics
• delays in discharge often occur because of problems with discharge
medication
The following chapter describes how, based on the findings from this
preliminary phase, a new model of care is developed, implemented and
evaluated, aimed at improving care with respect to medication.
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4. CHAPTER 4 - IMPLEMENTATION AND
EVALUATIVE PHASE: PHASE THREE
AND PHASE FOUR
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4.1.	 INTRODUCTION
In section 3.1, I explained this research comprises four phases:
Phase one - a preliminary phase to gain an understanding of the study
environment - methods one, to gather and analyse preliminary data
Phase two - reflection on emerging themes and identification of key issues
relating to the use of medicines - results one, of preliminary analysis
Phase three - development and implementation of a new model of care -
methods two, and
Phase four - evaluation of the model in the study setting and exploration of
issues which would influence adoption throughout the trust - results two.
As detailed in section 3.2 the research was conducted in an acute university
hospital trust in the North of England. The main implementation and evaluative
phase of the study (phases three and four) was conducted on two acute
medical wards within the main hospital, ward A and ward B. Patients admitted
to these wards were usually under the care of one of four consultants in general
medicine who were fully supportive of the project. Ward A had 30 beds, with
patients generally under the care of two of the consultants. Ward B had 28
beds, with patients generally under the care of the other two consultants.
Occasionally, because of bed shortages elsewhere in the hospital, patients
under the care of other consultants were accommodated in these wards, but
were not included in the study.
The patients studied were elderly people (over 60 years) with a range of
diagnoses. Recruitment to the study was opportunistic (convenience sampling),
with patients being included in the study as they were admitted to the wards.
As outlined in section 3.2, the design of the research followed an action
research approach. In chapter 3, section 3.5, I described the methods used in
the preliminary phase of my study, 'phase one' and then described and
reflected on the findings from the preliminary phase, 'phase two'.
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In this chapter I will describe how I developed and implemented a new model of
care based on the findings from the preliminary phase, which I refer to as
'phase three'. I will then move on to describe the evaluation and reflection of the
findings from this phase, which I refer to as 'phase four'.
4.2.	 PHASE THREE: METHODS TWO - DEVELOPMENT,
IMPLEMENTATION AND EVALUATION OF A NEW
MODEL OF CARE
In Chapter 3 I presented data from the preliminary phase showing the nature
and impact of medication problems in the care of older people in the study
Trust. In the third phase of the project, following the principles of action
research, I developed and implemented a series of interventions aimed at
avoiding or minimising these problems.
I prioritised interventions that were deliverable within the study setting and for
which there was some evidence (summarised in Chapter 2) that they might be
effective in improving care. These were:
• obtaining accurate and complete drug histories
• ensuring appropriate prescribing
• educating patients and improving concordance
• identifying iatrogenic factors in admissions
• improving communications with GPs
• avoiding errors, and, when they do occur, ensuring appropriate reporting
• ensuring complete and accurate recording of treatment in the clinical record
• optimising supply and administration of medicines to ensure timely treatment
on the wards and efficient provision of discharge medicines
• educating other health professionals in medicinal therapeutics.
As I set out in section 2.5.5, pharmacists are well placed to deliver these
interventions and developing their role is a feature of current health policy. In
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this phase of the study, I therefore focussed on the contribution that a
pharmacist could make to improving care.
4.2.1.	 Interventions
A new approach to professional practice of pharmacists was developed, based
on these priority areas. Interventions were selected and planned, and
comprised the following. The pharmacist:
. is based on the ward full time, available for all patients and ward staff for
consultation
. attends the ward rounds, monitoring and advising on the prescribing and
administration of drugs
. takes a second medication history following admission to the wards studied,
using a structured proforma (see appendix 6.2)
. assess patients' knowledge about their medicines and compliance (see
appendix 6.3)
. undertakes a formal medication review using indicators of appropriate
prescribing
plans and co-ordinates med(cines aspects ofdiscnarge
educate patients about their medicines
provides information to GPs about patients' drug therapy during admission
and following discharge
4.2.2.	 Aims
The main aims of this new approach to pharmacy practice were:
1. To provide a source of expertise about therapeutics to a team of health care
professionals.
2. As a result of being involved with that team, change prescribing behaviour.
3. As a result of changing prescribing behaviour, reduce the risks associated
with drug therapy to which patients are exposed and improve patient care.
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4.2.3.	 Intervention instruments
In this section I describe the instruments developed to implement the
intervention, Instruments were developed based on my experience in the
preliminary phase of the project, from instruments already in use at the study
trust and from appropriate literature. Instruments facilitated implementation of
the intervention and also assisted in data collection for evaluation.
	
4.2.3.1.	 Drug history
I developed and piloted a structured proforma for drug history taking (see
appendix 6.2). This was used to guide the author to obtain information about:
prescribed medicines, including dose, frequency and indication; medicines
bought by patients, including herbal and homeopathic; allergies; side effects of
medicines; and social drugs such as smoking and drinking. On this proforma I
could make a note of the differences between my drug history and that of the
admitting doctor, and record any changes to therapy following the second drug
history. The second drug history was taken within two days of admission when
the patient arrived on the wards studied.
	
4.2.3.2.	 Medication review
The medication review was developed from the literature (Cantrill eta!., 1998,
Department of Health, 2001 a), and my own professional experience, and
included:
1. Assessment of patients' knowledge
Patients' knowledge about their medication was assessed based on 6 criteria:
the number of drugs the patient recalls they take, the number they know or
partially know the name of, the number they know the purpose of, the number
they can recall the overall dose for, the number they know the daily frequency of
and where appropriate, the number they know the strength of. A score for each
criterion was calculated as a proportion of the total number of drugs the patient
was taking at the time of admission, determined following the second drug
history. For example if a patient was taking 4 drugs and recalls:
. that they take 4, score = I
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• the name of 3, score = 0.75
• the purpose of 2, score = 0.5
• the dose of 3, score =0.75
• the daily frequency of 3, score = 0.75
• the strength of 1, score = 0.25
This allowed a more detailed analysis of particular aspects about patients'
knowledge their medication regimen, for example, patients may be more likely
to recall the overall dose rather than the strength of their medication. On the
other hand, they may be less likely to know the actual names of their
medication, but can recall that they take something, for example a patient may
say, 'I take one for my heart'. The 'proportionate' scores for each criterion were
grouped into the following percentage ranges: 100%, 75-99%, 50-74%, 25-49%
and less than 25%. For example, a patient with a score of 1'for knowledge of
all their medicines names would be classed as having 100% knowledge for this.
A patient with a score of 0.63 would be classed as having between 50 - 74% of
knowledge of their medicines names.
A standardised total score out of 10, for patients' overall knowledge of their
medication, was calculated as the mean of all six proportionate scores
multiplied by 10. This was also was grouped into the percentage ranges listed
above.
2. Patient compliance instrument
Medication compliance is difficult to assess. Drug levels or pharmacological
markers are sometimes available, but interpretation as a measure of
compliance is complicated by potential pharmacokinetic differences between
drugs and patients (Eraker et a!., 1984). This approach was considered
inappropriate for this study as patients would be taking a wide range of drugs,
and technical measures such as those would not be practical. Pill counts are a
widely used compliance measure used in research but tend to be inaccurate
(Raynor, 1992). Interviews may not accurately detect non-compliance as
patients tend to overestimate adherence because of embarrassment,
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forgetfulness or fear (Eraker et aL, 1984). How the question is asked is
significant and careful phrasing may lead to more honest reports. Questions
should not be being threatening, accusative or embarrassing. Not all patients
brought their medication into hospital with them and even for those who did, it
was not possible to ascertain whether that was all their medicine or whether
they had supplies also at home. A pill count was therefore considered
inappropriate.
It was decided the most practical method was to use a questionnaire
administered by myself (see appendix 6.3). The questionnaire for patients was
based on Goldberg et al's (1998) method of assessing patient compliance with
medical treatment. Goldberg et al's questions constructed for patients were
influenced by the distinction between forgetfulness and the decision not to
comply used by Morisky et al(Morisky et a!., 1986). An item was added to
ascertain if the patient took the medication late rather than at the prescribed
time. Goldberg et al's (1998) final compliance index was based on four items,
asking patients whether they:
1) Forgot to take medicines
2) Took medicines late (more than 2 hours)
3) Decided to take less medicine
4) Decided not to take at least one medicine
Instead of a dichotomous reply into 'yes' and 'no', as used by Morisky et a!
(1986), Goldberg et al's (1998) respondents were asked to answer with one of
four different degrees of non-compliance:
a) Once a month or less
b) A number of times a month
c) A number of times a week
d) At least onceaday
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When patients said that they did not take their medicines as prescribed, I
questioned them to ascertain reasons why, for example, they forget to take their
medication, they sometimes take medicines late, and medicines are sometimes
deliberately omitted or doses altered. I also asked patients whether anyone
helped them with their medicines and if they had any routines to help them
remember to take their medicines. If patients deliberately altered their own
medication regimens, they were questioned as to the reasons for this. These
were all open-ended questions and categories were developed depending on
patients' responses.
3. Assessment of appropriateness of prescribing
I reviewed patients medicines according to the following criteria (Cantrill et a!.,
1998, Department of Health, 2001a):
• the indication for the drug is recorded and valid according to the BNF
• untreated indications which may require therapy are reviewed
• the reason for prescribing a drug of limited value is recorded and valid
• there is evidence of efficacy
• the drug prescribed is the cheapest in its therapeutic class, providing it is
just as safe and effective, unless a valid reason is given
a generic product is prescribed if one is available, unless the BNF
recommends otherwise
• the dose and dosing schedule are appropriate based on current evidence,
unless a valid reason is given
• the duration is within the ranges in the BNF, unless a valid reason is given
• the formulation is suitable
• the drug is not contra-indicated in that patient
• the patient is not suffering any hazardous or unpleasant adverse drug
reactions
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. if there are any potentially hazardous drug-drug interactions, the prescriber
is aware.
4.2.3.3.	 Patient reminder chart
A patient reminder chart was developed (see appendix 6.4), which gave
patients written information about the name of their tablets, the dose and
frequency, the purpose of their medicines, and any special instructions.
4.2.3.4.	 Discharge information for GP
A form was developed (see appendix 6.5), to give GP5 additional information
about drug therapy during admission, and following discharge, along with any
monitoring that was required.
4.2.3.5.	 Piloting research instruments
All the instruments were piloted and refined prior to implementation of the next
phase of the project. I used a sample of 20 patients, aged 60 years or over, to
improve the instruments and become familiar with the techniques involved.
These patients were recruited opportunistically as they were admitted to the
study wards, during a two week period in October 2000. Patients were excluded
if they were too ill, or if they had an abbreviated mental test score (AMTS) of
less than five (see appendix 6.6) (Hodkinson, 1972). The nurses helped me in
recruiting patients by suggesting patients they considered appropriate.
4.2.4.	 Implementation of interventions
From November 2000 to March 2001 this new approach to practice was
implemented on two acute medical wards within the study Trust, ward A and
ward B. Following the ethnographic work, I decided that it would not be possible
to work simultaneously on the two wards therefore, for the first two months I
worked on ward A and for the second two months I worked on ward B. I worked,
as a pharmacist, on the wards along side the doctors and nurses, providing
'patient centred' pharmacy services as outlined above. I spent my whole
working day on the wards, and was contactable via a pager at all times.
The preliminary ethnographic findings identified the therapeutic problems that
were occurring and interventions that might be effective in addressing them. It
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also provided a valuable insight into the workings of the wards and the
prevailing clinical and management culture (which was itself a contributor to
some of the problems). Clearly, it was important to embed the interventions
within the ward culture while, at the same time, acting to change that culture
where appropriate. Interventions that were explicitly in conflict with working
practices and ethos would be unlikely to succeed. The ethnographic findings
helped me to develop ways of working and relationships which were a good fit
with existing practice and which enabled me successfully to integrate changes
in practice.
As discussed previously, the patients involved in the study were elderly, as they
have more medication related problems than younger people, and most of the
patients on the wards studied fell into this age category. Convenience sampling
was used, as patients were admitted to the wards studied. Each ward had an
admissions book, in which the nurses entered the patient's name, details and
diagnosis. Each morning I checked the admissions book and noted the names
of potential participants. I then spoke to the nurses, who were aware of the
inclusion and exclusion criteria, and asked which patients they considered
potentially appropriate for inclusion in my study. They were very helpful in
guiding me as to which patients were too ill or too confused to take part and this
meant I did not have to assess all patients admitted to the ward.
Patients included in the study were over 60 years of age, under the care of one
of the four specified consultants, and had an abbreviated mental test score
(AMTS) of greater than or equal to five out of ten. It was felt inappropriate to
include patients with an AMTS of less than five as they would not be able to
consent. Patients whom I considered too ill to participate were excluded.
Patients admitted to the wards on Friday evening or Saturday were excluded as
I intended to take the drug history no later than 24 hours after arrival on the
study ward.
I gave patients an information sheet and explained about the study (see
appendix 6.7). I explained that the study aimed to improve the use and
management of medicines within the Trust and when patients are discharged.
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Patients were asked if they were agreeable to taking part and so they signed a
formal consent form, (see appendix 6.8).
	
4.2.5.	 Evaluation of interventions
As detailed in section 2.7, health care is complex, and patient outcomes are
influenced by a range of factors. As it was deemed most appropriate for this
research, an evaluative study was undertaken. Evaluation research is used to
find out if, how and to what extent the objectives of particular activities, such as
provision of service, have been or are being met. This type of research
addresses the question, "Did it work?" So did the new approach to pharmacy
practice work?
	
4.2.5.1.	 Case study approach
A case study approach was used for the evaluative study. A case study focuses
on specific situations, which may be a single case, a number of cases, or an
organisation. In this study 'the case' comprised the two wards studied, patients
enrolled into the study and the various health care professionals. Case study
evaluations are valuable for the study of complex circumstances and social
settings (Bowling, 1997). Case studies typically use multiple methods and
sources of evidence to establish construct validity (Yin, 1994), and as a design
lend themselves well to both qualitative and quantitative approaches.
To evaluate the new approach to pharmacy practice implemented in this
project, detailed information were collected using a variety of data collection
procedures.
Differences between the admitting doctor's drug history and that obtained by
myself were recorded and compared. I recorded any subsequent changes to
therapy following my drug history. I also recorded all changes to medication
following the structured review.
Patients abbreviated mental test score (AMTS) results were recorded, and their
knowledge of their medication regimen was assessed. Patients' knowledge and
understanding about their medication was assessed and scored using the
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system described in section 4.2.3.2. Results from the compliance assessment
were recorded, scored and categorised as outlined in section 4.2.3.2.
I recorded all my activities on the ward and all interventions into drug therapy
were recorded and categorised, using a form which had been validated by
pharmacists from the study Trust (see appendix 6.9) and was already used by
pharmacists. Interventions were categorised according to the main people
involved, the primary reason for the intervention, and the clinical significance of
my action. Significance ratings were assigned retrospectively to each
intervention by two separate hospital pharmacists, independent to the study and
a measure of agreement between the two assessors was obtained using
Cohen's Kappa. A value of I indicates perfect agreement, whilst a value of 0
indicates that agreement is no better than chance. The significance ratings were
as follows:
1. Intervention detrimental to the patient
2. Information only
3. Minor benefit e.g. administration of intravenous cefuroxime and
metronidazole in the same bag
4. Moderate benefit e.g. a recommendation which would bring care to a
more acceptable and appropriate level (i.e. standard of practice)
5. Significant benefit e.g. changed sub-therapeutic dose, optimised therapy,
changed inappropriate therapy
6. Very significant benefit e.g. prevented serious toxicity or discomfort
7. Potentially life saving
I recorded all instances where I intercepted errors, along with all impact on
prescribing practice.
Again following ethnographic technique, data were gathered from participant
observation during the implementation phase, and informal discussions with
doctors, nurses, ward clerks, general practitioners, community pharmacists and
patients. Participants were asked what they thought of the new approach to
pharmacists working along side doctors and nurses in this way.
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A short questionnaire was administered to patients to assess their satisfaction
with the standard of care regarding their drug therapy, and to gain insight into
their understanding of their therapeutic regimen, and adherence issues. Open-
ended questions allowed respondents to raise issues which were important to
themselves.
4.2.6.	 Focus groups and in-depth interviews
Following the four month active study period on the wards I sought the views of
health care workers about the new approach to pharmacy practice. Data from
interviews and focus groups were triangulated with the case study data, to
evaluate the new approach to pharmacy practice, and also to identify factors
which could either enhance or inhibit its large scale implementation in a Trust.
The case study data and interview and focus group data were combined to
explore issues around the same topics and enable a broad examination of
themes for discussion. The interviews and focus groups also provided an
opportunity to investigate in more depth, issues relating to the use of medicines
within the study hospital that participants felt were important, and to explore
their experiences.
In order to develop questions to ask participants about implementation of the
new approach to pharmacy practice I needed to consider issues relating to
change in practice within organisations in general.
If the proposed new approach to pharmacy practice was to be implemented
across mainstream general medical care within the study Trust, what is required
for it to be successful? What are the barriers to its successful implementation?
What will facilitate its successful implementation? How can the culture towards
care of patients with respect to their medication be changed? How much of the
model would require a hands-on approach from pharmacists, and which parts of
the model could be delivered effectively by other health care professionals?
As it is the views of professionals that are sought, the most appropriate
methods were focus groups and in-depth interviews, using constant
comparative analysis to identify themes. This approach allows more detailed
data to be collected and provides a rich insight into the issues addressed in the
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research question. Interviews are an appropriate method of producing data as
they provide opportunities for informants to discuss priorities, opinions and
ideas. As it was necessary to obtain the views of staff who are in key positions
to influence implementation of the model, theoretical and purposive sampling
were used (Bowling, 1997). Interviewees were selected following theoretical
sampling, which involves selection of informants based on the developing
analysis and coding of data. Interviewees were therefore selected to gather
additional information in an attempt to corroborate, or otherwise, existing data
and to elaborate of the categories. The process of gathering new data stops
when additional data is not adding to the analysis i.e. theoretical saturation.
Theoretical sampling was considered impractical for the focus group
recruitment. Appropriate focus group participants were identified using
purposive sampling, whereby participants are recruited with a known particular
characteristic, i.e. the pharmacy staff who would be involved with the proposed
service developments.
4.2.6.1.	 Interviews
Following the four month evaluation of the interventions on the wards, semi-
structured interviews were conducted with the four general medicine
consultants and one nurse who were involved with in the project. Semi-
structured interviews were also conducted with two registrars, two senior house
officers, three house officers and one senior nurse who had not been involved
in the project, but were working in general medicine. This method allowed me to
cover the areas which I wished to explore, but also to probe issues raised
during the interview.
I telephoned the four consultants and asked if they would be willing to take part
in an interview and they all agreed. I asked them to suggest some other doctors
of varying grades and nurses whom I could interview. Following their advice I
contacted the doctors and nurses they suggested, by paging them or
telephoning the ward. I explained the purpose of the interviews and asked them
if they were willing to take part. All agreed, although one of the nurses was
unable to participate as she was on holiday.
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These staff were then sent a covering letter confirming the interview and what it
would involve, with additional information about the project depending upon
whether or not they had prior involvement in the project. The doctors and nurse
without prior involvement received a letter, which informed them about the aims
of the study, what the project involved, the main findings, and the main issues to
be covered during the interview (see appendix 6.10). The consultants and one
nurse involved in the project received a letter which briefly informed them of the
main issues to be covered in the interview (see appendix 6.11).
I conducted all interviews and used an aide memoir which varied depending on
the health care worker interviewed and whether or not they were involved in the
project (see appendices 6.12 and 6.13). This included a list of issues and
questions, which enabled the interviewee to develop ideas and speak more
widely on the issues raised.
From these interviews, I hoped to gain the opinions and views of the medical
staff on the proposed change in pharmacy practice following the study
interventions, and the problems relating to medicines they currently experience.
Issues covered included:
. whether they were supportive of the proposed changes
how they feel about pharmacists being fully integrated members of the
multidisciplinary team
. what the perceived barriers are and how can these be overcome
. whether patients' care would be improved
. whether there any cultural problems which may impede implementation, and
how can these be tackled.
Doctors and nurses were asked about:
• views of pharmacists as professionals
• their perceptions of the roles of pharmacy staff
• exactly how pharmacists could further contribute to patient care and
• how they could help them in their work
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• involvement of patients in their own care, for example patient education
• the problems as they perceive them, relating to medicines within the study
Trust, such as medication errors
. their own competencies, and those of their colleagues, including whether
they have sufficient knowledge of therapeutics, and whether they receive
enough training and support about drug therapy.
This would help refinement of the model of pharmacy practice, for wider
implementation. Potential interprofessional and interpersonal problems were
explored.
A pilot interview was conducted with a pharmacist playing the role of doctor, to
help refine the actual questions, and to train myself in the use of the technique.
Some questions were felt to be too long, and were rewritten to be shorter and
more succinct. Some were felt to be closed, and were therefore revised.
With the permission of the informants the interviews were tape recorded and
transcribed in full, by myself, following the interview. All but one agreed to the
interview being tape recorded. One participant refused and I took notes, which
were fully transcribed immediately following the interview. Supplementary notes
were taken even in the recorded interviews, in case of failure of recording
equipment.
4.2.6.2.	 Focus groups
Following the four month evaluation of the interventions on the wards, four
focus groups were conducted with pharmacy staff from the study Trust. It was
decided to group pharmacists and technicians separately, as they have different
professional responsibilities and are therefore likely to raise differing concerns
and issues about the proposed developments in pharmacy services. Bringing
people together on the basis of shared experience is often most productive;
however, differences between participants are often illuminating (Kitzinger,
1 994a).
After a brief presentation to inform pharmacy staff about the project and focus
groups as a method, then they were invited to participate. Sixteen pharmacy
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staff participated in four focus groups see (tables 4.1 and 4.2). At the time of the
study there were 13 pharmacists in post, and 17 technicians. All volunteers
were given a letter which briefly summarised what was involved in focus groups
and informed them about the aims of the study, what the project involved, the
main findings, and the main issues to be covered during the focus group (see
appendix 6.14).
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Table 4.1 Focus group participants - pharmacists
Focus	 ID Grade Job description 	 Years
group	 qualified
1	 A	 E	 Formulary / electronic prescribing 	 10
B	 D	 Orthopaedics / plastics	 5
C	 D	 Medical admissions	 4
D	 D	 Quality and performance
	 18
2	 A	 D	 Surgery	 12
B	 C	 Orthopaedics	 2
C	 D	 General medicine - elderly 	 6
D	 E	 Principal clinical pharmacist 	 2
Table 4.2 Focus group participants - pharmacy technicians
Focus	 ID Grade Job description	 Years
group	 qualified
I	 A MTO2 Dispensary	 23
B MTO2 Ward based	 10
E MTO2 Ward based	 12
C MTO2 Dispensary I aseptics	 3
2	 A MTO2 Dispensary	 34
B MTOI Dispensary	 1
C MTO2 Dispensary I aseptics	 17
D MTO2 Ward based	 20
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A schedule was used as an aide memoir for the focus groups (see appendix
6.15). The objectives of the focus groups were to obtain the views of pharmacy
staff on implementing the proposed patient centred pharmacy practice
throughout mainstream care of general medicine. In particular:
• their feelings about taking on new I extended roles
• pharmacist integration into the multidisciplinary team, providing patient-
focussed rather than the traditional pharmacy-based services
• perceived barriers and how to overcome or tackle these
• training requirements and support needed
• appropriate professionals to deliver the different components of the service
• the level of pharmacist involvement required
• monitoring and audit of the service
Participants were asked their views on the new approach to pharmacy services
piloted within the Trust, in particular their perceived advantages and
disadvantages for patients, doctors, nurses and themselves.
Each focus group was approximately one hour in length. They were held in the
education and training department of the study Trust. Participants and the
moderator sat in a circle to help establish a relaxed atmosphere. Refreshments
were served, but there was no break, as staff were needed back at work, so
there were time limitations. As the participants all knew each other introductions
were not required.
It was important to set up a non-threatening environment conducive to
expression of opinions. The moderator must therefore be seen to be impartial
and objective, with no vested interest in the outcome. For these reasons I
decided to have an individual who was independent of the research, and the
study Trust, to moderate the focus groups. It was decided that the moderator
needed to have background knowledge of the subject area, so another
pharmacist, from a different Trust facilitated the groups. She was given a
summary of the research and the aide memoir prior to conducting the focus
groups. She had prior experience of focus group moderation. This was an
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advantage as the role of the moderator is to guide the discussion, listen to what
is said, but not to participate, share views, engage in discussion, or shape the
outcome of the group discussion (Kruegar, 1998). Skill is needed to balance
keeping quiet, with knowing when to intervene. A key skill is to ensure that
interaction between research participants is encouraged.
With the informants' permission, the focus groups were tape recorded.
Informants were asked if they had anything to add after the tape recorder had
been turned off. I was a non-participant observer in the group, observing non-
verbal behaviour, interaction between individuals and group dynamics to ensure
that as much data as possible is available for analysis. Field notes were made
to supplement the transcripts.
4.2.7.	 Analysis
Data from the case study approach were analysed using the software package
SPSS, (Statistical Package for Social Sciences). Differences in drug histories
and changes to medicines following this and the medication review were
quantified, and categorised. Patient characteristics were entered into SPSS,
along with their abbreviated mental test score.
The proportionate scores for patients' knowledge of their medication for each
criterion along with the overall score and the ranges in which these were placed
were entered into SPSS.
Patients' responses to the four items, relating to compliance with their
medication regimen, from the questionnaire were entered into SPSS. For
example for the each item the response could be one of four alternatives, as
described in section 4.2.3.2. Answers to the open ended questions were
categorised and the resultant categories entered into SPSS.
All interventions into drug therapy were entered into SPSS as categorical
variables, including errors intercepted and instances where prescribing
behaviour had been altered. The short patient questionnaire to assess
satisfaction with the service was also analysed using SPSS. Responses to open
ended questions were analysed and used to illustrate patients' feelings.
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A descriptive analysis was carried out, with frequencies calculated for
categorical variables and mean and standard deviation for quantitative
variables. Relations between variables were assessed using Pearson's
correlation.
Observational work, informal discussions and open ended questions were
transcribed, and analysed in the same manner as the interviews and focus
groups data.
I transcribed the interviews and focus groups verbatim. The transcripts were
supplemented with observational data obtained during the interviews and focus
groups. A large amount of very rich and dynamic data was generated from
these.
QSR NUDIST software package was used to facilitate analysis of the
transcripts. This package enables complex organisation and retrieval of data
and avoids 'cut and paste' techniques i.e. cuffing sections of data and pasting
them on to index cards that could be filed under the appropriate category.
Within the computer package themes are categorised and stored by their
contextual theme using labels and the themes also maintain their contextual
position in the raw transcripts. NUDIST makes the categorisation of qualitative
data easier by enabling entry of verbatim transcripts and marking of text by
theme which the computer can retrieve and sort as instructed. While
programmed coding of words and phrases, with 'look up' tables and dictionaries
stored in the machine, can be carried out by qualitative analysis packages,
concept matching remains the job of the researcher. Within this study I used
NUDIST to create names and phrases (themes) and highlight related areas of
text from my transcripts to be categorised (coded) under the created headings.
This enabled me to build and modify subsets of categories which ultimately aim
to describe the full range of data. Whilst NUDIST facilitated the data analysis,
the creation of themes and categorisation of data was undertaken by myself.
Basically the computer took over the manual tasks associated with the coding
process e.g. writing marginal codes, making photocopies of transcripts or field
notes, cuffing out all chunks of text relating to a code, and pasting them
together. NUDIST does not automatically do these things, I had to interpret my
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data, code and then retrieve the data, but the computer takes over the manual
labour involved (e.g. wielding scissors and pasting paper together).
The transcripts were read many times and the data systematically examined to
identify and group recurrent themes and coding, and to classify and develop
categories. This is known as 'open-coding', whereby the data are examined
word by word and line by line, and codes were freely generated, often reflecting
the words of the respondents themselves. For example, the code 'patient
education' was given to the response:
"Often we don't educate patients about their medications, just because
we're busy.......
House officer EB
QSR NUDIST was used to carry out this coding process. A constant
comparison approach was followed, whereby each category was searched in
the entire data set and all instances were compared until no new categories
could be identified (Strauss and Corbin, 1998, Pope and Mays, 1995). Each
item is systematically checked or compared with the rest of the data to establish
analytical categories. Categories are added to reflect as many of the nuances in
the data as possible, rather than reducing the data to numerical codes. Sections
of the data, such as discrete incidents, frequently included multiple themes, and
QSR NUDIST software facilitated cross referencing to deal with this (Pope and
Mays, 1999). The global codes were then reviewed and sorted into broader
codes. This can be referred to as data reduction, whereby data are condensed,
focussed and simplified (Miles and Huberman, 1984). Once the data were
coded they were re-examined to look for similarities which would allow the
global codes to be collapsed into substantive codes and grouped together into
categories.
Data analysis was inductive, following a grounded theory framework, the core
category of which is conceptualisation (Strauss and Corbin, 1998). Grounded
theory is the generation of emergent conceptualisations into integrated patterns,
which are denoted by categories and their properties. This is accomplished by
the rigorous steps of grounded theory, woven together by the constant
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comparison process, which is designed to generate concepts from data (Glaser,
2002).
4.2.8.	 Summary
An action research approach was followed for this project:
Phase three was the action stage of the project and I developed and
implemented patient centred pharmacy practice, whereby the pharmacist
worked along side doctors and nurses on the two wards studied providing the
specified services.
Phase four was the evaluation stage. A case study approach was used to
evaluate the new approach to pharmacy practice. Focus rozps anO inierv)ews
supplemented this and provided information about factors which could either
enhance or inhibit its wholesale implementation in a Trust. Health care staff
were also asked in more depth about issues relating to the use of medicines
within the study hospital.
4.3.	 PHASE FOUR: RESULTS TWO - EVALUATION AND
REFLECTION
This section provides a summary and reflections of the findings from the
evaluative study, focus groups and interviews. Discussion of the emergent
topics are given in chapter 5.
As a reminder, initially an assessment study was conducted, using ethnographic
technique, to assess, the current situation within the study Trust, with respect to
the use on medicines, and how patient care could be improved by more
appropriate employment of the expertise of the pharmacist.
Then a new approach to pharmacy practice was developed, with specific
interventions aimed at addressing problems identified, and improving patient
care. As described, this new model for pharmacy practice was then
implemented and evaluated on two acute medical wards.
I begin by describing my experience of conducting the research.
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	4.3.1.	 Experience of conducting the research
In this section, I will try describe my experience of conducting the research and
give an insight into my interactions with doctors, nurses and patients, their
reactions to this project, and my own feelings about undertaking the work.
Throughout the research I recorded all my actual interventions into patient care
and activities undertaken and made detailed descriptive field notes in a number
of instances which I felt were particularly significant, for example about
conversations, attitudes, interprofessional dynamics, relationships with patients.
In hindsight, it would have been helpful to keep even more detailed field notes
of all my activities for example the every day encounters with patients, staff and
other people involved in the project. However, at the time of conducting the
research I felt I had insufficient time to record data in this manner. In retrospect,
it would have been useful to keep a brief day-to-day diary throughout the
project.
	
4.3.1.1.	 Stakeholders
At the beginning of the project, I felt it was important to identify the key
stakeholders. These included the director of quality and performance at the
local Health Authority, the four consultants I was to be working with, and the
head of pharmacy at the study Trust. Doctors, nurses, and other ward staff and
pharmacy staff were also very important. The local Health Authority funded two
years of the research programme.
An important early task was to identify the political issues around this project
and the different agendas of each group. Negotiation and consensus with
stakeholders was necessary to recognise and deal with the politics of the
project in a creative and constructive way.
The head of pharmacy at the study Trust had originally sought funding from the
Health Authority for a research project to investigate medicine practices in the
hospital and the professional roles of pharmacy staff. The main objectives were
to highlight suspected problems in current practices and the benefit of
developing ward based pharmacy services. The head of pharmacy had a
specific agenda in that he wanted the Trust to invest in pharmacy. The
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consultants also wanted more pharmacy input on the wards. At times, I felt
under pressure and pulled in different directions and I felt it was important that
this did not adversely influence the project. The main stakeholders were keen to
see service development and I sometimes found it difficult to balance this with a
robust research programme. Furthermore, on occasions, negotiation and
justification about my chosen research methodology was necessary as some
people had different ideas about how the research should be undertaken.
4.31.2.	 Initial concerns
Although I had some experience of working on hospital wards prior to this
project, this had been limited to a service which involved me simply visiting
designated wards on a daily basis to monitor prescriptions and attending
selected Consultant ward rounds. However, I had not worked along side doctors
and nurses, based on wards fulltime rather than in the pharmacy, as was the
intention in this study. The prospect of working in this way was initially
extremely daunting. I was unsure how the doctors and nurses would react to me
and was afraid some may dislike having a pharmacist working along side them
and perceive me as interfering, 'nit picking' or checking up on them. I worried
that they may feel having a pharmacist working on the ward in this way was
unnecessary. I was concerned that doctors and nurses would be confused
about my role, as I was introducing a completely novel service within that Trust.
Furthermore, my role as a researcher may add to this confusion as I was also
trying to evaluate the service at the same time and would be undertaking
activities that were unique to a study setting i.e. measuring and recording
activities. I worried this would cause problems in understanding of my role or
worse still may cause people to be wary and suspicious of me.
Moreover this study was conducted within an acute general medical setting and
my previous work on wards had been, primarily, provision of clinical pharmacy
services to neonatal and paediatric departments, and a neuro-rehabilitation
department. Although I had provided clinical pharmacy services to general
medical wards to cover for other pharmacists whilst they were on holiday I was
did not have a great deal of exposure in this area. I was concerned about
whether this would influence my 'performance' within this study.
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I was however, able to reassure myself of my competence as I have always
quickly adapted to new working environments and have a broad therapeutics
knowledge base. In addition to ward-based work, my previous experience
includes managing patients' anti-coagulation, developing evidence-based
treatment guidelines, providing education and training for pharmacy, nursing,
and medical staff, providing drug information and manufacturing services; and
reporting to clinical directorates on drug usage and costs when required.
Furthermore, during the preliminary, assessment phase of the project I spent a
lot of time the study wards and became familiar with the setting and practices,
and the staff. This gave me a good grounding from which to begin the
intervention phase in which I would provide specified services on the wards.
4.3.1.3.	 Preliminary dialogue prior to intervention phase
Before actually starting the intervention phase on the wards I arranged
meetings with the doctors, nurses and pharmacy staff to introduce myself and
explain about the research. I discussed the activities I was proposing to
undertake and asked for feedback.
It was difficult to arrange these meetings as all staff were very busy, but I
managed to have a meeting with the doctors from the two study wards, one with
the some of the nurses from each ward and a meeting with various pharmacy
staff.
4.3.1.3.1.	 Doctors
The meeting with the doctors comprised three house officers, two senior house
officers and one registrar. All felt it would be useful having a pharmacist as a
resource on the ward for medicines information, and as a group, they seemed
on the whole to be keen about the project. Three of the doctors had prior
experience of pharmacists working on the wards along side them and had found
it very helpful. In particular, they liked having someone to ask for advice about
therapeutics. The doctors were curious as to why there are differences in the
level of pharmacy input on wards, between hospitals. I explained that this varied
depending on management of pharmacy departments, support from Trust
management and resources.
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Some of the doctors felt that it would be very useful to have me attending the
ward rounds but the registrar said he felt I would be bored for most of the time
as only a small proportion of time on ward rounds is spent talking about drugs. I
felt however, that it was important for me to attend ward rounds as this is when
the main therapeutic decisions are made and I would be more involved with not
only patients, but also the medical team. I also believed this would facilitate my
work on the ward and help with inter-professional relationships.
Some of the doctors commented that I would be stopping their 'sloppy'
prescribing, which was quite surprising, as they were openly admitting that they
did not always take care when writing prescriptions. I worried that the doctors
may therefore feel it was not necessary to improve their prescribing, as I would
be a safety net. Whilst the doctors were keen to have this added layer of
security I worried that this may put strain on the doctor pharmacist relationship if
they perceive me as checking up on them and acting as a prescribing police
woman.
The doctors echoed some of the issues I highlight throughout the study, in
particular the delay between medicines being prescribed and patients actually
receiving a dose. They complained that drug kardexes frequently state 'out of
stock / no stock', or 'on order'. They also said that medicines patients bring into
hospital with them are often 'lost' when patients are transferred from the
admissions ward. I agreed with them and explained that these are the types of
problems I intend to address whilst working on the wards.
All agreed taking a second drug history would be beneficial, as they are very
busy on the admissions ward and it is often difficult to obtain and accurate and
complete drug history, especially if patients are confused or ill and they cannot
tell doctors what medicines they take. If carers come in with patients, often they
don't know about the medicines and patients frequently do not bring their
medicines with them. The doctors acknowledged that the computer print offs
patients get from their GP are not always reliable and up to date, yet my
experience on the wards found that these slips are often used for the drug
history.
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All of the doctors said that the elderly people they see on the wards are
frequently on many medicines, some of which are inappropriate. Despite
acknowledging that admission to hospital is an ideal time to review patients'
medicines they said this is rarely done, unless the medication is relevant to that
particular admission. They all said it would be very worthwhile for me to
undertake a structured medication review in the study.
All the doctors said that a great deal of time is wasted with discharge
prescriptions, in particular errors that they themselves make which are then
queried by pharmacy and sometimes patient discharge is delayed. They all said
that they find it difficult to write discharge prescriptions during ward rounds, so
they are left until the end. This often means prescriptions do not go down to
pharmacy until late afternoon and delays in discharge result. I explained that I
would also be writing discharge prescriptions and they all felt that would be
extremely helpful, would free up a lot of their time and would result in quicker
discharge for patients.
One concern was raised about drugs such as prednisolone, which require a
tapering dose. I explained that I would discuss the discharge prescriptions with
the medical team before I wrote them.
I had a number of concerns about writing the discharge prescriptions for
doctors. Taking over this job would hopefully improve patient safety and
increase efficiency; however, doctors may not then improve their prescribing
practices. In addition, freeing up doctors' time would only be beneficial if they
used it appropriately, for example for other clinical activities.
The doctors admitted that they do not give GPs enough information about
changes made to patients' medicines whilst they are in hospital. They said it
would improve continuity of care if I give GPs additional information about drug
therapy.
The doctors also were keen for me to educate patients about their medicines as
they said they do not do this very often. They also felt it would save the nurses'
time.
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I explained that I would be promoting prescribing from the hospital formulary list
of drugs, which is in development with the surrounding Primary Care Groups
(PCGs). The registrar asked, "What are formulaly drugs?" This was quite
alarming, not only because he should have known, but also because he was the
most senior doctor at the meeting. I felt this was a reflection of the current level
of pharmacy input on the wards within the study Trust. I explained to the doctors
what was meant by 'formulary drugs' and gave examples. This highlighted to
me that I would need to pay particular attention to this when working on the
wards, and educate doctors about the formulary whenever possible.
I found this meeting very encouraging and felt more confident about starting
work on the wards. It seemed that the doctors would welcome my input into
patient care. I suspected that the main reason they were keen was that I would
be relieving them of some of their workload, although they did seem to think
patients would benefit also.
4.3.1.3.2.	 Nurses
I met with 6 nurses from the two study wards prior to the intervention phase.
They had many concerns relating to medicines use all of which I had identified
in my preliminary study. They were supportive of all the activities I proposed to
undertake on the wards and were extremely enthusiastic about the project.
They were particularly keen about having someone to ask advice about
therapeutics, writing discharge prescriptions, monitoring prescribing and
educating patients. They believed that patients would be discharged quicker as
the prescriptions would be written in a more timely fashion. They said however,
that waiting for patients discharge medication is not the only reason for delays
in discharge. One nurse said that a study should be undertaken looking at
social services. She said that patients spend weeks waiting for placement in
care homes or alterations to their houses.
The nurses also felt that pharmacy take a long time dispensing prescriptions
and that this holds up discharge. I explained that if discharges were anticipated
in advance and prescriptions written earlier, medicines could be on the ward
ready for patients to go home. The nurses agreed but felt that this is not always
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possible. They all felt that patient safety would be enhanced if pharmacists
wrote the prescriptions as the doctors frequently make errors.
Like the doctors, their primary concern appeared to be lessening their workload,
although they did seem more concerned with the benefits for patients than the
doctors did. This may be because the nurses spend all their time caring for
patients and perhaps form more of a bond with patients. They may be more
aware of the needs of patients and the shortcomings in care. As with the
doctors, this meeting made me feel more comfortable about starting my work on
the wards.
4.3.1.3.3.	 Pharmacy staff
The meeting with pharmacy staff comprised three pharmacists (Operational
services manager, formulary pharmacist and a clinical pharmacist) and five
pharmacy technicians. The pharmacists agreed that drug histories taken by
junior doctors are often inaccurate and incomplete, and they felt this was a very
good use of a pharmacist on the wards.
One of the pharmacists gave an example of the problems that can arise from
the drug history process. A patient he encountered on a surgery ward was
prescribed completely different medicines to those listed in the admission drug
history. The pharmacist queried this with the doctor, It came to light that the
patient had been assessed prior to their operation in the admissions clinic and
the doctor said that when she was asked about her usual medicines she had
just 'made them up.' When she was actually admitted, she brought all her
medicines in with her, and was prescribed them all hence the difference.
All felt that the admissions ward was not the best place for pharmacists to take
a second drug history. They said that this should be undertaken when patients
are transferred to another ward, as long as it is done shortly after admission.
All believed that a structured medication review was also a good use of
pharmacist time, as they felt GPs do not get much time to do this. One of the
senior pharmacists felt strongly that surgeons would be more reluctant than
general medical doctors to change medication, as they are more concerned
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with the operation than other concomitant medical conditions and the
associated therapy. Although in this study I am working in a general medical
setting, this will be an important consideration if services were to be rolled out
across other directorates.
All were particularly keen for me to write discharge prescriptions as they felt it
would enhance safety and efficiency. They reinforced my own views that much
time is wasted sorting out errors on discharge prescriptions and that this can
result in delays in discharge. They also felt that this would reduce waste as
doctors frequently prescribe unnecessary medicines on discharge prescriptions.
They felt that doctors just copy all the medicines from the drug chart whether
the patient needs them or not and sometimes even prescribe drugs on the
discharge prescription that have been stopped on the drug chart.
Pharmacists felt that I should communicate information about drug therapy to
GPs, as this is currently not effectively done. They felt that information about
monitoring drug therapy was particularly important yet very rarely given to GPs.
One pharmacist said that GPs may change patients back to the medication they
were taking prior to admission if they are unclear as to why drugs have been
stopped or started.
All were keen for pharmacy staff to fill in patient medicine reminder charts as
the nurses currently do this and errors have occurred. They all felt that another
member of pharmacy staff should check this before giving it to the patient as
patients frequently use only these when taking their medicines without looking
at instructions on the labels. We discussed the issues around this and we
decided, for this study the safest system would be for me to write the reminder
chart on the wards and then send it down to pharmacy with the discharge
prescription so it could be checked by another member of pharmacy staff.
We discussed issues concerning the hospital formulary. One pharmacist raised
concerns about changing people from combination products, which aren't on
the hospital formulary, to their component parts, as this may result in
compliance problems when patients are discharged. I agreed and we decided it
would be better to consider patients individually and if compliance was felt to be
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a problem, combination medicines should not be altered. A pharmacy
technician asked what should be done if a patient is prescribed a non-formulary
drug but they bring their own medication in with them. The formulary pharmacist
said that if they have enough to last them until they go home and sufficient to
take home, then it could be continued. If not then it must be changed.
I finally asked the pharmacists and technicians what they thought about the
project, and they all said it is extremely valuable, and believed, without doubt,
that it would improve patient care and efficiency of services. They thought I was
taking a lot on however, and had concerns about how I was going to manage
everything I proposed to do.
After this meeting, I felt much happier about starting work on the wards as I felt I
had the support of pharmacy staff. I found their insights into practices relating to
medicines extremely helpful. Initially I worried that some pharmacists may be
slightly resentful towards my working on the wards as I had not worked in the
Trust previously and they themselves may have liked the opportunity to
undertake similar work. In addition, some of the pharmacists were already
visiting wards and undertaking various activities such as prescription monitoring
and I worried that they may feel that the project was unnecessary. After the
meeting, I knew this was not the case and they felt the project was extremely
valuable in developing services. I knew that I would need their support for the
project to be successful, as without it I could encounter numerous problems.
4.3.1.4.	 Implementing and evaluating the patient centred pharmacy
services
When I started the intervention phase of the project I worked on ward A for two
months then worked on ward B for two months. My working hours were 8.3Oam
until 5.00pm. Although I had met with the doctors and nurses and explained
what I was intending to do on the wards, when I started there was still
uncertainty about my role. It also took time to acclimatize to working on the
wards full-time, as I had not done this before. On the first Monday morning, I felt
very much thrown in at the deep end and I had to get started straight away. I
was extremely busy undertaking all the activities whilst simultaneously
collecting data for evaluation and sometimes I found it very difficult. I had to
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work very hard and frequently worked beyond my designated working hours. I
believe that had this not been research project and I was not also collecting
data my work would have been much easier.
I found the ward clerks helpful in informing me of admissions and discharges
and keeping me up to date with what was happening on the wards. I built up a
good relationship with each of the ward clerks as they worked in the ward office,
and that is where I sorted through much of my data.
4.3.1.4.1.	 Taking drug histories
I found it time consuming taking the drug histories, as initially I followed up all
possible sources, such as interviewing the patient, contacting their GP, talking
to carers, and contacting the community pharmacist if necessary. Most patients
were perfectly happy to cooperate, although a few questioned why I was asking
them to recall their medicines again, as they had already done this following
their admission. Two patients refused to cooperate and give a drug history. A
number of the patients were aware that they had not been receiving some of
their usual medicines and were concerned. Some had actually mentioned this to
nursing staff but still the medication was not prescribed.
Following the second drug history, I discussed any changes I proposed with the
doctors. They accepted all my recommendations and they did not appear to feel
that I was criticising or threatening them. Although the doctors were grateful that
these mistakes were being highlighted, they rarely appeared concerned about
their errors. Junior doctors did not appear overtly concerned about the
consequences of inaccurate drug histories. I recorded in patients' notes if they
were taking any other medicines for example over the counter medicines,
homeopathic or herbal medicines although the doctors were rarely interested in
this.
4.3.1.4.2.	 Undertaking the medication review
As with drug histories, doctors were happy for me to suggest changes to
patients' medication, although often they preferred to wait until the consultant
ward round. I was not afraid to suggest changes to medicines and the doctors
reacted very positively. From my observations prior to the intervention phase, I
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found that doctors only made changes to medication relating to the admission,
usually because they have insufficient time to follow up the history behind the
prescribing. I therefore felt that my review was particularly helpful. On
occasions, however, the doctors were unwilling to alter patients' medicines that
were not pertinent to the admission. The medication review was time
consuming as it often involved telephoning patients' GPs and sorting through
previous medical notes and investigating indications for drugs.
4.3.1.4.3.	 Interaction with patients
Most patients were very pleased that I was taking such an interest in their
medicines, and talking to them about their treatment. I was able to find out
much information about patients' medication practices by chatting with them.
The patients seemed to be honest when I asked them questions about
compliance and several openly admitted to not taking their medication as
prescribed. I sensed that they are less honest with the doctors and nurses, but
in addition doctors and nurses tend not to have in-depth conversations with
patients about their medication regimen and compliance with this. Some
patients asked me not to tell the doctors, as if they were afraid of them. The
doctors and nurses frequently commented that patients wouldn't tell them some
of the things they were disclosing to me, for example if they weren't taking their
medication as prescribed.
On some occasions, information I discovered from patients about their
medication practices greatly influenced subsequent care and treatment
decisions. I identified patients at risk of medication related problems who
otherwise, probably would have gone unnoticed. For example, I identified that a
blind person may have difficulty with her medicines following discharge. She
said she knew which ones to take by feeling them. She had just been started on
warfarin and many other tablets had also changed. I arranged for her to have a
compliance aid and organised the management of this following her discharge.
The nursing staff were amazed when I told them about this as they said that it
would never have occurred to them that the patient was blind and would
therefore need extra help with her tablets on discharge.
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The doctors and nurses were more than happy for me to talk with patients and I
was often asked to educate patients about their medicines. As the doctors and
nurses became accustomed to having me on the ward I was increasingly asked
to talk with patients about their medicines in particular when changes had been
made, non-compliance was suspected or when patients were being discharged.
They often commented on how helpful it was having me there to do this.
4.3.1.4.4.	 Attending ward rounds
Initially when I participated in ward rounds I sensed that the doctors and nurses
felt there was no point to me being there, as some asked what I was doing there
yet still did not involve me in discussions. The consultants, however, being
supportive of the study, actively involved me in discussions about patients.
Eventually the doctors and nurses became accustomed to my attendance at
ward rounds. One junior doctor however appeared to continue to resent my
presence on ward rounds as she continued to ignore me or make derogatory
comments about my being there. This may be because she felt insecure,
although I sensed also there was a degree of arrogance and she felt that as a
pharmacist I was of lower status. On several occasions she unfairly dismissed
my comments. This made me feel uneasy when I was on ward rounds with her,
and I was uncomfortable suggesting changes to patients' treatment. This only
occurred with one doctor however.
I found the ward rounds very helpful, as they enabled me to keep well informed
about the patients. I was able to influence prescribing in a proactive rather than
reactive approach. A considerable amount of time on ward rounds involved
talking about issues not relating to therapeutics, but much of this was still
valuable for me to gain a more complete understanding of the patient's
condition. I was able to remind the consultants about treatment plans for
patients. I believe that my attendance at ward rounds also ensured that patients'
drug therapy was always fully discussed as the mere fact that I was there drew
attention to the medication.
In addition to this, I felt that attending ward rounds improved inter-professional
relations. The junior doctors and nurses became more accustomed to having
me involved in the team, and they saw that the consultants respected me and
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my input into patient care. Patients also saw that I was working with the doctors
and nurses, and was not just someone who looks at their drug chart and chats
to them about their medicines. This appeared to increase their confidence in me
and after ward rounds patients would often stop me and ask me to explain
things that had been discussed. Being accepted as part of the team was one of
the most important factors for the success of this project.
Whilst on the ward rounds I would attempt to anticipate when patients would be
discharged and if their medication was unlikely to change, I wrote the discharge
prescription. This worked very well on the whole as the prescriptions could be
sent to pharmacy and the medicines would be ready on the ward for
discharging patients. On a few occasions however, changes to patients' therapy
after the prescription had been written meant a subsequent prescription had to
be written which was inconvenient. All staff were happy for me to write the
prescriptions, mainly because it was more efficient. The junior doctors were
happy they didn't have to do a job they dislike, whilst the nurses were pleased
they no longer had to pester doctors to write prescriptions. It was however,
difficult to separate the patients included in my study from the other patients on
the ward when it came to my writing discharge prescriptions. At first, I tried to
write them only for patients in my study, but doctors and nurses were confused,
as it was not obvious to them which were study patients and which were not. I
had indicated this on the patient board in the office but whilst on the ward round
obviously this was not available. In addition to this, I feared I may lose credibility
with the doctors and nurses if I were to refuse to do things for certain patients
yet not others. I therefore wrote most of the discharge prescriptions, both for all
the study patients and other patients on the wards. This was very time
consuming.
4.3.1.4.5.	 Monitoring and advising on prescribing and administration of
drugs
I intervened in prescribing on many occasions whilst working on the wards.
However, I found it uncomfortable questioning the doctors about their
prescribing. The majority of doctors were pleased when I pointed out errors or
offered advice, and only very occasionally seemed irritated or annoyed. I think
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that often junior doctors were pleased an error had been spotted and rectified
before the consultant had seen it.
Doctors responded better when I pointed out errors due to inaccurate
admissions drug histories rather than other errors occurring on the study ward. I
think that this is because, generally, they were not responsible for the
inaccurate drug history and therefore do not feel 'blamed'. They could blame
another doctor. When talking to a doctor about an error for which they are
responsible they are more likely to feel criticised. I had to be very diplomatic and
sensitive in my approach when highlighting errors or questioning and advising
about prescribing. Whenever possible tried Ito ensure it was only myself and
the doctor present.
Sometimes when advising about prescribing, the doctors pointed out reasons
why my suggestion was not a good idea. When I first started working on the
wards, I was slightly embarrassed when this happened, especially if the reason
was fairly obvious. As time passed and I built up working relationships with the
doctors I felt more relaxed about this and was more at ease having
conversations with them about prescribing.
As the doctors became more accustomed to my activities on the ward, they
began to refer problems associated with patient's medication to me. Whilst I
was very pleased that I was developing a good relationship with the ward team,
and they were finding it useful having me on the wards, I had to prioritise the
patients included in my study and this meant that sometimes I could not do what
they requested. This sometimes led to problems and misunderstandings and I
kept having to remind them about the research.
The nurses in particular valued me as a resource. Throughout the day, they
regularly asked my advice about medication. They frequently commented on
how useful it was having me on the ward and regularly asked me to sort out
problems with patients' medicines, such as drugs that were prescribed
incorrectly or supply problems.
When I highlighted medication problems associated with nursing practices the
nurses frequently became defensive or denied any knowledge about the
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situation. For example, when drugs had not been administered and annotated
'on-order' on the drug chart the nurses would often say that the previous shift
must be dealing with it. On some occasions however, medication continued to
be omitted, even when I had ensured is was available on the ward and when
this was highlighted to nurses often they would say that they knew nothing
about it. Because of shift changes and different nursing staff working on the
wards administration problems such as these were often difficult to resolve.
Nurses avoided taking individual responsibility for patients' medicines and I
found it difficult to influence them to change.
43.1.4.6.	 Role ambiguity
A degree of confusion about my role continued throughout the study. Doctors
and nurses would regularly ask me questions such as, "so do you do this......."
and, "do you do that.......". When new staff arrived on the ward there was
added confusion and it was necessary to exçilak my ae a ae
Some staff never grasped the concept of a parmacst oT\cng on The warOs.
Some nurses confused me with the pharmacy technician who comes to top up
the ward's drug cupboard. The whole process of becoming accepted on the
ward and getting doctors and nurses familiar with my role, had to be repeated
when I changed wards after two months. However, the second time was easier
as I had experience from the first two months.
4.3.1.4.7.	 Interpersonal and professional dynamics
Most of the doctors and nurses were very pleasant to me throughout my time on
the wards and appeared to appreciate my efforts. On occasions however, some
staff were less accommodating.
One of the registrar's behaviour towards me was trivialising. He was pleasant
and courteous, but on occasions made sarcastic and derogatory comments
about my role on the ward, suggesting that my purpose was simply to re-write
drug charts and do the jobs that the doctors did not wish to do. I felt that he did
not value my input into patient care and saw me as someone to do the trivial
jobs on the ward. This made me feel as though I needed to justify my being on
the wards and prove myself. Some doctors who were slightly cynical at first,
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with time came to appreciate the work I was doing when they began to see
benefits for patients and themselves.
I found it very hard work to undertake all my activities on the wards, practising
as a pharmacist, and record all the data I needed. The time constraints meant I
did not get much opportunity to engage in the social aspects of ward life. I didn't
have time to go on tea breaks with the nurses and I feel this may have affected
interpersonal dynamics. Had this not been a study and I did not have to collect
data as well as undertake the activities I think I would have had more time to
form relationships with the ward staff and therefore may have been accepted to
a greater extent. Despite this however I did get along very well with all the
doctors and nurses on a personal level, and most of them on a professional
level. I think however, at the end of the day, all the staff knew I was only going
to be working on each ward for Iwo months in a research context and so this
must have had an affect on the relationship I built with them.
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4.3.2.	 Case study findings
During the implementation stage of the project 90 patients were recruited,
based on sampling criteria outlined in section 3.3. Their ages ranged from 60 to
100 years, with an average age of 77 years. 49 patients were female (54.4%),
and 41 were male (45.6%). The length of stay in hospital varied from I to 35
days, with a mean of 9.91 (standard deviation 7.25 days), and there was no
significant difference between males, 8.95 (SD 6.08) and females, 11.35 (SD
7.79), (t (88) = -1.6, p = 0.176).
Patients recruited into the study had diagnoses within the following categories:
Respiratory system 30%
Cardiovascular system: 20%
Gastrointestinal system 12%
Other infections 12%
Central nervous system 11 %
Collapse 4%
Inflammatory conditions I %
The mean abbreviated mental test score (AMTS) for patients was 8.5 out of 10,
ranging form 5 to 10, and there was no significant difference between males,
8.44 (SD 1.45) and females, 8.53 (SD 1.56), (t (88) = -0.29, p = 0.647).
At the time of admission, on average 7.58 medicines were being taken per
patient, a total of 682 medicines, ranging from 2 to 16 per patient, see figure
4.1. Females were, on average, taking more medicines than males, 8.37 (SD
3.3) vs 6.63 (SD 2.51), (t (88) = 2.7, p = 0.007).
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Figure 4.1 Number of drugs taken by patients at the time of admission
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4.3.2.1.	 Knowledge about medication
As described in section 4.2.3.2, patients' knowledge of their medicines was
assessed. For two patients it was not possible to assess their level of
knowledge of their medication regimens, as both did not want to cooperate as
they were not interested in their medication. For the remaining patients, the
mean score was 5.8 out of 10 (SD 2.9), ranging from 0 to 10. There was no
significant differences in knowledge of medication regimen between males 5.6
(SD 3.2) and females 5.9 (SD 2.6), (t (88) = -0.442, p = 0.66).
The scores for knowledge and understanding about medication correlated
significantly with the abbreviated mental test score (Pearson correlation equals
0.55, p<O.O1). As expected, patients with lower cognitive ability, determined by
the AMTS, knew less about their medicines.
Hardly any patients could give a comprehensive accurate account of the
medication they were taking at the time of admission (0 to 2 days after
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admission), and most had a poor understanding about their treatment regimen.
Some patients relied heavily on their relatives or carers to manage their
medicines and knew very little themselves. A few however, were very well-
informed about their medicines, and appeared to manage them very well.
When relatives and carers were questioned about patients' medication, in
general, they were very knowledgeable about the exact medicines the patient
takes, the doses, and the purpose of the drug. One patient however who was
admitted in November 2000, had not been taking her medication prior to
admission, see case 1. On questioning, she appeared disinterested in her
medication, and her husband knew nothing about her drug therapy. He said he
thought she'd been taking them all.
Only 2% (n=90) of the patients had 100% knowledge about their medicines.
39% (n=90) had more than 75% knowledge, 27% (n=90) had between 50 and
74%, whilst 34% (n=90) of patients knew less than 50% about their medicines
see figure 4.2.
One patient, who was taking 8 tablets, when questioned, said:
1 can't remember any of them, I take that many.....they're all for my
heart......
Patient EF, see case 2
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Figure 4.2 Patients overall knowledge of their medication regimen given as
percent
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38% of patients correctly communicated the number of drugs that they took, see
figure 4.3, however, only 21% of patients could remember or partially remember
the names of all of their medicines, see figure 4.4. Many patients referred to
their medication as the 'little white ones' or the 'blue tablets'. In these
circumstances, I had to investigate the identity of tablets. Certain drugs such as
inhalers were easy to identify from the colours patients gave. In fact most
patients referred to their inhalers by their colour rather than name, for example
the 'blue one' invariably referred to a salbutamol inhaler, 'the brown one' was
generally beclomethasone, and the 'green one' was ipratropium.
18% of patients knew the purpose of all their medicines, but 16% did not know
why they took 3/4 or more of their medicines, see figure 4.5.
29% of patients knew the correct overall doses of all their medicines, but 14%
could not recall the doses of 75% or more, see figure 4.6.
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Figure 4.7 Proportion of medicines that patients knew the frequency of
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Figure 4.8 Proportion of medicines, where appropriate, that patients knew the
strength of
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72% of patients recalled the dose frequency of over half of their medicines, with
40% able to recall this for 75% or more, see figure 4.7. However, 63% of
patients did not know the strengths, where appropriate (i.e. tablets, syrups and
suspensions, creams and inhalers that are available in different strengths) of
75% or more of their medication, see figure 4.8.
4.3.2.2.	 Compliance with prescribed medication regimen
For two patients it was not possible to assess their compliance, for the reasons
stated above. Of the remaining 88 patients, only I patient admitted to forgetting
to take their medicines at least once daily, but only 53.3% said they almost
always remembered to take their medicines as prescribed, see table 4.3.
Reasons for forgetting to take their medicines are given in table 4.4.
4.5% of patients said they took their medicines late every day, with only 51.1%
claiming that they nearly always took their medicines on time, see table 4.5.
Table 4.3 How often patients forget to take their medicines (n=88)
Frequency Percent
(n=88)
Once a month or less	 48	 53.3
A number of times a month
	
23
	
25.6
A number of times a week
	
14
	
15.6
At least once a day	 I
	
1.1
N/A
	
2
	
2.2
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Table 4.4 Reasons associated with those who go forget to take medicines
(n=40)
Frequency
(n=40)
Simple forgetfulness 	 18
On holiday / day out
	 6
Forgets medicines that consider are less important 4
No reason offered	 3
Forgets dose but takes later that day
	 3
Forgets when unwell
	 3
Person who usually reminds patient isn't around
	 1
It is a new medicine	 I
Too busy	 1
Percent
45
15
10
7.5
7.5
7.5
2.5
2.5
2.5
Table 4.5 How often patients take their medication late (n=88)
Once a month or less
A number of times a month
A number of times a week
At least once a day
N/A
Frequency
(n=88)
46
23
13
4
2
Percent
51.1
25.6
14.4
4.5
2.2
71 % of those who take their medicines late attributed this to forgetfulness, and
other reasons were: when on holiday; if out of house; inconvenience; and
watching a late film.
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6.7% of patients said they deliberately did not take one medicine every day, and
63.6% said they nearly always take their medicine as prescribed, see table 4.6.
Reasons for omitting medicines include: omits if going out to drink alcohol;
because of adverse effects; to alter pain relief; cutting back sleeping tablets;
patient does not believe their medication is doing any good; omits £water tablet'
as it is inconvenient if they are going out; their medication is unpleasant to take;
the patient feels they do not need their medication; they are not aware it is to
continue after the first prescription runs out; and the patient doesn't know why
they are taking the medication.
One patient who had stopped his frusemide prior to admission, said:
"I stopped the water tablet because it drove me round the bend, going to
the toilet all the time...........
The same patient had been started on digoxin for atrial fibrillation I month ago,
according to his records from the GP. On questioning however, the patient
denied that he took digoxin, and said that he had started taking it but he ran out
of tablets. When asked why he had not requested more tablets from the doctor,
he said he didn't realise he was to keep taking them.
Another patient said that her GP used to change her tablets so often that when
he started her on isosorbide mononitrate (for angina) she decided not to take it,
see case 2.
Table 4.6 How often patients decide to not to take at least one medicine (n=88)
Frequency Percent
(n=88)
Once a month or less	 56	 63.6
A number of times a month
	
11
	
12.2
A number of times a week
	
13
	
12.2
At least once a day	 6
	
6.7
N/A
	
2
	
2.2
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3.3% of patients said they reduced the dose of their medicines every day, whilst
68.9% of patients said they rarely took less than the prescribed dose, see table
4.7. Clearly there are occasions when it is not detrimental for patients to alter
their own medication, for example not taking or reducing the dose of painkillers
if they don't need them, or other 'when required medication', Intentional non-
compliance in these circumstances is a good thing.
Table 4.7 How often patients decide to reduce the dose of their medication
Frequency Percent
(n=88)
Once a month or less	 62	 I 68.9
A number of times a month
	 I 9	 110
A number of times a week	 11	 112.2
At least once a day	 3	 13.3
N/A	 3	 3.3
Reasons for reducing doses included: altering pain relief; reducing sleeping
tablets; the patient feels they do not need the medication; and adjusting insulin
according to their BM.
89 patients gave information about whether or not they received help taking
their tablets at home. Only 42 patients said that they managed their medicines
completely on their own, see table 4.8.
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Table 4.8 Help patients receive with their medicines at home
None
Yes - carer I relative always helps or reminds me
Yes - carer I relative sometimes help or reminds me
Yes - carer / relative administers my medication
Friend helps me
Yes - carer / relative fills up dossette box
Yes - chemist fills dossette box
Frequency Percent
(n=89)
42	 46.7
21	 23.3
10	 11.1
5	 5.6
2	 2.2
8	 8.9
1	 1.1
73 patients stated they had routines to help them remember to take their
medication. Most said they take them around their meal times (26.7%). 10%
said they always kept their tablets in a visible position. 14 patients said they had
no routines and 3 said someone else always gives them their medication. Other
examples include, putting all their tablets 'out' the night before or in the morning
and leaving them in pots, and recording that they've taken them in a diary.
43.2.3.	 Inaccurate drug histories
Drug histori?s taken by the admitting doctor were frequently incomplete and
inaccurate, see table 4.9. The mean number of drugs the admitting doctor
recorded the patients as taking was 5.29 (range 0 to 13, SD 3.05), in total 476
drugs for all 90 patients. The mean number of drugs I recorded the pqtients as
taking after the second drug history was 7.58 (range 2 to 16, SD 3.09), in total
682 drugs for all 90 patients. The difference between the two drug histories was
statistically sjnificant, (t (89) = 9.3, p <0.01), with the admitting doctor missing,
on average, 2.29 drugs from each patient's history (maximum 11 drugs, i total
206 drugs for 90 patients).
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Table 4.9 Results from analysis of medication histories (n90)
Number of:
	 Total no. Mean Mm	 Max
drugs
Drugs patient takes according to admitting Dr 476
	 5.29	 0	 13
Drugs patient takes according to myself 	 682	 7.58	 2	 16
Drugs recorded in error by admitting doctor 	 5	 0.006 0	 1
Drugsomittedinerrorbyadmittingdoctor 	 211	 2.34	 0	 11
OTC medicines patient taking (none recorded 50
	 0.6	 0	 3
by admitting Dr)
Drugs prescribed in error after admitting Dr's
	 5	 0.006 0	 1
drug history, stopped after my drug history
Drugsstarted aftermydrug history, after	 98	 1.1	 0	 9
being omitted in error
Drugs prescribed at incorrect dose after Dr's	 38	 0.4	 0	 4
drug history
80% of all patients had one or more errors of omission (drugs in use but not
recorded in the doctor's drug history) or commission (drugs recorded in the
doctor's drug history but not being used by the patient), and 34.5% had three or
more.
At the time of admission, patients took a mean of 0.6 over the counter
medicines i.e. every other patient took I non-prescription medicine, none of
which were recorded in the patients' notes. These included analgesics,
medicines for coughs and colds, supplements and vitamins, herbal and
homeopathic medicines, and sleeping tablets.
Following the second drug history, a mean of 1.1 drugs were added to patients'
therapy, after being mistakenly omitted (maximum 9 drugs, and the total
number for 90 patients was 98). For the 90 patients 5 drugs in total were
stopped following the second drug history, as the patient had been prescribed
them mistakenly. For example, a patient was prescribed bendrofluazide
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following admission, as this had been recorded in the admitting doctor's drug
history. The patient had never taken bendrofluazide and it was not indicated.
Another patient was recorded by the admitting doctor as taking 'hydrochiorin',
and this was prescribed on the drug chart following admission. There is no drug
with this name. In total there were 38 dose changes following the second drug
history (maximum 4 for one patient, mean 0.4).
The second drug history was taken when the patient arrived on the study wards
having been transferred from the admissions ward. As this could be up to three
days following admission, changes to medication based on the second drug
history were often delayed. One patient was prescribed an additional 9 of her
usual medicines following the second drug history, but this did not happen until
she arrived on the study ward, which was two days after she had been
admitted. She was taking amlodipine, aspirin, bendrofluazide, citalopram,
nitazepam, ferrous sulphate, thiamine, cimetidine and vitamin B compound
strong. One man possibly suffered a withdrawal reaction, as his usual
perphenazine was not prescribed following admission (see case 3).
Even when doctors took accurate drug histories patients did not necessarily
receive their correct medication. Medication was sometimes inadvertently
omitted, or doses were incorrect. For example, a patient's drug history stated
that she took penicillamine 500mg and thyroxine 75mcg each morning, and
Lodine® SR 600mg at night. However, the doses she was prescribed were
incorrect. She was prescribed penicillamine 250mg and thyroxine 5omcg each
morning, and her Lodine® was prescribed for the morning. Incorrect doses of
inhalers were often prescribed despite the correct dose recorded in the doctor's
drug history. All errors such as these were corrected following the second drug
history taken by myself. After the second drug history a complete and accurate
drug history was recorded always in the notes.
Table 4.10 presents the class of drugs prescribed after the second drug history,
after being omitted in error. The largest number were from BNF class 2,
cardiovascular system drugs.
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Table 4.10 Drugs added to patients' therapy after the second drug history is
taken, by British National Formulary (BNF) class (98 drugs in total)
BNF class	 Total no.
	 Percent
of drugs
I - Gastro-intestinal system
	 5	 5
2 - Cardiovascular system
	 37	 38
3 - Respiratory system
	 19	 19
4 - Central nervous system
	 II	 11
5 - Infections	 0	 0
6— Endocrine system	 7	 7
7 - Obstetrics, gynaecology and urinary tract disorders I
	 I
8 - Malignant disease and immunosuppression
	 0	 0
9 - Nutrition and Blood
	 8	 8
10 - Musculoskeletal and joint diseases
	 3	 3
11—eye	 3	 3
12 - Ear, nose and throat
	 0	 0
13—Skin	 4	 4
Table 4.11 summarises the outcome when a drug was identified as being
omitted from the drug history. Of the 206 drugs discovered as having been
omitted from the admitting doctor's drug history, 72 were prescribed following
my drug history. Despite being recorded in the admitting doctor's drug history,
26 drugs had been mistakenly missed off the patient's prescription, and were
added to the drug chart after my second drug history. Despite being omitted
from the admitting doctor's drug history, 60 out of the 206 drugs were actually
prescribed following admission (28.6%), however, there was no documentation
in the notes that the patient was taking that particular drug at the time of
admission. I recommended an alternative drug be prescribed for 17 of the
omitted drugs identified in the second drug history, and advised that 15 drugs
210
should not be prescribed as there was currently no valid indication, or the drug
was inappropriate.
Table 4.11 Outcomes when drug identified as omitted from drug history on
admission
Frequency Percent
Drug prescribed after discovering omission
	 72	 34.3
Hydroxocobalamin injection given 3/12 monthly
	 2	 1
(information only)
Dr's decide good opportunity to try the patient 	 1	 0.5
without drug
Dr's prescribe formulary alternativ&	 1	 0.5
Dr's decide patient doesn't need drug	 6	 2.9
Patient takes when required, but currently don't 	 22	 12.4
need (information only)
I recommend a formulary alternative	 7	 3.3
Patient says drug not effective therefore requests 	 1	 0.5
drug not be prescribed
I advised prescribing a drug with fewer side effects 10 	 4.8
or interactions
I advised not to prescribe as currently no valid 	 15	 7.1
indication or the drug is inappropriate
Patient receiving drug by alternative route 	 8	 3.8
Drug prescribed despite omission from drug history 60 	 28.6
Dr has prescribed an alternativ&	 1	 0.5
Total	 206	 100
*The reason why these drugs had been omitted, or alternative drugs prescribed,
was not recorded in the patient's notes by the prescriber.
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4.3.2.4.	 Structured medication review
In total there were 152 changes to patients' medication following the review
(mean 1.7). A mean of 0.94 drugs per patient were stopped after the structured
medication review, i.e. nearly I drug per patient, see table 4.12. A mean of 0.57
drugs were started following the review, as I identified that patients were not
receiving drugs from which they might benefit. Patients' medication was
reviewed several times throughout their admission, depending on the length of
their admission and the complexity of their medication regimen.
Table 4.12 Results from structured review of medication following admission
Number of:	 I Sum Mean Mm	 Max
Drugs stopped following structured review 85	 0.94 0	 5
Drugs started following structured review 	 51	 0.57	 0	 4
Dose changes following structured review	 16	 0.13 0	 2
Total changes to medication regimen	 152	 1.7	 C	 9
following structured review
The changes to medication as a result of review are summarised in table 4.13.
The figures represent the number of interventions following the medication
review, and a single intervention may include one drug being stopped and
another started, therefore the total number of interventions does not match the
total number of changes to medication presented in table 4.12.
18 drugs were stopped as they were not indicated, for example, four drugs were
stopped for one patient, (see case 5).
Analgesics were changed to minimise the risk of adverse effects, for example
non-steroidal anti-inflammatory drugs (NSAIDs), dihydrocodeine, codeine or co-
proxamol to paracetamol, where possible. Patients were commenced on drugs
from which they might benefit, for example, in appropriate patients, aspirin and /
or simvastatin for cerebrovascular disease prophylaxis; bisphosphonates for
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osteoporosis prophylaxis; aspirin for patients with atrial fibrillation in whom
warfarin was deemed inappropriate.
Patients admitted on treatment doses of lansoprazole, were assessed and if
there was no indication for the high dose, it was reduced to the maintenance
dose. Sub-therapeutic doses were increased, for example low doses of inhaled
beclomethasone.
Following my review, contraindicated drugs that had been continued following
admission were stopped, for example thymoxamine in a patient with suspected
liver disease. The doctors were apparently unaware of the drug and that it was
contraindicated in liver disease.
Drug therapy was altered i an attempt to improve compliance, for example
three times daily captopril changec o once daIy lisinopril, frusemide twice daily
changed to once cjly, nicardpine tb1e time s cily changec o mlodipine
once c1iIy. Attemptec whc1rwal of pzocpiqps w ipjtjd, in
collaboration with tie penW
	
s.
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Table 4.13 Nature of changes to drug therapy following medication review
Frequency
n=104
Changed to alternative drug with less risk of side effects 	 21
Drug not indicated 	 18
Dose altered as inappropriate 	 16
Drug changed to formulary preference 	 15
Patient hasn't been taking drug	 5
A different drug in the same class prescribed 	 5
Drug has the potential to cause/is causing side effects 	 4
Drug stopped as of limited benefit 	 4
Patient would benefit from a drug previously not prescribed 3
Drug changed to aid compliance 	 3
Drug prescribed twice as different formulations
	 3
Drug interaction	 2
Formulation changed
	 2
More effective drug prescribed	 2
Duration of therapy outside BNF recommendation 	 I
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4.3.2.5.	 Interventions into patients' drug therapy, interception of
errors and impact on prescribing
All my interventions into drug therapy, were recorded and categorised according
to their nature, see table 4.14. The main staff involved in the intervention, the
primary reason for the intervention and the time taken were also recorded. Each
intervention was graded according to its clinical significance, by a hospital
pharmacist independent to the study. As this process is largely subjective, a
second hospital pharmacist graded the interventions, and the level of
agreement between the two was assessed.
On average, there were 7 interventions into drug therapy for each patient,
ranging from 1 to 16, total 627. As expected, the number of interventions
correlated significantly with the number of drugs the patient was taking
(Pearson correlation equals 0.654, p<O.0l). There was no relationship between
the lenh of stay, the age of the patient, or paiepts' knowledge and
underatanding of their medication regimen and the number o my interventions
into drpg tl-erapy.
I 4ature of intervention
Ipterven jops into drug therapy were classjfi?d accordirg to their nature, see
table 4. i4 . A high percentage of interv ptlons rated to eucaing palients
about their medicines and a large proportion of interventions involved ensuring
that patients were prescribed the correct medicines at the appropriate dosage.
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Table 4.14 Nature of my interventions into drug therapy
Frequency Percent
Patient I relatives I carers educated about medication 	 163	 26
Dose alteration	 80	 12.8
Drug incorrectly omitted from prescription 	 60	 9.6
Advise about choice of therapy	 56	 8.9
Information about medication added to patients notes 	 52	 8.3
Drug stopped as inappropriate / not indicated 	 27	 4.3
Associated with administration / formulation / route 	 27	 4.3
Miscellaneous	 25	 4
Recommend instigation of tests (U&Es, LETs etc)*	 24	 3.8
Prevention I detection of adverse drug reaction
	 23	 3.7
Drug I drug or drug / diseased interaction	 20	 3.2
Information provided to Dr / nurse / patient I GP	 18	 2.9
Non-formulary drug changed to the formulary preference 15
	 2.4
Drugs prescribed but not administered (no valid reason 	 14	 2 2
recorded)
Medication prescribed as indicated but previously not	 13	 2 1prescribed
Therapeutic drug monitoring or pharmacokinetics 	 10	 1 6
recommendations
Total	 627	 100
*U&Es - Urea and electrolytes, LETs - Liver function tests
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4.3.2.5.2.	 Main people involved
Table 4.15 presents the main people who were involved when I made an
intervention into patients' drug treatment. For example, for interventions
involving educating patients about their medicines, the patient would be classed
as the main person involved, or when advising about drug therapy on a ward
round, the consultant may be classed as the main person.
Table 4.15 Main people involved in intervention into drug therapy
Main person involved	 Frequency Percent
Total	 627	 100
House officer	 186	 29.7
Patient	 164	 26.2
Consultant	 123	 19.6
Myself only	 84	 13.4
Senior house officer	 24	 3.8
GP / community pharmacist	 22	 3.5
Nurse	 21	 3.3
Registrar	 3	 0.5
4.3.2.5.3.	 Primary reason for intervention
The primary reasons for interventions are listed in table 4.16. 'Maximising
patient care and minimising risk' include interventions that safeguard the
patient, for example from drug interactions, overdoses or adverse drug
reactions. 'Ensuring effective use of therapy for maximum benefit to patient'
interventions are aimed at optimising therapy, such as ensuring drugs from
which patients would benefit are prescribed, or making sure that therapy is used
in a way that it gives maximum therapeutic benefit to the patient. The 'drug
changed for economic reasons' category includes interventions that aim to
increase the cost effectiveness of prescribing. The final category covers
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4
4.6
0.6
interventions that ensure hospital policy and legal requirements for prescriptions
are upheld.
Table 4.16 Primary reason for interventions into drug therapy
Frequency Percent
627	 100
450	 71.8
144	 23
Total
Maximising patient care or minimising risk
Ensuring effective use of therapy for
maximum benefit to patient
Drug therapy changed for economic reasons
Ensuring prescription written according to
hospital / legal requirements
4.3.2.5.4.	 Clinical significance of interventions
The clinical significance of interventions as assessed by the independent
pharmacists, 1 and 2 (not myself), are listed in tables 4.17 and 4.18,
respectively.
Table 4.17 Clinical significance as determined by independent pharmacist 1
Information only
Minor benefit to patient care
Moderate benefit to patient care
Significant benefit to patient care
Very significant benefit to patient care
Potentially life saving
Total
Frequency Percent
216	 34.4
62	 9.9
196	 31.3
128	 20.4
18	 2.9
7	 1.1
627	 100
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Frequency Percent
246	 39.2
35	 5.6
162
	
25.8
137
	
21.9
40
	
6.4
7
	
1.1
627
	
100
Table 4.18 Clinical significance as determined by independent pharmacist 2
Information only
Minor benefit to patient care
Moderate benefit to patient care
Significant benefit to patient care
Very significant benefit to patient care
Potentially life saving
Total
A measure of agreement between the two assessors was obtained using
Cohen's Kappa, which equals 0.34. A value of I indicates perfect agreement,
whilst a value of 0 indicates that agreement is no better than chance. Although it
appears that there is a lot of disagreement between the two assessors, looking
at the cross-tabulation (table 4.19) often they only differ by one category, for
example, 'information only' for one assessor, while the other says 'minor
benefit', or 'minor benefit' according to one assessor, and 'moderate benefit'
according to the other. For example, a patient was prescribed his usual
alfuzosin following admission, which was not stocked on the ward. He had
brought his own in with him, but had handed them to staff on the admissions
ward. When the patient was transferred from the admission to the study ward,
his medication was not and the nurses on the study ward were going to order
more from pharmacy. I ensured the medical staff were aware that he had
brought his own medication into hospital and retrieved it from the admissions
ward, so it could be used during his admission. The patients therefore received
his medicines promptly, as it was not necessary for the ward to order it from
pharmacy, and the tablets were returned to him when he was discharged, thus
preventing waste. One assessor categorised this intervention as 'information
only' and the other, as 'minor benefit'.
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Another example is that of a patient who was prescribed lansoprazole 30mg
daily (treatment dose) following admission, instead of her usual dose of 15mg
daily (maintenance dose). No dose was recorded in the drug history, and the
house officer was unaware of why the patient was taking this medication. From
previous notes I discovered the drug had been prescribed for oesophagitis in
1996, and so a maintenance dose of 15mg daily was sufficient. The house
officer was informed, this was recorded in the patient's notes and the dose was
reduced. One assessor classed this intervention as 'minor benefit', while the
other classed it as 'moderate benefit'.
The assessors also varied in the consistency of their intervention classification.
For example the same assessor categorised educating patients about their
medicines such as using inhalers via a volumatic device or the special
instructions for taking bisphosphonates in the 'information only' category for
some instances, but for others classed it as a 'significant' intervention, or
starting certain medicines after obtaining an accurate drug history was
categorised as 'very significant' on some occasions, but only 'moderately'
beneficial for others.
Clearly this is a somewhat arbitrary and subjective method for assessing the
perceived clinical significance of my interventions into patient care. However
these criteria were already in use in the study hospital (Campbell, D - personal
communication) and give an indication of the impact of the my activities in this
study.
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4.3.2.5.5.	 Examples of interventions within each category
Interventions classified as 'information only' include instances I provided basic
information to patients about their medicines. Also included in this category
were:
recording a complete and accurate drug history in the notes when the
admitting doctor's was inaccurate
general advice to doctors and nurses about therapeutics
recording treatment decisions and plans in patients' notes and
communicating medication changes and treatment plans to GPs.
Interventions categorised as being of 'minor benefit' included:
making sure medicines were ordered by the ward in a timely fashion, so
avoiding missed doses
stopping drugs that had been prescribed regularly when the patient usually
only takes them when needed, such as analgesics and laxatives
changing the dosage or formulation of medication to help patients manage
their therapy
. when appropriate, changing non-formulary drugs to the hospital formulary
preferences, for example omeprazole to lansoprazole
if non-formulary drugs were to be continued, ensuring these were obtained
in a timely fashion either by using the patient's own, or making sure they
were ordered promptly from pharmacy
. where appropriate changing the dosage times to those the patients were
used to at home
giving patients information about medication so they could make informed
decisions regarding their therapy, for example explaining the risks and
benefits of warfarin
ensuring that medicines that patients usually take are prescribed following
admission, although there would be low potential for harm if they had been
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omitted. For example hypromellose eyedrops, cod liver oil capsules and
fybogel which, if not prescribed during the admission are unlikely to
adversely affect patient care, but when omitted, can cause distress for
patients and disrupt their routines.
Examples of interventions classed as being of 'moderate benefit' were:
• making sure patients' usual medicines are prescribed which, if omitted, are
more likely to be detrimental to patient care, for example simvastatin, long
term benzodiazepines, hormone replacement therapy, osteoporosis
treatment or GTN spray
• making sure medications which were being administered incorrectly, are
given as they should be, such as etidronate 1
 and alendronate2
• making sure the correct formulations are prescribed and administered, for
example nifedipine 60mg 'long acting' once daily had been prescribed but
the nurses were giving three 20mg 'modified release' tablets of nifedipine,
(this happened quite frequently) and bezafibrate 400mg was prescribed
once daily, without indicating that it was the 'modified preparation' so the
standard preparation, which should be given as three daily divided doses,
was given. This would result in sub-optimal blood levels.
• interventions to prevent adverse drug reactions, for example reducing the
dose of bendrofluazide from 5mg to 2.5mg daily, stopping ibuprofen in a
patient who was admitted with abdominal pain and changing co-proxamol
and NSAIDs to paracetamol wherever possible
• stopping drugs of limited efficacy such as thymoxamine and oral salbutamol;
optimising antibiotic prescribing
1 Food should be avoided for at least 2 hours before and after a dose of Disodium Etidronate,
particularly calcium containing products such as milk.
2 Alendronate tablets should be taken with a full glass of water on an empty stomach at least 30
minutes before breakfast (and any other oral medication). The patient must then stand or sit
upright for at least 30 minutes and not lie down until after eating breakfast.
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ensuring drugs were prescribed for the correct duration, for example steroids
and antibiotics
instigating investigations both during admission and by the GP, following
discharge, such as baseline liver and thyroid function tests in patients
commenced on amiodarone
advising doctors about therapeutic drug monitoring
assessing patients' appropriateness for warfarin therapy and advising
doctors
optimising drug therapy to patients' preferences where possible, for example
changing a potassium formulation, as the effervescent tablet burned the
patient's throat; and ensuring patients' usual dosages of medication are
prescribed, for example beclomethasone lOOmcg twice daily prescribed
instead of the patient's usual dose of 500mcg twice daily.
This category describes interventions which bring about a more acceptable and
appropriate level of care.
Interventions considered to be 'significant' included:
ensuring patients usual medicines are prescribed, which if omitted would
compromise patient care, for example co-careldopa, beclomethasone,
ipratropium and salbutamol inhalers, nitrate patches, thyroxine, diltiazem,
isosorbide mononitrate, digoxin, aspirin, gliclazide, and fluoxetine were
started after I intervened. Two patients were also given their 3 monthly
vitamin B12 injection after I contacted the GP and discovered they were due.
ensuring therapeutic doses are prescribed, for example ACEI in heart
failure, carbamazepine for trigeminal neuralgia, thyroxine and penicillamine
reducing excessive doses of drugs such as nitrates, proton pump inhibitors
and sedatives
• undertaking a detailed drug history to find out which drugs have been tried in
the past in a patient with Ménières disease, and advising the doctors which
drug to prescribe
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advising patients taking long term benzodiazepines about the risks of these
drugs, and liaising with GPs and hospital doctors to reduce the dose, with a
view to stopping the benzodiazepine, (see case 2)
interventions to prevent drug-disease or drug-drug interactions, for example,
stopping trazadone in a patient who had suffered a myocardial infarction
reducing doses or stopping drugs where appropriate in renal and liver
disease
stopping dothiepin in a patient also taking fluoxetine
stopping co-prescription of GTN patches and isosorbide mononitrate
ensuring a patient did not take indomethacin which he was prescribed for
gout flare-ups at the same time he took ibuprofen for his back pain
stopping drugs which had the potential for or had caused serious adverse
effects, for example stopping Co-proxamol and dihydrocodeine in a patient
admitted with falls, (see case 7)
ensuring patients actually received their prescribed medication
• stopping drugs when there was no current valid indication, (see cases 5, 8
and 9)
altering medication in an attempt to improve compliance for example,
changing three times daily captopril to once daily lisinopril, three times daily
nicardipine to once daily amlodipine or isosorbide mononitrate from three
times daily to twice daily for a patient who admitted to forgetting her evening
dose; educating patients who were confused about medicines (see case 9)
or patients who had not been taking medicines correctly, for example
inhalers or Didronel PMO
• ensuring patients were given key information about their medicines, such as
warfarin and steroid instructions or avoiding sunlight with amiodarone
• advising patients how to reduce the risk of adverse effects from their
medicines, for example washing their mouth out after using high dose
steroid inhalers
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• ensuring evidence based prescribing for example, stopping inappropriately
prescribed enoxaparin for 3 patients, and adhering to national guidelines
such as the British Thoracic Society guidelines for asthma, (see case 6) the
NSF for CHD, or the British Hypertensive Society Guidelines for blood
pressure control
distinguishing 'true' allergies to antibiotics from side effects that patients
perceive to be an allergy, and thus enabling useful antibiotics to be
prescribed
ensuring drugs were not inadvertently stopped.
When my input into patients' drug management was considered to considerably
improve care and prevent serious toxicity or discomfort this was classed as a
'very significant intervention'. Examples were:
ensuring prophylactic therapy is prescribed where appropriate for example
cardiovascular disease and osteoporosis prophylaxis, and prophylaxis
against deep vein thrombosis
. instances where I ensured medicines were started which had been omitted
and this could have been extremely detrimental for the patient such as
anticonvulsants and antidepressants with the potential for severe withdrawal
reactions
discontinuing a patient's usual insulin on their drug chart when an insulin
drip had been started to ensure both weren't administered by mistake
• stopping co-prescribing of drugs that could lead to severe adverse reactions
such as regular Lodine® and ibuprofen, warfarin and NSAIDs, or
bendrofluazide and frusemide (where no indication to be given together)
preventing co-administration of certain IV drugs which would interact if
given in the same bag, or via the same y-site connection.
The following is a further example of an intervention classed as 'very
significant'. During a patient's admission he was prescribed a course of
antibiotics for a chest infection. He usually took penicillin prophylactically
following a splenectomy, but had not been receiving it because he was taking
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antibiotics prescribed for his chest infection. Once that course had finished the
penicillin was not re-prescribed, so I ensured that this was re-started. I also
prevented warfarin being inadvertently given to a patient with a previous history
of haemorrhagic cerebrovascular accident (see case 9).
The seven occasions that interventions were considered to potentially life
saving were instances where I highlighted that patients were allergic to an
antibiotic and this had not been recorded on the drug chart or in the patients'
notes.
4.3.2.6.	 Doctors and nurses views
I had Informal discussions throughout the four month intervention and
evaluation of the interventions on the wards with the four consultants involved in
the project, four house officers, two senior house officers, and four nurses.
During these discussions, I asked the doctors and nurses their views on the
service developments undertaken in the study, and the effect on patient care.
4.3.2.6.1.	 Consultants
The four consultants involved in the study all felt the new approach to pharmacy
practice was very successful, and greatly improved patient care with respect to
their medicines. Educating patients was felt to be particularly useful. Having a
pharmacist involved in the entire patient journey, from taking a drug history
through to coordinating discharge medication was considered very beneficial.
"They (patients) got better assessed at the start because you were taking
history, it meant that discharges were happening more quickly and more reliably
and it meant that we, we knew we wouldn't be giving people adverse drug
reactions,"
The consultants said that patient care was improved by my monitoring of
prescribing, reviewing patients' drug treatment, flagging up drug interactions,
preventing errors and adverse drug reactions and advising about therapeutics.
They felt my presence gave a feeling of security, reduced risk and created a
safer environment.
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The consultants all felt that discharge of patients was much quicker with less
risk, "also the speed at which we were getting the discharge medication written
up and knowing that it is going to go down to pharmacy and not return with a
query was also a great advantage." One consultant said that the discharge
summary written by myself was much clearer and more detailed than those
written by junior medical staff. My observational work supported this as
discharge summaries were often very brief and contain little or no information
regarding medication changes. Whilst having a pharmacist write discharge
prescriptions and summaries is an option, it should be obligatory that all doctors
provide accurate and complete information to GPs when a patient is discharged
from their care. Systems should be in place to ensure this happens.
They appreciated having me permanently on the wards and attending ward
rounds in the study. One consultant however, felt that in practice, if this
approach to pharmacy practice was to be implemented across the Trust, it may
not make the best use of pharmacist's time attending all ward rounds, as only a
small proportion of time is spent discussing medication. It may be more practical
for pharmacist and doctors to have regular liaisons and keep up good
communications.
The value of having a professional with expertise in therapeutics readily
accessible to medical staff and patients was acknowledged by the consultants.
It was considered considerably more useful having a pharmacist working along
side the doctors and nurses, rather than simply visiting the wards and leaving
messages about medication for doctors and nurses, for example 'post-it' notes
on drug charts.
"Well, from my point of view, from a consultant point of view, having a
pharmacist on the ward round, informing me on the spot of what the
consequences of my decisions were with respect to medication changes
was really very very useful..............that was one of the great things
about having you on the pilot, was the fact you've got an instant
reference."
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This was however in direct opposition to the previous remark, so opinions about
the value of a pharmacist attending ward rounds differed between some
consultants. Nevertheless, I felt it was extremely useful as I was there at the
time decisions regarding drug therapy were made, therefore was in the full
'picture' as far as patients' medication was concerned and didn't have to
investigate why certain decisions had been made. I feel, had I not attended
ward rounds, more of my time may have been wasted because I would need to
chase up doctors and to enquire about therapeutic issues.
It was felt that I increased awareness and knowledge of therapeutics.
"And it also, / guess, improved the level of knowledge of certain drugs,
certain interactions, certainly to the junior staff and I guess the seniors as
welL"
The consultants were supportive of all the activities I carried out and were keen
to see this continue.
"All of it, I liked all of it
"I would like the pharmacist doing everything that you did in the study, for
example teaching patients about their medicines, making sure they know
all about their medicines."
"I think it was a luxury to have a ward-based pharmacist and I think that
is something that / would always want."
They said that the doctors and nurses on the wards studied also greatly
appreciated a pharmacist's input.
"The doctors and nurses loved it; they came to rely on you..."
certainly the nurses found that they were confident in having you
around"
They said some patients were very positive about the care they received from
myself.
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"One or two patients came back to the outpatient clinic and when they
were talking about their medicines they said 'oh well the pharmacist said
to do this, and the pharmacist said to do this and the pharmacist said to
do that' and they seemed to be very positive about it."
The consultants were very positive about my work and the concept of having
pharmacists working as I did in the study and did not identify any
disadvantages. However, they had been working closely with me for the
previous four months and were very supportive of the study, which may have
caused them to suppress any negative views they did have. They may have not
wanted to upset me by highlighting disadvantages. In addition, they are
consultants in general medicine and medication is a very significant part of their
patient care. Consultants from other specialities, for example surgery, where
medication is perhaps less of a priority, may not be so enthusiastic about the
approach to pharmacy practice developed in this study.
4.3.2.6.2.	 Nurses
The nurses working on the wards studied all expressed their appreciation of
having a pharmacist working along side them on the wards.
"Every ward should have a permanent pharmacist; life has been so much
easier having you around." (Staff Nurse)
They felt that the project had been a success and were very supportive of the
new approach to pharmacy practice. In particular, they felt nursing time was
saved, so they could undertake other important clinical activities.
"That's particularly important because we're always understaffed." (Staff
Nurse)
This was a particular factor for the nurses as they had less work to do. It might
be argued that this is the main reason they appreciated having me around.
Perhaps if there were more nurses and the ward was less understaffed they
may not be so supportive.
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Discharges were felt to be much 'smoother', and less rushed, and this approach
to pharmacy practice could result in discharge being speeded up by at least one
day for some patients.
"The discharge prescriptions get written in plenty of time and since we've
had you on the ward there's never an occasion where the patient is
waiting for their discharge medication to go home." (Staff Nurse).
The nurses appreciated not having to worry about the discharge prescriptions.
Nurses felt that money is saved as a pharmacist helps prevent 'bed-blocking'
due to delays in processing of discharge medicines. "Before (the project) we
were forever chasing the doctors to write discharge prescriptions......on the
ward round they'll (the doctors) will decide the patient can go home, but then
they don't write the prescription until after the ward round is finished, then it
doesn't go down to pharmacy until the afternoon and doesn't get back to the
ward until the evening. Then it's often too late, especially if the patient needs an
ambulance." (Ward Manager).
The nurses said that more information was given to GPs about medication
when I was involved and they felt that the risk of errors on discharge
prescriptions was reduced. "Because the discharge prescriptions are written so
quickly, there is very little in formation put on about the drug treatment the
patient has received in hospital, changes to medication and so on, and there
are frequently mistakes and problems which delay discharge.....with the
pharmacist doing them, it's much quicker and safer, and the GP gets more
information. "(Staff Nurse)
The nurses said that the doctors also appreciated having a pharmacist around
permanently, "they have more time to do other things...........they trust you to
write the discharge prescriptions, and it saves them time and saves them the
risk of writing prescriptions in haste." (Staff Nurse). Again though, it may be that
they simply liked having less work to do.
All felt that the risks associated with prescribing are minimised when a
pharmacist is on the ward, available to advise junior doctors, at the time of
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prescribing. "The junior doctors make mistakes and it's really helpful having a
pharmacist on the ward to monitor what they are doing." (Ward Manager)
They said that an important aspect of having a pharmacist on the ward, working
as part of the team was improved communication between the healthcare
professionals. The relationship between pharmacists, and doctors and nurses
was much better, and they cooperated more fully which led to further
improvements in-patient care.
Nurses said that patients received more information about their medication
regimens from a pharmacist. "The nurses haven't really got time to go through
all the patient's medication the way you have been doing, and sort out any
problems.......discharge is usually very rushed and all we can do is quickly and
briefly talk through their medicines, but that's not sufficient. At least you can
spend some time with them and explain everything." (Staff Nurse)
The nurses did not have any negative comments, but again this could be
because I worked with them nurses throughout the study, and they may not
have wanted to upset me.
4.3.2.6.3. Doctors - registrars, senior house officers and house officers
The doctors appreciated having a pharmacist working along side them, as it
freed their time to pursue other clinical activities. They found it very helpful
having a pharmacist on the ward to advise at the time of prescribing, and gave
them more confidence having their prescribing monitored. The doctors said that
having a pharmacist on the ward reduces the risks associated with drug
therapy.
"It's brilliant for me, it saves me a lot of work, as well as making
prescribing safer, looking at the drug chart scanning through everything,
checking there's no interactions or anything we've missed obviously,
which on a busy ward round is easy for us to miss, things like that"
(House Officer)
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"Having them double checking, it is nice to know that someone else is
looking at the scripts you've written, cause / think we all do make
mistakes." (House Officer)
Having a pharmacist intimately involved in patient care ensured all medicines
were reviewed and prescribed, if appropriate.
"Sorting out the medication that patients are taking really helps. When
you're on nights, and you can't get a drug histoiy it can be really difficult".
(House Officer)
"Reviewing patients' medications is very useful as well, because it
doesn't get done routinely, as we just don't have the time...." (Senior
House Officer).
The doctors were happy for me to write the discharge prescription, as this
saved them time, made life easier for the nurses as they were always chasing
the doctors up to do this in the past, and errors were reduced. They also felt
more and information was communicated to the GP relating to medicines.
"For us it saves time because if patients are going home and we have to
write a discharge prescription, you know, if they're on a huge number of
medications, it can just take ages, to do five of those or whatever, and so
it saves loads of time in that respect...." (House Officer)
Doctors particularly appreciated having a pharmacist's assistance in warfarin
management. "It's great having a pharmacist there to deal with the warfarins
and stuff which is a big area I think where we are hopeless at doing........
having someone that knows a bit about what they're doing prescribing that and
organising the blood forms, cause again it's easy to forget you've got a patient
that's on warfarin."
The doctors felt that patient care is benefited by having a pharmacist to give
patients comprehensive verbal and written information about their medication.
"Knowing someone checks their tablets, / mean most patients haven't got a clue
what they're on and why they're on, and at least if someone takes an interest it
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might make them think about it and try and remember what they're on and why
they're on it and things." (House Officer)
Advising about the hospital formulary was found to be helpful, and doctors felt
that having a pharmacist working along side them on the wards improved their
knowledge of therapeutics.
"it is helpful.......when you don't know what low weight heparin they use
or, or you know we use lansoprazole here, where, where / worked before
we used omeprazole, and you know it's just helpful having someone
saying, "well this is the one we use," so that you know which one to
prescribe" (House Officer)
"I think, certainly one of the big values of having a pharmacist is, it it's
very good for our education, cause if someone comes and says, "look,
you've prescribed that wrong," then you don't do it twice, certainly"
(House Officer)
Some junior doctors appeared reluctant to be 'told' about drugs and I felt some
initially didn't appreciate having me around, although none said anything to me
about this. However, this may be because I had less contact with seemingly
hostile doctors and if I had, then their comments may have been less positive.
It may be that the doctors are supportive of pharmacists working in this way just
because it means they have less work to do, rather than any effect it has on the
patients.
4.3.2.7.	 Patient satisfaction
Patients had very positive views on the care they received from myself. Many
felt they received more information from a pharmacist than the other healthcare
professionals involved in their care.
88 patients (97.8%) said that they found it helpful having a pharmacist giving
them information about their medicines. The 2 remaining patients were
indifferent and said they would take them anyway.
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Some patients said that when they had been in hospital in the past they did not
come into contact with a pharmacist, throughout the admission. 87 patients had
been in hospital before, and 90.8% of these said the care relating to their
medicines was better during this admission. "In the past when I've been in
hospital no one has actually sat down and explained what has been done with
my medicines, and it was veiy confusing when I went home."
"Last time / didn't get any information, I was just given them and
expected to take them."
Seven patients (8%) said the care was the same, and only one patient felt the
care relating to his medicines that he had been given during this admission was
worse than previous admissions. The reason for this was that previously he had
been allowed to keep his medicines in his bedside locker and administer them
himself. Self administration of medicines was not policy in the study Trust so
this was not possible.
96.7% of patients felt better about taking their medicines following the
information given to them by a pharmacist. "It's good to be given information;
you're scared to take them if you don't know anything about them."
Patients appreciated being given a chart with all their medicines listed, along
with the doses, and what each is for. Some said they did not absorb information
very well in the hospital environment, so it was useful to have some information
to refer to at home. "People don't realise when you're at home often you can't
remember what you were told in hospital about your medicines. Older people do
have a tendency to forget."
Some patients commented that they would have kept taking medicines that had
been stopped during this admission if I had not explained why they should not
continue to take them. Other patients were not aware that the tablets started in
hospital were to continue, until I explained this to them.
Patients felt more at ease asking me about certain issues, for example if they
could have a couple of pints with their tablets, and whether new medication can
have side effects.
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A few patients commented they didn't have to wait around as much after having
been told by the doctors they were being discharged, compared with previous
admissions.
I didn't have any negative views from patients, but there may be several
reasons for this. As it was me who had implemented the interventions, and was
also evaluating them, patients may not want to have offended me. Basically I
was asking them what they thought about what I was doing. Another
explanation may be that patients just liked having someone to talk to. The
doctors and nurses are very busy and perhaps some patients just liked having a
chat.
4.3.2.8.	 Case summaries
The following are a selection of detailed case summaries from the 90 patients
enrolled in the study, which highlight my activities during the intervention phase
of the study. Each case illustrates various ways I contributed to patient care and
compliments the data presented in section 4.3.2. I selected these vignettes as
they were particularly interesting from a therapeutics perspective, and I had a
lot of involvement in the care. The cases however, were selected deliberately
because they involved multiple therapeutic problems therefore presenting a
biased view and overestimation of the positive benefits of the intervention.
Case I —SH
This case highlights my contribution to patient care by identifying and
attempting to improve non-compliance with medication. It demonstrates the
value of involving patients and families in their care to optimise care and
minimise the risks associated with medication and the role pharmacists can
have in this. It also illustrates how pharmacists can improve communication
about medicines between primary and secondary care.
Admission I
This 72 year old lady was admitted from November 16th 2000 and was
discharged after eight days, only to be readmitted November 28th for a further
eight days. The first admission was with right sided weakness. She had an
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AMTS of 7/10, and lived with her husband. She also suffered from angina,
arthritis and epilepsy. The admitting doctor took an accurate and complete drug
history which comprised:
aspirin 75mg 2 each morning
isosorbide mononitrate 20mg twice daily
glyceryl trinitrate (GTN) spray 400mcg to be used when required
sodium valproate EC 200mg 2 each morning, I at lunchtime, 2 at night
All her usual medicines except the GTN spray were prescribed following
admission and I ensured this was added.
When I spoke to the patient, she was unable to give clear information about the
medicines she was taking (her knowledge score was 3.8 out of 10) and gave
the overall impression that she did not place any importance on her drug
therapy. Her husband was also present and he knew nothing about her
medication. SH said that she took tablets for epilepsy and her heart, and she
used a GIN spray when she gets chest pain.
She had brought all of the medication listed above, in with her. The labels on
the boxes indicated they had been dispensed in February 2000, although none
had been taken, and the GIN spray had not been used. When I contacted the
OP surgery, the receptionist said that the last prescription issued to the patient
was February 2000. She had clearly not been taking her medicines for up to
nine months.
When SH was asked about compliance, it was also clear that she was not
taking her medication, and she did not appreciate that she needed to take them.
She said that she doesn't think her tablets "do her any good" therefore she
doesn't take any of them. Her husband said he had assumed that his wife had
been taking all her tablets herself, but she hadn't been. He said that now he
knows, he would make sure she did take them. All her usual medicines were
prescribed, as although she hadn't been taking them for nine months, the
doctors felt she still needed them.
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Aspirin was correctly omitted until day four of admission a Computerized
Tomography (CT) scan revealed she had suffered a left parietal lobe infarct
rather than a haemorrhagic stroke.
On day five she was diagnosed with atrial fibrillation (AF), and amiodarone was
commenced at the usual dose titration. I advised the doctors to check baseline
liver and thyroid function tests. A baseline chest x-ray had been performed
when she was admitted.
As SH was in atrial fibrillation (AF) warfarin was indicated. This was discussed
during a ward round, and I explained to the consultant about her poor
compliance and knowledge about, or interest in, her medicines of which the
doctors and nurses had been unaware. I advised it might be safer for the patient
to remain on aspirin, as the risks with non-compliance with warfarin were
considerable. The dose of aspirin was increased to 300mg daily on my advice.
I advised a medidose (compliance aid) be given on discharge, to help with
compliance, and contacted the patient's usual community pharmacist, to ensure
they would continue to refill the compliance aid when the patient returned home.
I arranged for weekly prescriptions to be issued by the GP surgery, as
requested by the community pharmacist, to enable the compliance aid to be
refilled each week.
She was discharged on all her usual medicines, with amiodarone and aspirin
300mg. The doctor did not put any information on the discharge prescription
about medication. I completed an additional information sheet for the GP, which
included: the reasons why warfarin had not been commenced; all medication
changes and rationale; instructions for the GP to monitor LETs and thyroid
function tests every 6 months (BNF, 2002); and information relating to the
patient's compliance problems and steps taken to address this. I ensured the
patient's discharge notification letter was written and her medication ordered 2
days before she was discharged.
I counselled SH and her family thoroughly prior to discharge, in particular the
specific instructions to avoid sunlight when taking amiodarone, and about the
compliance aid and the procedure for refill by the chemist.
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Admission 2
SH was readmitted four days following discharge, with dyspnoea. The admitting
doctor recorded a drug history, but omitted the GTN spray, and the dose of
sodium valproate was incorrect. I ensured the GTN spray was prescribed and
corrected the dose of sodium vaiproate.
'Impression - LVF secondary to cardiac event' was recorded in her notes, and
she was prescribed frusemide. On day two she was seen by the cardiac
consultant who stopped the amiodarone, as sinus rhythm had not been
restored. He recorded that she should not be prescribed digoxin unless her
heart rates exceeded 100 beats per minute.
A chest x-ray showed she had a chest infection, so she was prescribed
antibiotics, nebulised bronchodilators and oral steroids for seven days, and her
frusemide dose was increased.
An echocardiogram revealed she had good left ventricular function, and she
was discharged on December 6th 2000. I ensured the discharge notification
letter was written the day before discharge, and her medication was on the ward
in a timely fashion. She was discharged on the following medication:
Isosorbide mononitrate 20mg bd
Sodium valproate 200mg EC, 2 each morning, 1 at lunchtime, 2 at night
Aspirin 300mg EC each morning
Frusemide 120mg daily
GIN spray 1-2 puffs pin chest pain
Again no information was given by the doctor about changes to her medication.
I provided an information sheet for the GP explaining why amiodarone had been
stopped, and why digoxin had not been started. I suggested to the doctors that
the frusemide should be reviewed as she had not been taking it prior to
admission. They agreed and I instructed the GP to do this.
The patient and her husband told myself that the compliance aid supplied to
them during the previous admission had really helped with her medication. Her
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husband said he had 'kept her right' and she said she hasn't forgotten to take
any. They both agreed that the information I gave about her medicines was very
helpful, and made them realise how important it was to take them. The patient's
GP was contacted two months following discharge, to investigate whether she
had been obtaining repeat prescriptions. The GP revealed that she had indeed
been getting her weekly prescriptions, and also informed me that he had
recently checked her blood level of sodium valproate and this was within
therapeutic range, a further indicator that the patient was now taking her
medicines as prescribed.
When I asked the GP whether he found the additional information about this
patients medication that I gave him useful he said that he found it 'extremely
thorough and definitely facilitated the continuing care of this patient..'
He said '.... . often when patients are discharged, and their medicines have been
changed, the information we receive is incomplete and useless....
important information such as diagnoses, changes to medication,
investigations needed and the future management plan should be accurately
communicated to GPs as soon as possible, when all patients are discharged.'
He commented that the attention paid to addressing the patient's poor
compliance was especially helpful, and that it is easy for patients like SH to 'slip
through the net' in primary care.
Case 2 —Patient NW
This case demonstrates the advantage of a pharmacist taking a second drug
history and review of prescribing following admission. Again, the pharmacist's
role in attempting to minimise the risks associated with medicines is highlighted.
This 67 year old lady was admitted having suffered a myocardial infarction. She
had a past medical history of: type 1 diabetes mellitus (diagnosed in 1992 and
poorly controlled), three previous myocard ial infarctions, atrial fibrillation,
arthritis, osteoporosis, raised cholesterol and gout. The admitting doctor
recorded the patient as taking: allopurinol, aspirin, digoxin, frusemide and co-
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proxamol, but had missed the following from the drug history: simvastatin,
isosorbide mononitrate, lormetazepam, GTN spray and insulin. Despite this the
GTN spray and insulin had been prescribed, along with the other drugs
recorded, but simvastatin and isosorbide mononitrate had not. I recorded a
complete and accurate drug history in the notes, and ensured simvastatin and
isosorbide mononitrate were prescribed. She was taking 10 drugs in total prior
to admission.
The patient usually takes lormetazepam I mg at night for sleeplessness, but I
advised this be omitted from her prescription as it is recommended for only
short term use (BNF, 2002), and should be avoided in the elderly, as it may
predispose to falls. Rather than stopping the benzodiazepine abruptly, I advised
gradual withdrawal be initiated according to guidelines in the BNF. I explained
the risks of benzodiazepines to the patient, and she agreed to try a withdrawal.
NW was transferred to the equivalent daily dose of diazepam (1mg
lormetazepam 5mg diazepam). The GP was instructed to reduce the
diazepam dose to 2.5mg daily after two weeks, then after a further two weeks,
stop, or withdrawal could be slower if necessary. However, I do not know what
lasting effects this intervention would have, It is difficult to withdraw patients
from benzodiazepines and it is possible that she remained on them following
discharge.
The patient's usual co-proxamol had been prescribed following admission, and I
advised this be changed to paracetamol to reduce the potential for adverse
effects. Again, following discharge, her usual co-proxamol may be re-
prescribed.
NW scored 4.3 out of 10 on her knowledge of her medicines. When asked
about compliance with her medication, she claimed she never forgets her
tablets. However, she said that the GP prescribed isosorbide mononitrate a few
years ago, but she decided not to take it, '..... . the doctor used to change my
tablets al/the time, so when he started that one / decided not to take it......./
didn't/ike them and / kept forgetting to take them.' When I contacted the GP
surgery this was confirmed as she hadn't ordered a prescription since March
2000. I informed the doctors about this and advised them to change her daily
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dose from three times daily to twice daily, which they did, to help compliance. It
may be however, this would have no effect and the patient would continue to be
non-complaint following discharge.
The patient also said she suffered side effects from ibuprofen prescribed by her
GP a couple of months ago. 'I took one but later, / collapsed on the kitchen floor
and / felt terrible so I didn't take any more......./ feel like my doctor uses me like
a guinea pig.'
I educated the patient about all her medicines and the importance of taking
them, as she appeared to have been non-compliant prior to admission. I
communicated all medication changes were to the GP and as she had been
started on lisinopril (an ACEI), I asked the GP to check her U&Es after 2 weeks,
and review the dose if necessary. The patient clearly was suspicious about the
medical profession and it is conceivable she may ignore the advice I gave her.
She was non-compliant before admission and may continue to be following
discharge, despite my efforts.
Case 3 - Patient HP
This case illustrates the value of having a pharmacist on the ward to investigate
why patients are taking certain medication and advise doctors and nurses.
This patient was admitted with shingles, which had become infected. The GP
letter stated that the patient had emphysema and had recently been started on
antibiotics and prednisolone for a chest infection. The admitting doctor recorded
the patient as taking: multivitamins, salbutamol nebules, amitriptylline,
perphenazine, prednisolone and amoxicillin for a chest infection, diclofenac and
dihydrocodeine for pain, but omitted the patients' usual inhalers: salbutamol,
beclomethasone and salmeterol which I recorded.
Following admission, antibiotics were prescribed for his chest infection and for
the infected shingles. Oral, high dose steroids had been prescribed for his
chest, and paracetamol and his usual amitriptylline were prescribed. The
patient's phenerzine had also been prescribed immediately, following
admission, but was discontinued with no doses having been given, as the
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doctors thought it was for short term relief of itch associated with his shingles.
Chiorpheniramine was prescribed to relieve his itch. He was prescribed
acyclovir for his shingles.
On day two of his admission, when he arrived on the study ward, I undertook a
second drug history, and his usual inhalers were then prescribed. I contacted
the GP and discovered that for 2 years, the patient had been taking 2 Triptafen®
each night, for depression. The constituents of Triptafen ®
 are amitriptylline
25mg and perphenazine 2mg. The BNF now recommends this preparation is
'less suitable for prescribing', so the GP had recently changed the patient's
prescription to the separate components at equivalent dosages, amitriptylline
50mg and perphenazine 4mg each night. This was recorded in the patient's
notes and the doctors informed.
The patient had been complaining of hallucinations and 'feeling like a monster.
I advised the consultant that this may be a withdrawal reaction because his
usual perphenazine had been abruptly withdrawn. The perphenazine was then
re-prescribed, but I contacted the GP and advised that when the patient is
discharged this should be slowly withdrawn as it is of questionable benefit. I
knew this drug was not stocked by pharmacy and asked if the patient could
arrange for his own tablets to be brought from home. I contacted the patient's
wife and she brought in the tablets. I placed the tablets in the drug trolley and
informed the nurses. She also wrote on the patient's prescription chart 'Patient's
own in drug trolley'.
The hallucinations could also be a side effect of aciclovir. The patient was
admitted with an eight day history of shingles, and had been started on aciclovir
following admission. Aciclovir is only effective if started at the onset of infection.
In light of this, and the potential for adverse effects, I advised the doctors to stop
his aciclovir.
Despite ensuring the perphenazine had been prescribed on day two of
admission, the patient had not received any by day four and the nurses were
annotating the prescription chart 'no stock'. I again told the nurses his own
tablets were in the drug trolley, and after this perphenazine was administered.
243
Case 4— Patient DB
This case demonstrates the value of reviewing medication to ensure prescribing
is appropriate, It also shows the risk of errors and the value of having a
pharmacist on the ward for therapeutics advice.
DB was a lady of 76 years, admitted with a fractured pelvis. She also had
osteoporosis, type 2 diabetes, hypertension, mitral valve regurgitation, and had
a mastectomy for breast cancer four years ago.
An accurate drug history was taken following admission. DB was very
knowledgeable about her medication with an overall score of 8.3 out of 10. She
was able to recall 12 of her 13 medicines and knew the purpose and dose of
them all. She said that she took all her medicines as prescribed, although
admitted to forgetting her evening dose of nicardipine, which is to be taken
three times daily. She tries to cut down on her painkillers as much as possible,
and occasionally she misses her Fosamax® as it must be taken with a full glass
of water and this sometimes makes her feel sick. To help her to remember to
take her medicines, each morning she puts her tablets out into rows, and then
and puts them in her drug box (a little trinket box).
Following my review of her medication, the ferrous sulphate was stopped as it
was no longer indicated having been started in 1963 because she had heavy
periods, and had been continued ever since, even though she had a
hysterectomy in 1965. It was making her constipated and the dose was sub-
therapeutic. I suggested nicardipine be changed to once daily amlodipine and
three times daily captopril be changed to once daily lisinopril to help with
compliance, so the doctors did this.
She had been prescribed alendronate (Fosamax) at lOam and the nurses had
incorrectly been giving it after breakfast. I advised this be given at 7.3Oam half
an hour before breakfast, according to the manufacturer's instructions.
DB complained of nausea, caused by the morphine she was taking. The doctors
had not prescribed an antiemetic so I ensured this was started. Despite being
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prescribed an enema, one day later this still hadn't been administered, so I
reminded the nurses.
By day 10 of admission, the patient was in increasing congestive cardiac failure
and the consultant wanted to give IV frusemide instead of oral bumetanide. She
asked me to calculate the equivalent dose, which I did.
Her insulin dose was altered several times during the admission, and she was
eventually prescribed a glucose, potassium and insulin infusion. The house
officer forgot to cross the usual insulin off the drug chart, so I highlighted this to
prevent insulin from being given twice. It would be hoped however that a vigilant
nurse would have spotted this and not administered it twice.
The patient had been taking tamoxifen for four years, since her mastectomy, for
breast cancer. A possible side effect is oedema. As she has congestive cardiac
failure and it had become a struggle to control it with diuretics, I suggested the
tamoxifen be stopped, and the doctors accepted this advice. This may or may
not have been considered had I not highlighted it.
She was transferred to a community hospital for convalescence, so I counselled
her on all her medicines before she left.
Case 5 - Patient RC
This case is a good example of the benefit of a pharmacist reviewing
medication to ensure prescribing is appropriate and patients are not continued
on unnecessary medication. It also demonstrates the advisory and educatory
role of pharmacists.
RC, aged 66, was admitted on November 12, 2000, with shortness of breath
which was found to be caused by a pulmonary embolism (PE). She had a past
medical history of breast cancer in 1996, and a left hip replacement. Prior to
admission she was taking tamoxifen, dihydrocodeine, indomethacin, dothiepin,
diazepam, ferrous sulphate and cimetidine for indigestion. The admitting doctor
took a complete and accurate drug history. The GP surgery confirmed this list of
medicines except for dothiepin, for which they had no record. The patient told
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me this had been prescribed when a doctor had been called to the house. It
presumably had not been added to the GP computer system. The doses of
indomethacin and dihydrocodeine however were different to those given by the
patient.
The patient was very knowledgeable about her tablets, scoring 9.5 out of 10.
She knew the name and purpose of all of her medicines, and knew the dose of
all but one. She explained that ferrous sulphate was started two to three weeks
ago, as the GP thought anaemia was causing her shortness of breath.
Diazepam had been started two to three weeks ago as the GP thought the
shortness of breath was caused by panic attacks. Dothiepin had also been
prescribed by the GP for presumed panic attacks two to three weeks ago.
She told me that she cuts back on her painkillers every day, if she can, but
never forgets to take medication.
Following admission a VQ scan confirmed a pulmonary embolism. Tinzaparin
was commenced, and warfarin was added.
Following my medication review the following changes were made. Dothiepin
and diazepam were stopped since they had been started for panic attacks. The
symptoms of shortness of breath were found to be due to a pulmonary
embolism, not panic attacks. Ferrous sulphate was also stopped, as she was
not anaemic. Dihydrocodeine was changed to paracetamol, to reduce the
potential for adverse effects and indomethacin was stopped, to the reduce risk
of gastric adverse effects and interaction with warfarin. Cimetidine was changed
to ranitidine to avoid interaction with warfarin. RC was very pleased the ferrous
sulphate, dothiepin, and diazepam had been discontinued. She said that she
knew she wasn't having panic attacks, and was not happy about being
prescribed dothiepin and diazepam in the first place.
No reference was made to medication changes in her PDL so I completed an
additional information sheet to the GP explaining them all. I arranged her
warfarin follow-up in the community. She was to be managed in a warfarin clinic
ran by a local community pharmacist, to whom I then provided a written record
of the patient's INR results and warfarin dosages throughout the admission, a
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copy of the discharge prescription and additional information relating to the
patient. Later, I was contacted by the community pharmacist who said that the
information provided had been extremely helpful for EK's continuing care. He
commented that usually they receive very little information when patients are
discharged, and are rarely given data relating to warfarin initiation, INR control
and warfarin dosages during patients' admissions. It was therefore very difficult
to provide continuity of care when patients are discharged. He said that
communication of this nature was an excellent idea, and he wished he received
this level of information for all his patients following admission to hospital.
Case 6 - Patient ET
This case illustrates the benefits of a pharmacist taking a second drug history
following admission, and undertaking a structured medication review, It also
highlights the role pharmacists have in ensuring evidence and national
guidance is adhered to, providing advice about therapeutic monitoring, and
patient education.
ET was a lady of 70 years admitted on January 25th 2001 with increasing
shortness of breath. She had recently suffered a myocardial infarction, and had
been discharged from the study Trust the day prior to this, She also suffered
from asthma, hypertension, angina, peripheral vascular disease and had left
ventricular failure on echocardiogram.
At the time of the current admission she was taking dothiepin, aspirin,
lansoprazole, frusemide, lisinopril, simvastatin, verapamil, paracetamol, and
was using a salbutamol and salmeterol inhaler, and a GTN spray. The admitting
doctor recorded and prescribed all of these except the salmeterol inhaler and
the GTN spray. I recorded these omitted drugs and ensured they were
prescribed.
During the previous admission it was thought that the patient's pain could be
gastric in origin, so she was prescribed lansoprazole at a treatment dose of
30mg daily. Later, a myocardial infarction was confirmed by cardiac markers,
but the lansoprazole was not stopped. Following my review of her medication,
the lansoprazole was stopped as it was not indicated.
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The patient was allergic to penicillin but this had not been recorded by the
admitting doctor, nor recorded on the patient's drug chart, so I did this. Later in
the admission, the patient was prescribed amoxicillin and co-amoxiclav. I made
sure this was stopped before any doses were given, and changed it to
erythromycin.
I advised the doctors to revise her asthma treatment as it was not in line with
current national guidelines. This was done, salmeterol was stopped and a
regular inhaled steroid, beclomethasone, was prescribed, according to current
guidelines. The GP had actually written in the referral letter "the patient has
been taking repeated courses of steroids for her chest." Despite this the GP had
not commenced a regular steroid inhaler. I educated the patient how to use her
inhalers via a volumatic, as her technique was poor.
ET was not very knowledgeable about her medicines, scoring only 3.2 out of 10.
She said however, that she never forgets to take her medication, as her
husband takes care of it all.
The patient told me that during her previous admission, she had not received
her usual inhalers at all. On looking through her notes, the drug kardex for the
previous admission the nurses had been writing 'self in the box to record
administration. When the nurses write this, it means that patient is administering
the medication themselves, and the nurses should be satisfied that this is
actually happening. She didn't have any inhalers, so she couldn't administer
them herself. On the discharge prescription from the previous admission, it was
marked that the patient had her own inhalers, so none were supplied by
pharmacy, but the patient said she did not have her own. During the current
admission despite the beclomethasone having been prescribed, the patient was
still not receiving it two days later, although the nurses had again been writing
'self administered' on the drug chart. The patient had not been given a
beclomethasone inhaler. I therefore made sure the patient was given inhalers,
and was using them as prescribed.
During this admission the patient was found to have paroxysmal atrial fibrillation
(PAF) so Amiodarone was prescribed. The doctors had not checked her
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baseline liver and thyroid function, so I ensured this was done. A low molecular
weight heparin, enoxaparin was prescribed by the doctor who diagnosed PAF.
In this clinical situation, there was no evidence base to support prescribing
enoxaparin. The junior doctor's knowledge of therapeutics in this area was
clearly lacking. Inappropriate prescription of enoxapann injections leads to
unnecessary risk and discomfort to the patient, along with substantial waste of
resources. I advised the doctors and the enoxaparin was stopped.
The patient was not considered appropriate for warfarin therapy, so aspirin was
continued. She was found to be vitamin B12 deficient and was therefore
commenced on replacement therapy.
During admission she had a persistent temperature and was treated for a chest
infection with antibiotics. She made a slow recovery and was discharged
February 17th• As she was found to be hypotensive, verapamil was stopped.
I educated ET about her medicines. ET said that she finds her medicines can
be baffling, lieven when you have it all written down it's helpful to have someone
go through it with you." When asked about information given to her during her
previous admission, she said no one had talked to her about her medicines
when she was discharged, Uit all happened very fast last time.. ..in the blink of
an eye we were home, so there was no time. - ." She said that the information
about her medicines given to her this time was definitely better. I talked this
patient through all of her medication and gave her written information, and she
seemed to take it all in although I cannot be certain of the long term affect. She
was on a lot of medication, and it is possible she will forget a lot of what I told
her. I hope that having written information also will help. This, of course, will be
the case for many patients whom I educated about their medicines, however it
is still important that information is given to patients, and even if only a small
amount is retained, it is better than receiving none or very little education.
I ensured the discharge medicines arrived on the ward in a timely fashion. The
doctor who wrote the discharge summary did not refer to any of the changes to
ET's medication. I completed the additional information sheet detailing all
changes to therapy, and requested the GP follow up thyroid and liver function
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tests, in light of the Amiodarone. The discharge notification letter written by the
registrar, followed a month later. The only reference to medication was that
vitamin B12 and Amiodarone had been commenced. Nothing was mentioned
about lansoprazole and verapamil being stopped or beclomethasone inhaler
started
Case 7— Patient SP
This case illustrates the educational role of the ward pharmacist, and the lack of
communication between medical staff and patients about changes to medicines.
SP, aged 82 years, was admitted on November 1, with falls. She was
prescribed co-proxamol, dihydrocodeine, voltarol gel and quinine sulphate prior
to admission. She told me that she had falls and headache with codeine.
The admitting doctor omitted the voltarol gel and quinine from the drug history. I
recorded these in her notes. Following my drug history I advised the voltarol gel
not be prescribed, in accordance with the prescribing policy. The patient was
adamant that she wanted to receive her quinine saying that she 'swears by it'.
Although it is not efficacious, I advised it be added to her therapy, as she was
distressed at the prospect of not receiving it.
Following my review of SP's medication, co-proxamol was changed to
paracetamol, to minimise the risk of adverse effects, in particular falls, the
reason for this admission. Dihydrocodeine was stopped also as it may
predispose to falls. The doctors may or may not have stopped these drugs
anyway, but the doctors had not considered her medication to have contributed
to her falls, prior to me highlighting it.
The patient scored 10 out of 10 for knowledge about her medicines and she
said she never forgets to take her tablets, but often takes fewer painkillers if she
can.
The doctors had not explained the changes to her medicines, and when the
nurse tried to give her the new painkillers, she became very confused. She said
'these are not my usual ones.' I explained to SP that co-proxamol and
dihydrocodeine had been stopped as they may have been causing her to fall,
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and that she was being given paracetamol instead. I told her that she should not
take co-proxamol and dihydrocodeine together in the future, it would be best to
avoid them altogether and stick with just paracetamol. She was grateful for the
explanation and said, "no one had told me and I was really worried when the
nurse bmught in my tablets, I thought they're not mine!"
There was no information about the medication changes in the discharge
summary, and as it was likely her medication was partially responsible for the
admission, this should have been stressed. I completed an additional
information sheet to the GP explaining why her analgesia was changed to
paracetamol alone, and that co-proxamol and dihydrocodeine should not be re-
started. I believe my interventions would have a lasting effect in this case, as
the patient was very knowledgeable about her medication and understood that
her previous regimen may have contributed to her falls.
Case 8 - Patient DF
This case highlights poor documentation of drug therapy in patients' notes and
bad communication about medication across the primary/secondary care
interface. The potential for errors and the value of a pharmacist obtaining a
second drug history and medication review are demonstrated. This case also
shows the value of pharmacists educating patients and being involved in
discharge.
DF, aged 72 was admitted with increasing shortness of breath. She also
suffered from asthma, ischaemic heart disease, congestive cardiac failure, and
epilepsy (post meningitis). The admitting doctor recorded the following drug
history:
carbamazepine 400mg bd
frusemide 40mg od
aspirin 150mg od
phenytoin 300mg od
Calcichew D3 2 od
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betahistine 8mg tds
nitrazepam 20mg on
co-codamol pin
senna pm
salbutamol inhaler
Becloforte inhaler
Atrovent inhaler
GTN spray 2 pm
On looking through the patients notes from previous admissions (24.10.99 and
30.12.99), documentation relating to her medication was clearly incomplete and
accurate. In October betahistine had inadvertently been omitted from the
admission drug history, and not prescribed throughout this admission. The
consultant also omitted it from the discharge letter, but following discharge, the
GP however had continued to prescribe it, as when she was re-admitted in
December, she was still taking betahistine. She was discharged on 11
medicines following this admission, but the consultant provided dosages for
only four of these in the discharge letter.
When the patient was discharged in December, her salbutamol and
beclomethasone inhalers, phenytoin and thiamine were omitted from her
discharge prescription and the consultant discharge letter, with no explanation.
On looking through the notes from these admissions, none of these drugs had
been stopped on her drug chart prior to discharge, and no reference was made
to this in the notes, it therefore appears to be a mistake at the time of discharge.
Despite this error, however, the patient was still taking these medicines at the
time of this most recent admission.
I took a second drug history, which revealed that the admitting doctor had not
recorded that the patient uses salbutamol and ipratropium nebules, or takes
spironolactone and thiamine. Recorded at the incorrect dose were:
carbamazepine, which should have been controlled release 200mg twice daily
and 100mg standard preparation once daily; aspirin, which should have been
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75mg daily; phenytoin, which should have been 200mg twice daily; and
nitrazepam, which should have been 10mg each night. The inhalers did not
have any doses recorded.
The patient brought in a repeat prescription sheet with her when she was
admitted, dated 14.10.99. The admitting doctor's drug history matched this
identically, so it appeared that this had been used to obtain the drug history,
which is why the doses of some of her medications were incorrect, and
spironolactone had been omitted. The patient was unclear of the doses she
took so I contacted the GP surgery to clarify this and the GP explained her
anticonvulsant doses had been altered and spironolactone started on 30.10.00.
I recorded this in the patient's notes.
The doctor also recorded that the leading up to this admission, the patient
'thought she was able to manage with OTCs (over the counter medicines)', but
did not specify what OTCs were being used. I recorded she had been using
buttercup syrup. This would have no effect on patient care but ensured all
medication was documented.
Despite being omitted from the admitting doctor's drug history, thiamine was
prescribed. The doses of her anticonvulsants were changed, following my drug
history, and the aspirin dose was reduced to 75mg od. The nitrazepam dose
was reduced to 10mg on, and the consultant decided against prescribing
spi ronolactone.
DF actually took 17 medicines, but could recall only 8 of these to me, and knew
the name of only 6. DF told me that her daughter fills up a med idose container
(compliance aid) with her medication, each week, although some tablets are too
big so they are left in the boxes. She has carers who come in the morning and
at night and check that she has taken her medication, so compliance was
assumed to be good.
Correspondence from the doctors she had seen in the outpatient clinics to her
GP, on two occasions questioned why she was taking thiamine, and suggested
this be stopped, however, the GP had not done anything about this. I advised
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betahistine and thiamine be stopped to rationalise her drug therapy, and the
doctors agreed.
She was treated for a chest infection, with steroids, antibiotics and nebulised
bronchodilators. I assessed her inhaler technique and found it to be very poor.
She said that she couldn't manage at home only on her inhalers, without using
her nebules, and insisted her inhalers didn't work. The reason she was not
getting any benefit from her inhalers was her poor technique. I contacted the
GP who said he didn't think she needed a nebuliser and that she could manage
with her inhalers but she refuses to. He welcomed any attempt to reduce her
nebuliser usage, as they are very expensive. I educated her how to use her
inhalers via the volumatic device and she co-operated. I followed up by
assessing her technique each day. Her technique improved and she was
maintained on inhalers throughout the rest of the admission. The patient would
not have received intense counselling and follow-up had I not been there. From
my participant observations it was clear that this does not happen. Nurses and
doctors said they don't have the time to undertake such activities. The nurses
told me that after the decision has been made to discharge a patient, often they
must wait for their medication to arrive on the ward from pharmacy as the
prescription is seldom written in advance, and this holds the discharge up. By
the time their medication arrives on the ward, patients are obviously keen to
leave as soon as possible and may be agitated having had to wait. In addition
the nurses are keen to get patients off the ward to free up the bed. Inhaler
technique is rarely addressed at this point and education about medicines, if
provided at all, tends to be minimal. My observations also lead me to believe
that inhaler technique is rarely considered during admission.
Nothing was written on the discharge summary about the changes made to
DF's medication, so I completed an additional information sheet for the GP
explaining all therapy during admission and all changes to medication, with the
reasons. I recorded that DF had been counselled on using her inhalers and that
ideally this should be followed up by the practice nurse, and communicated that
her blood levels of her anticonvulsants had been within the therapeutic range.
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Case 9— Patient RG
This case highlights the role pharmacists could have in ensuring accurate
documentation of therapeutics is maintained, and that patients receive their
usual medication whilst in hospital. It also demonstrates the important role
pharmacists have in minimising the risks of drug therapy, providing therapeutics
advice, providing accurate and complete information to GPs about medication
following discharge and patient education.
RG was a gentleman of 82 years of age, admitted in November 2000 with a
chest infection. He also had two recent admissions previously this year, in July
he was admitted having suffered a haemorrhagic stroke. He had been receiving
warfarin prior to this, but it was discontinued following the stroke. In August he
was in hospital for 11 days with a chest infection.
The admitting doctor recorded the following brief drug history:
Frusemide x2 I day
?medication unsure
On interviewing RG, I was able to record the following history:
Frusemide 80mg om
Captopril 12.5mg bd
Ipratropium bromide inhaler 4omcg bd
Beclomethasone inhaler 500mcg bd
Lactulose lOmI bd
Naproxen EC 250mg od
Salbutamol inhaler 200mcg pm
Paracetamol 500mg-Ig pm
Senna 2 on pm
Vistamethasone drops I drop to the right eye bd
However, despite the incomplete drug history taken by the admithng doctor,
seven out of ten of the patient's medicines were subsequently prescribed, (the
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exceptions being the eye drops, naproxen and lactulose). I ensured the eye
drops were prescribed, but advised lactulose and naproxen be discontinued.
Naproxen should be avoided if possible, as it can cause gastrointestinal side
effects and lactulose is not the hospital formulary laxative. The patient had been
prescribed frusemide 40mg twice daily, so I made sure it was changed to 80mg
once daily, so the patient did not need to get up to the toilet during the night
which, in addition being inconvenient, also increases their risk of falls.
On talking to the RG and his wife, I discovered the steroid eye drops had been
prescribed by the eye infirmary following a cataract operation and he was to use
these until the end of the month. This was then recorded in the notes, along
with the date the eye drops were to stop.
Following my review of his medication, the patient was changed from twice daily
captopril to once daily lisinopril, to help with compliance.
An electrocardiogram following admission revealed that RG had fast atrial
fibrillation so digoxin was commenced. Antibiotics were started for his chest
infection. On day three he was found to have paroxysmal atrial fibrillation, so
digoxin was stopped and Amiodarone commenced. His baseline liver function
and thyroid function had not been measured, so I ensured this was done, and
recorded in his notes that this should be repeated every 6 months.
On day three, I found an old warfarin book for RG on the ward. One of RG's old
warfarin books, from a previous admission, which had been filed in his notes
had somehow found its way to the box where all the warfarin books of patients
currently on the ward, were kept. Patients on warfarin have a hospital warfarin
record book which is kept separately from their notes, often in a little box in the
ward office. This book is used to prescribe warfarin, rather than the drugs chart,
as warfarin doses change depending on the patient's INR. The book only
contains information relating to the warfarin, with no reference to concurrent
conditions or other medication. Warfarin is usually prescribed, by the junior
house officers after 5pm, when blood results arrive back on the ward. The junior
doctors are inexperienced in prescribing warfarin, request frequent blood tests
and alter warfarin doses regularly. When the blood results arrive, the doctor
256
goes through all the warfarin books and prescribes the warfarin dose for that
day, or the next few days if the patient's INR is stable, and indicates when the
next blood test is required.
Often warfarin is prescribed by junior doctors who are not familiar with the
patients, if the nurses cannot get in touch with the house officer actually
responsible for that patient. For example as the blood results often arrive back
on the ward after 5pm, most house officer have gone home for the night. The
on-call house officer is then called to prescribe the warfarin. They tend to just go
through the books and prescribe the warfarin based on the most recent INR and
previous warfarin dosages.
Because of this system, there was significant potential for warfarin to be
inadvertently prescribed to RG, and as warfarin is contraindicated in patients
with a previous history of haemorrhagic CVA, the potential for serious harm to
the patient is high.
Although the patient's vistamethasone eye drops were prescribed, the patient
told me that he was not receiving his usual eye drops. On his drug chart, the
nurses had been writing 'self in the box to record administration. In the case of
RG he was not administering his drops himself, as he could not manage it and
at home his wife does it. This therefore meant the nurses had just been writing
'self and really had no idea whether he was administering them. I highlighted
this with the nursing staff and ensured he did receive his drops from that point
onwards.
On day nine of admission it was noted that he was becoming increasingly
confused at night. It was thought that the amiodarone could have caused this.
He was seen by the cardiovascular consultant, who said that the amiodarone
may well have caused his confusion and he would therefore recommended it be
stopped and replaced with a beta-blocker for rate control. He noted that the
patient had COPD, and stated that as beta-blockers are contra-indicated in
COPD, nothing should be prescribed, as he is not symptomatic.
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The patient was advised that if he has symptoms of atrial fibrillation or atrial
tachycardia, such as palpitations, dizzy spells, he should go to his GP.
The house officer wrote in the notes on day nine, '? restart warfarin.' I advised
the doctors that warfarin is contraindicated in patients with a history of
haemorrhagic CVA, and recorded this in the notes.
Nothing was written on the discharge notification letter about medication, so I
added:
'changes to medicines - captopril changed to lisinopril, lactulose
stopped, naproxen stopped, only I week betamethasone eyedrops
needed until stop (post cataract)'
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4.3.3.	 Focus groups and interviews
Semi-structured interviews were conducted with the four general medicine
consultants and one nurse who were involved with the project. Semi-structured
interviews were also conducted with two registrars, two senior house officers,
three house officers and one senior nurse who had not been involved in the
project, but were working in general medicine. The interview schedules can be
found in appendices 6.12-6.15. The interviews varied in length from
approximately 30 minutes to one hour and 30 minutes. Participants varied in
how much they said. Some spoke at length with very few prompts, others said
less and I needed to encourage them to talk.
Four focus groups sessions were held, two with pharmacists and two with
pharmacy technicians, as detailed in the previous chapter. Each focus group
included four participants. The focus group schedule can be found in appendix
6.15. The focus groups also varied in length. The pharmacists talked a lot and
needed few prompts, whereas the technicians spoke less and at times needed
much encouragement. This may be because the pharmacists were more
confident than the technicians. From my observations it appeared that the
technicians found the focus group environment intimidating.
As was explained in more detail in sections 2.7.4.5 and 4.2.7 analysis of the
focus groups and interviews was carried out following the principles of grounded
theory. Constant comparative analysis was used to develop categories and
identify emerging themes. The themes identified and sub-categories are listed
in table 4.20.
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Table 4.20 Main themes and subcategories identified from the focus groups and
interviews
Themes	 Sub-categories
Aspects of medicines related
	
Inefficiency of care
care within the study Trust	 Time limitations
Quality of care
Patient involvement in their care
I ntra-professional variation
Culture towards medicines within the Trust
___________________________ Experience of services provided by pharmacy
Medicines safety
	
Errors
Admissions due to medication problem
Competency of doctors and nurses
___________________________ Appropriate prescribing
Enhancing management of	 Drug histories
therapeutics	 Medication review
Efficiency of services
Expedite discharge
Enhancing safety
Prescribing guidance and focus on therapeutics
Cost of therapeutics
Communication
Concepts of patient centred pharmacy services
__________________________ Concerns about suggested service development
Educative role of the	 Patient healthcare professional relationship
pharmacist	 Health literacy
Educating patients
___________________________ Educating Drs and nurses
Changing practice 	 Resources
Inter-professional dynamics
Competency of pharmacy staff
Facilitating change
Implementing patient centred pharmacy services
Professional aspirations of pharmacy staff
__________________________ Roles and professional boundaries
As the analysis is interpretive, coded data are not quantified and statistically
analysed. The concern is not so much with distribution within populations, rather
process, view points and social mechanisms within the study setting. A non-
mathematical process of interpretation is carried out for the purpose of
discovering concepts and relationships in the raw data and then these are
organised into a theoretical explanatory theme in the following chapter.
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4.3.3.1.	 Aspects of medicines related care within the study Trust
This section describes the existing practices and culture relating to medicines
use in the study Trust from admission, throughout the inpatient journey and on
discharge back into the community, as viewed by the participants. It excludes
interventions and changes in practice made in the acute phase of the study.
Inefficiency of services relating to medicines was a concern and this is
discussed in section 4.3.3.1 .1. Another issue raised was time limitations and
staff shortages examined in section 4.3.3.1.2. Problems relating to poor quality
of care are presented in section 4.3.3.1.3 and lack of patient involvement in
their care, in section 4.3.3.1.4. Section 4.3.3.1.5 is about intraprofessional
variation and section 4.3.3.1.6 presents participants views about the culture
relating to medicines in the study Trust. Finally in section 4.3.3.1.7, participants
experiences of services provided by pharmacy, prior to this study, are
examined.
4.3.3.1.1.	 Inefficiency
When asked about problems relating to medicines junior doctors, nurses and
pharmacy staff expressed frustration at the inefficiency of patient care relating
to medicines. Systems and procedures relating to medicines, and shortcomings
of staff were blamed. Unnecessary delays in discharge were felt to be the main
problem, which results in beds being blocked. The junior doctors admitted that
failure to have discharge prescriptions written in a timely fashion resulted in
delays.
"I suppose the biggest problem from our point of view is getting
discharge scripts done, and stuff, cause we're under such pressure to
get, you know if you're doing a ward round and you're accumulating
discharge scripts, it's lunchtime before your finished the ward mund and
then you have to sit down and write them all out and then they have to go
to pharmacy, and if the patient's going that afternoon it, that's a big
problem." (House Officer)
Whilst doctors acknowledged their delays at writing discharge prescriptions as a
problem, none suggested any solutions. Pharmacy staff were frustrated as
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doctors tell patients they can go home, but the discharge prescription has not
been written.
"On the ward round the patient's told 'oh you can go home' but it will be
another what three hours before the doctor returns to write the
prescription and then it will be sent down, and obviously you know it
could be later in the day the pharmacy's busy so it will be another three
hours until it's dispensed, so that patient could be waiting six hours easily
to get their medication... "(Pharmacist)
In addition doctors and nurses said that ambulances cannot be booked until
discharge medicines are ready, which also holds up discharge. Frustration was
expressed about delayed supply of medicines to wards. Pharmacy staff
however, feel that nurses do not always order medication in a timely fashion.
Doctors appeared, however, to have very little insight into the supply of drugs
from pharmacy, and the problems that are sometimes encountered in obtaining
medicines from suppliers.
"I get cross, well / don't understand why it takes so long for the drugs to
come up from pharmacy, the nurses say it eve,yday, and sometimes it's
a really important drug that the patient really needs, but because it's an
unusual drug or one that we don't stock in the hospital it seems to take
about four days before they get it, which prolongs the patient's
admission, so it's wasting a lot of time and money all round really, and
not helping the patient's satisfaction, that is a big problem actually."
(Senior House Officer)
The hospital drugs formulary also leads to inefficiency in supply of medicines.
"Non-formula!)' drugs causes a problem, sometimes if they come in on
an item that's non-formulat'y, it takes a while to get an alternative sorted
out." (Pharmacy Technician)
Pharmacy staff felt wastage of medicines is a big problem as the nurses do not
re-use patients own and do not mark on prescriptions when patients have their
own supply, according to pharmacy staff. They claimed that delays are also
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caused when prescriptions are sent to pharmacy with information missing, such
as doses of medicines, and essential patient details. In addition, often when
patients are transferred between wards the nurses do not also transfer the
patient's medicines, so the ward that is receiving the patient re-orders
medicines, resulting in duplication of work and waste.
4.3.3.1.2.	 Time limitations and staff shortages
The consultants said time limitations also resulted in inaccurate, incomplete
drug histories taken by their junior doctors. They are aware that discharge
prescriptions are written hastily leading to mistakes and omission of important
information.
The registrars and junior doctors also said that they do not have sufficient time
to take drug histories, undertake medication reviews, educate patients and write
discharge prescriptions.
"Sometimes the patient doesn't know what they're taking if they're
confused or very ill, and the relatives often don't know. You want to go
back and find out what they're taking, but often you forget or you're too
busy and then it doesn't get done." (Senior House Officer)
"When you're really busy and you write a discharge prescription you
don't necessarily put in, we don't always put enough information on it
(House Officer)
All grades of doctors felt that because they had insufficient time, medicines
were often not comprehensively reviewed. Staff shortages and lack of time were
blamed for medicines not being administered despite being prescribed.
"If they can't get a cannula in, the person misses the antibiotics.....you
know you accept people are busy.......they don't do it in a malicious
way, it's not done because they're lazy it's done because they've got
their time full with other things." (Consultant)
Doctors said they cut corners because they are rushed.
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"You think 'oh / should look this up but I haven't really got time to look it
up because if! do it's going to take me an extra how ever long" (House
officer)
"I know that's terrible but you don't always have time to look everything
up and you know, so sometimes you don't question things" (House
Officer)
The nurses also said that neither they nor doctors have sufficient time to talk to
patients about their medicines.
4.3.3.1.3.	 Quality of patient care relating to their medicines
Most participants, particularly the consultants appeared to feel that the quality of
patient care with respect to medicines is lacking. Resources were felt to be a
major factor in this. When asked about the culture within the Trust, with respect
to quality of patient care and clinical governance one consultant said:
"People are trying to do their best, but there is not enough funding, and
so we just have to try and do what we can with what there is. They (Trust
management) are very pro patient care and clinical governance, or they
say they are, but they are working within a budget so there is only so
much they can do."
On describing the culture within the study Trust with respect to quality of patient
care and clinical governance, another consultant said, "It's probably fairly
lacking actually." Resources again were blamed for this, "I mean the culture of
governance, of actually moving things on is really not that great but that as with
many other things comes down to a financial matter. If you look everywhere
else they have employed governance people, to an extent the modem matrons
who drive these things forward, who measure, who get good practice and
disseminate, we don't have that yet."
Some participants felt that whilst everyone wants to do their best for patients,
the Trust appears to be more concerned about cost savings and reducing
waiting times than quality of care or clinical governance. The consultants said
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that there are insufficient resources, and a lack of adequate systems in place to
monitor quality of care.
"I don't think we're at the top of the table on making measures for
governance, certainly it's compulsory but I don't really feel that
governance governs us." (Consultant)
This was felt to be marker of the pressures being applied from Government.
"All they're (Government) interested in, is not having bodies waiting on
trolleys for emergency admissions, people not waiting for their operation
for longer than however long it is, and to keep financial stability."
(Consultant)
Another consultant expressed similar views, "in eveiyhospi/aiin Ihe counfij' iTs
driven by the patients charter and by government standards, and so the sort of
thing they focus on is how long they wait to see someone in out-patients and yet
they don't look at the quality of care delivered and the sort of figures published
are how long people wait to have an operation, but nobody looks at the
outcomes of those operations."
One consultant felt that the quality of patient care suffered during holiday
periods such as Christmas and Easter as speech and language therapists,
pharmacists, physiotherapists and occupational therapists go off on holiday
leaving the doctors and nurses to work and discharge people without the people
behind them.
4.3.3.1.4.	 Patient involvement in their care
When asked whether patients are given sufficient information about their
medicines all participants felt that patients' involvement in their own care was
lacking, blaming lack of time and inclination on the part of doctors and nurses.
"From my point of view my patients on the rehab unit, no they don't get
enough counselling." (Registrar)
"Doctors don't have time to counsel patients properly." (Consultant)
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alts not really good enough to plant a cupful of tablets in front of
someone and say, 'take them', and that's what happens." (Staff Nurse)
Several participants suggested that nursing staff had inadequate knowledge
about drugs, to educate patients. Many nursing staff are not confident in giving
patients accurate and complete information. The following comment from a
ward manager was particularly concerning as she is in charge of all the nurses
on the ward.
"A lot of the nurses probably don't actually really know the ins and outs of
the drugs themselves." (Ward Manager)
Doctors and nurses appeared unclear as to whose responsibility it was to
educate patients about their medicines and doctors said they rarely talk to
patients about their medicines. It appeared, from some comments, that
educating about medicines patients is not a priority.
"We just say, you know 'you're on steroids, you're on antibiotics, you've
been given some nebulisers,' I think that's about as far as we ever get, to
be honest... "(House Officer)
"We prescribe and don't think to explain why we've prescribed. / know,
certainly I've written stuff up on ward rounds and haven't said why.......
certainly / think we prescribe a lot without involving, as if the patient
wasn't there, saying, 'well let's double the dose of this,' without saying,
'oh we're going to increase your tablets,' we, you know we just do it."
(House Officer)
Some doctors, however, acknowledged that they should be doing more.
"I really only ever do it for warfarin, I suppose that's really bad isn't it?"
(Senior House Officer)
"To be honest I don't remember counselling anyone since I started this
job, and I probably should do cause there has been the odd one who
we've given, you know, who we've started an inhaler on, and you have to
wonder what their ability was." (House Officer)
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Whilst admitting, for various reasons that they did not talk to patients enough
about their medicines, the doctors and nurses did not consider what could be
done to improve this.
From their comments it appeared that the doctors interviewed make value
judgements about the level of information they perceive that patients can
understand and how much they 'know' their disease. Doctors also appear to
make judgements about what constitutes a 'minor' change to medication as
oppose to 'significant' changes, whilst also admitting that they are not even very
good at letting patients know about 'significant' changes. Some doctors did not
acknowledge the importance of informing patients of the purpose their
medicines.
4.3.3.1.5.	 Intra-professional variation
Three of the consultants felt that patient care with respect to medicines varies
across the directorates, and that the importance placed on medicines differs
between individual doctors, and nurses. When asked about nurses' knowledge
and competency in therapeutics one consultant said:
"Some nurses are really interested in prescribing and drugs, sometimes
when / do things on the wards some nurses will say 'why did you do
that? Why did you prescribe this?" (Consultant)
Talking about reviewing medication, the same consultant said:
"Being a geriatrician and having experience in pharmacology / try to do
this anyway, / try to review every drug kardex during each ward round.
This may not be the case for some of my colleagues" (Consultant)
This may be speculation on the part of the consultants, or through past
experience of working as junior doctors or within other directorates. This opinion
was however, supported by comments from other participants.
Doctors working in surgery and orthopaedic directorates were felt to be less
interested in the medicines aspects of patients care than those working within
general medicine. Talking about the attitudes within other directorates a nurse
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commented: "I mean the geriatricians are very keen, but! don't know about the
other physicians, like the surgeons, because there it seems the drug therapy
isn't considered of great importance, whereas in genera! medicine it's
essentiaL"
One consultant said that the competency of junior staff varies and this affects
the attention paid to medicines on ward rounds.
"I think the times that we don't look at charts it's because we've been
distracted into doing something or we don't make decisions to review
medication is cause we're too busy doing something else at that
moment, and it, in a way it reflects the sort of quality of junior staff you're
working with, so at the present I have to think entirely for them, because
the staff I'm working with at the moment are not at the level of presenting
problems to me......whereas older juniors present how far they've got,
and then you can stand back and make changes."
4.3.3.1.6.	 Culture towards medicines within the Trust
Some doctors and nurses interviewed appeared to have a blasé attitude
towards medicines and do not see them as an important part of patient care. On
talking about taking a drug history one Senior House Officer said, "well it's partly
that we can't be bothered, to get exact doses and exactly what the story is. .."
The doctors referred to 'important', and 'not important' medicines, and
distinguished between significant and minor therapeutics events, when talking
about errors or changes to therapy. They expressed frustration that nurses do
not realise which medicines are 'important' and sometimes do not administer
them. Participants felt that medicines are not taken seriously and that they
simply do not matter, right from the doctors and nurses through to the Trust
management.
"I think people should be taking medication more seriously.......it always
surprises me that important drugs, people are very happy, not to give the
phenytoin, or amiodarone, or digoxin, and just write, 'out of stock"
(Consultant)
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"This Trust seems to have an attitude of, 'medicines don't matter' and
you see it from the top, right down to the nursing staff.....it boils down to
this, that 'medicines are only a small part of their job, " ( Pharmacist)
"The drug and therapeutics committee has no teeth what so ever
(Pharmacist)
Many participants, in particular consultants, felt that health care professionals
involved in patient care do not feel any ownership of care provided, so
ultimately no one takes responsibility. For example, when patients are admitted
and it was not possible to obtain an accurate drug history, the admitting doctor
often does not follow it up. Also, the nurses do not feel an individual
responsibility to ensure patients actually receive the medicines they are
prescribed.
"You ask why it hasn't been given, and no one knows. And that happens
quite a lot I think, and they just say it was someone else from another
shift', you know, and I said, 'well why does it happen?" (Consultant)
4.3.3.1.7.	 Experience of services provided by pharmacy
Pharmacy services to wards prior to the study were appreciated by all doctors
and nurses, but the consultants said they don't have a lot of contact with
pharmacy staff on the wards.
"Although we have ward based pharmacists here we often don't know
who they are. We've got one at the moment on ward one, and I don't
know her, cause you don't see her at the intervals when I'm there."
(Consultant)
It was felt that pharmacy did not have prominence in the study Trust, and the
location of pharmacy in the basement of the pharmacy contributed to this.
'?think it's probably got worse now they're in the dungeons, and no one
sees them, you know, at least you got to see people on the main
corridor, but I rarely see the pharmacists now, which is a shame"
(Consultant)
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It was clear that wards get varying levels of service, which doctors and nurses
were aware of, and questioned why. A basic level of ward pharmacy services
are provided to most wards within the Trust which comprise: a pharmacist
generally visits the ward on a daily basis, and reviews patients' drug charts and
pharmacy technicians refill the wards' drug cupboard. On a few wards
technicians actually look at drug charts and order medicines that are not kept as
stock on the ward. Pharmacy staff are not based on the wards, and spend the
majority of their time in the pharmacy department. At the time of the study,
within the pharmacy department staff are involved in supply to the wards and
answering queries about medicines. Pharmacists also provide outpatient
anticoagulant management clinics.
It was apparent that only one pharmacist in the Trust attended ward rounds at
the time of the study, but only once a week. This, however, was greatly
appreciated by the doctors working on the ward involved. One of the house
officers said that on this ward round if patients are being discharged the
pharmacist will write the drugs on the discharge prescription for the doctor to
then complete. She reviews the drug charts, checks for interactions, advises on
prescribing, shows the doctors exactly how to write prescriptions for controlled
drugs and manages warfarin prescribing. The house officer working with the
pharmacist felt that the risks associated with drug therapy are greatly reduced
with pharmacist involvement; patients are discharged quicker because the
discharge medicines are sorted out sooner and warfarin therapy is managed
better.
Some pharmacy staff expressed frustration with current pharmacy practices,
and they felt progress to expand ward pharmacy services within the Trust was
hindered by their lack of time, the culture towards medicines and lack of
resources. They commented that ward pharmacy services vary greatly across
directorates and between Trusts, and that true multidisciplinary teams with true
integration of pharmacy staff, exist only as pockets of excellence within NHS
hospitals.
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Pharmacists were frustrated that they cannot make simple alterations to drug
charts, because of Trust policy. Some felt their services weren't seen as an
important part of patient care.
"The thing is at the minute, if you don't go to the ward, would you be
missed7....the ward doesn't stop functioning if you're not there, I think
we've got to get to a point where if we're not there, they're asking why."
(Pharmacist)
They said that ward staff are more concerned with the supply function of
pharmacy.
"Particularly wards that have got technicians, / think they would miss the
technician more than the pharmacist, cause I think the nurses are just
bothered about, the ordering to be honest they want the drugs there."
(Pharmacist)
Some pharmacists are now involved in pre-assessment clinics which have
proved successful. Pharmacists commented that even though they are not
based on the wards, by visiting on a daily basis they build up relationships with
the ward staff, which is helpful in sorting out medication queries.
Doctors said that pharmacists currently leave 'post it' notes, or 'little green
sheets' on drug charts to communicate prescribing advice, which although
generally useful, the doctors sometimes found these irritating. Doctors said that
often when messages are left by pharmacists in this manner, the pharmacist is
unaware of information about the care of the patient, which would explain why
certain therapeutic decisions have been made.
Doctors and nurses appeared to be appreciative of activities that lessen their
work load but appear to place less importance on potential improvement in
patient care and enhanced safety. Data indicate that some doctors are relatively
ambivalent about the patient centred approach to pharmacy practice piloted in
this study, acknowledging the benefits of delegating routine or arduous tasks,
such as taking medication histories, counselling patients and ensuring
medicines arrive on the wards in a timely fashion, yet conversely, are not
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entirely convinced of the advantages of full involvement of pharmacists in
patient care.
Doctors appreciate having the back up of someone monitoring their prescribing,
for example flagging up errors, advising about interactions and adverse drug
reactions, advising about therapeutics, obtaining unusual drugs and reminding
them of stop dates for antibiotics and steroids. However, they said that having
pharmacist actually based on the wards would be better as they would be more
likely to ask their advice. Doctors commented that because pharmacists are not
closely involved with patients their contribution to patient care is limited.
"Most of the time they're (pharmacists) not well-informed enough, to
make a decision on my patient, / mean, I will like have, sit down with
them and tell them all about this patient, this patient has this, that and the
other, but this, that and the other, so I mean it, it does take a long time it
would be easier if there was somebody there." (Registrar)
Some of the doctors reported prior experience of working with pharmacists and
commented that pharmacy involvement was better in other hospitals. When
asked about her experience of working in places with more pharmacist
involvement in patient care, a doctor said that in her previous workplace she
knew all the names of the pharmacists whereas here she doesn't, "I don't feel
that same sort of connection.... / don't feel it has much impact on what I'm
doing day to day."
Some doctors had experience of pharmacists reporting errors back to doctors
which they felt was valuable. The nurses also appreciated pharmacy
involvement on the wards, but again would like greater integration into the team,
pharmacists attending ward rounds, educating patients about their medicines
and coordinating discharge
4.3.3.2.	 Medicines safety
Many issues involving the safety of medicines use were raised by participants.
In section 4.3.3.2.1 participants views about errors are presented and then in
section 4.3.3.2.2 admissions due to medication problems are discussed.
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Concerns were raised about the competency of doctors and nurses in
therapeutics and these are presented in section 4.3.3.2.3 issues relating to
inappropriate prescribing of medicines are discussed in section 4.3.3.2.4.
Often safety issues arise when hospital policy relating to medicines in not
adhered to for example patients keeping medicines in unlocked bedside
cabinets. Pharmacists said that often doctors are unaware that patients are self
medicating and the medicines they are taking are not prescribed on the drug
chart. A pharmacist when asked to talk about medicines safety highlighted this.
"It does happen and they don't tell you that they've been taking their
favourite painkillers and leaving them in their handbag, on top of what
they're given in hospital. One lady, on ward 6 this week, didn't let on
she'd been taking her zopiclone, and she came in with respiratory arrest,
and yet the day after she took her own sleeping tablet out of her handbag
without telling anybody, 'til I sort of queried it. They ((the doctors)) were
quite horrified, she'd respiratory arrested and she was taking these
tablets." (Pharmacist)
4.3.3.2.1.	 Errors
When asked about issues relating to medicines safety, all participants
spontaneously said that errors frequently occur, and many of the doctors and
nurses seemed to accept it as an inevitable part of patient care. Some doctors
and pharmacists said that nurses sometimes administer medicines when the
prescription is illegible which can lead to mistakes. The nurses complained
about doctors' writing.
"They've (doctors) got to be careful how they're prescribing these things.
They cannot always just fob it off on the nurse, saying 'oh, well it was the
nurse that gave it, so it's her fault.' They've got to take responsibility for
how they're writing everything." (Ward Manager)
Doctors and nurses spoke very openly about errors and needed very little
prompting. Junior doctors said they often miss drug interactions and adverse
drug reactions, or start patients on contraindicated drugs. Some doctors, nurses
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and pharmacists said that doctors often forget to fill in the drug allergies section
of the medication charts and quite often people are given penicillin when they
are allergic to it. The nurses said that junior doctors sometimes confuse drugs
with similar names, for example one of the nurses described an incident in
which a patient had been prescribed sodium valproate instead of sodium
docusate, and received three days of the wrong drug.
When asked why errors occur doctors said they happen when drugs are being
transcribed for example, from one drug chart to another or to the discharge
prescription. They indicated drugs are sometimes continued when they
shouldn't be.
"Errors do happen, we had a patient on the ward last week who, Sando K
wasn't stopped for ages and he ended up with a really high potassium
and things like that which can be serious, but no one had picked that one
up" (House Officer)
Nurses said that they frequently give intravenous drugs without another nurse
checking them. One nurse said that the design of the current drug chart
reinforces this practice. She said that for intravenous drugs there is only space
on the drug chart to sign that it has been administered, with no space for a
second nurse to sign that they have checked it. She told me that she cannot
convince the nurses that they must have a second nurse check intravenous
drugs.
"It's going straight into a vein, it's highly dangerous, so it's, there, there is
obviously a problem within the Trust in actually seeing just how serious
this is." (Ward manager)
Many doctors, nurses and pharmacists said that when junior doctors first start
there are lots of medication errors and this was felt by most doctors and some
consultants to be part of their learning experience.
"it's mostly the house officers who make the mistakes obviously, and it's
all a learning experience, so I do try and let them know if they've done
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something wrong, just as part of their learning, but even/one's human
aren't they?" (Senior House Officer)
"Lots of minor things, dosages wrong, or wrong time, a classic one is
wrong time of day, people given frusemide at nigh 	 cholesterol things
in the morning and you know all those sorts of things, and that
happened a lot when we all first started, obviously because we'd never
prescribed anything before" (House Officer)
Doctors said that errors occur more frequently when they are tired, or short of
time. Several doctors, as indicated above, appeared to believe that mistakes
are inevitable, as for this doctor:
"You've often got 10 patients waiting to be seen, to be clerked in, and if
the GP's written the doses on, you haven't got, really got time to clad on
clarifying that.....and you know, it's not 'til a couple of days later
sometimes the mistakes are spotted" (House Officer)
When asked about medication errors doctors qualified them as 'minor' or
'significant', and appeared to be unconcerned about the 'minor' ones as long as
were spotted.
"Most people, if they've made a minor error, and it goes spotted or
something, then they don't think about it twice." (House Officer)
UTheres a kind of medical culture of 'Oh well that's only gone wrong
once, and it's not a major thing anyway, that's, that's kind of alright"
(Consultant)
When asked whether she feels that doctors rely on nurses to spot prescribing
errors a nurse said they do and that errors will therefore happen if nurses
haven't got an 'up to date' education. She recalled an incident where a nurse
successfully highlighted an error, although the doctor involved seemed
unconcerned:
"We had a patient prescribed, oh it was haloperidol, 50mg of haloperidol
instead of 5, and even when it was pointed out to the doctor, the doctor
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couldn't see the problem with that, so that's wonying, when an SHO
cannot see the problem with prescribing 50mg of such a powerful drug."
(Ward manager)
She said that the consequences of making mistakes should be stressed to
doctors and nurses, not just for patients but litigation and their own registration,
"I mean in some respects this Trust desperately needs one of those massive
court days."
The doctors also said that they treat the nurses as a safety net relying on them
to detect their prescribing errors. On the other hand, nurses said that they
receive insufficient training about therapeutics within the Trust, and therefore
may not notice prescribing errors.
"I mean from our point of view, I mean this might seem like a real cop
out, but whatever's prescribed we can give, unless it's like a glaring error
that we would notice." (Staff nurse)
Although all participants felt that it is important to investigate why errors happen,
they also said that mistakes are inevitable. Doctors who had been involved in
medication errors said that they were more cautious now, for example one
doctor who had prescribed penicillin to a patient who was allergic to it said that
she now checks whether a patient has drug allergies more than she would have
done previously. Despite acknowledgement that the Trust is trying to nurture a
'no blame' culture, participants said that errors are frequently not reported,
especially if they are deemed 'minor' and doctors and nurses are frightened to
admit to mistakes because they feel they will be blamed. One consultant said
that doctors aren't told about the procedures of reporting an error.
All participants felt that errors are taken more seriously by the nurses than
doctors.
"I think the nurses take an error very seriously, whatever it is because
they are the people who give out the medication." (Consultant)
276
Pharmacy staff said that nurses sometimes order incorrect medicines, and
sometimes prescriptions are illegible. They felt that the attitude of the doctors
and nurses when pharmacy staff highlight errors is blasé without consideration
of potential consequences. They said that some wards made more of an issue
of medication errors than others. It was felt that junior doctors get complacent
about making mistakes and they are protected by the system. They said no one
indicates that what they are doing is wrong and seniors do not set examples, as
confirmed by this consultant:
"I mean I guess in the end it is their (the junior doctors) prerogative to.. .to
get it wrong in the end." (Consultant)
4.3.3.2.2.	 Admissions due to medication problems
When asked about problems they encounter relating to medicines doctors and
nurses said that patients are frequently admitted to hospital because of
medication problems. They felt that a substantial number of admissions were
due to non-compliance with medication and re-admissions often occur because
discharge medication is not explained properly.
Doctors said that people are frequently admitted with heart failure due to non-
compliance with diuretics, or digoxin toxicity. Patients discharged on reducing
doses of medicines such as amiodarone are sometimes readmitted, having
misunderstood the instructions and continued taking three doses daily. Doctors
and nurses felt that if patients had a better understanding of their medication
admissions could be avoided.
Patients sometimes are admitted due to medication errors in nursing homes.
One doctor recalled a patient who was admitted from a nursing home with a five
times overdose of phenytoin and phenobarbitone. Her levels were highly toxic,
and for two days the doctors thought she had suffered a stroke, but realised it
was drug toxicity when results of her blood levels returned.
4.3.3.2.3.	 Competency of doctors and nurses
When asked about their knowledge of therapeutics many doctors said their
understanding was lacking in this area in particular dosages, adverse reactions,
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contraindications of drugs, drug interactions and special instructions for certain
drugs, and admitted they are 'hopeless at managing warfarin'. Consultants,
nurses and pharmacy staff reinforced this.
Junior doctors said they do not feel confident about prescribing. They said
medical students are not taught how to prescribe, and therapeutics constitutes a
very small part of the medical school curriculum. When asked how she felt
when she first started work, a Senior House Officer said, "I didn't have a clue, I
felt, you know, I mean we did pharmacology and things at university but that
was in the third year, so by the time you got to the fifth year you'd forgotten it
all."
"I can't even remember how much we did, but I think it was in the third
year we did pharmacology for a couple of weeks or something, and
you're supposed to be able to prescribe everything, so obviously it's not
really adequate training, and I think you just end up learning most things
on the job." (House Officer)
Junior doctors said that during their induction week they are only given brief
guidelines about how to prescribe, and how not to. They felt however, that they
are given so much information during this first week that they remember very
little. Doctors also felt that postgraduate training in therapeutics was lacking.
"I suppose the difficulty is we were told about them at the beginning, but
they tell you so much at the beginning that you only remember, it's
probably 5% of what they told you." (House Officer)
"I think it probably isn't that well taught, it's on an ad hoc basis more
often by consultants." (Consultant)
"When you think about, you know dwgs are basically the total
management of medical patients and it seems to be that education for us
in terms of drugs is really neglected." (House Officer)
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Doctors, nurses and pharmacy staff said that doctors frequently take inaccurate
and incomplete drug histories, and they always overlook 'over the counter'
medicines.
"Our juniors are notoriously poor at drug histories because they don't
have the time to spend but also they don't ask the right questions..."
(Consultant)
Doctors admitted that they rarely communicate comprehensive information
about medicines, and treatment plans to GPs.
"Sometimes when I'm writing summaries I forget to say, 'we definitely
stopped this, we meant to,' and I think sometimes GPs just go back to
what patients were on before because they think it's been an error, rather
than a definite decision, and I think I'm bad at being able to say that on
the discharge summafy," (Consultant)
When asked about reasons for prescribing errors doctors said that occur
because they sometimes do not check doses.
"A lot of doctors will just scroll down what they think the dose is, or what
it should be and just hope, which is sad really because there are enough
BNFs round the place, I mean it's not that difficult to use." (Consultant)
Nurses said that doctors do not take sufficient care when prescribing and often
there is insufficient information on prescriptions to enable medicines to be
administered.
When asked about problems they encounter, relating to medicines, pharmacy
staff said that nurses often do not supervise patients taking their medicine whilst
undertaking the drugs round, instead signing the drug chart indicating the
medicine has been administered, but tablets are placed in a little pot and left by
the patient's bedside. They said, sometimes for inhalers nurses write 'self'
under the administration record when patients do not have their relevant
in ha lers.
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"Quite often if someone is on more than one inhaler, they might have just
one of their inhalers, and the nurses say, 'have you got your inhalers?'
and they'll say, 'yes I've my inhaler,' but they haven't taken all of them,
then the nurses will sign for all three." (Pharmacist)
Pharmacists said that when patients are nil by mouth often important medicines
aren't administered when they could be. They claimed that patients sometimes
go home with medicines that were stopped during the admission because
nurses have not retrieved those medicines that patients brought into hospital.
Doctors criticised nurses, as they sometimes do not administer medicines, and
annotate the drug chart as 'no stock', or sometimes give no reason. Some said
they think nurses do not understand the importance of making sure patients
receive certain medicines and don't always ensure that medicines are obtained,
for example when pharmacy is closed they do not phone around other wards or
call in the on-call pharmacist.
"There's not perhaps so much understanding among the nursing staff,
what is and isn't important when it comes to medicines." (House Officer)
Pharmacy staff also recognised missed doses as a problem and said that
doctors are not always aware if a patient isn't receiving prescribed medicine.
"Things like missed doses, I think there's a culture there of, ?t doesn't
matter if a patient misses a dose.' The drug's not there on the ward so
they just think, 'we'll give it tomorrow" (Pharmacist)
4.3.3.2.4.	 Appropriate prescribing
Doctors admitted that they aren't good at reviewing medicines and are reluctant
to stop drugs.
"A patient came in today, he'd been on warfarin 15 years, he didn't have
a clue why, and no one else had a clue why either in his notes, people
had obviously just kept prescribing it because it's there and no one's
thought about it." (House Officer)
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When asked about reviewing medication, doctors said that generally they would
only attempt to rationalise the medicines that were pertinent to the problem with
which they were admitted. Patients sometimes continue to take drugs which are
not needed or inappropriate simply because no one thinks to stop them. Often
elderly patients are taking too many sedatives. Many participants said that
antibiotics, especially intravenous antibiotics are often continued too long in
hospital.
Some participants felt that sometimes patients are prescribed warfarin when the
risks may outweigh the benefits.
"Patients who have come in and they're blind and they're on warfarin,
you're like, 'how do you manage your warfarin?' and they go, 'well it's the
bottle which is difficult to open,' I'm like 'OH MY GOD' and you think
maybe this patient shouldn't be on warfarin, or someone else should
supetvise their warfarin taking." (House Officer)
Some participants said that when inappropriate medicines have been changed
during admission the GP often restarts them.
4.3.3.3.	 Enhancing the management of therapeutics
All participants were fully supportive of the service developments piloted in this
study. They felt that patient care would be improved if the service was
implemented across the Trust. In section 4.3.3.3.1, participants views on a
pharmacist taking a second drug history are discussed, and then in section
4.3.3.3.2 I discuss their views on a pharmacist undertaking a structured
medication review. In section 4.3.3.3.3 I talk about participants views on how
efficiency of patient care may be improved if pharmacists worked in the way I
did in this study. In section 4.3.3.3.4 I explore perceptions about how
pharmacists may expedite discharge and in section 4.3.3.3.5 I look at the role
pharmacists may have in enhancing safety. In section 4.3.3.3.6 I discuss a
theme related to pharmacists provision of prescribing guidance and focus on
therapeutics and section 4.3.3.3.7 examines the effect of pharmacists on the
cost of therapeutics. Section 4.3.3.3.8 is concerned with communication relating
to medicines and section 4.3.3.3.9 focuses on participants concepts of patient
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centred pharmacy services. Finally, in section 4.3.3.3.10 I look at concerns that
were raised, relating to the proposed service developments.
4.3.3.3.1.	 Drug histories
When asked if it would be useful if a pharmacist took an additional drug history
all participants felt that patient care would be improved as patients would
receive their usual medicines promptly and drugs would not be inadvertently
omitted. Doctors said that it would be a great help if pharmacists could decipher
patients' medicines following admission, and phone GPs when there are
uncertainties. As already highlighted, making sure patients receive their usual
medicines following admission is a significant problem within the Trust.
"I think a second drug history is a major advantage, in the cool of the
day." (Consultant)
I asked when the pharmacist drug history should be taken and some doctors felt
that this should be done on the admissions ward as then patients would receive
their usual medicines sooner. They said that sometimes patients wait several
hours to be seen by a doctor on the admissions ward.
"And by that time they've missed whatever regular meds they're
supposed to have had at say 2 o'clock, they haven't had, they don't get
them til six or something because we've not been around and often if we
don't get to them til after five and the GP surgery shuts so you can't even
ring the GP to ask about the meds, so having someone that could write
down their regular meds on their drug chart and bring it to us and say
can you sign these would be really helpful." (House Officer)
Other doctors felt the second drug history should be taken when the patient is
transferred to a longer stay ward, as patients may not have all the information
about their medicines if they have been rushed it and they may not know
exactly what they take.
Participants said that pharmacists would be better than doctors at obtaining
accurate and complete drug histories, as medication is their main focus. This
would also free up doctors' time to pursue other important clinical activities.
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Some potential disadvantages of pharmacists taking drug histories were
highlighted, for example problems may occur with very sick patients as they
must be assessed by doctors and their medicines sorted out very quickly. Most
felt that a second drug history was a good idea as it was a double check but
one pharmacy technician said this may be considered by some to be a waste of
time. Another pharmacy technician commented that elderly patients may get
confused if lots of people are asking them questions. On the other hand, some
participants felt patients may be more open with pharmacists than doctors, and
if they know they aren't receiving a medicine they should be, they are more
likely to mention this to pharmacy staff than busy nurses and doctors,
understood to be busier.
4.3.3.3.2.	 Medication review
Doctors and nurses were asked what aspects of having a pharmacist on the
wards would be helpful. Doctors felt that having a pharmacist present on the
wards and attending ward rounds would remind them to review medicines more
often. Having the pharmacist undertake a formal medication review would be
extremely useful, as doctors said that unless pertinent to the admission,
medicines are not reviewed.
All participants felt that patient care would be improved if pharmacists actually
investigated why patients are taking all their medicines, because the doctors
haven't the time to do this, which results in inappropriate medicines being
continued.
"Sometimes when patients come in, it's unclear what they're on, why
they're on certain things, especially why they're on certain medications if
they've been on them for a long period of time, and when you get elderly
people coming in with huge long lists of tablets and you want to know
which ones you can stop, I definitely think pharmacists could be involved
in deciphering why people are on medicines." (House Officer)
One of the consultants said that pharmacist review of medicines may be more
useful in areas other than general medicine, as within other directorates
medicines are not such a priority and are not reviewed at all.
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4.3.3.3.3.	 Efficiency of services
When asked about having pharmacists based on wards working closely with
doctors and nurses as I did in this project, all participants felt efficiency of
patient care with respect to medicines would be enhanced.
Pharmacy staff said that the study wards and wards with more pharmacy
involvement don't phone pharmacy as much with queries on prescriptions, and
this saves an enormous amount of time, '?t's already making a difference, but it
would be much better if it was the whole hospital" (Pharmacy Technician).
Duplication of work is reduced on these wards because communication is
better. All participants believed having a pharmacist undertaking the activities
piloted in this study, would free up doctors and nurses time for other important
clinical activities.
"I think definitely in patient care would be much better, plus / think the
doctors would concentrate maybe more on the patient, they would be
away from the prescription and things, so probably they would get some
more time to concentrate on the patients' management, so that would
make a difference" (Registrar)
"Because if you can free up some doctors time to do more clinics then
you'll cut their waiting lists...." (Pharmacist)
All participants felt that if patients had access to pharmacists they would not
need to ask doctors and nurses about their medicines. Having a pharmacist
working along side doctors and nurses would also mean that drug related
problems would be resolved more efficiently, as ward staff would have instant
access to somebody.
"Like sometimes if you ring pharmacy, it can take ages for somebody to
get back to you, whereas if they're there, you know you've got someone
on the case........ "(House Officer)
"If we were going to look them (drugs) all up, would just take hours,
because we're not so familiar all the time, especially at our level as we're
just junior, and pharmacists deal with them a/I the time." (House Officer)
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Doctors and nurses said that having a pharmacist on the ward rounds, adding
medication to the drug charts, writing discharge prescriptions and reviewing
medicines would speed ward rounds up greatly.
4.3.3.3.4.	 Expedite discharge
I asked participants about the potential effects having a pharmacist undertake
the activities piloted in this study may have on discharge of patients. All
believed the length of patients' admissions could be reduced, because of better
management of therapeutics and quicker discharge of patients.
"I think it may well shorten a person's stay in hospital, particularly if you
can sort of make arrangements quickly, for discharge, it might save a
day, in discharge, so I think it has potential for shortening the length of
stay." (Consultant)
Participants believed that processing of discharge prescriptions would be
quicker if pharmacy staff were intimately involved in the planning, as all the
appropriate information such as strengths of inhalers, and type of insulin, would
be communicated to pharmacy. Pharmacy staff could anticipate discharges in
advance and therefore ensure that discharge medicines are on the ward
sooner.
4.3.3.3.5.	 Enhancing safety
When asked about potential benefits if this new approach to pharmacy practice
was implemented throughout the Trust, all participants said that the risks
associated with medicines would be reduced. All participants felt that because
pharmacists would have more impact at the point of prescribing, there would be
fewer errors and less unnecessary prescribing.
All participants felt that if pharmacists wrote discharge prescription there would
be fewer errors. When asked if it would be helpful for pharmacists to write
discharge prescriptions, a nurse said:
"Particularly this past week where I've had two scripts written by the
doctors that have been incorrect, if I had a pharmacist doing it, I would
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feel more safe that that script was being written coffectly." (Ward
Manager)
When asked how safety relating to medicines could be improved all doctors and
nurses felt that errors could be reduced if pharmacists reported them back to
medical staff, although they emphasised that the approach must be non-
confrontational to avoid antagonism.
"it is just helpful having someone to point it out, cause often perhaps
you're off duty by the point it's spotted and one of the nurses have said,
"ooh there's something odd, someone's prescribed this tds you only get it
bd," and it's just changed, it would be helpful if someone said, 'right well
any mistake of that nature need to be handed back to the person, who
ever it is, whether it's a consultant, " (House Officer)
"I think that would be valuable, because I think we've all made mistakes
and if someone stood there and said, 'look this week I went to ward 5
and spotted 15 mistakes in one day,' I think everyone would turn around
and go, '15 mistakes in one day, you know that, that's fairly significant,'
I mean you don't necessarily have to name names" (Senior House
Officer)
Some suggested a newsletter reporting common problems, and high risk areas.
When asked how they would feel about educational sessions led by
pharmacists, all doctors and nurses said these would be well received.
Participants suggested that these could include anonymous examples of
frequent mistakes, serious errors, and errors that have occurred in other Trusts.
Within these sessions, doctors and nurses could be invited to examine the
processes and systems within the Trust relating to medicines, and explore ways
of preventing errors.
"Maybe the pharmacist on the ward should keep a list of all the mistakes
that have been made and once a month, have a meeting with the junior
doctors and discuss how things could be different, what mistakes were,
why, how, when, what should have been done etc, and that way they can
learn from their mistakes." (Senior House Officer)
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A consultant warned that feedback of errors should be not so infrequent it
doesn't make any difference and not so frequent that people actually saturate
and turn off, and it should be relatively hard hitting.
With greater pharmacy involvement in patient care all participants felt that errors
could be identified and rectified sooner.
"Patients would get the optimum treatment because mistakes would be
rectified sooner." (Senior House Officer)
Junior doctors said they would greatly appreciate having a pharmacist checking
their prescribing.
". . .. to spot the odd error that we make, dosage wise or interactions wise,
and things on the chest ward particularly, things like antibiotics
interacting with theophyllines and all those sorts of things that we always
forget about." (House Officer)
"There will always be a role for a pharmacist in doing that kind of double
checking, because as much as you can say to a doctor 'you mustn't
make any errors' it happens and you need someone e/se, because there
will obviously be times when nurses not aware of what a correct dose is
or whatever..... " (Senior House Officer)
When asked about specific areas in which pharmacist could improve medication
safety, doctors and nurses identified warfarin management, in particular,
monitoring and prescribing during admission, identifying patients at risk of
adverse effects, educating patients, and coordinating management
arrangements following discharge. It may be that they said this simply because
it is an aspect of their job which they dislike, although my own experience and
ethnographic data confirm that this is an area of patient care that is particularly
badly managed by doctors and nurses.
Many participants felt the risks associated with patients taking medicines
incorrectly would be reduced as patients would receive more comprehensive
education about their medicines and this may lead to fewer re-admissions.
287
Because of the risks associated with drug therapy in hospital and the benefits of
the pharmacy service developments which were demonstrated in this study,
one consultant said it would be detrimental not to implement this throughout the
Trust. He said that patient care would be improved because pharmacists would
assume greater ownership of care with respect to medicines, than doctors and
nurses do.
The ward manager interviewed felt very strongly that the culture towards
medication errors within the Trust must be changed. She said that there needed
to be 'champions for the cause', going out and drumming the message home to
doctors and nurses. She talked about the new policy for the prescription, supply
and administration of drugs which is about to be published.
"It really needs for the drugs policy to be explained verbally, rather than
just giving out drugs policy to a ward and saying 'read that, go away',
because everyone will just carry on what they're doing. We need to go
out to the wards, explain it, all the reasons behind it." (Ward Manager)
4.3.3.3.6.	 Prescribing guidance and focus on therapeutics
Pharmacy staff said that if they were based on wards, providing patient centred
pharmacy services they would have greater impact on prescribing, with more
significant interventions into patients care. They felt prescribing advice would be
proactive rather than reactive as it is with standard pharmacy services.
When asked whether they would find it helpful having a pharmacist working on
the wards, doctors and nurses all welcomed the concept, in particular to offer
advice about choice of therapy, drug dosages, administering and prescribing
drugs they are less familiar with, and the drugs formulary. They said having the
pharmacist 'on-tap', actually working on the wards would be a huge advantage
and doctors and nurses said they would be more likely to ask for advice.
"I mean, just an external agency who knows what they're on about is
useful, flagging things up, any inaccuracies but also potential benefits of
doing something, and we can take it or leave it you know, but it's great
having that extra input." (Consultant)
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'When you've got a fairly clear diagnosis but the best treatment for it is
in doubt in the sense that there are a number of things that you can use,
and maybe some things that we haven't even heard of, and it think in that
sort of role, choosing between things, that's where a pharmacist could
really help." (Consultant)
"if they're on the ward then you're more likely to ask their advice about
maybe things that you hadn't used before, you feel more able to talk to
them and discuss it rather than, I mean certainly here I have phoned up
the pharmacy a few times about things but you just feel more able to, to
ask their advice if they're there in person." (Senior House Officer)
Of course, those interviewed may have simply been saying what they thought I
wanted to hear, although when I was working on the wards the doctors and
nurses did appear to appreciate having me there a resource for advice about
therapeutics.
When asked if pharmacists should be based on the wards working as part of
the team most doctors felt this would be beneficial as pharmacists would know
the patients, therefore prescribing advice would be more useful.
uHaving someone that knows the patient on the ward and knows the
situation. I had a patient recently who had veiy complicated, antibiotic
regimen to go home with, lots of IV antibiotics and all that sort of thing, so
having someone that knew the patient and knew what was going on
would be very helpful." (House Officer)
"If you had a person allocated to your ward, available for questions, and
the person knows the patients because they work on the unit and they
see them, and you ask their advice, rather than having to speak to some
stranger on the phone, who doesn't know the patient, doesn't know what
the problems are and having to go thmugh the whole history, / would see
that as a major advantage...." (Registrar)
Some participants felt it would be beneficial to have a pharmacist responsible
for the medicines to ensure continuity of care as many different health care
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professionals will be involved in a patient's care throughout the admission and
patients may be transferred to different wards.
"I think it is important to have someone whose sole job is that, you know,
or at least someone who's a lead in that.....and that is your only goal, it's
a priority to you, it won't be a priority to the nursing staff, cause they've
got ten other priorities, and now that the Juniors' hours are down, their
priorities are very different." (Consultant)
"On the ward rounds I was happy when you'd done the discharge paper
because someone with time to focus does it properly, you know, the
juniors are swapping, they're going to emergency ward, they're on nights,
they've just been on days off, I mean it's a nightmare, you never know
quite who you'll see on the ward round. The only continuity these days is
senior staff." (Consultant)
Consultants said that it was important to have the specialist knowledge of
pharmacists available to doctors and nurses, and the need for pharmacist input
into patient care equated to that of occupational therapists and physiotherapists.
4.3.3.3.7.	 Cost of therapeutics
When asked about the economic implications of pharmacists working in the
manner proposed in this study, most participants believed that the costs
associated with therapeutics would be reduced. They felt that savings would be
made for the Trust and for GPs through more effective use of patients' own
medicines brought into hospital, minimisation of wastage and more rational
prescribing.
"I think it would save money, especially people that are on expensive
drugs like lansoprazole and they don't need to be on it and antibiotics
that they've had for too many days, especially IV antibiotics are a big
problem and prescribing the wrong antibiotics, al/that sort of thing, it
would save an awfullot of money, I'm sure." (Senior House Officer)
Some participants also said that by reducing the risk of errors, the Trust would
reduce the potential litigation and the associated costs.
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"We need to think about if there were any major problems, you know, a
patient was prescribed inappropriate medication and suffered as a result,
the cost implications of that" (Pharmacist)
When asked whether they thought the proposed pharmacy services would be
cost effective most participants felt they would be as readmissions would be
reduced through closer involvement of pharmacists in patient care, and cost
savings would therefore be achieved.
"10% of admissions are due to drug related problems as cited by several
articles, If we could for example prevent half of these, so 5% of these
admissions are avoidable by improving compliance or avoiding drug
interactions, making sure patients are taking their medicines properly.
For example in this trust last year there were 15,000 admissions, with
each admission on average cost 350 pounds per patient per week. If 750
of these admissions, which are 5% could be avoided, we would save
262,500 pounds. That makes having pharmacists doing this kind of work,
cost effective." (Consultant)
"If you talk about it in terms of preventing the revolving door syndrome,
then it's definitely cost effective having pharmacists working like that,
definitely." (Staff Nurse)
One consultant however, said that he was unsure as to whether money would
be saved in terms of drug costs, as pharmacists, as well as stopping
inappropriate medication, would be unearthing drugs to be added to patients'
therapy which wouldn't have been prescribed otherwise, through obtaining
accurate drug histories. He said however, that overall, the Trust would save
money through avoidance of medication related problems.
Another consultant felt that the money would be saved as the length patients'
admission could be reduced with greater pharmacist input into care.
4.3.3.3.8.	 Communication
When asked about the value of having a pharmacist involved in the discharge
process all participants felt that communication about medicines to GPs would
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improve. They felt that this might help prevent GPs reverting to the medicines
patients were taking prior to admission, when they have been changed in
hospital and GPs would have sufficient information to follow the treatment plan.
when asked about communicating information to community pharmacists some
felt that in some circumstances this would be useful.
All participants spontaneously said that communication about medicines
between all the health care professionals involved in patients' care would be
improved with closer pharmacy input at the ward level. Attendance of
pharmacists at ward rounds, and working as part of the team was felt to be
extremely important for communication. Documentation about medicines would
be improved if pharmacists were involved. Communication between ward and
pharmacy staff would be better, which would enhance the contribution of
pharmacy staff to patient care, and increase the efficiency of services. This
would also improve intra-professional relationships as there would be greater
understanding of the pressures different staff are under.
4.3.3.3.9.	 Concepts of patient centred pharmacy services
When pharmacy staff were asked at the beginning of the focus group what they
considered 'patient centred pharmacy services' to comprise, most were vague
and unclear in their answers. Answers included:
"Making the patient the number one priority so that they get the best
service" (Pharmacy Technician)
"I think you have the patient, and all the services go to the patients."
(Pharmacy Technician)
"That there's more focus on the patient, you're doing it more for them."
(Pharmacy Technician)
"Patients having involvement in their own care." (Pharmacy Technician)
"Trying to locate things around the patient so the patients aren't moved
around the hospital too much, just a more flexible approach so that
292
setvices kind of go to patients, rather than having them transported
around the hospital for various different things." (Pharmacist)
Some pharmacists identified some key activities which matched my own
concept of patient centred pharmacy services, such as educating patients,
taking drug histories, working in teams alongside medical staff, pharmacy staff
based on wards caring for patients throughout their admission and coordinating
the medicines aspects of discharge.
All participants were aware of the work I had been undertaking on the wards
and with probing, they began to explore how pharmacy services could be
developed. All felt that patient care would be improved if pharmacists took drug
histories, reviewed medicines, wrote discharge prescriptions, participated in
ward rounds, advised on prescribing, and liaised with GPs. Technicians said
that efficiency would be enhanced if they were responsible for ordering all drugs
on the wards, as there would be less duplication of work. Pharmacists said that
they should be proactive rather than doing everything retrospectively, and that
they should be able to prescribe certain medicines such as laxatives, analgesics
and warfarin to improve patients' access to medicines.
When asked how they would like to see pharmacy services developed the
consultants said they would like pharmacists to undertake all the activities
piloted in the study: taking medication histories, reviewing medicines, educating
patients, advising on and monitoring prescribing, attending ward rounds, taking
total responsibility for medicines aspects of discharge, communicating
information relating to medicines to GPs, reporting errors and feeding back to
staff, and educating doctors and nurses about therapeutics. Pharmacist
involvement throughout the entire patient journey was considered by all to be
really valuable. They said that pharmacists ideally should be more visible and
have a presence on wards.
The doctors and nurses echoed the consultants' views. The junior doctors were
particularly keen that pharmacists were closely involved and familiar with
patients so they could offer useful patient specific advice. They also would like
pharmacists to take over warfarin management, write discharge prescriptions,
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sort out other medication issues such as compliance aids, and ensure drugs are
available on the ward in a timely fashion. Nurses wanted pharmacy technicians
to order alt drugs for the ward. Most importantly, all participants felt that
pharmacists should be integrated into the ward team to maximise their input into
patient care.
It may be however that doctors and nurses simply want to do less of the work
they don't enjoy, hence state they would like pharmacists to undertake these
activities.
4.3.3.3.10. Concerns about suggested service developments
When asked about potential problems with the proposed service developments
a number of participants raised concerns. One technician felt that if she was out
on the wards, she would miss out on what was happening in the pharmacy.
"I personally feel that if I was out all day on the wards, I'd miss out on a
lot in the dispensaty, just the general goings on, you'd miss what was
happening"
A pharmacist pointed out that patients experiencing these enhanced pharmacy
services would then have high expectations and may be dissatisfied if they are
re-admitted to either this or another hospital and the service is not the same.
Pharmacists felt that in order to get support for patient centred pharmacy
services it was necessary to actually highlight how bad things were, and they
feared this might upset people.
Some of the junior doctors said that it would be more useful for pharmacists to
attend only the consultant ward rounds as when they do ward rounds alone,
they make few changes to drug therapy. One consultant felt that it was not
always necessary for pharmacists to attend ward rounds, as long as there were
regular communications between doctors, nurses and pharmacists.
A concern about pharmacists pre-empting discharge and writing discharge
prescriptions in advance was that sometimes prescriptions were amended at
the last minute.
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"the problem is if you change things at the last minute, cause quite often
we change things at the last minute, make fine tuning"
(House officer)
One doctor identified a potential disadvantage of pharmacists taking over
anticoagulant management. When doctors are arranging for INRs to be
checked, they often coordinate this with other blood tests if needed, so the
patient does not have many separate blood tests. If pharmacists were arranging
the INRs and not liaising with doctors, patients may end up having many blood
tests separately.
Doctors, nurses and pharmacy staff expressed concerns that junior doctors may
not use their extra time usefully if pharmacists were carrying out the activities in
the study. Some felt that it was important that doctors do not become lax in
prescribing and rely on pharmacists to detect all their errors.
"Maybe they wouldn't think about what they were doing as much as we
do now, you know, 'does this drug interact with that drug,' and 'should I
be reducing this in renal failure,' you know, maybe they won't be thinking
about it as much..." (Registrar)
Another potential problem with the proposed service developments highlighted
by participants was deskilling of staff. Some pharmacy technicians felt that if
they were to undertake more ward based activities they may lose other 'core'
skills such as those for dispensing and aseptics. There were also concerns
about deskilling of doctors and nurses if pharmacists undertook more activities
traditionally carried out by them. Pharmacy staff stressed that doctors still need
to learn how to prescribe and manage drug therapy.
Some pharmacists worried that doctors may just leave jobs such as drug
histories, until a pharmacist is around, which may result in delays in patients
receiving their medicines.
4.3.3.4.	 Educative role of the pharmacist
Providing education about therapeutics was viewed as a major area in which
pharmacists should become involved and doctors, nurses and patients would all
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benefit. In section 4.3.3.4.1 participants views about relationships between
patients and healthcare professionals are discussed and any potential
advantages for patients if pharmacists had greater involvement in their care. In
section 4.3.3.4.2 views about health literacy of patients are presented and in
section 4.3.3.4.3 pharmacists' involvement in patient education are discussed.
Finally in section 4.3.3.4.4 participants opinions about pharmacist involvement
in education of doctors and nurses are examined.
43.3.4.1.	 Patient healthcare professional relationships
When asked about advantages for patients, in having pharmacists working on
the wards some participants said that patients are more likely to approach
pharmacists about medication problems because doctors and nurses are
perceived to be busier. In addition patients could build up a relationship with the
pharmacist and this would encourage them to ask questions about their
medicines.
One consultant said that many patients would prefer to hear information from a
pharmacist rather than from a doctor, as often patients don't believe what she
says, or don't listen. Another felt that older people fear doctors. One consultant
said that he felt patients would be more open with pharmacists about
compliance issues, and that problems may be uncovered through close
involvement of pharmacists in patient care, that otherwise might not have been.
"I got the impression that the patients had been much, much more
honest about compliance issues to you, than the doctors, which was
revealing in a number of instances"
4.3.3.4.2.	 Health literacy
Participants felt that most patients were not knowledgeable about their
medicines, in particular their purpose. When asked what they think patients
need to know about their medicines some doctors agreed they do need
information but were sceptical about the value of this.
"I think they need to know basically why they're on what they're on, but
most patients that goes in one ear and out the other.....others just don't
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want to know, and there are some patients that are hopeless and just
won't remember what you've said or are confused and therefore not
appropriate to talk to," (House Officer)
All participants felt that the level of information given to patients should be
tailored to individuals, although doctors said they do not have time to assess a
patient's level of knowledge or understanding.
Doctors said that patients often claim they have allergies, when in reality they
don't, or they have suffered a side effect of a medicine and incorrectly
categorised it as an allergy. Pharmacy staff said that often patients don't regard
some of their medication as drugs, for example, eye drops, inhalers, alternative
medicines and over the counter drugs, and therefore fail to tell doctors when a
drug history is taken.
One nurse said that the traditional system of managing medicines in hospital
has an adverse effect on patients understanding of their medication. Patients
are disempowered and the system does not help patients gain an
understanding of their drug therapy.
"a patient comes into hospital, and they have been self medicating for
years, and suddenly they have all their medication taken off them, they
might be in for a few weeks, even a few months, and we dish out the
tablets, we don't tell them what they are and we just put them in front of
them and then all of a sudden we send them home and expect them to
do it again, plus there might be new ones or they might be having
different strengths of the ones they've been on before, it's bound to be
confusing, and I think it's vital that they know, they maybe don 't need to
know exactly how it works or what it does or what it interacts with, but
they need to know what it's for, what the dose is, when they should take
it and why they shouldn't take what they were taking before, because /
think if patients don't know what tablets are for then they're not going to
take them." (Staff Nurse)
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4.3.3.4.3.	 Educating patients
When asked about pharmacists' role in educating patients about their medicines
many doctors and nurses felt that pharmacists are therefore the ideal people to
do this as they have greater knowledge in therapeutics
"If the medicines are described by somebody from the pharmacy to the
patient, it will be more authentic and genuine as well, from someone who
knows about the drugs much more than someone who has not much
idea about that, and I think the patients would feel better about that as
well." (Registrar)
"If the patients had any worries about their medication they can ask
pharmacy staff 'cause the nurse might not necessarily know, which is a
benefit to the patient and also to the doctors and nurses because they're
(patients) asking pharmacy direct...." (Pharmacy technician)
Some participants felt that educating patients should be a corroborative effort by
pharmacists, doctors and nurses, '?t has to be kind of two way process in terms
of pharmacists doing more, but us also being aware of the importance of it, and
doing more." (Senior House Officer)
Doctors and nurses felt that pharmacists could have a particularly important role
educating patients about more complex therapies, such as warfarin.
"That's something else that pharmacists do very well that we're rubbish
at, is the warfarin counselling, I mean, you know I've never had any
training in warfarin counselling, we just make it up as we go along, going
through the little book and that saves us ages (of time), 'cause some
patients have a million and one questions." (House Officer)
Some participants recognised the importance of reinforcing medicines
education whenever possible, in particular for 'revolving door' patients who have
frequent admissions because they aren't taking their medicines properly.
"They need counselling every time you have contact. . .you need to pass
something positive on to them every time you have contact with
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them......so if they can remember another thing when you've seen them
that day...." (Pharmacist)
Pharmacy staff felt that patient compliance with medicines could be improved if
they were based on the wards, and actually observe how patient manage their
medicines. For example some patients cannot take Sando K as it burns their
throat, but doctors and nurses often aren't aware of problems such as this.
Pharmacists could also assess which patients are appropriate for compliance
aids, educate patients and their carers, and coordinate arrangements for
discharge.
Some participants felt it was important not to overload patients with information
about medicines as this may be counter productive. If pharmacy staff were on
the wards they could educate patients throughout the admission, instead of the
patient being bombarded with information immediately prior to discharge.
"If you had a pharmacist working with you could spend time explaining
exactly what the tablets were for, whenever you're giving the tablets and
therefore it's not just a huge big shock, at the end of the hospital stay,
'right you're on your own now" (Staff Nurse)
A number of participants said that more time should be spent educating patients
with cognitive impairment, and relatives and carers of patients. Some people
thought that pharmacy staff should get involved with structured patient
education, such as talks or seminars to patients about rehabilitation following a
heart attack.
4.3.3.4.4.	 Educating Drs and nurses
When asked how pharmacists might help doctors and nurses, participants said
that by anticipating and highlighting adverse drug reactions and interactions,
and flagging up prescribing errors their practices relating to medicines would be
improved.
"When someone brings up an issue with you and discusses it, you're far
more likely to remember it and take on the in formation, because there's
no way we can sit down and memorise eveiything, but when you're using
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it in practice and when people are highlighting issues to you, you do tend
to remember it the next time you come to prescribe something." (House
Officer)
Participants felt that pharmacy led provision of therapeutics education and
support, along with pharmacists working with doctors and nurses daily on
wards, would promote the safe use of medicines and could have a huge impact
on the culture towards medicines within the NHS.
"You are hopefully going to be instilling into them, habits of a lifetime that
they're going to take forward and then when they are specialist registrars
or GPs or consultants, they will, they will feed on to their own juniors, so
it's something, as much as anything, you're doing for future generations."
(Registrar)
Some doctors said that they would appreciate a resource pack on each ward
with information and protocols relating to prescribing in specific patient groups,
for example patients admitted with respiratory or gastrointestinal conditions, or
elderly patients. Many doctors felt that the Trust should have a prescribing
guide, which includes prescribing protocols for medical conditions they are likely
to encounter, giving them the drugs to use, the dosage and the duration.
Some junior doctors and nurses also said they would appreciate guidance in
what to tell patients about their medicines. They said that if pharmacists are
physically on the wards, they would be more likely to use them as an
educational resource.
"There are many different types of tablets, and many different types of
patients, so it would be great to refer back to a pharmacist on the ward
on a regular basis......" ( Registrar)
Pharmacists felt they could educate doctors and medical students to prescribe
effectively. They felt it would be useful if student doctors and nurses spent a
small amount of time in pharmacy to improve their understanding of the service
and enhance intra-professional relations.
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4.3.3.5.	 Changing practice
From the interviews and focus groups, many issues were identified that could
influence the proposed development of pharmacy services across the Trust.
These are summarised below under various headings. In section 4.3.3.5.1
issues raised about resources are examined and in section 4.3.3.5.2 I present
views about how interprofessional relationships might influence development of
services. I section 4.3.3.5.3 matters relating to competency of pharmacy staff
are discussed. I move on to talk about participants view on how change might
be facilitated within the Trust, to enable development of services in section
4.3.3.5.4, and then in section 4.3.3.5.5 I discuss the practical aspects raised, by
participants. In section 4.3.3.5.6 views about the professional aspirations of
pharmacy staff are examined and finally in section 4.3.3.5.7 I talk about issues
raised relating to roles and professional boundaries.
4.3.3.5.1.	 Resources
When asked about barriers to implementation of the proposed service
developments throughout the Trust, resources were felt by many participants to
be the principal inhibitory factor. Pharmacy staff worried that moving more
pharmacists and technicians to wards would leave too few staff in the pharmacy
department to carry out the 'core' pharmacy functions of supply and aseptics.
They said that the activities piloted in the study could not be implemented
across the Trust, with current staffing levels. Pharmacists felt that although
there would be cost savings made through better management of medicines,
the financial implications of employing more staff must be considered. They
believed however, that implementation of this approach to pharmacy practice
throughout the Trust would reduce workload on the dispensary and improve the
efficiency of services.
Some participants said the cost implications of not providing the services should
be considered, for example drug errors, inappropriate prescribing, adverse drug
reactions, and readmissions because of medication problems, although this is
extremely difficult to quantify.
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Most believed that there are insufficient resources available in the Trust to
invest in pharmacy services, and other areas are likely to be given priority.
Some felt that the trust may only invest in the proposed services if they involved
a considerable reduction in costs.
"If you reduce the drug budget, or save them having a major litigation
case you know, you might stand a chance of, of putting the thing into
practice." (Consultant)
The consultants said that resources within the Trust are limited and although
doctors' and nurses' time would be freed up through implementation of the
services piloted in the study, investment in such services would unlikely be
instead of more doctors and nurses.
"A ward based phaimacist could be totally responsible for the discharge
of the patient, in terms of tablets......and that would release that staff
nurse who's in short supply anyway for some other role.....I would place
that highly if I thought it was going to take off pressure fmm the existing
staff, but I don't think I could support a pharmacist per ward if I still had
too few staff nurses or junior doctors, because the overlap between jobs
wouldn't be that great whereas the nurses are allowed to give out tablets,
discharge patients, phone social workers and all the rest, you would not
be taking on some of their role, other than the medication role...."
(Consultant)
4.3.3.5.2.	 Interprofessional dynamics
When asked about potential interprofessional problems, a number of pharmacy
staff felt that some nursing staff may not want them encroaching on what they
perceive is their territory. They said some doctors and nurses may think
pharmacy staff are interfering or criticizing them, but others would see them as
a valuable part of the team. Pharmacy staff felt that some doctors look upon
them as 'nit pickers', or having a sort of policeman role for medicines use but
this might be improved with greater integration into the medical team.
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"You've got this sort of monitoring, teacher, policeman role, of like you
know marking the kardex, ticking the boxes." (Pharmacist)
"You'd probably feel part of the clinical team more, rather than just the
policeman who comes around and, you know I get upset when the
doctors say to me, 'have you spotted any errors?' and I hate that, It gives
the impression that al/I'm doing is picking on them, and, you know, that's
the last thing I want to do." (Pharmacist)
It was felt by a number of pharmacists, that to be fully accepted as part of the
medical team and to provide the best care for patients, the working hours of
pharmacy staff should be more in line with other healthcare workers in the
Trust. The current services run from 8.3Oam until 5pm at night, with an on-call
service for supply of appropriate medicines, and medicines information.
We won't be accepted fully until we're like in the same boat as, you
know if the doctor sees you on the ward at 10 o'clock at night, when he's
on the ward, or she's on the ward then, they'll be much keener to kind of
welcome you as an allied profession, cause if they think, 'I suppose
you're in the same boat.' I think at the moment they think 'oh well, it's
a/right for you, you're on your way at 5 o'clock, you don't know what
you're on about"
Some pharmacy staff also said that patient care would only be improved if GPs
were prepared to listen, because changes made to drug therapy must be
continued following their discharge.
Some pharmacists felt that the doctors and nurses are not actually aware of
what pharmacy staff do either on the wards, or within pharmacy and intra-
professional relationships would be improved with greater understanding. Most
pharmacy staff believe that medical staff would vary on their uptake of the
service developments and there are some consultants that they would not wish
to approach.
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Many doctors and nurses said that pharmacy staff must emphasise they are
there to help doctors and nurses, and they should be careful and non-
threatening in their approach.
"Some people may feel threatened by an outside person coming on to
the ward; they may feel that they are picking out their mistakes. So it is
important to let them know that you're there to help them and you are not
witch hunting." (Consultant)
"Don't treat the doctors like idiots. In a previous presentation, the
pharmacist was talking about how to write prescription charts, and was
telling the doctor to print their name out in capital letters under the
signature, and the doctors were saying to me afterwards 'of course we
know that, the pharmacist was treating us like idiots" (Consultant)
"It's a threat to them, they're tiying to prove that they know these things
and they don't want to have the thought of somebody coming up and
saying, 'actually you've got that wrong,' so where at the moment they
may be seeing it in a negative viewpoint, it's a case of changing that
round so they can see the positive sides to that where the pharmacist is
actually there helping them to grow in their knowledge of pharmacy and
drugs." (Ward Manager)
The consultants felt that it would be important to get it across to doctors that
pharmacists are an added layer of protection and an added layer of service for
the patients, and communication should be non-confrontational. Participants
acknowledged that some medical staff may not welcome assistance in
therapeutics from pharmacy staff and that the degree of appreciation would
vary. Some doctors may feel they are losing some of their 'power', or having
their decisions questioned, or losing freedom to choose what they prescribe.
Junior doctors may appreciate advice about therapeutics and having their
prescribing monitored, as they have limited experience, On the other hand
however, they may feel threatened, defensive or humiliated, or feel that they
ought to know more about therapeutics.
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"My guess is their (junior doctors') insecurity breeding a degree of
arrogance and assuming they know everything, most of them will
anyway, it is a problem, done it myself at times" (Consultant)
"yes.. .a deg.ree of who are you2.... you k'iow I am the medic. - .1 am
omnipotent... .1 know eveiything. . i don't need anyone else to tell me
what to prescribe, I have decided, therefore it should be given, sort of
approach from some of the juniors. . .one or Iwo consultants as welL"
(Consultant)
One consultant talked about the negative effect of publicity about medication
errors (Audit Commission, 2001), on doctor— pharmacist relationships.
"The publicity from that report that has been on the radio, doesn't help
pharmacists............., it is painting doctors in a bad light. Basically what
they are saying is that the pharmacists are going to clear up after these
terrible doctors, when really this just gets doctors' backs up, and it is not
the best thing to do."
All participants felt that the senior staff must be supportive in order for junior
medical staff to alter their prescribing habits based on pharmacy involvement
and if there were problems with junior staff, senior staff should address these.
Many participants said that doctors and nurses would start to depend on
pharmacy input as they do speech and language therapists, dieticians,
occupational therapists, or physiotherapists involvement, however sometimes
pharmacists are perceived to be 'pedantic' and obsessional about drugs, which
can be irritating for medical staff.
Overall, the medical staff felt that patient care would be improved by having
pharmacy staff working along side them on the wards, and they anticipated very
few problems providing communications were good and pharmacists were
sensitive in their approach. This integration of pharmacy staff into the medical
team was felt to be critical in changing practice, and to implement truly patient
focussed care professional boundaries must be crossed. Doctors also said that
they would be happier to take advice or even criticism about their prescribing if
they had this kind of relationship with pharmacy staff.
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"Everybody must be focussed on the patient reduce the boundaries of
hierarchy, you know, this is your job, that's my job, keep out of my way,
whatever, and if we're to be serious about the concept of patient
focussed care, people have just go to get over it, and if, if doctors do
have a bit of a problem with that, well tough." (Staff Nurse)
4.3.3.5.3. Competency of pharmacy staff
Although doctors and nurses could see advantages of the proposed activities, in
the focus groups, pharmacy staff actually expressed concerns about their own
competency. Pharmacists said they wanted to work in the manner proposed in
this study, but some questioned their own ability and knowledge. When asked
about education requirements, pharmacy technicians said they would need
more training about therapeutics, such as drug interactions, counselling patients
about their medicines. It was felt that training requirements should be
continually reassessed as this would alter as pharmacy staff take on new roles.
Even after training some technicians felt they may not be able to undertake
certain activities for example taking drug histories, coordinating discharge
arrangements, providing medical staff with medicines information, dispensing
unsupervised. All pharmacy technicians were unwilling to have ultimate
responsiblity for medicines aspects of patient care.
"From a personal point of view, I just don't feel I have a deep enough
knowledge, and I don't feel that I ever will unless I go back to college and
do a degree in pharmacy. Yeah and I don't feel / will ever have a deep
enough knowledge to have the confidence to like check every
interaction." (Pharmacy Technician)
All participants said that written procedures should be produced detailing the
activities to be undertaken and technicians always want the ability to refer back
to a pharmacist, when necessary. They also said that they would need practical
knowledge of what actually happens on the wards, as many don't have this
experience.
"It's about having the background knowledge, but also not just on clinical
stuff and drugs but also what goes on, on the ward, I feel that I'm very
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ignorant of what, I've never been on.......the wards" (Pharmacy
Technician)
Some pharmacists said they would not feel comfortable with reviewing patients'
medicines with their current level of knowledge, especially pharmacists who had
been qualified longer as they felt pharmacy training was less clinically
orientated in the past. Some pharmacists felt that although they had undertaken
a postgraduate clinical diploma, because they had not used it in their everyday
work they had forgotten it.
Pharmacy staff felt that the best method to improve their knowledge and
confidence was through mentorship, whereby they work on the wards along
side more experienced colleagues to learn about therapeutics, and the
provision of patient centred pharmacy services. Mentorship should be a
continuous process and pharmacy staff also felt they would learn and gain
experience through actually working on the wards. No pharmacists had
experience of this type of mentorship, but all felt it would be advantageous.
When asked how they felt about taking on new responsibilities, some
pharmacists appeared not to have the confidence to participate in ward rounds,
as they fear how they will be viewed by doctors. Some pharmacy technicians
said they would not have the confidence to interact with doctors and nurses.
When asked their views about the proposed activities doctors also recognised
that there would be training needs for pharmacists. Some consultants worried
about intra-professional variation between pharmacists.
"You (referring to myself) were very dedicated and fitted in very well on
the wards. You wanted the project to work and to be successful. Will
everyone else who comes along afterwards be this dedicated? Other
people may have different personalities and may not integrate into the
ward team as effectively." (Consultant)
"Some may not want to take on this additional role because they might
feel that it is not something they're trained for, advising and seeing
patients might feel quite alien to them." 	 (Consultant)
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Consultants felt that pharmacists often lack empathy with patients, and this may
be a reflection of minimal patient contact in their training. They commented that
pharmacists do not seem to feel comfortable on the wards.
"The only criticism I do have of pharmacists is that they, a lot of them
seem very remote to the patients they're trying to treat with medication,
it's, it's as if the patients are almost not part of the equation, they're
almost more focussed on the drugs than they are on the people taking it,
and I think that just reflects lack of training."	 (Consultant)
It was suggested that the undergraduate pharmacy degree should involve more
training based on wards and working with patients.
4.3.3.5.4.	 Facilitating change within the Trust
When asked about uptake and acceptance of the proposed change in practice
participants felt that inevitably some people would be reluctant. Pharmacy staff
said that they would support the practice changes as long as they were fully
informed and felt involved. They said that consultants who are supportive
should be encouraged to promote the idea to their colleagues, and once the
service was implemented successfully in one area within the Trust it is likely
that others would desire the same. Participants felt it was likely that doctors and
nurses would be supportive of patient centred pharmacy services if they were
told that it would save them time.
There was a strong feeling that to gain support within the Trust, the new
approach to pharmacy practice must be continually shown to demonstrate
improvements in patient care, but proving this has inherent difficulties. Some
suggested presenting data to show errors prevented, interventions into patient
care, occasions when discharge has been quicker or when patients have
received their medicines more promptly. However, the limitations of these data
were recognised, as they are not necessarily indicative of improved patient
outcomes. Others suggested using re-admissions rates and length of hospital
stay as markers of the impact of pharmacy services, but acknowledge that any
effect pharmacy input has on these is very difficult to isolate.
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All participants felt that the trust would only support patient centred pharmacy
services if money would be saved. Whilst the overall opinion was that cost
reductions would be made for example through prevention of drug errors,
avoidance of litigation, and reduced re-admissions, participants agreed this
would be difficult to quantify. Some participants felt that pharmacy staff could
sell the proposed service developments to Trust management as evidence of
clinical governance. Consultants said however, that Trust management, would
only support services if they impacted on the 'golden criteria': waiting lists,
emergency admissions and the Trust overspend.
When asked how best to introduce the services, consultants said this should be
done by writing to each clinical director, all consultants and senior nurses, as
these people are pivotal to successful implementation. Senior staff must ensure
that doctors and nurses know what pharmacists are there for and that they are
part of the team, not merely an 'add-on extra'. Pharmacists could then run small
teaching groups with doctors and nurses to say who they are, what they do,
what they aim to achieve, and what they can offer. They said that senior house
officers and particularly the nurses would be the most important as they are
more permanent staff, whereas house officers move every six months.
"What generally happens is, if the nurses take something on board, it
becomes part of the ward routine and the junior doctors adapt to that,
that's in practice, what happens." (Consultant)
Doctors said that a session to introduce pharmacy services during junior
doctors' induction week may be useful, but as they have many other things to
concentrate on it may be overlooked. They felt that the weekly doctors'
lunchtime educational meeting would be an excellent forum to promote patient
centred pharmacy services as many doctors aftend and GPs were also present.
Each directorate also have regular meetings and pharmacy staff could also
speak at these. A nurse felt that implementation of the services may be more
successful though a campaign with a multidisciplinary team of a pharmacist,
doctor, and nurse providing educational sessions, complemented by wards
visits.
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4.3.3.5.5.	 Implementing the new services - practical aspects
When asked about implementing the proposed services, appropriate training
and resources were considered a pre-requisite. Good communication is vital
and ward staff should have written protocols of what pharmacy technicians and
pharmacists do, and don't do on the wards which should be provided when the
services are introduced to enhance efficiency and prevent confusion or
exploitation. There will be misunderstandings of the activities to be carried out
by pharmacy staff, but this is inevitable when any new services are introduced.
When asked if they felt the proposed services would be successful, all
participants felt that, with perseverance, patient centred pharmacy services will
become embedded into the culture of the ward.
All participants felt that development of pharmacy services would require
collaboration between all staff from the beginning in order to obtain their
support, and ensure the continuity of patient care.
"Obviously before it starts evetybody would have to be involved, it would
be no good pharmacy saying 'right this is what we're going to do, ' you'd
have to integrate the doctors and the nurses..." (Pharmacy Technician)
When asked about the practical aspects of the new pharmacy services, all
participants felt that uniformity of service across the Trust would be very
important, and pharmacy staff must be adequately covered over holidays or sick
leave by staff who will provide the same level of service, to maintain confidence
of medical staff and patients in the service. The service provision must be
consistent, over a long period of time, for a change in culture to occur. It must
be a continuous service, not sporadic.
Pharmacists said they want to have certain activities they undertake formalised
such as writing up warfarin doses for doctors to sign, altering dosage times, and
re-writing drug charts.
When asked about potential difficulties, participants felt that provision of patient
centred pharmacy services to community hospitals might be problematic. These
wards and rehabilitation wards however, would need less pharmacy input as
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there are fewer admissions and discharges than acute wards. Some
participants felt that pharmacists should work on the admissions wards taking
drug histories and influencing prescribing immediately following admission,
whilst others thought they were better placed on the longer stay wards.
It was felt that pharmacy working patterns should change to reflect those of
doctors and nurses not only to improve interprofessional relations but because
doctors and nurses may need pharmacy input more outside of normal
pharmacy hours. Some doctors and nurses felt that patient centred pharmacy
services should be available 24 hours a day 7 days a week, albeit in a limited
capacity. Pharmacy staff had mixed views on this, with some supportive and
willing to work out of their usual hours, whilst others were more reluctant.
Pharmacy staff said that resources should be maximised through skill mix, with
assistant technical officers maintaining the supply role of pharmacy and aseptic
services, freeing up pharmacy technician time to work on the wards. Acquiring
more assistant technical officers would greatly facilitate implementation and with
training, pharmacy technicians could carry out several of the activities
undertaken in this study, such as obtaining drug histories, counselling patients
and ensuring the medicines reach patients in a timely fashion. All pharmacy
staff acknowledged that pharmacists must be careful not to simply delegate jobs
they do not like, to technicians.
When asked about pharmacists' working patterns, all participants recognised
that to ensure all patients receive appropriate services relating to their
medicines pharmacy staff must be physically on the wards. The amount of time
spent on the wards, however, should reflect the work load of the ward. The time
input of pharmacists could be modified to target areas or activities where
pharmacy staff can achieve the maximum input into patient care. Pharmacists
must be visible and available on the wards so doctors, nurses and patients can
seek their advice. Most participants felt that pharmacists should attend ward
rounds in order to be fully involved in patients care and have maximum
influence on prescribing. It was felt that pharmacy staff should have greater
'presence' on the wards, so they would be more familiar with the patients, and
more approachable to patients, doctors and nurses. Pharmacists said that
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problems may arise when they have other responsibilities and commitments, for
the pharmacy department, which take them away from the wards.
4.3.3.5.6.	 Professional aspirations of pharmacy staff
When asked their feelings on taking on these new roles most pharmacy staff felt
their jobs would be more rewarding and interesting if they were more involved
with patients. They would feel they were doing a better job. Job satisfaction
would be enhanced and it was felt that developing patient centred pharmacy
services would also help in recruitment and retention of pharmacy staff, whilst
also raising the profile of pharmacy within the Trust.
Some pharmacy technicians said that although they would like to work on the
wards more, they also enjoy aspects of their work in the pharmacy department,
such as aseptics so they would like to have a rotation system, which enabled
them to work in a variety of areas. Some technicians were keen to get involved
in educational programmes for patients.
A number of doctors and nurses expressed concern that some pharmacists
may not want to take on extended roles.
"We're talking about a total cultural change for pharmacists. Some
probably won't want to change. That is the same with all change in
professions." (Consultant)
Whilst acknowledging improved job satisfaction, some pharmacy staff felt
uneasy about taking on extended roles, as they lack confidence in their ability
and would be afraid to take on more responsibility. Although pharmacists were
keen for technicians to extend their roles to provide more patient centred
services, and provide medicines information services, some technicians were
not keen to do this. Pharmacy technicians said they would not be prepared to
write prescriptions, but all would be happy to counsel patients about their
medicines. They would dispense prescriptions without the direct supervision
from a pharmacist, so long as a pharmacist professionally checks the
prescription, and is accessible for queries.
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Pharmacy technicians said that they should be formally registered and
accredited and this would facilitate the development of new services. Some
technicians feel they are poorly rewarded in comparison with technicians
working for other Trusts, and claimed technicians working within other hospitals
in the region are paid higher rates to do the same job. They feel their grading
and salaries do not reflect the work they currently do and are insufficient to take
on extended roles.
4.3.3.5.7.	 Roles and professional boundaries
A great deal was said about professional boundaries, and the importance of
being clear in defining the roles of people involved in patients' care. When
asked about the practical aspects of service developments, all participants said
that pharmacy staff must be clear in defining their roles and responsibilities right
from introduction of the new services so services are consistent across the
trust. This must be effectively communicated to doctors and nurses so they
know what to expect from pharmacy staff. Often doctors and nurses are
unaware of the roles of pharmacy staff, but with better communication they
would know exactly what pharmacy technicians and pharmacists do. Pharmacy
staff must be prepared to continually reinforce their responsibilities and not be
afraid to refuse to do things asked of them which are outside of these.
Some pharmacy staff felt that the different roles of pharmacy technicians and
pharmacists should be explained to patients, but doctors and nurses felt this
may confuse them. Pharmacy staff felt that they were not easily identifiable
which confuses patients, but by working as part of the team this would improve,
as patients would be able to distinguish them from doctors and nurses. Patients
would be more aware of the role of pharmacy staff, and would use them as a
medicines information resource.
Participants were keen for pharmacists to extend their roles to encompass
some of the activities traditionally undertaken by doctors. One consultant
suggested developing the concept of 'pharmacy practitioners', just as nurse
practitioners are now being used to provide more clinical help to doctors.
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"Nurse practitioners are doing all sorts of things now which doctors did
before, you might have to think about it in the same way with
pharmacy.......perhaps it would be useful to have, say, a pharmacy
practitioner doing all the stuff that the junior doctors are doing at the
moment."
When asked whether pharmacists should be able to prescribe drugs,
pharmacists were eager to extend their role in this manner as they feel this
would improve patients' access to medicines, ensure efficiency of medicines
use and minimise risk. Consultants were also in favour of this, but they were
concerned about the lines of responsibility. They said this would be particularly
useful when a diagnosis is clear, but there is uncertainty about the best
treatment, for example deciding on anti-emetics, analgesia, laxatives or
antibiotics.
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5. CHAPTER 5- DISCUSSION AND
CONCLUSIONS
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5.1.	 INTRODUCTION
In this chapter, I will summarise the main results the study. I will move on to
relate my findings to existing literature and discuss how my work extends this. I
will also explore the limitations of my study and the strengths and weaknesses
of the methods adopted. I will then discuss the lessons for practice and finally
consider implications for future research.
5.2.	 SUMMARY OF FINDINGS
Following an action research approach, this study comprised four phases:
Phase one - a preliminary phase to gain an understanding of the study
environment
Phase two - reflection on emerging themes and identification of key issues
relating to the use of medicines
Phase three - development and implementation of a new model of care, and
Phase four - evaluation of the model in the study setting and exploration of
issues which would influence adoption throughout the trust
In this section, I will briefly summarise the main issues identified throughout this
study.
5.2.1.	 Medicines safety
Many issues relating to medicines safety were identified during the study. Errors
frequently occur and many of the doctors and nurses seemed to accept it as an
inevitable part of patients care. Examples include medicines not being
prescribed due to inaccurate drug histories, transcription errors, prescribing
contra-indicated drugs, dosing errors and mixing up drugs with similar names.
Prescribing errors were considered by some to be part of a doctor's learning
experience. Doctors classified errors as either 'minor' or alternatively
'significant' and appeared unconcerned about 'minor' errors as long as they
were spotted or caused little or no harm to patients.
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Errors are frequently not reported, especially if they are deemed 'minor' and
doctors and nurses are frightened to admit to mistakes because they feel they
will be blamed. A ward manager expressed frustration that the Trust
management do not feel that mistakes matter, and this filters through to the
doctors and nurses.
Patients are frequently admitted to hospital because of medication problems
and it appears that many of these admissions are due to non-compliance. Re-
admissions can occur because discharge medication is not explained properly.
In this study, few patients were able to give a comprehensive, accurate account
of their medication regimen and nearly half of patients interviewed admitted to
forgetting to take their medication as prescribed at least a number of times each
month.
A number of unsafe practices were identified for example nurses frequently give
intravenous drugs without another nurse checking them, patients keeping
medicines in unlocked bedside cabinets, patients self medicating without the
doctors' knowledge, doctors not taking sufficient care when prescribing for
example not checking doses and writing illegible prescriptions. Nurses often do
not supervise patients taking their medicines. Drug therapy is poorly
documented in patients' notes, and doctors rarely communicate comprehensive
information about medicines and treatment plans to GPs.
It appears that medicines related activities are not considered a priority by
doctors and nurses. A lot of their job is concerned with other aspects of patients'
care, which they perhaps take more time and consideration in undertaking, and
medicines aspects come last. It may be however, that other aspects of patient
care also suffer.
5.2.2.	 Culture re'ating to medicines
There appeared to be a blasé attitude towards medicines amongst doctors and
nurses in the study Trust, and in interviews they made surprisingly frank
comments about less than ideal practices. Consultants, junior doctors and
nurses often blamed lack of time and resources for poor care relating to
medicines. From my observations, it seemed that medicines are not seen as an
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important part of patient care; for example, doctors rarely review medicines
unless they are pertinent to that admission even though they are aware that
some drugs may be inappropriate, If it is not possible to get an accurate drug
history at the time of admission, this is often not followed up. Doctors and
nurses conceded that patients are given insufficient education about their
medicines, but seem not to consider this a particularly important part of patient
care.
Throughout the study, doctors and nurses acknowledged sub-optimal aspects
of medicines related patient care but appeared to accept this as an inevitable
part of care and lack concern. There was however considerable
intraprofessional variation with respect to the importance placed on medicines.
My observations indicate that some doctors are more concerned about
medicines than other doctors and similarly some nurses are more concerned
than other nurses.
5.2.3.	 Inefficiency
Systems, procedures and shortcomings of staff lead to inefficiency of patient
care. Delays sometimes occur in supply of medicines to wards because nurses
do not order medicines in a timely fashion and sometimes patients can miss
several days of their usual medicines. There are sometimes delays in obtaining
non-formulary drugs, or ensuring an alternative is prescribed. Wastage of
medicines is a problem, through not reusing patients' own drugs and failure to
transfer patients' medicines between wards.
52.4.	 Competency of professionals
Doctors and nurses competency relating to therapeutics was sometimes
lacking, for example knowledge of dosages, adverse reactions, indications and
contraindications of drugs, drug interactions and special instructions for certain
drugs. Junior doctors said they feel unprepared for prescribing when they leave
medical school, as therapeutics constitutes a very small part of the medical
school curriculum. Sometimes nurses do not administer medicines as they are
out of stock or sometimes no clear reason is apparent. Several doctors and
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pharmacy staff felt that some nurses do not understand the importance of
making sure patients receive certain medicines.
The doctors rely on nurses as a safety net in detecting prescribing errors, but
the nurses felt they have insufficient knowledge about therapeutics and
therefore may not notice errors.
5.2.5.	 Effective management of therapeutics
This study identified various ways in which the management of therapeutics
could be enhanced within the study Trust. Whilst doctors and nurses
appreciated the limited existing pharmacy services provided to wards, they said
that they would prefer more direct patient orientated pharmacy input, with better
interprofessional communications and greater patient contact. At the time of the
study, pharmacy services varied between wards and essentially comprised
supply of medication, a medicines information service, and, for some wards,
pharmacist visits to review drug charts. The new approach to pharmacy practice
developed and evaluated in this study was found to be very successful.
5.2.5.1.	 Ensuring appropriate prescribing
As a result of my intervention, I believe patient care was improved because an
accurate drug history was recorded in patients' notes, which resulted in patients
receiving their usual medicines promptly, drugs were not inadvertently omitted
or prescribed inappropriately and continuity of patient care was facilitated,
especially when communicating information to GPs about medication changes. I
feel that undertaking a structured medication review ensured prescribing was
appropriate, patients were not taking unnecessary drugs and this ensured they
received medication from which they would benefit. In interviews and focus
groups doctors, nurses and pharmacy staff felt these were particularly useful
interventions. Pharmacy staff may be the most appropriate individuals to
undertake these activities.
I believe that having a pharmacist based on wards, providing more patient
orientated, medicines focussed care enabled a greater impact on prescribing,
and improved interprofessional communications. Prescribing advice was
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proactive rather than reactive as with standard pharmacy services and I was
more familiar with patients' management, therefore prescribing advice was
more useful to doctors and nurses.
5.2.5.2.	 Enhancing safety
I feel that having a pharmacist working on the wards, attending ward rounds
enabled better and earlier detection of prescribing errors and resulted in better
documentation about medicines in patients' notes. Being present at the point of
prescribing, encouraged doctors and nurses to ask for advice.
Pharmacist involvement in discharge reduced risk to the patient through fewer
errors and minimised delays in discharge whist also facilitating continuity of care
through improved information about medicines to GPs.
5.2.5.3.	 Educative role of the pharmacist
Therapeutics education for patients, nurses and doctors was a particularly
useful intervention in this study and doctors, nurses and patients were very
supportive of this. The risks associated with patients taking medicines
incorrectly may be reduced if patients receive more comprehensive education
about their medicines, which may lead to fewer re-admissions. Pharmacy staff
may be the most appropriate individuals to undertake this as they have a more
comprehensive knowledge of therapeutics and patients may feel more relaxed
and open talking to them than the doctors and nurses. Pharmacy staff may
have a valuable role in negotiating with non-compliant patients. Having a
greater presence on the wards and subsequent increased familiarity with
patients enabled me to educate patients more effectively.
5.2.5.4.	 Enhancing efficiency of patient care
As a result of my interventions the efficiency of patient care was enhanced,
doctors and nurses time was freed up to pursue other clinical activfties and
pharmacy time was saved.
Doctors, nurses and pharmacy staff felt that better management of therapeutics,
resulting from more intense pharmacy input into patient care may reduce the
length of admissions and planning discharge medication in advance, for some,
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patients may expedite discharge. Some doctors commented, however, that
better management of therapeutics might incur increased drug expenditure if
more drugs are prescribed.
My interventions reduced the risk of errors, which may minimise potential
litigation and associated costs. Overall, it is possible that the Trust would save
money through avoidance of medication related problems.
5.2.6.	 Changing practice
Various issues relating to changing practice were identified, for example
resources, interprofessional problems, reluctance of pharmacy staff because of
training and accountability issues, and intra-professional variation of pharmacy
staff. I felt that pharmacy staff themselves might be one of the biggest barriers
to developing services in this Trust. It may be that my desire for the project to
work and ability to integrate into the ward team effectively may have
significantly contributed to the success of this project.
5.3.	 RELATING MY FINDINGS TO EXISTING LITERATURE
In this section, I discuss how my findings relate to existing literature, whether
they confirm or refute it and what my findings add. My findings relating to
medication errors confirm and also add to existing literature. Error reporting is
very poor in the study Trust, with many doctors not even being aware of
reporting procedures. Several barriers to reporting medication errors were
identified in this study and have also been identified in the literature
(Department of Health, 2004), namely:
• Lack of an awareness of the need to report, what to report and why
• Some errors go unnoticed
• Errors which do not harm the patient and are deemed 'minor' are frequently
not reported
• Fear of disciplinary action or litigation
• Lack of familiarity with reporting mechanisms
• Staff feeling they are too busy to report
• Lack of feedback when errors have occurred.
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As reported in the literature (Bates DW eta!., 1995), prescribing errors were the
most frequent medication errors I encountered during the course of my work on
the wards, and the most common recalled by doctors, nurses and pharmacists
in interviews. Reasons for prescribing errors were identical to those cited in the
literature (Department of Health, 2004): inadequate knowledge of the patient
and their clinical condition, inadequate knowledge of the drug, calculation
errors, illegible handwriting, drug name confusion, dosage formulation, zeros
and decimal points, unusual routes of administration, uncommon and/or
complicated dosage regimens, repeat prescribing and poor history taking.
My results add to those of Dean et a! who suggested that human error theory
can be used to identify the causes of potentially serious prescribing errors
(Dean B eta!., 2002). I believe this theory can also be applied to other causes
of medication errors such as administration errors. Errors identified in my study
could be divided into active failures and latent conditions using Reason's model
of accident causation (Reason J, 1990). An active failure was present in most
errors identified by myself or described by interviewees and took various forms.
Slips included getting doses wrong. Lapses included forgetting to cross off a
patients' insulin when an infusion had been put up or prescribing a drug at a
new dose and forgetting to cross off the prescription for the old dose. Mistakes
were made when doctors had insufficient knowledge, for example prescribing a
low molecular weight heparin when there was no clinical indication. Examples of
violations were when relevant rules were not applied, for example, doctors
taking inaccurate drug histories, not filling in sufficient information on the
discharge prescriptions correctly, nurses not ordering drugs in a timely fashion
so patients miss doses, nurses allowing patients to keep medicines in unlocked
bedside cabinets, and not ensuring patients can use inhalers correctly.
Latent conditions were also identified and doctors cited multiple factors
contributing to errors, which supports existing literature (Dean B et a!., 2002). In
my study, doctors and nurses blamed working conditions, for example, hastily
written discharge prescriptions at the end of ward rounds. Time limitations and
understaffing were blamed for errors following inaccurate drug histories, doctors
not reviewing medication or nurses not administering medication despite it
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being prescribed. Poor communication for example, illegible handwriting and
lack of documentation about drugs also caused mistakes.
The culture relating to medicines also contributed to medication errors, as many
doctors and nurses appeared to consider drugs unimportant. As a
consequence, the culture of medication safety was poorly developed. Dean et a!
(2002a), on interviewing doctors who had made mistakes, also found that many
doctors did not seem to consider the task of prescribing drugs important and I
found this in my study. Classifying this as a latent condition, they state that the
act of prescribing was often embodied in a drug's name ("put them on
verapamil") and the details of the dose, form and frequency, route, duration etc,
left to the house officer to complete. They found that there was a low self-
awareness of making errors with another factor being doctors' and nurses' lack
of knowledge of therapeutics and my findings support this.
The Government is committed to improving safety within the NHS and
improving the safety of medicines (Department of Health, 2001a, Department of
Health, 2004), but this does not appear to be filtering down to doctors and
nurses actually working on the wards. Many doctors and nurses in the study
trust did not appear to share this commitment, rather accepting medication
errors as an inevitable part of care. Studies of medical training have shown how
doctors are socialised into the norms of a culture where uncertainty and the
inevitability of medical error are learnt and reinforced (Lester and Tritter, 2001).
Doctors, nurses and pharmacists felt that managers do not consider medicines
important and senior doctors do not set examples, and it appears from the
literature that this is not unique to the study Trust. The Audit Commission report
(2001), which identified shortcomings in medicines management arrangements
in many hospitals, found only 11 out of 105 hospital consultants surveyed in
four hospitals, reported that reviews of the use of medicines fed into the wider
clinical audit work and their clinical governance agendas. Individual consultants'
clinical freedom still takes precedence over corporate clinical responsibility and
prescribing practice is seldom reviewed systematically. Only nine of 105
consultants reported that prescribing practice formed part of their regular
performance review meetings with clinical directors. Consequently,
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opportunities are being missed to improve care through learning from errors and
near misses. In another study a consultant felt that the hospital management in
his hospital has a token attitude to risk management (Dean B et a!., 2002), and
similar comments were made by interviewees in my study.
The negative culture towards medication errors within the Trust was reinforced
as doctors had a strong sense of identification with each other with respect to
their common uncertainties. They accepted that they all make mistakes, but did
not criticise one another, rather spoke as if in unity with their colleagues. This
has also been reported in the literature. Rosenthal interviewed 60 doctors and
found that shared experiences of making a mistake created a powerful sense of
mutual empathy which often led to understanding and forgiveness of mishaps
and a strong norm of non-criticism, described as a 'conspiracy of tolerance'
(Rosenthal M, 1995). He concluded a final common theme of the exclusivity of
professional judgement, that is, the conviction that only a fellow doctor can
make judgement about another doctor's mistakes. In a critical review of the
literature on medical error Lester and Tritter suggest the learnt dispositions of
medical cooperation is encouraged by the length of the medical degree and
tribalism is encouraged by the apprenticeship style of medical education (Lester
and Tritter, 2001). They suggest that these learnt dispositions may help explain
aspects of doctors' responses to medical error, for example their reluctance to
criticise other doctors and why, when challenged, doctors turn to each other
rather than seeking help outside the medical network. Pharmacy staff in my
study felt doctors are 'protected by the system'.
These are also important factors in barriers to learning from mistakes. Pride in
individual and organisational expertise can lead to denial and to a disregard of
external sources of warning, particularly if a bearer of bad news lacks legitimacy
in the eyes of the individuals, teams or organisations in question. Human
alliances lead people to "forgive" other team members their mistakes and act
defensively against ideas from outside the team (Smith D and Elliot D, 1999,
Toft B and Reynolds S, 1997, Firth-Cozens J, 2001). My interview data and
ethnographic findings support this.
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The doctors I interviewed were very open, honest and appeared blasé about
bad practices relating to medicines, and errors. A reason for this may be that
the doctors were not worried about any repercussions if they make errors.
Some doctors however feared being blamed if they reported errors. Lester and
Tritter also describe the importance given to the disposition of status in medical
training and that this may also create a feeling of elitism and collegiality (Lester
and Tritter, 2001). This was particularly noticeable in the comments of one
consultant I interviewed who said:
"I mean I guess in the end it is their (the junior doctors) prerogative to.. .to
get it wrong." (Consultant)
In addition, my findings suggest that some doctors may also be unappreciative
of pharmacists giving them advice and preventing errors for this reason.
"yes...a degree of who are you ? ----you know I am the medic..l am
omnipotent....! know eveiything...! don't need anyone else to tell me
what to prescribe, I have decided, therefore it should be given, sort of
approach from some of the juniors.. .one or two consultants as welL"
(Consultant)
This theory is in contrast however, with the work of Davidoff, who suggests that
a cultural barrier to improvement in the healthcare system is shame, because
improvement means that, however good your performance has been, it is
not as good as it could be" (Davidoff F, 2002)
The doctors in my study said that they rely on nurses to detect their errors,
however Dean et a! (2002a) found that doctors perceived pharmacists as their
main source of defence. This may reflect the differences in pharmacy practice
between that study setting and my own.
The significant potential for intravenous drug errors was highlighted in my study
and this has been identified as being associated with considerable risk in
several other studies (Taxis and Barber, 2003, O'Hare et a!., 1995, Hartley and
Dhillon, 1998, Wirtz et a!., 2003). Despite this being one of the Government's
prime targets in increasing patient safety (Department of Health, 2001a,
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Department of Health, 2004), there seemed to be little attention paid to this in
the study Trust and in the Trusts included in the studies cited above. In my
study, this risk was only highlighted by nurses probably because nurses
generally prepare and administer IV drugs. One factor they cited as contributing
to this risk was the culture within the Trust, for example, nurses often administer
IV drugs without a second check even though this is hospital policy and more
worryingly they do not realise the importance of having a second check. In
addition, the design of drug charts was also cited as a contributing factor as
there is no place on the IV section of the chart for a second nurse to sign they
have checked and this was felt to reinforce bad practice. In the literature
reviewed, poor design of charts was not cited as a contributory factor, although
misuse of drug charts was. It may be, therefore, that chart design is only a
problem in the study Trust. Lack of appropriate training was cited as the main
latent condition for IV drug errors in one study (Dean B et a!., 2002). My findings
support this, as although nurses in the study Trust need to attend a training day
before they can administer IV drugs, this is not regularly updated. This confirms
other studies which had concerns about nurses' lack of training in handling IV
medication (Campbell T and Lunn 0, 1997, Wilkinson R, 1996).
I found that doctors and nurses competency relating to therapeutics was
sometimes lacking and this also confirms existing literature (Audit Commission,
2001). Concerns about the poverty of therapeutics training in undergraduate
programmes for doctors have been raised in the literature (Department of
Health, 2004, Department of Health, April 2001, Barber et a!., 2003, Maxwell et
aL, 2002), and my findings support this. Doctors themselves expressed
concerns about their competency and said they received insufficient training in
therapeutics both pre and post qualification, which again supports previous
work (Audit Commission, 2001, Clack GB, 1994, Jones eta!., 2001, Panayiotou
and Fotherby, 1996b).
The GMC recommends that undergraduates must know about and understand
the principles of treatment and this should include the effective and safe use of
medicines as a basis for prescribing (General Medical Council, 2003). Doctors
in my study, however, who came from a range of medical schools, said they do
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not feel confident about prescribing because, as medical students, they were
not taught how to prescribe, and therapeutics constitutes a very small part of
the medical school curriculum. This supports the findings of Maxwell et a!, who
found that few courses ensure that undergraduates are taught and tested on
how to prescribe and give drugs safely (Maxwell et a!., 2002). Dean et a! found
that junior doctors lacked knowledge about how to choose the dose of drugs as
the doctors they interviewed were not taught this at medical school. I also found
that lack of knowledge of doses was a particular problem and doctors said they
end up learning most things 'on the job'.
The GMC recommend that that good prescribing practice, acute and chronic
pain relief, the principles of evidence-based practice and assessing the quality
of care should be covered through in-house service training and where
appropriate educational sessions. From interviews with doctors and my
ethnographic work, it appeared that in-house training in therapeutics in the
study Trust was lacking and this confirms existing literature (Audit Commission,
2001, Wilton J, 1995, Wilson DH, 1993, Bogg J eta!., 2001, CrantJ etaL, 1989,
Standard Committee on Post-graduate Medical Education, 1991. COPMED and
UK Conference of Deans, 1995, Panayiotou and Fotherby, 1996a).
Many nurses in my study seemed to lack knowledge of therapeutics and this
corroborates existing literature (Thornton T, 1997, Jordan S, 1994, Latter et a!,
2000, Boggs P et a!, 1988, Markowitz JS et aL, 1981, lves G et aL, 1996, King,
2004, Manias and Street, 2001). The nurses also said they receive insufficient
training in therapeutics both pre and post registration and this supports existing
literature (Courtenay M, 1991, Morrison-Griffiths et aL, 2002, Jordan S and eta!,
2002, Davis J and Hemingway S, 2003, Hemingway S and Freeman J, 2002,
Hemingway S, 2003).. This is particularly worrying, as in both my study and that
of Dean et a! (2002a), doctors saw nurses as a source of defence against
medication errors, although in my study nurses felt they had insufficient training
and may not notice errors unless they are glaringly obvious. Many nurses in my
study felt they had insufficient knowledge of therapeutics to communicate
information to patients and their carers, which has also been found in the
literature (Latter S et a!., 2000).
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I found that communication about medicines were poor, particularly inaccurate,
incomplete drug histories taken on admission and this is consistent with existing
literature (Feely M eta!., 1984, Lau et a!., 2000, Beers M H eta!., 1990, Walker
C, 1991, Gleason KM et a!., 2004). Lau et a! (2000) found that 67% of patients
had one or more registration errors (the combination of omission and
commission errors), and 18% had three or more. In my study 80% of all patients
had one or more registration errors, and 34.5% had three or more. Unlike Lau et
a!, I also looked at OTC and homeopathic drugs and took dosing and regimen
errors into account, although these were not included in the above figures. A
difference in the number of registration errors may be a reflection of the different
methods used to obtain a drug history Lau et a! interviewed patients and
checked community pharmacy records, and these were the only sources of
information about medicines used. I used multiple sources to obtain a drug
history, whereas most existing studies use only one or two sources of
information.
Beers et a! used only a patient questionnaire to elicit a drug history, and
compared this with the admitting doctor's. They found 83% of patients had one
or more registration errors, and three or more were found in 46%. They included
OTC medication in these figures however, whilst I considered these separately,
so their results cannot be directly compared with mine.
In addition, I explored the consequences of taking an inaccurate drug history,
while many studies tend to focus simply on the number of discrepancies
between admitting doctors' drug histories and a second drug history. Unlike
previous studies investigating the accuracy of medication histories, I
triangulated my results with interview and ethnographic data, further
corroborating my findings.
In my study, information relating to medication was poorly communicated to
GPs following patients' discharge and this also consistent with the literature
(Department of Health, 1991, Department of Health, 2004a, Mottrani et a!.,
1994). Both the preliminary discharge letter (PDL) and the subsequent
consultant discharge summary (CDS), frequently omitted important information
relating to medication. My results supported a study which found that very few
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PDLs gave exactly the same information as the corresponding CDS (Gardiner,
1998). Doctors in my study admitted they aren't very good at communicating
information about medicines to GPs when patients are discharged.
My findings support those from other studies, which suggest that patients being
discharged from hospital have a poor understanding of their medication (Cantrill
and Clark, 1992, Dyson eta!., 1995, Puller eta!., 1989, Cochrane eta!., 1992).
This, compounded with incomplete information communicated to GPs about
medication, can lead to medication problems when patients are discharged,
although I was unable to follow this up in my study due to time limitations.
Many patients in my study admitted to non-compliance. Reasons induded
forgetfulness, lack of understanding of their treatment regimen, deliberate non-
compliance because of side effects or perceived inefficiency of treatment, or
lack of understanding of their condition. My findings support existing literature
(Partridge eta!., 2002, Chewning eta!., 2001, Sung eta!., 1998, lnsull, 1997,
Cramer and Rosenheck, 1998, Donnan eta!., 2002, Buck eta!., 1997,
Greenstein and Seagal, 1998, Chisholm, 2002, Chisholm et a!., 2000, Salzman,
1995, Barat et a!., 2001, Lowe and Raynor, 2000). 1 found that often patients
are not given adequate information about their medicines which is also
consistent with other studies (Barat et a!., 2001). My findings add to the
literature with interview data from doctors and nurses who admitted they are not
good at educating patients about their medicines or involving them in
therapeutic management.
My findings confirmed my initial subjective view that pharmaceutical care
services were lacking in the study Trust. Cotter et a! and the Audit Commission,
in large-scale surveys of Trusts reached the conclusion that development of
these services was variable (Audit Commission, 2001, Cotter et a!., 1995). I was
able to confirm from my in-depth study of medication processes that this was
the case in the study Trust. In particular, at the time of my study, hospital
pharmacists spent little time working on the wards and did not integrate
effectively into ward teams. Pharmacist interventions into patient care tended to
be reactive rather than proactive and only one pharmacist attended a ward
round. The primary function of pharmacy services was that of supply.
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Although there are many studies which examine factors required for the
effective management of therapeutics and interventions by pharmacists to
improve care, there appears to be a lack of evidence to support a holistic
pharmaceutical care model in the secondary care setting. Studies have tended
to focus on discrete, fragmented segments of care such as drug histories,
pharmacist impact on prescribing decisions, errors intercepted by pharmacists,
patient education about therapeutics and pharmacist input at discharge. This
study is the first to examine how the management of therapeutics can be
enhanced throughout the whole patient journey, taking a holistic approach. A
pharmaceutical care model is, to my knowledge, unique. In this study, the care
relating to medicines is examined from admission through to discharge, and a
model of pharmaceutical care was developed to optimise this. This study did not
focus on one discrete part of care, it explored a total new way of working for
pharmacy staff to enhance patient care throughout their journey.
In addition, there appear to be no studies using action research to explore this
area. This study is unique in that, I started by examining the problems within the
study Trust, then tailoring interventions to improve care with respect to
medicines based on my findings. Unlike my research, most studies evaluating
interventions to improve management of medicines do not describe an
evaluative phase in which problems are initially identified or a 'diagnostic
analysis', rather assume the problems exist and then implement a pre-detined
intervention. Also, adding to existing literature, I explored doctors, nurses,
pharmacy staff and patients' views on the pharmaceutical care model, following
up the intervention implementation and assessment with interviews and focus
groups. This research also explores the factors, which may influence the
proposed wholesale implementation of pharmaceutical care interventions
throughout the Trust, and there appear to be no studies that have done this.
My results are in agreement with existing literature, that, in general, achieving
wholesale change in practice may be difficult (Moss et a!, 1998, Moran and
Bnghtman, 1998, Goldie and Sheffield, 2001). A strong theme emerged that
pharmacy staff themselves, although expressing dissatisfaction and frustration
with their current limited direct input into patient care may be reluctant to
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change and this may be the biggest barrier to developing services. Bateson et
a! used similar methods to those used in my study such as observations and
qualitative interviews (Bateson C and Duggan C, 2000). Similar to my findings,
they also discovered that despite similar feelings of dissatisfaction and that their
clinical role was not fully perceived by other health care professionals,
pharmacists lacked vision of ideal pharmaceutical care and had a narrow
understanding of the concept, even at mid-management level.
My findings about the reluctance of some pharmacy staff to undertake the
activities I proposed support existing literature relating to changing practice. In a
study about developing generic healthcare support workers Rolf et a!
suggested that blurring boundaries between professional areas of practice
would have both positive and negative consequences (Rolfe eta!., 1999).
Healthcare workers, from a variety of disciplines and clinical areas, felt that a
move away from 'professionally' defined roles was threatening to their identity.
They were concerned about interaction with an increased number of
professional staff as they would be uncertain as to whom they would consult
regarding care decisions. The support workers appeared insecure at the
thought of not 'belonging' to a certain group of staff and were concerned as to
where their support would come from.
This could also be the case for pharmacy staff. If they were to take on new roles
based on the wards, they would no longer be working together in the pharmacy
department. They may feel that they do not 'belong' to any group of staff. They
would not 'belong' with nurses or with doctors, which may breed a degree of
insecurity. No doubt pharmacists do feel a degree of security from the
pharmacy department itself, and their colleagues. Out on the wards they would
be working with doctors, nurses, other healthcare workers and patients. Roll et
a! found that professional groups were concerned about the blurring of
boundaries in relation to issues of responsibility and accountability of care.
In my study, another concern about the extended roles for pharmacy staff was
the notion that pharmacists would be perceived as 'interfering', for example with
clinical decisions made by doctors or management of medicines traditionally
done by nurses. Whilst a number of recent studies suggest professional
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boundaries in health care are now overlapping, other researchers working in
this field have encountered similar problems relating to interprofessional
relations (Snelgrove and Hughes, 2000). Snelgrove et a! conducted an interview
study with doctors and nurses to investigate perceptions of their roles and areas
of overlap. Doctors drew a sharp distinction between medical and nursing roles,
emphasizing their control over diagnosis, treatment and prescribing. Doctors
perceived themselves as being the key figures in the management of the
treatment process, and the carriers of medical knowledge, whilst nurses
acknowledged their continuing subordination to doctors in many areas of work.
Doctors sought to legitimize professional power, by maintaining that clinical
responsibility must go hand in hand with the authority to make decisions
unfettered by the intervention of others. My findings also suggest there is a
notion of doctors' supremacy in the study Trust, which may adversely affect
development of services.
5.4.	 CHALLENGES, AND LIMITATIONS AND STRENGThS
WITHIN THE STUDY
In this section I discuss some of the challenges I was faced with during the
course of this research and the limitations and strengths of the approaches
followed. I begin by discussing the methodological difficulties I encountered and
examine the action research approach used in this study.
5.4.1.	 Methodological issues
As already discussed, an action research approach was adopted for this study,
as it is particularly suited to identifying problems and their solutions in clinical
practice (Hart and Bond, 1995). Using this approach allowed me to use a range
of research methods, both qualitative and quantitative, and enabled
triangulation of data to help reduce the limitations of any single approach.
I was able to follow the action research modet very closely within this study,
which I would categorise as the 'professionatising type' according to Hart and
Bond's criteria (Hart and Bond, 1995). In keeping with this typology, my
research was informed by an agenda grounded in practice, which also reflects
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the aspirations the pharmacy profession hold to enhance their status and to
develop a research-based practice.
There are inherent difficulties in trying to evaluate service developments, as it is
rarely possible to link their effect directly to patient outcomes. The action
research approach used in this study facilitated the development and evaluation
of a new approach to delivery of patient care with respect to medicines. Closely
following the model first described by Lewin (Hart and Bond, 1995), I undertook
an initial evaluative phase to gain understanding of the existing problems
(diagnosing), followed by a reflective phase to identify key issues (action
planning). I then developed and implemented a new model of patient care
relating to medicines (action taking), and evaluated this model and explored
issues which would influence wholesale implementation (evaluation).
Evaluation of this model however, is difficult, as it is only one part of the total
patient care package provided by health care professionals. From the
diagnostic and action planning phases I have attempted to define the tactive
ingredients' of the model of care, although there are many intangible elements
such as my own personality and competency, patient characteristics, inter-
professional relationships and organisational culture which also influence
outcomes. I have combined quantitative and qualitative methods in an attempt
to overcome the problems associated with the evaluation of this complex
intervention into patient care.
Using a case study approach, t objectively evaluated the discrete segments of
patient care, such as history taking, medication review, patients' knowledge
about medicines and detection of errors. This provided insight into how patient
care was improved although I could not be sure that patient outcomes truly
benefited. I attempted to further strengthen my findings with qualitative data
from ethnographic findings and interviews with patients and various health care
staff.
5.4.2.	 Weaknesses of tools
There were weaknesses associated with some of the tools used to assess the
discrete segments of the model of care, for example that used to ascertain
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patients' knowledge of their medication regimen. Patients taking more drugs are
more likely to have a lower score as they have more drugs to remember, and
patients taking fewer medicines are more likely to have a higher score. Some
patients may be very knowledgeable about their medicines as they only take a
few, whilst other patients may be on many medicines and only remember some
of them, but still recall quite a lot of information. This is clearly a flaw in the tool
itself. For this and other reasons, differences in knowledge scores between
patients, may not actually reflect real differences in their knowledge of their
medication regimen. However, there will be exceptions.
The tool for assessment of compliance also had weaknesses. Firstly, it relied
completely on the honesty of patients, and they may be untruthful about taking
their medication. Secondly it did not differentiate between non-compliance and
patients altering their medication regimen positively, for example reducing
analgesia or hypontics.
Some patients brought a current list of their medicines into hospital, and used
this when I asked them about their medication regimen, whilst others did not.
There may be several reasons why some patients had lists with them and
others did not. The patient's route of admission may be a factor. Patients
admitted as an emergency may well have a comprehensive list of their
medication but were not sufficiently prepared to bring it along. On the other
hand patients may not be as organised about their medication and do not have
a comprehensive list so even if their admission is planned they would not be
able to recall their medication regimen from a list. The scoring system used in
this study therefore cannot be considered a completely reliable and accurate
reflection of the knowledge a patient has about their medication.
The tool to assess clinical significance of interventions into patient care also had
flaws. I attempted to minimise bias by using two separate hospital pharmacists,
independent to the study to rate interventions. Ratings were however,
subjective although assessors were working to a set of criteria aimed at
minimising any bias. In addition, using only pharmacists to rate interventions
introduces bias. It would have been useful to have a group of heatthcare
professionals comprising pharmacists, doctors and nurses evaluating
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interventions and arriving at consensus for clinical significance ratings. Time
limitations within the study prevented this however.
54.3.	 Time limitations
With action research, a researcher can only loosely plan the approach in
advance and has to learn to develop methods and strategies in the field.
Energies are not only taken up with data collection, but also with facilitating
change. Within this project I had to plan the research strategy, develop the
methods, go out into the field as a participant and actually deliver the new
approach to practice, and collect data to evaluate the project. Considerable
amounts of data were assimilated, which placed large demands on my time.
I needed to gain access to the field then establish myself in the study settings,
which involved a considerable amount of time. After a period of time, evaluating
the model of care I then left the study setting to continue the evaluation.
Because of my research time table, the need to complete my thesis and limited
fund ing I feel I spent insufficient time in the study setting to achieve any long
lasting, meaningful change.
The study is limited by involving only one hospital and a relatively small number
of participants and settings. More time would have provided the opportunity to
gather a wider range of data in more depth. For example, more follow-up of
patients following discharge to gain more insight into the effect of enhanced
communication relating to medicines, provided to GP5 would have been useful.
I had insufficient time to follow patients up following discharge to explore the
effects of education on compliance with medication and also the effects of
supplying information to GPs about drug therapy.
With hindsight, I realise that it would have been valuable to examine the Trust
drug and therapeutic committee. This would have yielded valuable insights into
the corporate approach to medication issues, and the interaction between
senior management and professions in the Trust.
I did not undertake an economic evaluation, which would have been useful. Had
I the time I could have explored the costs associated with implementing this
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new model of care. This however, would be very difficult to measure. It would
be very time consuming and would involve a different set of methodologies
outside the current study. I would need to take into account the cost of
latrogenic illness, length of hospital stay, avoidance of litigation, the benefit of
rational medicines management, formulary development and adherence.
5.4.4.	 Role duality and boundaries
When I, practising as a pharmacist, augmented my role within the research
enterprise, some difficulties arose. In trying to establish and sustain a place
within the multidisciplinary team and simultaneously maintain the research
perspective, role conflict was occasionally encountered. For example, there was
confusion over the boundaries of my activities. These mainly arose when new
staff arrived on the wards and although the project purpose and the role of
participants had been explained, some staff still did not fully understand. This
resulted in my being asked to do things that were not related to the project, and
because of time demands, stress was placed on me. Some staff could not
understand why I was unable to undertake some activities and not others, and
this required considerable negotiation and communication skills on my part.
5.4.5.	 Political dimensions
Diagnosing the issues to be addressed in action research requires the
researcher to make judgements (Williamson and Prosser, 2002). These may be
regarded as subversive, even as acts of sabotage, however collaboratively they
have been made, because they involve questioning organisational and
individual practices, norms and beliefs. This however, was very rarely the case
in this project. I sought to generate useful information to inform decision-making
and foster choice.
The change inherent within the action research process could prove particularly
threatening to those who have a vested interest in the status quo; making some
individuals feel particularly vulnerable. I was required to act tactfully to facilitate
co-operation and progress, whilst minimising resistance, when issues such as
these were encountered. For example, junior doctors sometimes did not
appreciate being advised about their prescribing behaviour.
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As an interviewer, I had an effect on participants. I believe that junior doctors,
nurses and pharmacy staff responded differently towards me if I had been a
consultant. I am an approachable young pharmacist and I am in no doubt that
their responses would be different had I been an older, less approachable
senior figure. Someone with more power would be intimidating and they may
not have been as honest.
It may be that the apparent honesty displayed was a method by which doctors,
nurses and pharmacy staff emphasized resource issues, and they possibly
exaggerated the problems, but by triangulating interview data with my
ethnographic findings and intervention evaluation it is clear that what they say
does actually happen.
5.4.6.	 Ethical considerations
There were numerous ethical considerations within this project, as multiple
methods were used. Within the overall action research approach, particular
issues concerning the close relationship between the researcher and
participants, and the explicit aim of changing practice, give rise to unique ethical
dilemmas (Williamson and Prosser, 2002). For example, confidentiality and
anonymity were problems in this study, and may be compromised by the fact
that I can be easily associated with having worked within the study sethng
during data collection and therefore people from the organisation reading the
finished thesis may be able to identify the key players. This has been
highlighted in existing literature (Meyer, 1993).
Obtaining fully informed consent from participants was difficult, as the nature of
the proposed change was unknown and determined by the emerging reality as
the research process unfolded. Informed consent cannot be as meaningful as in
other research approaches as neither researcher and/or participants know in
advance exactly which direction the project will take (Meyer, 1993, Williamson
and Prosser, 2002). Consent within an action research project centres around
the participants' willingness to take part in the project ideas and acceptance of
the researcher as a facilitator of change.
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Meyer describes the problems associated with the collaborative nature of action
research (Meyer, 1993). Collaboration implies equality of relationship between
participant and researcher, which in theory is not present in other forms of
research. The collaborative action research approach infers that research is
done with and for people rather than on people. The extent to which this is
possible is questionable. By acting as a participant observer on the wards, I
inevitably found myself listening to people and building up the necessary
rapport to successfully carry out my research. In essence, I became a people's
friend. Despite attempts to remain neutral, information that people gave to me
gave me power and as such can be threatening to others. I also had the power
of not being a full member of staff and I knew that whatever occurred, it would
not permanently affect me. Despite the intention to offer an egalitarian
relationship with participants, an action research approach can actually place
subjects at a greater risk of exploitation, betrayal and abandonment than more
positivistic methods.
Because of the collaborative nature of my research, as staff, such as junior
doctors and nurses on the ward changed during the intervention phase, I
needed to constantly renegotiate. True collaboration was difficult as the staff
were under an obligation to support the innovation because the consultants had
agreed to the project. This introduced an element of a 'top down' approach in
what started out as genuinely 'bottom up', which was contrary to the ideals of
action research. Despite the need for renegotiation with new staff, a degree of
close collaboration was achieved during this project, as I made considerable
efforts to ensure that all participants had a clear understanding of the research
and their role in it.
Within this research, despite my efforts to explain to patients and health care
professionals, the purpose of the study and exactly what I was doing responses
of participants ranged from misunderstanding by nurses who thought I was
there to 'top-up' the drugs cupboard, to patients thinking I was a medical
student. It was difficult to explain to everyone exactly what I was doing. To
inform and obtain consent from 'everyone' who entered the study environment
was problematic, and was compounded by the unpredictability of my
338
observations (Mulhall, 2003). Moreover, although participants may have given
their permission to be observed, they may not always be clear as to the extent
of the observation. For example, where nurses gave consent to being observed
giving patient care, did they by default give consent to be observed when talking
to colleagues? I encountered these ethical dilemmas in my research. It has
been suggested that a prescriptive approach to ideal ethical practice will
preclude researchers carefully considering social reality (Moore and Savage,
2002).
Informed, written consent was obtained from all patients recruited into the
evaluative study. They were informed that this was voluntary and that any data
collected relating to themselves would be kept confidential. Confidentiality and
anonymity were assured to all health care staff interviewed and focus group
participants. Consent to tape record the interviews and focus groups were
sought from all participants prior to the sessions. Only one participant refused,
and notes were therefore taken throughout the interview. Participants were
given the opportunity to check the transcripts for accuracy, following the
interviews and focus groups, to make any amendments they considered
appropriate, but all declined. Where possible fully informed consent would be
obtained from participants at each stage of the project, for example patients and
health care staff to be observed in particular settings, patients to be included in
the evaluative study and health care staff to be interviewed.
5.4.7.	 Validity and reliability
There are generally two concepts when discussing the credibility of scientific
research, 'validity' (accuracy of measurement) and 'reliability' (consistency of
measurement) (Silverman, 2001).
5.4.7.1.	 Validity
I have attempted to make the methods transparent to show I am 'measuring', or
explaining, what I claim to be measuring or explaining. The validity of my results
represents whether the data gathered reflected the reality. I have attempted to
give a clear account of the processes of data collection and analysis.
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By clearly documenting how people behaved in their "natural" everyday
situations, and examining in detail what people mean when they describe their
experiences, feelings, attitudes and behaviour, I have tried to give an accurate
representation of the phenomena studied. Interviews, focus groups,
observations, document analysis, informal discussions and data gathered
during the case study approach were all fully documented and rigorously
analysed. Instruments used for data collection were piloted, and I undertook
pilot participant observations and a pilot interview, to refine my technique.
I have presented a clear analysis of decisions made during the conduct of the
study, following an action research approach, to facilitate judgement of validity.
This has been described as reflexive validity, whereby articulation of the
researcher's influence on a study enables the reader to evaluate the
appropriateness of their influence (Waterman, 1998). The movements in the
action research spiral in this study (reflection, planning, acting and evaluation)
and the questioning of each together create a 'process of validation'.
There is an emancipatory element to action research to improve things, and the
ideals and philosophy behind action research contribute to the validity of its
approach (Waterman, 1998). The validity of action research projects does not
reside in their degree to affect change but in their attempt to improve people's
lives (patients or professionals).
In this project, I actually enacted the change whilst also researching it. In other
styles of research, this scenario would be seen to pose serious threats to
validity because of the vested interests of the researcher. The characteristics of
action research, questioning attitude, active search for opposing perspectives,
the movement between theory, research and practice and multiple methods
should hopefully reassure readers that action has been taken to minimise the
difficulty of vested interests.
The effect of the observer on the observed is a possible limitation of the
ethnographic methods used in this study. In my absence, error rates may have
been even higher and doctors' and nurses' behaviour relating to medicines may
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have been worse. However, I felt that the doctors and nurses within this study
accepted me and that modification of their behaviour was minimal.
Triangulation refers to an approach to data collection, in which evidence is
deliberately sought from a wide range of different, independent sources, often
by different means. In this project, triangulation was used to enhance
comprehensiveness and encourage a more reflexive analysis of the data, but
also in an attempt to enhance validity. The research design explicitly
incorporated a wide range of different perspectives from health care workers, so
the viewpoint of one group was not presented as if it were the sole truth about
any situation.
5.4.7.2.	 Reliability
Because the settings and groups studied in this research may be unique to the
particular context or time period it is difficult to judge reliability.
Although this study cannot be repeated in the same way a controlled
experiment can, this research was conducted rigorously and I have attempted
to give a clear account of the methods, data collection, and analysis to allow
readers to judge the evidence and interpretations presented. Meticulous records
of observations, interviews and documentation of the process of analysis were
maintained. However, it is not possible to say that, if repeated in the same way,
other researchers would find similar results. Some findings may be the same
others may not. Researchers with different personalities or characteristics may
approach the research in a different way
5.4.8.	 Generalisability
Because of the nature of this research, the findings cannot be generalised to
other Trusts. Sample sizes were small and non-random. Participants were
selected based on specific criteria, to explore selected settings and practices.
Generalisabitity involves the extent to which you can make some form of wider
claim on the basis of your research and analysis. The emphasis in this project
was not generalisabitity, rather development of a change in pharmacy practice
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within a specific Trust. Although the same phenomena may exist in other
Trusts, the findings from this study cannot be directly applied to these.
It is, however possible to generalise theoretically. The results can be used to
guide practice in other Trusts, as it is unlikely the results are unique to this Trust
alone. The analysis has not been based on data derived from a sample, which
is representative of a wider population, therefore it is not the intention to make
empirical generalisations, nevertheless I have no reason to assume this sample
and therefore the analysis are atypical.
If the new approach to pharmacy practice is successful in this study, at least it
has been demonstrated to be possible in a specified way and setting.
Explanations of how and why these processes worked, through detailed and
holistic analysis of the setting, derived from a range of data, sources and
methods, are likely to be useful for informing practice development in other
settings.
5.5.	 IMPLICATIONS FOR FUTURE RESEARCH
I had insufficient time to fotlow patients up following discharge. Future research
is required to explore the effects of education on compliance with medication
and also the effects of supplying information to GPs about drug therapy. This
would be time consuming but very useful in informing the whole area of
integrated pharmaceutical care. Visiting patients at home to check compliance
and assessment of the knowledge they retained about their medicines would be
helpful. Interviews with GPs following patients discharge could provide insight
into their views on the quality of discharge information provided by pharmacists.
It would be useful to undertake experimental studies on specific elements of the
model that require further investigation. There may be elements that are not
particularly effective and if identified, I may wish to eliminate them. For example
pharmacists attending all ward rounds in all settings or writing all discharge
prescriptions. On the other hand, that some elements offer major benefit and
are where resources should be concentrated in the future. For example patient
education.
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I identified that cultural change would be needed to implement the new services
and that this would be difficult. This poses interesting questions about best to
achieve the major cultural and organisational change that is needed. Research
in this area would be particularly useful. It may be useful to interview Trust
managers and others responsible for medicines use in the Trust, to ascertain
why the Trust seems to have the attitude that 'medicines don't matter'. It would
be valuable to examine the Trust drug and therapeutic committee to gain insight
into the corporate approach to medication issues, and the interaction between
senior management and professions in the Trust. It may also be valuable to
explore the views about my project and general medicines management issues
of health care workers and managers in Primary Care Trusts, in particular
members of the Professional Executive Committee and prescribing sub-
committee.
A further action research cycle should be undertaken to implement the model in
other areas within the study Trust and other Trusts and refine it to reflect needs
in different settings and hospitals. In repeating the study in different Trusts, it
would be interesting to see whether the culture relating to medicines differs. I
suspect it will not as the literature suggests the culture I encountered is actually
widespread.
A full economic evaluation of the problems relating to medicines use identified
in this study would be extremely useful further research. This should include
assessment of the costs of iatrogenic illness, implications of poor practice on
length of hospital stay, litigation due to medication errors and implications for
the economy due to lost days work. The cost of implementing the changes
suggested as a result of this study should also be estimated, taking into account
increased funding requirements for pharmacy staff, more appropriate use of
doctors' and nurses' time, potentially reduced length of admission, fewer
admissions due to iatrogenic illness, avoidance of litigation, development of and
adherence to a formulary and potentially improved compliance with medication.
It would be interesting to explore whether there are linkages between the
attitudes and practices towards medicines identified in this study with wider
determinants of good prescribing practice and medicines management, for
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example athtudes to implementation of NICE guidance (Ralph S, 2004,
Richards Mike, June 2004).
The Government's medicines management framework for hospitals
(Department of Health, 2003c), which is a self-assessment tool for hospitals has
two main purposes: firstly, to make clear to Trust Chief Executives their
responsibilities regarding the management of medicines within their Trusts and
the related health economy, secondly, to assist Trusts in developing systems
ahead of the Value for Money audits planned for 2005. It would be helpful to
undertake research to into whether this has had any impact in this or other
Trusts.
5.6.	 IMPLICATIONS FOR PRACTICE
Although this project was undertaken in a particular setting and results cannot
be generalised I have no reason to think this Trust is unique. The findings have
implications for this Trust and wider.
I believe that the model of pharmaceutical care developed and evaluated within
this study should be implemented throughout the study Trust and as a result
patient care would be improved. Pharmaceutical services should be more
patient orientated rather than primarily focussing on supply. Pharmacy staff
should be working on the wards, fully integrated into the health care team,
providing services to patients and medical staff in a structured, systematic way.
Pharmacy staff should work to provide standard services following a cohesive
and holistic approach.
The model of care would essentially comprise the activities evaluated in the
study, although different settings within the Trust would require varying levels of
input and activities should be tailored appropriately. Essentially, a pharmacist:
. is based on the ward full time, available for all patients and ward staff for
consultation
. attends the ward rounds, monitoring and advising on the prescribing and
administration of drugs
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• takes a second medication history following admission to the study wards
• undertakes a formal medication review using indicators of appropriate
prescribing
• plans and co-ordinates medicines aspects of discharge
• assesses patients' knowledge about their medicines and educates them
accordingly
provides information to GPs about patients' drug therapy during admission
and following discharge
Usually the admitting doctor will take an initial drug history on the admissions
ward and I propose that the pharmacist would take a second drug history when
the patient is transferred to another ward. It may be better, however, to have a
pharmacist working on the admissions ward and taking drug histories, then only
one drug history would be required.
I propose that pharmacists should write discharge prescriptions, in advance
where possible. Of course, there will be occasions where pre-empting discharge
is not possible, for example if medication is changed at the last minute.
Pharmacy services should ideally be available seven days a week, and the daily
hours of working expanded so they are more in line with those of doctors and
nurses. This may be unpopular with some pharmacy staff, which may be
problematic.
My findings and the literature however, suggest that this change in practice will
be difficult to achieve. Pharmacy staff would need more training, guidance and
support. Support of less experienced staff should take the form of mentoring,
and the whole service should be developed and supervised by a suitably
experienced manager. This manager must be extremely enthusiastic and
motivated to encourage the professional aspirations of pharmacy staff, and
dispel any professional insecurities. A whole change in the ethos of the
pharmacy department would be necessary, from the head of pharmacy right
through to the technical staff. As I discussed in section 5.3, it may be that
pharmacy staff themselves are the greatest barrier to change. Pharmacy staff in
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the study Trust felt that their services weren't seen as an important part of care,
but my experiences were very different. I believe this is because I was
undertaking activities in a much more structured and intense manner. The
doctors and nurses became accustomed to having me on the wards. Had I not
been there, the ward would still have functioned and the activities I was
undertaking would fall back to the responsibility of the doctors and nurses. The
situation is likely to return to how it was before for example, inaccurate drug
histories, patients receiving inadequate information about their medicines,
delayed discharges etc.
Doctors, nurses and pharmacy staff must all be fully informed and involved for
this new approach to pharmacy practice to be successful across the Trust.
Good interprofessional communication, definition of roles and consistency of
pharmacy services is essential. Effective skill mix of pharmacy staff would help
maximise resources.
Pharmacy staff who took part in the focus groups talked a lot about the use of
protocols in delivering the service developments, and definitions of their roles.
Indeed protocols are extremely valuable as they provide a clear statement of
best practice. They allow reallocation of jobs, reorganisation of work practices,
and ensure consistency of care, so that all staff follow best practice. They can
encourage better team working as the process of actually drawing up and
implementing protocols itself allows different professionals to understand each
other's roles better than they had before It would be dangerous to assume
however, that a high level of consensus always promotes efficiency. The
detailed specification of tasks entails a network of bureaucratic roles and
reduces the parties' commitment to their job. Because roles can never fit every
circumstance and cannot be kept completely up to date, people can always
utilize the rulebook to defeat the ends it was supposed to serve. There is
evidence to suggest that people often work best when there is a measure of
dissent, encouraging the growth of new ideas and the expression of human
individuality (Banton, 1965).
To gain support within the Trust improvements in patient care and cost savings
should be demonstrated, but this is difficult to measure. Changes in services
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may require additional funding which may be difficult to obtain, It may be that
services should be initially targeted to areas in which they would have most
impact. Pharmacist's time may not be best utilised by attending all ward rounds,
as only a small proportion of time is spent discussing medication, It may be
more practical for pharmacists to attend only selected ward rounds, have
regular, scheduled liaisons with doctors and nurses and keep up good
communications. Selection of the most appropriate ward rounds may be done
through discussions with doctors and/or trial and error. Other directorates may
not be as concerned with medicines as a general medicine setting. For
example, surgeons may be more reluctant than general medical doctors to
change medication, as they are more concerned with the operation than other
concomitant medical conditions and the associated therapy. This is an
important consideration when rolling out services across other directorates as
these consultants may need more convincing of their value. Therefore the new
services should first be instituted in non-surgical settings.
Another potential solution for developing services with limited resources could
be that a pharmacist works intensively on a ward for a month highlighting to
doctors and nurses errors and how bad things really are. This would hopefully
raise the profile of medicines and improve practice. The pharmacist could then
move onto another ward in the Trust and repeat the exercise.
For this model of pharmaceutical care to be successfully implemented within the
Trust a change in culture relating to medicines is required throughout the
organisation. The efforts of pharmacy staff alone will not be sufficient. Doctors
and nurses must also change their ways of working and attitudes towards
medicines. My experience and the literature suggest this again would be very
difficult to achieve. It would entail a great deal of motivation and enthusiasm
from pharmacy staff and Trust managers. In interviews, doctors and nurses
appeared to accept a less than ideal quality of patient care and blamed this on
understaffing and poor communication. Perhaps more doctors and nurses are
needed, or perhaps they need to manage their time better. On the other hand, it
may be that doctors and nurses use time limitations as an excuse for sub-
standard care. Perhaps working patterns of doctors and nurses need to be
347
examined and their priorities assessed, in addition to the pharmacy service
developments.
The consultants in particular seemed to express frustration about the pressures
applied on them, differing priorities from managers and the Government, and
lack of resources. This may be a reason why certain medicines aspects of
patient care are not considered a priority, especially as the views of consultants
will influence junior doctors and nurses. Any change in culture would require
support from Trust management and consultants.
The Government are committed to improving patient safety, however my
findings indicate this is not taken seriously in the study Trust (Department of
Health, 2000d, Department of Health, 2004e). Mechanisms should be in place
within the Trust by which all errors are reported, within a 'no blame' culture, then
fed back to staff to enable learning and pharmacists could coordinate this.
Traditionally doctors make the treatment decisions, nurses carry out their
instructions and pharmacy supplies medication. However, this division of labour
no longer exists as the only form of interaction between doctors, nurses and
pharmacists. For example, nurse practitioners have clinical responsibilities
including assessment and diagnosis of patients and some nurses can now
prescribe. Pharmacists are developing their roles to provide more patient
centred services such as those piloted in this study. Whilst interviewees
acknowledged that pharmacists should have significant involvement in patient
care, there was an implicit assumption that the pharmacist is acting as the
doctor's assistant or substitute.
The training of healthcare workers should address this multidisciplinary
approach to patient care and breaking down of role boundaries which is
required for optimum care of patients, and is part of Government's reform within
the NHS. Government have said that pharmacists must work more flexibly and
alongside other professionals and support staff. The training of, not only
pharmacists, but also doctors, nurses and other healthcare staff should reflect
this. Multidisciplinary training is a pre-requisite to ensuring that healthcare
workers are able to provide the best care for patients. This may create positive
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changes in collegiality, emphasising team working rather than medical
allegiances, and may perhaps help to decrease medical error by providing a
counterbalance to current problems of too much medical understanding and
forgiveness of error, and of feelings of exclusivity. Examples of interprofessional
training within the United Kingdom can be found at Southampton University and
St George's Hospital Medical School, London. (Department of Health, 2001f).
All healthcare professionals should have training and education, which includes
common learning with other professionals and this, should run from under-
graduate and pre-registration programmes through to continuing professional
development (Department of Health, 20010. Common learning should take
place both in practice and in the classroom, and should centre on the needs of
the patient.
Increased participation in the multidisciplinary team will require pharmacy staff
to view their role in terms of team care rather than provision of pharmacy
services. Pharmacy education should emphasise the duty pharmacists have to
patients, as opposed to a duty to professionals.
Another way to reduce errors might be for pharmacists to take on more of a
prescribing role. Pharmacists already write discharge prescriptions in some
hospitals (Jacklin and Patel, 2001), and I have shown it works well in the study
Trust. Pharmacists can already prescribe as a supplementary prescriber and
will soon be able to prescribe independently (Medicines and Healthcare
Products Regulatory Agency, 2005).
There are however, potential disadvantages to this new model of
pharmaceutical care I am proposing. Some doctors and nurses may adopt
riskier behaviour than normal because they assume pharmacists are checking
their work (Dean et a!., 2002a). Doctors and nurses must not simply rely on
pharmacy staff to ensure the medicines aspect of patient care is safe and
effective.
If pharmacy staff take on these new extended roles and junior doctors no longer
routinely undertake activities such as taking drug histories, reviewing
medication, educating patients, there is a risk that their familiarity with drugs will
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be lessened. The opportunity to learn about drugs may be further compromised
and deskilling of doctors and nurses may occur. The same may be said for
pharmacy staff. If they are working on the wards as I propose, they may
become deskilled at traditional 'core' pharmacy activities such as supply and
manufacturing, which may cause problems if staff levels dropped. Another
concern is that doctors and nurses may not use their extra time efficiently.
Doctors and nurses must use the time that is freed up to undertake other more
appropriate clinical activities.
There are a number of other practical improvements identified from this study
that would not necessarily require employment of a pharmacist taking on an
extended role outlined. For example a change in culture of complacency
amongst doctors and nurses towards medicines might be brought about by a
number of measures. Having pharmacists working within the medical team is
likely to raise the profile of medicines, but medical and nursing schools should
instil into their graduates the importance of medicines, which should then be
reinforced in working practice. Doctors must be encouraged to follow good
practices such as documenting the reason for prescribing a drug in patients'
notes, obtaining accurate drug histories, detailing allergies on the chart, and
adhering to existing prescribing policies. Prescription writing should be
recognised as a high-risk activity, which must be reinforced by seniors and
Trust managers. Actually discussing prescribing details, such as the dose,
indication and potential side effects when a drug is prescribed would be
beneficial and may encourage greater involvement of patients in their care if this
is done on ward rounds at the patients' bedside. In addition, pharmacy staff
could have greater involvement in formal training sessions for doctors and
nurses and produce educational material.
In addition to a change in attitudes towards medicines, it is clear from this study
that there is an urgent need to improve therapeutics education for doctors and
nurses, both pre and post qualification. Junior doctors should be taught how to
ascertain the correct dose of a drug and its frequency of administration, and
how to identify when it might need adjustment.
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It is important to establish a safety culture in the education of health care
workers. Improving health care begins with the focus on improving medical
education. Instead of a conspiracy of silence and a strategy of acceptance and
covering up, medical and nursing schools should encourage a culture of
openness about medication errors. It would be valuable to teach medical and
nursing students about the positive value of medical error and move to a
scenario where errors can be more openly admitted and discussed. In teaching
about errors it must be emphasised that some error is inevitable, even amongst
the most conscientious of individuals, and must not be perceived automatically
as character flaws.
Systems should be put in place to ensure medicines are ordered and arrive on
the ward in a timely fashion. This will involve changes at both ward and
pharmacy levels. Instead of pharmacists, junior doctors could take a second
drug history when patients are transferred from the admissions ward.
Doctors and nurses should be encouraged to involve patients in their own care
and educate them about their medicines to foster the doctor-patient, nurse-
patient relationship. This could lead to a greater value of the patient's
perspective and less emphasis on the exclusivity of professional judgement.
5.7.	 CONCLUSIONS
In this study I have shown that action research methodology can be used to
identify problems in medicines management in the hospital setting and to
develop and evaluate potential solutions. I believe I am the first worker to adopt
this approach in the area of prescribing and medicines use.
I identified a range of unsafe or suboptimal practices in medicines management.
While many of these have been described in previous studies, ethnography
provided a powerful tool which revealed a disturbing picture of inappropriate
attitudes to and practices with medicines. While health professionals
acknowledged these deficiencies they appeared to accept them as an inevitable
part of patient care and, prior to the study, lacked motivation to address them.
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Using action research meant that I quickly became integrated into the clinical
teams that were the subject of the research. Staff knew that I was studying their
practice but nevertheless did not appear to adjust their behaviour, enabling me
assemble an in depth picture of the realities of medicines management in older
people.
I developed and evaluated a holistic model of pharmaceutical care which aimed
to ensure appropriate, safe and efficient medicines management through
improved drug history taking, improved patient education, identification of
iatrogenic factors in admissions, better communications with GPs, avoidance of
errors, better documentation of drug treatment, optimised supply and
administration of medicines, and education of other health professionals in
medicinal therapeutics.
Errors and omissions in patients' medication were significantly reduced through
intervention both at admission and during inpatient stay. The quality and
quantity of information provided to patients and general practitioners at
discharge was enhanced. Adverse drug reactions were identified and avoided.
Evidence-based, appropriate prescribing was ensured in study patients.
Successful interventions had the potential significantly to improve clinical
outcomes. For example, in one patient nine medicines, all clinically necessary,
were missed at admission, but promptly restored to her treatment following my
intervention. Conversely, I identified a cocktail of medications that were being
given to one patient prior to admission and which became redundant following
an accurate diagnosis. These were mistakenly continued, with the risk of
serious harm, until my intervention. In addition to these tangible improvements
in care, interviews with patients also demonstrated increased satisfaction with
their care.
While these findings are not directly generalisable to other care settings, there
is no reason to assume that these findings are atypical. Therefore there are
potential implications for medicines management in other hospitals. While there
are a number of barriers to change, adoption of a pharmaceutical care model
using the principles in this study has the potential to improve patient care.
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6. APPENDICES
353
I')
6.1.	 ETHICAL APPROVAL FROM COUNTY DURHAM
HEALTH AUTHORITY ETHICS COMMITTEE
Direct Line:	 0191 333 3274
Em ciii	 Lia,:ne.Sufflerquai_perf.durI,am_J1,1.flOrt/ij'a1tN.Uk
Date:	 Monday, 22 May 2000
/
Our Ref:	 ethicsto5-00!O6mayOO
Sarah Smith
University of Durham
Centre for Health Studies
Elvet Riverside
New Elvet
Durham
DII I 3JT
i::	 Oti;hcnt I-iaI:h \ct1,r
\pji1c I!nuw
tancs:cr RüaJ
DurhDH1 5Z
Ii :r 19	 33 2
F:r
Dear Ms Smith
Stud y 06/May00:	 Efficacy of a structured niodel of pharmaceutical care for
elderly patients
Sarah C Smith
(Please quote 06/Mar00 on all correspondence)
At the meeting held on 15 May 2000 County Durham Local Research Ethics
Committee approved the above numbered study pending clarification that confused
paients who are unable to give their own consent would be excluded from the study.
Tue Conniittce would also like sight of the questionnaire before it is sent out to
patients.
On confirmation of these points Chairman's approval will be given in writing.
Yours sincerely
Mrs Jo Turnbull
Chairman - County Durham Local Research Ethics Committee
354
--
County Durham and Darlington
Health Authority
Appleton Houso
Direct Line: 0191 333 3274
	 Lancheter Road
Email	 Carol. Thorn@qua!-perf.D urham4lA .Northy.NHS. UK 	 Durham
DH1 SXZ
Date	 Friday. 16 February 2001 	
Tel: 0191 333 3232
Our Ref:	 ct//Ethics/02-01 /O6MayOO
	 Fat: 0191 3333233
Ms Sarah Tulip
Pharmacy Department
North Read
Durham
DH1 5TW
Dear Ms Tulip
Study 06/May00	 Efficacy of a structured model of pharmaceutical care for elderly
patients.
Sarah C Smith
Further to your letter received in this office on 19 January 2001 confirming that you will not
enrol confused patients who are unable to consent themselves in your study.
At the meeting held on 15 February 2001 County Durham and Darlington Local Research
Ethics Committee approved the above numbered study
I shall write to you once a year for a progress review. Otherwise, I would be grateful if you
could forward a report to this office on completion of the prolect.
Yours sincerely
Mrs Jo Turnbull
1 Chairman - County Durham & Darlington Research Ethics Committee
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6.2.	 DRUG HISTORY PROFORMA, SIDE I
PHARMACIST MEDICATION HISTORY
Patient name:	 D0B:	 D0A:
Bed:	 ___________________ __________________________
Community
pharmacist:	 Own meds:	 AMT:
Complete medication
h isto rv
Drug	 Dose and frequency	 Source of information
Side effects of meds
__________________ _______________________ (past/present)
_________________ ______________________	 Allergies_(details)
_________________ _____________________ 	
OTC_medicines
__________________ _______________________ 	
Social_drugs
Medication history taken by admitting doctor
Drug	 Dose and frequency	 Allergies noted
_________________ _____________________	
Social_drugs_noted
_________________ ______________________	
OTC_drugs_noted
__________________ _______________________ 	
Any other notes
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Drug history proforma, side 2
DETAILS OF HISTORIES OBTAINED FROM DIFFERENT SOURCES
GP surgery	 GP referral letter
Other	 Previous notes
Changes to medication following pharmacist dru g history
357
6.3.	 COMPLIANCE ASSESSMENT FORM
1. How often do you forget to take your medicines?
Once a month or less	 U
A number of times a month LI
A number of times a week LI
At least onceaday	 U
2. How often do you take your medicine late (more than two hours)?
Once a month or less	 U
A number of times a month Iii
A number of times a week U
At least once a day	 III
3. How often do you decide not to take at least one medicine?
Once a month or less	 U
A number of times a month LI
A number of times a week U
Atleastonceaday	 U
4. How often do you decide to take less medicine?
Once a month or less	 U
A number of times a month LI
A number of times a week U
At least once aday	 U
5. Does anyone help you take your medicines?
6. Do you have any routines which help you to remember to take your
medicines?
7. Do you have difficulty with the packaging of your medicines?
8. Do you have difficulty reading the labels on your medicines?
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6.5.	 FORM FOR DISCHARGE INFORMATION FOR GP
Patient name:	 GP:	 Ward:
________________________	 Consultant:
Date of admission:
Address:	 _________________________	 I I
Date of discharge:
Community Pharmacist:	 I I
________________________	 Hosp pharmacist:
Sarah Tulip (bleep
Unitnumber:	 ________________________ xxxx)
Medicines stopped during admission	 Summary of therapy in hospital
Medicine	 Reason
__________________ ______________________ Allergies
	 ADRs
Summary of discharge
Monitoring of therapy after discharge	 treatment plan
Expected Compliance
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6.6.	 ABBREVIATED MENTAL TEST SCORE (HODKINSON
H M, 1972)
1. Age
2. Date of birth
(year not required)
3. Year
4. Time of day
5. Place
6. Monarch
7. Year of first world war
8. Counting backwards from 20 to 1
9. Recognition of two people
Score for exact age only
Score for correct date and month
Score for current year only
Score if correct to the nearest
hour
Score if exact address or name of
hospital given ("in hospital" is
insufficient)
Score for current monarch only
Score for year of start or finish
(both not necessary)
Score if no mistakes or subject
corrects himself or herself
spontaneously
Score if roles of two people correctly
recognised for example, doctor and
nurse
10. Recall of three point address such	 Score if registered correctly near
as 42 West Street 	 beginning of test and on recall at
end of test
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6.7.	 PATIENT INFORMATION SHEET, SIDE I
MEDICINES MANAGEMENT FOR OLDER PEOPLE
You are being invited to take part in a research study. Before you decide,
it is important for you to understand why the research is being done and
what it will involve. Please take your time to read the following information
carefully. Ask us if there is anything that is not clear or if you would like
more information, before you decide whether or not you want to take part.
Thank you for reading this.
What is the purpose of this study?
Some people experience problems with their medicines, when they are
admitted to hospital, during their hospital stay, or when they are discharged
back home again. Some examples may be: not being given your usual
medicines in hospital, receiving a drug which causes you side effects, taking
certain medicines longer than you need to be, not being given enough
information about your medicines, not being able to read the labels on your
medicines, difficulty opening the containers your medicines are supplied in. In
this study we hope to develop and implement a system to ensure your drug
therapy in monitored and adjusted to your individual needs, and to ensure both
you and your GP are given sufficient information about your treatment plan
when you are discharged. The study is six months in duration.
Why have I been chosen?
Patients included in the study are over 65 years and are under the care of one
of the following consultants at X Hospital: Dr X, Dr X, Dr X or Dr X.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part
you will be given this information sheet to keep and be asked to sign a consent
form. If you decide to take part you are still free to withdraw at any time and
without giving a reason. This will not affect the standard of care you receive.
What will happen to me if I take part?
The pharmacist conducting the study will:
• Talk to you shortly after you have been admitted, to ask which medicines
you usually take.
• Discuss your drug therapy with doctors on the ward, and your consultant to
ensure your medicines are appropriate.
• Monitor your drug therapy throughout your stay.
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• Give you advice about your medicines when you leave hospital, and provide
you with a written reminder chart.
• Ask you questions about what you think of the care you've received in
hospital.
• Write to your GP to communicate any changes to your medicines, following
this admission.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research
will be kept strictly confidential. Any information about you that leaves the
hospital will have your name and address removed so that you cannot be
recognised from it. Your GP will be notified that you are taking part in this study.
You will not be identified in any report or publication.
Who has reviewed this study?
The Local Research Ethics Committee
County Durham Health Authority,
Appleton House,
Lanchester Road,
Durham
DH1 5XZ
Thank you for taking part in this study.
You will be given a copy of the information sheet and a signed consent form to
keep.
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6.8.	 CONSENT FORM
CONSENT FORM
MEDICINES MANAGEMENT FOR OLDER PEOPLE
Name of researcher: Sarah Tulip
1. I confirm that I have read and understand the
patient information sheet for the above study 	 U
and have had an opportunity to ask questions.
2. I give permission for the researcher to access
my medical notes.	 LI
3. I give permission for the researcher to visit me
at home if I am one of the patients who is 	 U
randomly selected for this part of the study.
4. I agree to take part in the above study. 	 U
Name of patient Date
	
Signature
Name of researcher DateSignature
1 copy for patient, I for researcher, I to be kept with the hospital notes
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6.9.	 INTERVENTION RECORD FORM, SIDE I
STUDY TRUST - CLINICAL PHARMACY INTERVENTION RECORD FORM
1. Nature of intervention	 1 2 3 4 5 6 7 8
Patient/relative/carer education
Dose alteration
Drug incorrectly omitted from prescription
Advise about choice of therapy
Therapeutic information added to patients' notes
Drug stopped as inappropriate/not indicated
Associated with administration I formulation I route
Miscellaneous
Recommend instigation of tests (U&Es, LFTs etc)*
Prevention I detection of adverse drug reaction
Drug I drug or drug I diseased interaction
Information provided to Dr I nurse I patient I GP
Drug changed to the formulary preference
Drug not administered (no valid reason recorded)
Medication started as indicated not previously
prescribed
TDM or pharmacokinetics recommendations
2. Main people involved
House officer
Senior house officer
Registrar
Consultant
Nurse
Patient
GPlcommunity pharmacist
Myself only
3. Primary reason for intervention
Maximise patient care or minimise risk
Ensure effective drug use for maximum patient
benefit
Drug therapy changed for economic reasons
Ensure prescription written to legal/hospital
requirements	 - - - - - -
4. Clinical significance of interventions
Information only
Minor benefit to patient care
Moderate benefit to patient care
Significant benefit to patient care
Very significant benefit to patient care
Potentially life saving
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Brief description of activity:
1.	 2.
Date:	 Date:
Patient name:	 Patient name:
Details:	 Details:
3.	 4.
Date:	 Date:
Patient name:	 Patient name:
Details:	 Details:
5.	 6.
Date:	 Date:
Patient name:	 Patient name:
Details:	 Details:
7.	 8.
Date:	 Date:
Patient name:	 Patient name:
Details:	 Details:
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6.10.	 LETTER TO DOCTORS AND NURSES WITHOUT
PRIOR INVOLVEMENT IN THE PROJECT ABOUT
INTERVIEW
Sarah Tulip
Research Pharmacist, University of Durham, s.c.smithdurham.ac.uk
Date
Participant X, Ward X
Dear Participant,
Re: Interview for research project: 'Medicines Management in Older People: An Action Research
Study in a Hospital Setting'
Thank you for agreeing to participate in an in-depth interview as part of the final stages of my research
project. I would like to confirm that the interview will take place on [date] at [time], in [place]. Please let me
know if there are any problems with this. I also want to give you a little more information about the project.
The main objectives of the study were: to develop, implement and evaluate a structured approach to
pharmaceutical care with the aims of improving the quality of care for older people, with respect to their
medication, and minimise risk. The work is supported by Dr X, Dr X, Dr X and Dr X. A new approach to
pharmacy services was piloted for 6 months on 2 acute medical wards within [the study Trust].
The care package comprised:
• A second drug history followed by formal medication review undertaken by a pharmacist
• A pharmacist based on the ward full-time, attending all ward rounds, monitoring and advising on
the prescribing and administration of drugs planning and ordering discharge medication, in
advance wherever possible
• Provision of written and verbal advice to patients about their medication
• Provision of additional information to the general practitioner about medication on discharge
Some of the main findings from the pilot study are summarised below:
• Comments from doctors and nurses were very positive:
-Time was freed to pursue other clinical activities
-Risks associated with drug therapy are reduced
-Better communication across the primary/secondary care interface
-Discharges speeded up
-Improved patient information
• A second drug history recorded by a pharmacist is beneficial to patient care
• On average I drug per patient was added to each patient's therapy after the second drug history
• Prescribing practice is improved, e.g. in 90 cases', 151 changes were made to therapy following a
structured review
In the next 12 months I hope to investigate the feasibility of implementing this model of pharmaceutical
care across different wards. I want to obtain the views and opinions of people who are in key positions to
influence implementation, using in-depth interviews. Questions will seek to identify any perceived barriers
to implementation, and find out what people actually think about the proposed changes to pharmacy
services.
With your permission the interview will be tape recorded, although the report will be completely
confidential. If you want to talk to me about the project please do not hesitate to get in touch. Thank you
once again for agreeing to participate.
Yours Sincerely,
Sarah Tulip
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6.11.	 LETTER FOR THE CONSULTANTS AND ONE NURSE
WITH PRIOR INVOLVEMENT IN THE PROJECT
ABOUT INTERVIEW
Sarah Tulip
Research Pharmacist, University of Durham
s.c.smithdurham.ac.uk
Date
Participant X
Ward X
Dear Participant,
Re: Interview for research project: 'Medicines Management in Older People: An Action Research
Study in a Hospital Setting'
Thank you for agreeing to participate in an in-depth interview as part of the final stages of my research
project. I would like to confirm that the interview will take place on [date] at [timel, in [place]. Please let me
know if there are any problems with this. I also want to give you a little more information about the project.
In the next 12 months I hope to investigate the feasibility of implementing this model of pharmaceutical
care across different wards. I want to obtain the views and opinions of people who are in key positions to
influence implementation, using in-depth interviews. Questions will seek to identify any perceived barriers
to implementation, and find out what people actually think about the proposed changes to pharmacy
services.
With your permission the interview will be tape recorded, although the report will be completely
confidential. If you want to talk to me about the project please do not hesitate to get in touch.
Thank you once again for agreeing to participate.
Yours Sincerely,
Sarah Tulip
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6.12.	 AIDE MEMOIR FOR INTERVIEWEES FAMILIAR WITH
PROJECT (CONSULTANTS AND ONE NURSE)
What aspects of having me on the ward did you like/find useful?
Contrast with standard pharmacy services
Examples?
Aspects of the project disliked or could have been improved?
Impact on the quality of patient care I risk?
Economics of care - rolling out the service throughout the trust?
Although you've been involved with the project right from the beginning, are you
still clear about the purpose of it?
How can we enhance doctors' nurses and patients' understanding of pharmacists'
new roles and the proposed services?
If we think this model of practice is practicable how can we implement it across
the board within this trust?
What problems / bamers do you think we would face?
Support form other consultants I doctors I nurses?
lnterprofessional problems? Cultural issues
Support from Trust management
Resources and investment in pharmacy services
How would you describe the culture and attitude amongst doctors and nurses,
with respect to medication errors?
Changing culture I practice
Competency of doctors and nurses in therapeutics
Training and support of doctors and nurses in therapeutics
Further service developments
What could / should we be doing in the future?
Role boundaries, should a line be drawn beyond which pharmacists can and can't
do things?
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6.13.	 AIDE MEMOIR FOR INTERVIEWEES UNFAMILIAR
WITH PROJECT
In your opinion, are there any advantages of having a pharmacist
permanently working alongside you on the wards?
Contrast with previous experience if applicable
What problems do you experience relating to medication within hospitals?
In what way could a pharmacist help you on the wards?
Which activities would be useful?
What problems would you perceive in having a pharmacist around all the
time on the wards?
Interprofessional problems?
Perceptions of pharmacists as professionals
Competency of pharmacists
Understanding of roles I boundaries
De-skilling of doctors and nurses
Do patients get sufficient information about their medicines?
How often do you talk to patients about their medicines?
Best people to provide information
It is clear from my work that medication errors do occur quite frequently
albeit most are not of major significance. In your work have you encountered
this?
What are your feelings about this?
Culture towards errors
If we think this model of practice is practicable how can we implement it
across the board within this trust?
What problems I barriers do you think we would face?
Support form other consultants I doctors I nurses?
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6.14.	 LETTER FOR FOCUS GROUP VOLUNTEERS
Sarah Tulip
Research Pharmacist, University of Durham
Date
Dear Participant,
Re: Interview for research project: 'Medicines Management in Older People: An Action Research
Study in a Hospital Setting'
Thank you very much for volunteering to participate in a focus group as part of the final stages of my
research. I would like to confirm that the interview will take place on [date] at [time], in [place].
I am sure you know quite a lot about the project already but here is a little more information. The main
objectives of the study were: to develop, implement and evaluate a structured approach to pharmaceutical
care with the aims of improving the quality of care for older people, with respect to their medication, and
minimise risk. The work is supported by Dr X, Dr X, Dr X and Dr X. A new approach to pharmacy services
was piloted for 6 months on 2 acute medical wards within [the study Trust].
The care package comprised:
• A second drug history followed by formal medication review undertaken by a pharmacist
• A pharmacist based on the ward full-time, attending all ward rounds, monitoring and advising on
the prescribing and administration of drugs planning and ordenag discharge medcaton n
advance wherever possible
• Provision of written and verbal advice to patients about their medication
• Provision of additional information to the genera practoner aboit med\ca'toii or dsdnai
Some of the main findings from the pilot study are summarised below:
• Comments from doctors and nurses were very positive:
-Time was freed to pursue other clinical activities
-Risks associated with drug therapy are reduced
-Better communication across the primary/secondary care interlace
-Discharges speeded up and improved patient information
• A second drug history recorded by a pharmacist is beneficial to patient care
• Prescribing practice is improved, e.g. in 90 'cases', i5 changes were nade to therapy ioJJowinp a
structured review
In this stage of the research I hope to investigate the feasibility of implementing this model of
pharmaceutical care across different wards. I want to obtain the views and opinions of people who are in
key positions to influence implementation. Focus groups are therefore being conducted with pharmacy
staff, and your contribution will be extremely valuable.
Focus groups are a form of group interview. A moderator will guide the interview while the group will
discuss the topics that the interviewer raises. Focus groups are a way of listening to people and learning
from them. Technicians and pharmacists have been grouped separately as they have different
professional responsibilities and are therefore likely to raise differing concerns and issues.
A number of issues will be explored within the focus group:
• Participants feelings about taking on new / extended roles
• Opinions about the care package evaluated in this study
• Perceived barriers to implementing this on a wider scale, and how to overcome or tackle these
• Views on integration of pharmacy staff into the multidisciplinary team, providing patient-focussed care
rather than the traditional pharmacy-based services
• Training requirements and support needed
• Appropriate skill mix
With the permission of the volunteers, the groups will be tape-recorded, but in the report no names will
appear so it will be completely confidential. If you have any questions, please do not hesitate to contact
me. Thank you once again for agreeing to participate.
Yours sincerely,
Sarah Tulip
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6.15.	 FOCUS GROUP SCHEDULE
1. When you hear the phrase patient-centred pharmacy services, or
patient-focused services, what comes to mind?
2. What medicines related problems do you encounter in this hospital?
Examples? Why do these problems happen? How could they be avoided?
2. What do you think about this project?
Advantages and disadvantages of having pharmacy staff working along side
doctors and nurses on the wards?
For patients, doctors, nurses, yourselves?
3. If we think this model of practice is practicable how can we implement
it across the board within this trust?
What is stopping us doing it now? What is holding us back?
What problems / barñers do you think we wouki face?
Would all pharmacy staff be supportive of it? If not, why not?
How can we get everyone on board?
How can we enhance doctors' nurses and patients' understanding of
pharmacists' new roles and the proposed services?
Interprofessional problems?
Skill mix - technician, assistant technical officers' involvement
4. How do you feel about taking on these new, extended roles?
Competency of pharmacy staff, training requirements and support
5. How would you describe the culture and attitude on the wards,
amongst doctors and nurses, with respect to medication errors?
How can prescribing practice be improved?
6. How should we monitor and audit the service?
7. Further service developments
Is there anything else you think pharmacy staff should be doing?
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